Issues with the use of medicines in paediatrics: Off-label and unlicensed use, and formulation uncertainty by Czarniak, Petra
    
 
School of Pharmacy 
 
 
 
 
 
Issues with the Use of Medicines in Paediatrics: Off-label and 
Unlicensed Use, and Formulation Uncertainty 
 
 
 
Petra Czarniak 
 
 
 
 
 
 
 
 
This thesis is presented for the Degree of  
Doctor of Philosophy  
of  
Curtin University 
 
 
April 2014
   ii 
 
 
Declaration 
 
 
 
 
To the best of my knowledge and belief this thesis contains no material 
previously published by any other person except where due 
acknowledgement has been made. This thesis contains no material 
which has been accepted for the award of any other degree or diploma 
in any university. 
 
 
 
 
Signature: 
 
 
 
 
Date:  
   iii 
Abstract  
 
Background 
 
Many of the drugs prescribed for children are either unlicensed or have been 
prescribed outside the terms of their product license (off-label). In many of 
these cases dosages are extrapolated from data obtained from adult trials. 
Developmental changes that occur with age influence the pharmacokinetic 
and pharmacodynamic effects of drugs. Because of these effects, data such 
as efficacy, doses or toxicity extrapolated from clinical studies in adults may 
be inappropriate for children. Off-label and unlicensed prescribing in 
paediatrics is a global phenomenon due to a lack of adequate registration of 
paediatric drugs and formulations. Three small Australian studies conducted 
in inpatients and a neonatal intensive care unit have provided limited data on 
the extent of off-label prescribing in paediatrics in Australia. There are no 
data available in Australia that considers the extent of off-label and 
unlicensed prescribing in paediatrics in all hospital settings, including 
inpatients, outpatients and Emergency Department admissions. 
 
Aims 
 
To investigate the extent of off-label and unlicensed prescribing at Princess 
Margaret Hospital, which is the largest and sole paediatric hospital in 
Western Australia and to report on the stability of parenterally administered 
lincomycin used in an unlicensed manner. 
 
Methods 
 
Patient records from Princess Margaret Hospital (PMH) were randomly 
selected from all 145,550 patients seen at the hospital during 2008. The 1038 
randomly selected records for the retrospective study were from 55,591 
patients from Emergency Department admissions, 24,425 records from 
inpatients and 65,534 records from outpatients. Relevant data collected from 
each medical record included an identification number, type of patient 
   iv 
(inpatient, outpatient or emergency), sex, date of birth, weight, height, 
diagnosis, adverse effects, past medical history, ceased medications and 
reasons for ceasing, as well as prescribing details for each drug prescribed 
including date of prescription, dosage form, dose, strength and frequency of 
administration. Drugs were classified as off-label using an exclusivity 
hierarchical system based on age, indication, route of administration and 
dosage. All drugs were classified according to the WHO Anatomical 
Therapeutic Chemical (ATC) code. Standard statistical tests were applied. 
 
To provide data for currently used unlicensed formulations, the stability of 
lincomycin was investigated under accelerated storage conditions and at 
various pH values. The stability of lincomycin was also tested at 25 C in IV 
solutions including sodium lactate (Hartmann's Solution), 0.9% sodium 
chloride solution, 5% glucose solution and 10% glucose solution. 
 
Results 
 
A total of 1037 paediatric patients were included in the study, of which the 
majority were males (607; 58.5%). The age of patients ranged from newborn 
up to and including 18 years. Most records (403; 38.9%) were from the 
Emergency Department (36.6% outpatients; 24.5% inpatients) and a majority 
in each setting was males (57.8% Emergency Department; 65.4% inpatients; 
54.7% outpatients).  
 
A total of 2654 prescriptions for 330 different drugs were prescribed to 699 
patients (67.4%). The ATC category with the largest number of drugs was the 
nervous system (n = 1034; 39.0%). Of all drugs prescribed, 1905 (71.8%) 
were licensed, 681 (25.7%) were off-label and 68 (2.6%) were unlicensed so 
the overall extent of off-label and unlicensed prescribing was 28.3%. The 
ATC categories with a majority of off-label drugs (n = 295; 43.3%) were the 
nervous system and the alimentary tract (n = 139; 20.4%). The drugs most 
commonly prescribed in these categories were Painstop®, oxycodone, 
paracetamol and ondansetron. The ATC categories with a majority of 
unlicensed drugs were systemic hormonal preparations excluding sex 
   v 
hormones (n = 22, 32.4%) and sensory organ drugs (n = 13, 19.1%). The 
most commonly prescribed drugs in these categories were dexamethasone 
and dilacaine, both of which were hospital formulations.  
 
Inpatients were prescribed more off-label drugs than outpatients or 
Emergency Department patients (p < 0.0001). The highest percentage of off-
label prescribing occurred in infants (28 days to 23 months) and children (2 to 
11 years) (31.7% and 35.9% respectively) and the highest percentage of 
unlicensed prescribing (7.2%) occurred in infants (28 days to 23 months). 
The results were significant (p < 0.0001).  
 
The most common reasons for off-label prescribing were dosage (47.4%) 
and age (43.2%). Overall, the ten most commonly prescribed off-label and 
unlicensed drugs were ondansetron, Painstop Day®, salbutamol, oxycodone, 
paracetamol, midazolam, fentanyl, dexamethasone, ticarcillin with clavulanic 
acid and amoxicillin.  
 
The sample of lincomycin hydrochloride (Lincocin®) under investigation was 
found to meet the British Pharmacopoeia specifications for lincomycin 
content. Stability studies of 0.6 mg/mL lincomycin hydrochloride in 0.1 M 
hydrochloric acid solution, 0.1 M sodium hydroxide solution and 3% hydrogen 
peroxide solution at 60 C showed that degradation occurred most rapidly in 
hydrogen peroxide suggesting that lincomycin hydrochloride readily 
undergoes oxidation. Lincomycin hydrochloride was found to be stable in 
sodium lactate (Hartmann's) solution, 0.9% sodium chloride solution, 5% 
glucose solution and 10% glucose solution, with only a small proportion 
degrading over the 31 day period at 25C. Lincomycin hydrochloride had the 
greatest stability at pH 4.00, with a calculated shelf-life of 4.59 days at 80C. 
It was least stable at pH 2.00, with a calculated shelf-life of 0.38 hours at 
80C. 
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Conclusion 
 
This is the first random sample of off-label and unlicensed prescribing from a 
major teaching hospital. The findings provide a sound assessment of off-label 
and unlicensed prescribing in Australia. Particularly in inpatients, off-label 
prescribing was found to be high, with lower levels in outpatients and 
Emergency Department patients. This indicates that many patients when 
admitted to hospital will be exposed to drugs, doses or formulations which 
have not been evaluated for licensing in that paediatric population. 
 
Most of the commonly prescribed off-label and unlicensed drugs have been 
on the market for many years and have had a lengthy time for evaluation in 
paediatric patients, yet despite this, adequate data is lacking worldwide. An 
international evaluation committee should be established to evaluate current 
published data to provide evidence for efficacy, dosage and adverse drugs 
reactions in paediatric patients. 
 
Data on the stability of lincomycin hydrochloride have provided some 
evidence base for its unlicensed administration to children. 
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1.1 What the PhD is addressing 
 
Prescribing of off-label or unlicensed drugs exposes patients to medications 
that have not been independently evaluated for safety, quality and efficacy in 
that patient population. Infants and children, because of developmental 
pharmacokinetics and variable weight are more susceptible to adverse 
effects from such treatments. Although a number of studies have been 
published these have usually examined specific classes of drugs. This 
project is designed to describe the prevalence of off-label and unlicensed 
drug use, to identify drugs most commonly used off-label or unlicensed, and 
to identify factors associated with off-label or unlicensed drug use in a 
randomly selected Australian hospital paediatric population. It will also 
examine variables such as age, dose for age and any reported adverse 
effects of selected drugs from the study, since many drugs undergo 
metabolism by enzyme systems that change with age. This study will 
specifically investigate off-label prescribing in paediatric patients at Princess 
Margaret Hospital in four age groups defined for the paediatric population. 
 
Further, due to a lack of stability data of lincomycin in IV fluids, this thesis will 
provide evidence regarding the stability of lincomycin in various buffers and 
various IV fluids. These data are also useful when formulating preparations 
with respect to where the optimum pH maximum stability occurs. In addition, 
it provides essential stability data relevant to the safety of use of lincomycin. 
 
The research work was designed to achieve the following objectives: 
 To analyse the prevalence of off-label and unlicensed use of 
medicines in a Western Australian paediatric hospital with respect to 
the type of patient and drug classification. 
 To analyse the data for those drugs frequently used in an off-label or 
unlicensed manner. 
 To analyse the data for which age groups are most commonly 
associated with off-label and unlicensed prescribing. 
 To determine the stability of lincomycin in solution and in various IV 
fluids. 
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1.2 Introduction 
 
In 1999, the National Medicines Policy (NMP) was launched to improve 
positive health outcomes for all Australians through their access to and 
judicious use of medicines. The Therapeutic Goods Administration (TGA), 
which is the regulatory body for therapeutic goods and a division of the 
Australian Department of Health and Ageing established under the 
Therapeutic Goods Act in 1989, has a key role in the implementation of the 
NMP and is responsible for monitoring activities and conducting assessments 
to ensure that therapeutic goods available in Australia meet acceptable 
standards. In Australia, it is a requirement that drugs are licensed by the TGA 
to ensure that all new drugs meet requirements for efficacy, safety and 
quality.1 The Australian Register of Therapeutic Goods (ARTG) lists goods 
that have been evaluated and approved by the TGA. Therapeutic goods are 
defined as products for use in humans that influence the inhibition or 
modification of a physiological process; prevent, diagnose, cure or alleviate a 
disease, ailment, defect or injury or test the susceptibility of persons to a 
disease or ailment.2 Drugs to be listed on the ARTG  require a sponsoring 
company to make an application with supporting data on the quality, safety 
and efficacy of the product for its intended use.3 A similar process must be 
followed for paediatric drugs listed on the ARTG.  Any goods that are not 
listed are unregistered or unlicensed medicines. The term ''unregistered'' is 
often used interchangeably with ''unlicensed'' as overseas, drug approval is 
usually through a licensing process whereas in Australia, the process is one 
of registration.  
 
Many of the drugs used in children have either been not licensed for use in 
children (unlicensed) or have been prescribed outside the terms of their 
product license (off-label prescriptions) and dosages are often extrapolated 
from data obtained from adult trials.4 Developmental changes that occur with 
age influence the pharmacokinetic and pharmacodynamic effects of drugs. 
Because of these effects, data such as doses or toxicity extrapolated from 
clinical studies in adults may be inappropriate for children.5  
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1.3 Pharmacokinetic and pharmacodynamic changes in paediatrics 
 
Pharmacokinetic responses to drugs, such as drug absorption, metabolism, 
distribution and elimination, are substantially different in children compared to 
adults. These responses change with growth and maturation. For regulatory 
purposes, the International Commission on Harmonisation has defined the 
paediatric population into five distinct groups which broadly represent the 
ages at which the major changes in physiological, pharmacokinetic and 
pharmacodynamic parameters occur during development. These groups 
include preterm newborn infants (< 37 weeks gestation), term newborn 
infants (zero to 27 days), infants and toddlers (28 days to 23 months), 
children (two to 11 years) and adolescent (12 to 16 or 18 years of age, 
dependent on region).6 
 
1.3.1 Absorption  
 
Developmental changes in the paediatric population can affect the rate and 
extent of absorption from the gastrointestinal tract. As an infant grows into an 
adult, these factors undergo considerable maturational changes. In the 
newborn infant, the gastric pH is alkaline (pH 6 to 8) and changes to an 
acidic pH (1.5 to 3) over the next 24 hours.7 Acid concentrations and the 
volume of gastric juice do not reach adult levels until after two years of age 
and can influence the bioavailability of drugs. For example, H2-antagonists 
such as ranitidine can increase gastric pH and reduce the bioavailability of 
acidic drugs such as itraconazole whereas orange juice and carbonated 
drinks decrease gastric pH and increase the bioavailability of acidic drugs.7 
Milk and infant formula can also decrease the absorption of acidic drugs by 
increasing gastric pH. Gastric emptying rate is considerably delayed in 
infants and does not reach adult levels until six to eight months of age. Since 
most orally administered drugs are absorbed from the small intestine, the 
shorter gastric emptying time leads to a faster rate of absorption.7  
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1.3.2 Distribution  
 
Volume of distribution of drugs in children changes with age because of 
changes in body composition (especially the extracellular and total body 
water spaces) and plasma protein binding. Body composition changes most 
dramatically during the first year of life but changes continue through puberty 
and adolescence, especially in terms of total body fat.8 In a full-term neonate, 
total body water is approximately 75% and decreases to 60% (25% is 
extracellular and 35% is intracellular water) by one year of age. Adult values 
of 50 to 60% (20% extracellular and 40% intracellular water) are not reached 
until about 12 to 13 years of age.7 Due to the relatively large extracellular and 
total body water spaces in neonates and infants compared to adults, 
hydrophilic drugs such as aminoglycosides, have larger apparent volumes of 
distribution but lower plasma concentrations for the same weight-based 
dose.8 Therefore, in order to achieve recommended peak concentrations of 
aminoglycosides, larger milligram-per-kilogram doses are required.7 At full-
term, total body fat makes up 12 to 16% of body weight and increases to 20 
to 25% at one year of age. Total body fat increases rapidly in females at 
puberty and approaches twice the value of body fat compared to males. 
Therefore, children and adults will have a larger volume of distribution of 
lipophilic drugs than neonates and infants due to a higher percentage of body 
fat.7 
 
Plasma protein binding is altered in neonates and young infants due to the 
amount and composition of circulating plasma proteins. The important drug-
binding proteins include albumin, lipoproteins and alpha-1-acid glycoprotein. 
On average, albumin makes up 58% of all plasma proteins but in neonates 
and infants, the quantity of albumin and total plasma proteins are reduced.8   
Adult values of the total protein concentration including serum albumin and 
alpha-1-acid glycoprotein are not reached until one year of age and remain 
consistently stable in healthy children between two and 18 years of age.7 
Binding affinity for albumin is pronounced for acidic and neutral drugs such 
as digoxin, warfarin and beta-lactam antibiotics. Basic drugs such as 
propranolol bind to lipoproteins and alpha-1-acid glycoprotein.7 Only the free 
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fraction of drug, i.e. non-protein bound drug in the plasma, is able to 
distribute to its site of action. For drugs that are highly protein bound, only a 
small percentage will exist as the free fraction. Hence small changes in the 
binding of the drug can make a large difference to the free drug 
concentration.8 
 
1.3.3 Metabolism 
 
The liver is the principal organ of drug metabolism but the kidneys, intestine, 
lungs and skin may also be involved. Most drugs that are metabolised are 
converted to more water-soluble compounds for enhanced excretion from the 
body by the kidneys.9 At birth the majority of enzymes are either absent or 
present in considerably reduced amounts compared with adult values and 
evidence indicates that the various systems do not mature at the same 
time.10 
 
The two main enzyme systems involved in drug metabolism are phase I and 
phase II reactions. Phase I reactions include hydrolysis, reduction, oxidation 
and hydroxylation that usually convert the parent drug to a more polar 
metabolite by introducing or unmasking a functional group for a phase II 
conjugation reaction.9 In phase II reactions, the substrate may be conjugated 
with endogenous agents such as glutathione, glucuronic acid, glycine, 
acetate and sulfate to produce a more polar compound that can be 
eliminated easily by the renal and/or the biliary system.  
 
The cytochrome P450 family are the most important phase I enzymes with 
CYP1, CYP2 and CYP3 genes being important in human drug metabolism.  
The activity of a number of cytochrome P450 enzymes, including CYP2D6, 
CYP2C19, CYP2C9 and CYP3A4 is significantly reduced in the neonate. The 
activity of CYP3A4 in neonates is 30 to 40% that of adult activity, reaches an 
adult pattern by six months of age, increases between the age of one to four 
years and then gradually changes to adult levels during adolescence. The 
activity of CYP2C9 is reduced in the neonate, reaches adult levels by one to 
six months of age, increases with peak activity from three to 10 years and 
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decreases to adult values at puberty.7 This has the potential for 
pharmacokinetic consequences when drugs act as substrates for these 
enzymes. For example, phenytoin is a substrate for CYP2C9. In preterm 
infants, the elimination half-life of phenytoin is approximately 75 hours, 
decreases in term infants to 24 to 48 hours and in infants two weeks after 
birth, it decreases further to approximately eight hours.8  
 
The phase II enzymes consist of sulfotransferases, glucuronosyltransferases, 
arylamine N-acetyltransferases, methyltransferases and glutathione S-
transferases, all of which play an important role in biotransformation of 
drugs.7 Important differences exist between children and adults, and phase II 
enzymes do not follow the same development patterns.  
 
The reduced metabolism rates at birth are followed by a dramatic increase in 
metabolism rates in the older infant and young child, and the metabolic 
clearance of many drugs, including carbamazepine, phenytoin and 
theophylline, in the one to nine year age group is greater than in adults.10 
 
1.3.4 Elimination 
 
Excretion of drugs or their water soluble metabolites is mainly via the 
kidneys. Developmental changes in renal function, especially glomerular 
filtration, tubular secretion and reabsorption all impact on the renal 
elimination of drugs.7 There is a dramatic increase in glomerular filtration rate 
(GFR)  from birth due to changes in renal blood flow and GFR approaches 
adult values by approximately three to five months of age.7, 8  Renal tubular 
secretion increases more slowly but at eight to 12 months of age both 
glomerular and tubular function are close to values seen in adults.8   Renally 
excreted drugs, especially those with a narrow therapeutic range, should be 
based on the patient’s renal function to avoid toxicity due to decreased 
elimination and increased accumulation.7 
  
   8 
1.3.5 Pharmacodynamics 
 
Studying the pharmacodynamic effects of interactions between drugs and 
receptors in younger patients may be difficult although for some conditions, it 
may be relatively straightforward,  e.g. seizure control in a child with epilepsy. 
For others, e.g. assessment of pain relief in neonates, it may be much more 
challenging. Pharmacodynamic determinants may also be related to age-
dependent differences in the severity of adverse drug reaction (ADRs) such 
as increased liver toxicity of valproic acid in infants.8 
 
The choice and dosage of medicines in various age groups is influenced by 
developmental changes that affect the bioavailability, pharmacokinetics and 
pharmacodynamics of drugs, especially in early childhood. In children, in 
many cases the only medicines available have not been clinically tested for 
safety, efficacy and dosage for the age group for which they are used.8 
 
 
1.4 Past tragedies 
 
Several drug-related tragedies spurred the introduction of drug licensing 
processes around the world to ensure that drugs were shown to be safe and 
effective for their specific indications.11 In 1937 the death of 107 people, 
mainly children, was attributed to ingestion of sulfanilamide elixir that used 
diethylene glycol, also known as antifreeze, as a solvent.12, 13 No toxicity 
testing had been done on the product prior to marketing.14 The mechanism of 
some drug-related tragedies has been explained through pharmacokinetic 
studies, such as kernicterus after use of sulfonamides and gray baby 
syndrome after use of chloramphenicol.15 In neonates and infants with 
increased erythrocyte destruction and limited liver capacity for conjugation, 
bilirubin levels may be increased. Due to a decreased binding capacity of 
bilirubin to plasma albumin, bilirubin may be displaced from plasma protein 
binding sites by drugs that are highly bound to plasma proteins such as 
sulphonamides, thereby contributing to kernicterus.7 Kernicterus results from 
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the penetration of bilirubin into the central nervous system (CNS) nerve 
tissues and damages mitochondria.16 Gray baby syndrome has caused 
deaths in neonates treated with chloramphenicol when doses which 
exceeded the underdeveloped hepatic metabolism of the neonate were 
used.17 Chloramphenicol is eliminated via two important mechanisms - 
inactivation through conjugation with glucuronic acid and excretion of free 
chloramphenicol by glomerular filtration and the glucuronic acid conjugate by 
tubular excretion. In the newborn, deficiencies in the conjugating system and 
poor renal function result in toxic levels of chloramphenicol.17, 18 
 
In the United States (US), the Drug Laws of 1962 were introduced after the 
thalidomide catastrophe, which resulted in foetal malformations after 
exposure of the unborn foetus to thalidomide during pregnancy.14, 19 By 'legal' 
definition, drugs introduced since 1962 had to be safe and effective in the 
population for which they were to be marketed.19 The safety and efficacy in 
one population could not be transferred to another. Thus safety and efficacy 
in adults cannot be applied to children.14 Despite these laws, children have 
often been likened to 'therapeutic orphans', a term first coined by Shirkey in 
1968 due to the lack of pharmacokinetic, pharmacodynamic, efficacy and 
safety studies necessary for this population to be provided with safe and 
effective drug therapy.19  
 
 
1.5 Criteria for off-label and unlicensed prescribing 
 
Unlicensed and off-label prescribing is not illegal and may sometimes be 
clinically appropriate. However, the definition of off-label and unlicensed drug 
use of medicines varies across the literature, with some studies considering 
only one type of off-label use and others considering up to seven.20 The 
methods used to assess off-label and unlicensed prescribing also vary 
between studies, making direct comparisons difficult.21 
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The most common definitions, as used by Turner et al.22-24, describe off-label 
drug use as the use of a registered drug in a manner not listed in the 
approved product license with respect to age, dose, indication or route of 
administration. Some researchers also include drugs that are used when 
contraindicated in the definition of off-label.25 
 
Medicines may be prescribed outside the age range for which they are 
licensed by regulatory authorities. For example, the product information for 
midazolam, a benzodiazepine with anxiolytic properties, states that safety 
and effectiveness in children below the age of eight years have not been 
established.26-29 Despite this, midazolam is frequently used off-label in 
children below this age.22-24  
 
Medicines may be given at doses higher or lower than the approved range or 
they may be administered more frequently than approved. For example, the 
product information for salbutamol metered dose inhaler states that the adult 
and child dose is one to two inhalations, which may be repeated every four 
hours. In the hospital setting, higher frequencies are often used, in the range 
of six to 12 inhalations administered half hourly to four hourly, which is then 
off-label use.22-24  
 
Medicines may be used for indications that are not stated in the approved 
product information. While medicines are initially registered for specific 
indications, circumstances may arise where the drug is used for treating 
other conditions. Supporting evidence at various levels of validity for 
additional indications may have been reported in the literature but often the 
manufacturer's product information is not updated to reflect this. For 
example, clonidine is indicated for hypertension, migraine or recurrent 
vascular headache prophylaxis and menopausal flushing, however, in 
children it is often used as an analgesic or in the treatment of Attention Deficit 
Disorder.30 Despite not being approved for these indications in children, 
several studies have supported its benefits in the literature.31, 32  
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Medicines may be administered by an unapproved route for a particular 
formulation. For example, to avoid pain and discomfort to a patient, an 
injection solution may be administered orally rather than parenterally. This 
usually involves breaking an ampoule and administering the solution by 
mouth (e.g. midazolam injection administered orally) or as inhalation (e.g. 
tobramycin injection used as inhalation in cystic fibrosis).22-24  
 
Manufacturers often add disclaimers in the product information regarding the 
use of a drug in children, which can complicate the designation of the drug as 
off-label. For example, the product information for clobazam states that the 
drug is 'not recommended for children', despite evidence in the literature to 
support its use for seizures in children.30, 33 These types of disclaimers and 
absence of guidance were described by Shirkey more than 40 years ago as 
'orphaning' clauses.19 
 
According to Turner et al.22 an unlicensed drug is defined as the use of 
medicines without a product license or marketing authorisation. Categories of 
unlicensed drug use include formulation modifications to licensed drugs, 
drugs that are licensed but manufactured in a particular formulation under a 
special license, use of chemicals as drugs, new drugs available under a 
special manufacturing license, drugs used before a license has been granted 
and imported drugs (where a drug is licensed in another country).22  
 
Modification to or reformulation of registered (licensed) drugs is usually 
considered as producing an unlicensed formulation, which would not be 
registered with the TGA. Many licensed adult dosage forms, such as tablets 
and capsules, are inappropriate for use in children because they cannot 
easily be swallowed. A study by Tan et al.34 reported that, despite specific 
paediatric dosing information being provided in the Australian Monthly Index 
of Medical Specialities (MIMS)30, many of the medicines were not available in 
dosage forms appropriate for children. In order to obtain a suitable dose, 
crushing licensed tablets or opening a capsule and using the contents to 
prepare a suspension may be used.35 For example, preparing an omeprazole 
suspension from tablets or capsules (both of which are registered 
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formulations of omeprazole) would produce an unregistered (unlicensed) 
formulation which has not been approved by the TGA.24 
 
Medicines may be prepared extemporaneously by pharmacists compounding 
raw ingredients/chemicals according to a formulation published in a 
pharmacopoeia (e.g. British Pharmacopoeia)36 or other reference (e.g. 
Australian Pharmaceutical Formulary and Handbook).35, 37 However, relevant 
pharmaceutical analysis or quality assurance data, as well as bioavailability 
data and information on the stability of the product, is usually limited or not 
available.38 A study in the UK  investigating the inter-hospital constancy of 
captopril formulations used to treat children with heart failure, found that a 
wide variety of  unlicensed and untested liquid captopril formulations were 
used interchangeably without sufficient evidence of bioequivalence.39 
 
Pharmacists can prepare medicines extemporaneously. As part of the 
Therapeutic Goods Regulations 1990, compounding of formulations for an 
individual patient and an individual purpose by a pharmacist is excluded from 
the registration requirements of the Therapeutics Goods Act 1989.2 However, 
unlicensed drugs can also be prepared extemporaneously by TGA-licensed 
manufacturers of therapeutic goods. Novel formulations, such as caffeine 
injections for apnoea of prematurity may not be commercially viable for a 
manufacturer to take through the regulatory process, so licensed 
manufacturers in hospitals, that provide a greater level of quality assurance, 
are able to prepare a range of paediatric products.24  
 
In some circumstances, when there is no registered drug available and no 
pharmaceutical material of recognised standard, a non-pharmacopoeial 
substance or chemical may be used as a medicine.24 Examples include 
copper and zinc sulfate as dietary supplements and arginine used in the 
management of metabolic disorders.1, 24 
 
In some situations, where patients require access to therapeutic goods that 
are not listed on the ARTG, access may be obtained through the Special 
Access Scheme (SAS). The SAS provides access to unregistered drugs 
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which are awaiting approval in Australia or which may be registered overseas 
and unlikely to be registered in Australia on a single patient basis. With the 
exception of drugs of abuse, any unapproved therapeutic good can 
potentially be supplied by the SAS.40 'Personal Importation' also allows an 
individual to import unapproved therapeutic goods for personal use, unless 
prohibited by other laws.41 
 
 
1.6 Studies in off-label and unlicensed prescribing 
 
Unlicensed and off-label prescribing is a global phenomenon particularly 
involving paediatric drugs and formulations. The use of off-label and 
unlicensed medicines is usually reported in two ways. The percentage of 
studied children who have been given at least one off-label or unlicensed 
medication describes the prevalence whereas the percentage of individual 
prescription items that meet off-label or unlicensed criteria describes the 
frequency (or extent) of off-label and unlicensed prescribing. The extent of 
off-label and unlicensed prescribing in paediatrics has been reported to range 
from 7 to 60%, with 28 to 100% of paediatric patients receiving at least one 
off-label or unlicensed drug.  
 
Several retrospective and prospective studies have been conducted in 
different countries across the world. A summary of 35 studies that have 
reported the frequency of off-label or unlicensed prescribing from different 
patient types and various hospital settings including outpatients in a general 
paediatric ambulatory unit, medical and surgical wards, wards with several 
different paediatric specialities such as respiratory, gastroenterology, 
cardiology, neurology, nephrology, neonatal intensive care units (NICUs), 
medium care units, paediatric intensive care units, oncology inpatients and 
outpatients and Emergency Departments is provided in Appendix 1. Most of 
the studies were prospective (n = 25) and study periods ranged from four 
weeks to three years. The number of patients investigated ranged from 34 to 
1,708,755 and age ranged from preterm and newborn to 20 years, although 
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in one study 23 adult patients aged between 19 to 40 years were included.42 
Some studies have involved only specific patient types e.g. neonates or 
infants,1, 11, 43-45 oncology patients, gastroenterology or pain management.46-
49 Some studies investigated adverse drug reactions associated with off-label 
or unlicensed drug use.23, 50 In the hospital setting, the proportion of children 
that receive off-label or unlicensed drugs has been shown to be higher in 
intensive care units (ICUs) and in those with complex diseases. 
 
1.6.1 Studies in NICUs and other ICUs 
 
The highest prevalence of off-label and unlicensed prescribing has been 
reported in ICUs.1, 11, 23, 43-45, 51 Only five studies in the UK, France, Australia, 
Israel and Italy were exclusively in NICUs.1, 11, 43-45 The percentage of off-
label prescriptions reported in these five studies ranged from 47 to 63% and 
the percentage of unlicensed prescriptions ranged from 10 to 16%. The 
studies, conducted over four weeks to four months, included between 34 to 
105 neonates, found that the number of patients receiving off-label or 
unlicensed drugs ranged from 51% to 90% although in one study 93% of 
patients received off-label drugs.45  
 
In a prospective 13 week off-label and unlicensed study of patients admitted 
to neonatal intensive care in the UK, 70 patients (of which 49 were premature 
babies) received a median of 3.5 prescription episodes.43 Of the total 455 
prescription episodes, 54.7% were off-label, 9.9% were unlicensed and 90% 
of babies received at least one off-label or unlicensed drug. The ten most 
commonly administered drugs were gentamicin, benzylpenicillin, folic acid, 
Dalivit® (multivitamins), albumin, vitamin K, frusemide, caffeine, flucloxacillin 
and morphine. The most common off-label and unlicensed drugs were 
benzylpenicillin, folic acid, Dalivit® (multivitamins), vitamin K, caffeine, 
flucloxacillin, albumin, gentamicin, morphine, glycerin, sodium chloride, total 
parenteral nutrition (TPN). The authors concluded that off-label and 
unlicensed prescribing in the neonatal intensive care setting was far greater 
than in older children. 
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Similar findings were reported in a prospective study in a NICU in France 
which included 40 babies with a gestational age between 25 and 40 weeks, 
of which 88% preterm newborns had a birth weight lower than 100g.44 A total 
of 257 prescriptions, involving 55 different medicines, were administered, 
mostly antibacterial drugs, analgesics and drugs for respiratory diseases. Of 
the prescribed drugs, 62% were off-label for premature infants and 64% for 
newborns, most being off-label for age. The researchers reported that there 
were no therapeutic alternatives available. Testing drugs for registration for 
premature babies is very limited and guideline development in this situation 
may be a better option. 
 
Other studies have reported similar findings. A ten week prospective study 
involving 97 infants (with a gestational age was between 23 to 41 weeks) in a 
NICU in Australia, reported the median number of prescriptions that each 
infant received was seven.1 Of the total number of 1442 prescriptions 
(involving 69 different drugs), 47% were off-label, 11% unlicensed and 80% 
of infants received an off-label or unlicensed drug or both, but this proportion 
rose to 93% in extremely low birth weight infants. The ten most commonly 
used drugs were gentamicin, morphine, vancomycin, benzylpenicillin, 
theophylline, aminophylline, frusemide, vitamin K, 6% sodium chloride and 
phosphate. The most frequently used off-label drugs were morphine (for 
which the safety and efficacy in neonates have not been established), 
theophylline (which is not indicated for prevention or treatment of apnoea of 
prematurity), aminophylline (which is not indicated for prevention or treatment 
of apnoea of prematurity), phosphate (which is not indicated for prevention or 
treatment of osteopenia of prematurity), dobutamine (which is not indicated 
for treatment of hypotension in neonates), paracetamol (administration to 
infants under one month of age is not recommended), dopamine (which is 
not indicated for treatment of hypotension in neonates) and phenobarbitone 
(which is not recommended in neonates). The most frequently used 
unlicensed drugs were 6% sodium chloride, which was an 'in-house' product, 
and spironolactone, which was unlicensed due to modification of a licensed 
product. The researchers reported that in Australia, as in the UK, the 
incidence of off-label and unlicensed prescribing in NICUs was greater than 
   16 
among patients on general medical and surgical wards. The researchers 
stated that the frequency with which some drugs, such as morphine, 
methylxanthines and inotropes were used in an off-label or unlicensed 
manner, without other suitable alternatives, highlighted the need for the 
provision of evidence based data or registration.1 
 
A two month prospective study involving 19 preterm and 15 term newborns in 
Italy reported a median of 5.5 prescriptions per patient.11 Of 176 
prescriptions, 12% were unlicensed and 50.5% off-label. Drugs most 
frequently used off-label and unlicensed included parenteral nutrition 
infusion, amikacin, ranitidine, tobramycin, ofloxacin, calcium levofolinate, 
caffeine and sodium ferric gluconate complex. The most common cause for 
use in an off-label manner was that a higher dose than recommend by the 
manufacturer was used and related mainly to systemic antibiotics.11 
 
Similar findings were also reported from Israel where a prospective study in a 
NICU where 105 neonates were reviewed every two weeks during a four 
month period.45 Researchers reported that of 525 medications administered, 
59% were off-label and 16% unlicensed. Further, 93% of patients received at 
least one off-label medication. The main reasons for off-label prescribing 
were dose and age. Drugs prescribed off-label or unlicensed included 
ampicillin, theophylline, gentamicin, cisapride, morphine, cimetidine, 
frusemide, spironolactone and thyroxine sodium.45, 52  
 
1.6.2 Other studies 
 
Other studies have been carried out across several ward categories including 
the NICU. A prospective 13 week study in the UK involved patients from five 
wards covering a variety of different paediatric specialities and studied 4455 
drug courses administered to patients aged between one day and 18 years.23 
The median number of drug courses was three and although this study did 
not distinguish between off-label and unlicensed prescribing, overall  35% of 
drug prescriptions were off-label or unlicensed and 48% of the 1046 patients 
received one or more off-label or unlicensed drugs. The highest incidence of 
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off-label and unlicensed prescribing was in the ICUs, especially the NICU, 
which reported 55% of off-label and unlicensed prescriptions.23 The most 
common drugs used off-label or unlicensed were not reported because the 
study focused on ADRs associated with off-label and unlicensed use. 
 
A study from the Netherlands across different wards including the NICUs, 
reported a higher incidence of unlicensed prescribing.53 A five week 
prospective study conducted in four hospital units (wards) reported the 
incidence of unlicensed prescribing as 62% (which was higher than reported 
in other studies) and off-label prescribing as 14% in the neonatal ICU. The 
researchers found that 90% of patients received at least one off-label or 
unlicensed drug. Although the most frequently encountered unlicensed and 
off-label drugs were cisapride, caffeine and tobramycin, in the NICU, the 
most frequently used unlicensed and off-label drugs were caffeine, vitamins 
D3 and E, ipratropium and salbutamol, tobramycin and dexamethasone.53 
Another prospective study by the same researchers, which did not include 
patients from the NICU but in which data for 293 patients (aged zero days to 
16.7 years) from a paediatric ward and neonatology unit were recorded daily 
over a five month period, also reported a relatively high incidence of 
unlicensed prescribing with 28% of drugs unlicensed and 44% off-label. 
Further, the number of patients receiving one or more unlicensed and off-
label drugs was higher in newborns and small infants (98% of patients in 
these age groups compared with 88% in all children). In this study, the most 
commonly prescribed unlicensed and off-label drugs to all children were 
paracetamol, cefotaxime, amoxicillin, caffeine, vitamin K, cisapride, folic acid, 
ipratropium/salbutamol, salbutamol and budesonide.54 Importantly, the 
researchers stated that the reason for the high percentage of unlicensed 
prescribing in the Netherlands was that hospital pharmacies were allowed to 
manufacture medications (i.e. home-label) and modify commercial 
preparations to make them suitable for administration to children. The high 
use of home-label medications (41%) was attributed to the lack of 
commercially registered flexible paediatric formulations.  
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In a four month prospective study of the use of off-label and unlicensed 
medicines in the UK in a Paediatric ICU, 166 patients (aged one day to 15 
years, 52% less than one year old) received a median of three drugs in 862 
different episodes.51 Of these 268 (31%) involved drugs that were off-label or 
unlicensed and 70% of patients received at least one off-label or unlicensed 
drug. Drugs prescribed in an off-label or unlicensed manner included 
morphine, midazolam, chloral hydrate, sucralfate, adrenaline injection, 
dopamine injection and amiloride solution.51 
 
A high prevalence of off-label and unlicensed prescribing has also been 
reported in hospital settings in Europe. In a prospective study conducted over 
six months in Switzerland involving 60 randomly chosen paediatric inpatients 
(aged three days to 14 years) from six different wards from two hospitals, of 
the 483 prescriptions reviewed, 51% followed the terms of the marketing 
authorisation but 25% were off-label and 24% were unlicensed. 55 The ten 
most frequently prescribed off-label and unlicensed drugs were morphine, 
sodium chloride injection, heparin, spironolactone, hydrochlorothiazide, 
ondansetron, captopril, mefenamic acid and potassium chloride injection. 
Patients in paediatric intensive care, who had more complex therapy, had the 
highest prevalence of off-label or unlicensed prescribing (58%). This study 
found that all patients received at least one off-label or unlicensed drug but 
infants and toddlers (one to 23 months) received more unlicensed drugs 
(33%) than other groups.55  
 
Off-label and unlicensed prescribing was also found to be common in 
Finland.20 A two week prospective study involving 141 children (aged under 
18 years), reported 629 prescriptions were received by 108 children of which 
36% were off-label and 13% were unlicensed. In this study, 76% of children 
received at least one off-label or unlicensed drug. A greater percentage of 
children in the surgical ward (91%) than in the NICU or general ward 
received off-label or unlicensed drugs (79% and 63% respectively).20  
 
In a recent eight week prospective study in Malaysia involving 194 patients 
(aged between one day to 16 years) from a NICU, paediatric ICU and a 
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paediatric high dependency unit, a total of 1295 drugs were prescribed. Of 
these, 34.1% were off-label and 27.3% were unlicensed.56 Overall, 92% of 
patients received at least one off-label or unlicensed drug (82% received at 
least one off-label drug and 44% received at least one unlicensed drug). 
Children younger than two years were more likely to receive an unlicensed 
medicine compared to older children. The three most common off-label drugs 
were gentamicin, paracetamol and glycerin suppositories. The three most 
common unlicensed drugs were ferric ammonium citrate, caffeine solution 
and folic acid syrup.56 
 
1.6.3 Specialised wards 
 
Although studies conducted mainly in ICUs have reported a high proportion 
of children receiving off-label or unlicensed drugs (80 to 100%), studies 
conducted on children in specialised wards, such as cardiology, respiratory 
and oncology, have also reported a high prevalence of off-label and 
unlicensed prescribing.4, 42, 46 In a prospective study in the UK involving 51 
paediatric oncology patients (aged 0.6 to 16.3 years) with acute 
lymphoblastic leukaemia and other malignancies, inpatient and outpatient 
prescriptions were analysed for four weeks.46 Of 569 prescription episodes, 
26% were off-label and 19% were unlicensed. All patients received at least 
one off-label drug and the maximum number of off-label or unlicensed drugs 
was 13. With respect to unlicensed drugs, 16% required modification to 
produce a suitable preparation that could be administered to a child. Drugs 
included mercaptopurine, methotrexate, thioguanine and etoposide. Although 
these drugs have been the mainstay of treatment since 1980 and are likely to 
continue to be for some time, no suitable formulations for children have been 
licensed in over 20 years.46  
 
In a prospective two year study in Belgrade in a paediatric cardiology ward 
involving 544 children (aged four hours to 18 years), 76% of patients were 
prescribed one or more off-label or unlicensed drugs.4 Of 2037 prescription 
items, 11% were unlicensed and 47% were off-label for age or dose. 
Researchers reported that unlicensed drugs were used mostly in children 
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over two years of age and although unlicensed drugs were not prescribed to 
neonates, they received most of the off-label drugs (64%). Overall, the 
greatest number (72%) of off-label (55%) and unlicensed (17%) prescriptions 
was given to children aged from two to 11 years.4 
 
In a prospective six month study in Germany of paediatric respiratory and 
cardiology wards, of 417 patients aged one day to 40 years (median age was 
3.6 years; 23 patients > 18 years), 61% of patients received at least one off-
label prescribed drug.42 Of 1812 prescriptions, 31% were off-label. The 
highest percentage of off-label prescriptions was for cardiovascular drugs, 
including beta blockers, diuretics, calcium channel blockers, antiarrhythmics, 
vasodilators and antithrombotic agents, with 34% off-label for age.42 Although 
this study included 23 (6%) adults which could have reduced the rate of off-
label prescribing, the findings were similar to those reported in Belgrade by 
Bajcetic et al. who found that 44% of all cardiovascular drugs prescribed to 
paediatric patients were off-label.4 
 
Studies investigating specific drug groups in the hospital setting have also 
reported significant off-label or unlicensed prescribing. In a four week study 
investigating the nature of unlicensed and off-label analgesic agents in 
children, it was found that of 715 prescriptions episodes analysed, 33% were 
off-label but none was unlicensed.49 Although paracetamol was the most 
common analgesic used, it was off-label for 30% of prescriptions. Pethidine 
was always used off-label, while diclofenac and morphine were off-label 98% 
and 79% of the time, respectively. The most common reason for off-label 
prescribing was dose. The number of patients included in the study and the 
percentage receiving off-label prescriptions was not included in the study.49 
 
1.6.4 Other hospital wards 
 
Several studies have been conducted in medical and surgical wards. In a 13 
week prospective study in the UK of 609 paediatric patients aged four days to 
20 years, 2013 courses of drugs were administered of which 25% were either 
off-label or unlicensed.22 The researchers reported 36% of patients received 
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one or more off-label or unlicensed drugs. The ten most commonly 
prescribed off-label or unlicensed drugs were different in the surgical and 
medical wards. In the surgical ward, they included diclofenac, morphine, 
oxybutynin, paracetamol, ranitidine, sodium bicarbonate, sucralfate, 
cisapride, folic acid and Klean-prep® (macrogol 3350 plus electrolytes). In the 
medical ward, salbutamol, ipratropium, folic acid, multivitamin drops, 
cisapride, paracetamol, frusemide, dill water, amiloride and TPN were most 
commonly prescribed off-label and unlicensed.22 
 
Similar findings were reported in a prospective study involving 200 paediatric 
patients in surgical and medical wards in Australia with 36% of patients 
reported as receiving one or more off-label or unregistered drugs and 16% of 
drugs off-label or unlicensed.24 In the surgical ward, which included urology, 
ear, nose, throat and abdominal surgery, the most commonly prescribed 
drugs were paracetamol, morphine, metronidazole and ceftriaxone, whereas 
the most commonly prescribed off-label and unlicensed drugs were 
metoclopramide, Colonlytely® (macrogol 3350 plus electrolytes), ondansetron 
and clonidine. In the medical ward, which included renal, cardiology and 
neurology, the most commonly prescribed off-label and unlicensed drugs 
were chloral hydrate, aspirin, ciprofloxacin and sodium bicarbonate.24 
 
Similar findings were reported in Croatia.57 In a 12 month prospective study 
(performed on one predetermined day each month) involving several different 
wards and 691 patients (aged one day to 20 years), 1443 prescriptions for 
198 different drugs  were prescribed for 531 patients. Of these, 13.3% were 
off-label and 11.9% unlicensed. Almost half of the patients (47.8%) received 
either off-label or unlicensed drug. Wards with the most frequent off-label and 
unlicensed prescribing were neonatology, intermediate care, ICU, 
haematology and oncology but the highest prevalence of off-label and 
unlicensed drug use was in the neonatology ward. The five most frequently 
prescribed off-label drugs were pantoprazole, esomeprazole, ranitidine, 
oxymetazoline and granisetron and the five most frequently prescribed 
unlicensed drugs were nystatin, captopril, trivalent iron, macrogol and 
valproic acid.57 
   22 
Studies in paediatric medical wards in Europe have reported a higher 
incidence of off-label and unlicensed prescribing. A four week prospective  
study to determine the extent of off-label and unlicensed prescribing in 
paediatric medical wards in five European countries (UK, Sweden, Germany, 
Italy and the Netherlands) involved 624 paediatric patients aged four days to 
16 years.58 This study found that 46% of 2262 prescriptions were off-label 
(39%) or unlicensed (7%) and 67% of children were reported as receiving an 
unlicensed or off-label drug prescription during their stay in hospital. The 
wards in the countries differed in several ways. The paediatric wards in 
Germany and Sweden had general paediatric and respiratory cases, 
whereas in the UK and Italy, wards admitted mainly general paediatric 
patients (the UK also included children with surgery) and in the Netherlands, 
the ward had mainly patients with cardiac, renal, oncology and respiratory 
disease and few general paediatric cases. Consequently, the prescribing 
habits of the five countries was reported as very different with the most 
widely prescribed drug in the UK, Sweden, Germany and the Netherlands 
being paracetamol but in Italy it was beclomethasone. The five most 
frequently prescribed drugs differed for each country but included salbutamol 
in four countries (UK, Sweden, Germany and Netherlands) and paracetamol 
in three countries (Sweden, Germany and Italy). The commonest reason for 
off-label drug use in Sweden, Germany and Italy was dose and frequency 
and in the Netherlands, it was formulation.58 
 
Studies in Brazil have also reported a high incidence of off-label and 
unlicensed prescribing.59 In a five month prospective study in Brazil in a 
paediatric public hospital ward with several different paediatric specialities 
including respiratory, gastroenterology, cardiology, neurology and 
nephrology, researchers reported the extent of off-label and unlicensed 
prescribing as 45.1% with 82.6% of children receiving at least one unlicensed 
or off-label drug. There were 17% of patients that received both an 
unlicensed and off-label drug. The study included 272 patients (aged one 
month to 14.4 years) and a total of 1450 prescriptions. The ten drugs most 
frequently prescribed off-label were folic acid, cimetidine, ceftriaxone, 
phenobarbitone, vancomycin, metoclopramide, ceftazidime, digoxin, 
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amikacin and dexchlorpheniramine. Age/ weight was the most common 
reason for off-label prescribing in children under one year of age. The three 
most commonly prescribed unlicensed drugs were captopril, nifedipine and 
ursodeoxycholic acid.59 
 
In the US, a six month prospective study in a paediatric general ward 
investigating only off-label drugs, in which 1383 prescriptions were assessed 
for 403 patients (aged three days to 18 years), 31% were reported as off-
label.60 In this study, off-label drug use was defined according to indication 
and age. The most commonly prescribed medications that lacked an 
approved indication for children were ondansetron, salbutamol and ranitidine 
and the most commonly prescribed medications that were off-label due to 
age were ketorolac, salbutamol and fluticasone.60 
 
In a retrospective multicentre study in the US investigating only off-label 
prescribing, data from 31 tertiary care paediatric hospitals were collected for 
355,409 patients via the Paediatric Health Information System, an 
administrative database that contains inpatient data from 31 not-for-profit 
tertiary care hospitals.61 In this study, 78.7% of hospitalised paediatric 
patients were found to have received at least one off-label medication but the 
researchers defined off-label drug use based solely on age criteria (i.e. off-
label use was defined as use of a specific drug in a patient younger that the 
Food and Drug Administration approved age range for any indication of that 
drug). Drugs that were commonly prescribed off-label included morphine, 
midazolam, fentanyl, neostigmine, nystatin, bacitracin, metoclopramide, 
dopamine, bumetanide, spironolactone and potassium chloride. Patients 
receiving an off-label drug were more seriously ill and thus more likely to 
receive an off-label medication compared to patients that were less seriously 
ill.61 
 
A recent retrospective study in Australia investigated only the extent of off-
label prescribing for 887 prescriptions for 106 different drugs.62 The extent of 
off-label prescribing was 32%. The study involved 300 patients (aged one 
day to 11 years) admitted to a general paediatric ward. Drugs were more 
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likely to be off-label because they were prescribed at a dosage or frequency 
greater than approved for the patient's age or weight. The most commonly 
prescribed drugs were paracetamol, ibuprofen and oxycodone. The ten most 
commonly prescribed off-label medications were paracetamol, ibuprofen, 
oxycodone, ondansetron, salbutamol, amoxicillin, flucloxacillin, cephazolin, 
benzylpenicillin and prednisolone. There were 57% that received at least one 
off-label medication. The extent of off-label prescribing in this Australian 
study in Tasmania was found to be higher than reported previously in a study 
conducted in a paediatric hospital in Western Australia where 36% of patients 
received off-label or unlicensed drugs.24 However, the results were markedly 
lower than the 80% reported by O'Donnell in a NICU in Melbourne, 
Australia.1  
 
Many studies in hospitals have involved specialised centres. However, a 
prospective study in Ireland in a non-specialised paediatric unit (ward) in 
which drug prescription charts were examined from 74 paediatric patients 
(aged one week to 13 years) on one day per week over two months, 3.4% of 
drugs were reported as unlicensed and 19.4% as off-label.25 In this study, 
43% of patients received at least one off-label or unlicensed drug. The most 
common drugs prescribed off-label included terbutaline, ipratropium, 
ranitidine, paracetamol, senna, salmeterol, cephalexin and multivitamin 
drops. The most common unlicensed drugs were cyclizine injection, 
cisapride, clonazepam and morphine/ cyclizine injection. Off-label prescribing 
was predominantly due to a different dose prescribed than in the product 
license (52%), age (24%) and indication (24%).25 
 
The extent of off-label prescribing in Italy involving non-specialised wards 
was reported to be higher. In a prospective study of 1461 children (aged one 
month to 14 years) admitted to the general paediatric wards of nine Italian 
hospitals during a 12 week period, involving 4265 prescriptions (of which 10 
were excluded as they were unlicensed drugs), the average number of drugs 
per child was 2.9.63 Only 0.2% of drugs were unlicensed but as the study 
concerned itself with off-label prescribing, these drugs, which included chloral 
hydrate, captopril, ceftriaxone, theophylline and fludrocortisone, were 
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excluded from the study. The reason for the low rate of unlicensed 
prescribing in this study was that only general paediatrics wards were 
involved rather than speciality/subspeciality wards, where unlicensed 
prescribing may be higher. The overall extent of off-label prescribing was 
60% but differed between hospitals (range 44% to 71%). Some drugs e.g. 
cardiovascular drugs, had the highest rate of off-label use, with 100% of 
prescriptions off-label. The average proportion of paediatric patients receiving 
at least one off-label prescription was 81% but this was reported as high as 
96% in one Italian hospital. The rate of off-label prescribing varied according 
to the underlying condition (i.e. it varied from a minimum of 46% for otitis 
media to a maximum of 100% for hypotension). The main reason for off-label 
prescribing was dosage. Drugs most commonly administered at higher doses 
than approved in the product license included beclomethasone, paracetamol 
and betamethasone.63  
 
1.6.5 Emergency Departments 
 
Studies have investigated the extent of off-label prescribing in hospital 
Emergency Departments. In the US, a 30 day retrospective chart review 
study involving children aged 4 days to 17 years investigated whether or not 
drugs were approved by the FDA for patient's age.64 The study, which 
included 359 patients who received medication while in the Emergency 
Department, reported that 43% of patients received one or more drugs not 
approved for use at the patient's age. This study did not investigate 
compliance of dose, indication or route of administration. Children aged three 
to 11 years made up the highest proportion of non-approved drug use. 
Medication classes most commonly associated with off-label drug use were 
bronchodilators, benzodiazepines and narcotic analgesics.64 
 
In a retrospective four year study of eight paediatric Emergency Departments 
in Italy that specifically investigated the off-label use of antiemetics in children 
with vomiting related to acute gastroenteritis, 30% of antiemetics were 
administered off-label (10% for indication and 20% for dose) to 19,879 
patients aged zero to 17 years.65 Ondansetron and metoclopramide were 
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used off-label for both age and indication in all Emergency Departments 
studied. The researchers reported that off-label prescribing was more 
common in children aged less than two years.65 
 
1.6.6 Outpatients 
 
Several studies have investigated the extent of off-label and unlicensed 
prescribing in the outpatient setting. The exposure of children to off-label and 
unlicensed medicines in outpatient settings is not as high as in NICUs (90% 
babies)43 and in paediatric general ICUs (70%)51 but since a large number of 
sick children are treated as outpatients (in ambulatory clinics), the problem is 
nevertheless significant. In a two month retrospective study in Israel, Gavrilov 
et al. reviewed the medical records of 132 outpatient children (aged one 
month to 18 years) which evaluated 222 medicine prescriptions for 63 
different drugs.66 They reported that 8% of prescriptions were unlicensed and 
26% were off-label. The ten most commonly used off-label and unlicensed 
drugs were ferrous carbonate, thyroxine sodium, cisapride, salbutamol, 
clindamycin, amoxicillin trihydrate, budesonide, aluminium hydroxide/ 
magnesium hydroxide, amoxicillin trihydrate/ clavulanic acid and captopril. 
The most common categories of off-label medicine use were different dose 
and age. There were 42% of patients that received one or more off-label or 
unlicensed drugs. The researchers reported that many paediatric patients 
received medications that were not available in liquid form for oral 
administration and that the pharmacy department crushed tablets to make 
them suitable for children. However, bioavailability and stability data are often 
not available for those preparations.66 
 
A six month retrospective study was conducted in the UK in a paediatric 
gastroenterology outpatient department and included children discharged 
home following an in-patient stay. This study involved prescription records of 
all paediatric outpatients under the care of three gastroenterologists, 
retrieved from a pharmacy database.47 A total of 308 children (aged 20 days 
to 17 years, median age 8.1 years) received 777 prescriptions, referring to 69 
different drugs for various chronic gastrointestinal diseases including irritable 
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bowel disease, malabsorption and gastroesophageal reflux. Of the 777 
prescriptions, 49% were off-label (37.5%) or unlicensed (11.9%). Reasons for 
off-label prescribing included indication and age, with the majority off-label for 
indication. Off-label medications included domperidone, ranitidine, 
omeprazole, azathioprine, tacrolimus ointment, metronidazole, mesalazine, 
polyethylene glycol, paraffin oil and tripotassium dicitrobismuthate. 
Unlicensed medications included cisapride, omeprazole suspension, 
mercaptopurine liquid and glyceryl trinitrate ointment. The extent of 
unlicensed prescribing reported in this study highlighted that chronically ill 
children treated on an outpatient basis in sub-specialities such as paediatric 
gastroenterology are most likely to require the use of unlicensed medications 
in the community setting.47 
 
Off-label prescribing was also common in the outpatient setting in Estonia. In 
a retrospective 12 month drug utilisation study based on the Estonian Health 
Insurance Fund prescription database on subjects aged below 19 years, 
Lass et al.67 reported that of 467,334 prescriptions dispensed to 151,476 
children, 31% were off-label and 0.05% were unlicensed. In this study, drugs 
were classified as off-label if there was a lack of paediatric information in the 
SPC (Summary of Product Characteristics), if the drug was contraindicated 
or if it was prescribed to a child below the lowest approved age. A drug was 
classified as unlicensed if the product had no official marketing authorisation 
in Estonia. A majority of off-label drugs did not have any information on 
paediatric use in the SPC. Anti-infectives were the most commonly 
prescribed group of drugs. This study did not report the percentage of 
patients that received off-label or unlicensed drugs.67 
 
Several studies have investigated only off-label prescribing to outpatients. A 
retrospective study in the US by Bazzano et al.68 collected data from 7901 
outpatient visits by children (aged zero to 17 years) over a three year period 
from the National Ambulatory Medical Care Survey. Characteristics of an 
estimated 312 million visits, in which at least one medication was prescribed, 
were analysed. At 62% of prescription visits, at least one off-label 
prescription for age or indication was prescribed. Approximately 96% of 
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cardiovascular-renal, 86% of gastrointestinal and 67% of pulmonary and 
dermatological medication prescriptions were off-label. The five medications 
most commonly prescribed off-label were amoxicillin, albuterol (salbutamol), 
azithromycin, montelukast and amoxicillin/ clavulanic acid. Visits by children 
aged under six years had a higher probability of off-label prescribing (p < 
0.01), especially visits by children aged less than one year and children who 
received more than one drug were also significantly more likely to receive off-
label prescriptions.68 
 
Similar findings for the extent of off-label prescribing in outpatients were 
reported in a recent study conducted in Spain.48 A 10 month retrospective 
study in a paediatric gastroenterology outpatient clinic of a tertiary care 
university hospital included 609 patients (aged 22 days to 15.6 years) with 
the most common clinical diagnoses reported as gastroesophageal reflux 
disease, constipation, inflammatory bowel disease, H. pylori infection and 
intestinal malabsorption. Two hundred and seven patients received a total of 
331 drug prescriptions, of which 33.2% were off-label. However, in children 
younger than two years, 85.5% of prescriptions were off-label. The most 
frequently prescribed off-label drugs were domperidone, ranitidine, 
omeprazole, azathioprine, tacrolimus, metronidazole, mesalazine and 
polyethylene glycol. The main reason for off-label prescribing was related to 
age. Up to 47.3% of patients received at least one medicine under off-label 
conditions.48  
 
A retrospective 10 month study in Portugal in which data were obtained for 
700 randomly selected children (aged four days to 18 years), from the 
Hospital Electronic Medical Records database reported similar trends in the 
percentage of off-label prescriptions to the study in Spain. In this study, 92 
different drugs were prescribed on 724 occasions for 427 patients.69 The 
study, which considered only the medicines prescribed to be used after 
discharge, reported that 32.2% were off-label. At least one drug was used 
off-label for 28.1% of the studied population, corresponding to 46.1% of the 
427 patients. The five most commonly prescribed off-label drugs were 
amoxicillin/ clavulanic acid, paracetamol, amoxicillin, ibuprofen and 
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salbutamol and the most common reason for off-label prescribing was 
alteration in dose.69 
 
 
1.7 Adverse drug reactions (ADRs) 
 
In a meta-analysis in paediatric inpatients and outpatients the incidence of 
ADRs in hospitalised patients was reported as 9.53% and in outpatients as 
1.46%. Polypharmacy was identified as a potential predictor of adverse 
events and researchers raised concerns about the risk of ADRs with off-label 
and unlicensed drug use.70 
 
Several studies have analysed the potential association between off-label or 
unlicensed drug use in children and the risk of ADRs. The incidence of ADRs 
has been reported to range from 2.53 to 19.9% in prospective inpatient 
studies.71 
 
In a 28 month prospective UK study at the Alder Hey Children's Hospital, 
ADRs were studied in 899 critically ill infants and children aged zero to 16 
years.72 Seventy six ADRs, involving 35 different drugs, were reported in 63 
patients, with an overall incidence of 7%. The majority of ADRs were mild but 
19 were moderately severe and 8 were severe. About one third of the 76 
ADRs were associated with drugs used outside their product license for 
dose, indication or age and one (allopurinol injection) was used in an 
unlicensed manner. The most common drug reported to cause ADRs was 
midazolam; others included morphine, salbutamol, vecuronium, 
hydrocortisone and theophylline.72 
 
In a prospective 13 week study by Turner et al. in the UK, involving 1046 
patient admissions, ADRs were more commonly associated with the off-label 
and unlicensed use of morphine, other opiates and antihypertensives/ 
vasodilators.23 The researchers reported that ADRs occurred more frequently 
in ICUs and were commonly associated with off-label or unlicensed drugs 
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(6%) compared to licensed drugs (3.9%). Of the nineteen drugs involved in 
severe ADRs, 14 were either off-label or unlicensed. Critically ill patients 
were more likely to suffer an ADR which may be because they are exposed 
to more drugs. Although the risk of an ADR was associated with the number 
of medications administered (p < 0.0001), there was no significant 
relationship between the use of off-label or unlicensed drugs and the risk of 
an ADR (p < 0.106).23  
 
In an eight month prospective study in a 10-bed isolation ward at the 
University Hospital Erlangen-Nuremberg, Germany, involving 178 patients 
aged less than 18 years, 156 patients were prescribed drugs and monitored 
for ADRs.50 The study included 740 prescriptions of which 198 were off-label 
or unlicensed. The percentage of ADRs in patients that were prescribed 
drugs was 19.9% and the incidence of ADRs increased significantly with the 
number of drugs prescribed (p < 0.05). Thirty-one patients reported a total of 
46 ADRs. Of the 92 patients that were prescribed off-label or unlicensed 
drugs, 26 patients (28.3%) experienced an ADR whereas of the 64 patients 
prescribed only licensed drugs, five patients experienced an ADR (7.8%). 
The researchers reported that ADRs were associated with 6.1% of off-label 
or unlicensed drugs and 5.6% of licensed drug however differences between 
licensed and off-label/ unlicensed drugs were not significant.50  
 
More recently, an increased risk of ADRs associated with off-label and 
unlicensed drug use was reported in a five month study in a paediatric public 
hospital ward in Brazil.59 The prospective study, involving 272 patients aged 
zero to 16 years, of which 265 patients received at least one drug, reported 
that 82.6% of children received at least one off-label or unlicensed drug and 
17% of children received both. The overall incidence of ADRs in the whole 
study population was 12.5%. In patients exposed to at least one off-label 
drug, the incidence of ADRs was 16.3%. Off-label drug use was significantly 
associated with ADRs (RR 2.44; 95% CI 2.12, 2.89). The more common 
ADRs associated with off-label use were skin eruptions.59  
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Evidence from retrospective studies is conflicting. In a retrospective study in 
Sweden investigating spontaneous ADRs involving drugs prescribed for 
outpatients younger than 16 years of age, researchers reported that 42.4% of 
ADRs were related to the use of drugs prescribed outside the terms of the 
product license.73 This is in contrast to a more recent retrospective study in 
Denmark investigating spontaneous ADRs reports for children aged zero to 
17 years, which reported that of 4388 ADRs analysed, 17% were associated 
with off-label use  and of these, 60% were serious.74 
 
ADRs for children are underreported and this may be even more common for 
off-label and unlicensed drugs. There is accumulating evidence of harm and 
an increased incidence of ADRs associated with off-label and unlicensed 
prescribing.75 The proper evaluation of some drugs that have long 
established off-label uses has shown that they are either ineffective or 
harmful. For example, as a result the Paediatric Rule legislation in America, 
paediatric studies found a higher percentage of deaths were reported in 
patients who received propofol compared with controls in the paediatric 
ICU.76  
 
 
1.8 Ethical issues in off-label and unlicensed prescribing 
 
In Australia there is no legislation that requires drug companies to conduct 
paediatric studies. However, as the Quality Use of Medicines (QUM) is one of 
the central objectives of the NMP (defined as selecting management options 
wisely, choosing suitable medicines if a medicine is considered necessary 
and using medicines safely and effectively) the Medical Journal of Australia 
published some guidelines in 2006 as a practical and explicit approach to 
assist clinicians trying to make decisions about the appropriateness of off-
label prescribing.77 
 
Up to 90% of newborn children in ICUs are prescribed off-label or unlicensed 
drugs despite the lack of regulatory demonstrated efficacy, safety and toxicity 
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including ADRs. It is not illegal in most countries and may be appropriate in 
certain situations provided there is no alternative and the likely benefits 
outweigh the potential risks.53, 71, 78 The main ethical issue is around safety 
and ADRs and relates to concerns about harm to the patient.  
 
There are a number of barriers to conducting clinical trials in children to 
determine the safety and efficacy of drugs. Whereas research to improve 
child health is now considered an ethical obligation, previously there was an 
emphasis on the need to protect children against research.79 
 
 
1.9 Barriers to developing medicines for paediatric patients 
 
Drug manufacturers are reluctant to test drugs in children because of 
economic, ethical and legal reasons yet research to improve child health is 
now considered an ethical obligation.80 The consensus to protect children 
against research has moved to a need of having reasonable evidence of both 
safety and efficacy of paediatric medicines. One of the main barriers to 
research on children's drug development is probably the limited commercial 
interest because the paediatric population is smaller and healthier than the 
adult population. Diseases in children are rarer and often of short duration 
therefore the market for pharmaceutical companies may be limited.79 There 
is also a deficient infrastructure for conducting paediatric clinical trials and 
difficulties in trial design, including ethical difficulties. As paediatric age 
groups vary from preterm neonates to adolescents, they are not a 
homogenous group so the response to therapy varies with development, size 
and maturation of biochemical pathways. For proper research to be 
conducted there may be difficulties in predicting or determining the 
concentration-response or dose-response relationship. The different age 
ranges and the effects of growth and changing physiology on drug handling 
must be taken into consideration since these can affect health, even a long 
time after the drug has been administered, especially growth and sexual 
development.78, 79 Further, formulations suitable for children, especially very 
   33 
young children, may not be available and reformulating tablets or capsules 
from adult dosage forms may result in unknown pharmacokinetic 
consequences.78, 79 
 
Similar barriers to marketing medicines and formulations suitable for use in 
children have been identified in Australia. A Paediatric Medicines - Industry 
Scoping Study which consulted 21 pharmaceutical companies of varying size 
and scope identified economic, regulatory, logistical, ethical and technical 
barriers.81 In Australia, the size of the paediatric market is limited so there is 
a relative economic disincentive for manufacturers to commit resources to 
paediatric testing due to financial concerns relating to the cost/benefit ratios. 
Further, if pharmaceutical companies do not conform to government 
regulations, they will not be allowed to supply goods. The lack of paediatric 
research infrastructure and validated paediatric assessment tools poses 
additional challenges and recruiting paediatric patients may be a slow 
process when compared to recruiting adult patients. Technical barriers 
identified related to challenges of producing and administering medicines 
appropriate for children since adult formulations may not be suitable or not 
palatable for children.81 
 
 
1.10 Regulatory aspects 
 
1.10.1 United States perspective 
 
It is only in recent years that regulatory authorities have devoted attention to 
the paediatric use of off-label or unlicensed dugs. Between 1973 to 1997 in 
the United States, around 71 to 81%  of approved drugs contained no 
labelling information for children and despite lacking adequate data on 
efficacy, safety and appropriate dosing, many drugs were administered to 
children in an unapproved manner.12, 82 The first FDA regulations on drug use 
in children were the introduction of a paediatric section in the package insert 
in 1979.21 In 1994, the "Pediatric Rule" was introduced, which allowed adult 
safety and efficacy data to be extrapolated to children in certain cases where 
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the course of the disease and the drug's effect were sufficiently similar.83 
However, the results of these initiatives were not sufficient to adequately 
address the lack of paediatric information and other measures followed. In 
1997, as part of the Food and Drug Administration Modernisation Act 
(FDAMA), a new law, known as the paediatric exclusivity provision, was 
enacted.47, 84 This law provided an additional six months of marketing 
exclusivity in return for conducting paediatric studies.76 In 1998 a mandate 
was added to the "Pediatric Final Rule" requiring paediatric drug testing for 
all new drug applications, including all new molecular entities and all 
supplemental indications for approved drugs.12 
 
In 2002, the Best Pharmaceuticals for Children Act (BPCA) renewed the 
exclusivity provision and was extended through to 2007.60 Although the 
incentive has been the driving force in stimulating paediatric research studies 
into both new and more established drugs, the ''Pediatric Final Rule'' was 
overturned by a federal court in 2002 on the grounds that the FDA did not 
have authority to mandate that paediatric drug studies are conducted by 
manufacturers. However, in 2003 the ''Pediatric Research Equity Act 
(PREA)'' was established via Congress and enforced the power of the FDA to 
require drug makers to conduct paediatric trials.21 The paediatric research 
provisions have sometimes been referred to as "the carrot and the stick" with 
the BPCA offering the carrot - extending market exclusivity in return for 
specific studies on paediatric use - and the PREA providing a stick - requiring 
studies of a drug's safety and effectiveness when used by children.80 
Nevertheless, hundreds of drug trials have been conducted in children as a 
result of the US regulations that have provided information and new 
pharmacokinetic data and dosing instructions, safety data and  critical new 
warnings.85, 86  The PREA and BPCA  have resulted in 335 written requests 
issued (1998 to July 2011), 323 marketing applications were approved with 
post marketing requirements (through May 2011) and 415 labels changed 
(1998 to July 2011).87 In 2007, the Food and Drug Administration 
Amendments Act (FDAAA) amended and reauthorised the BPCA incentive 
and PREA authority until October 2012. The FDAAA also introduced the 
''Pediatric Review Committee (PeRC)'', which includes FDA employees with 
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expertise in various areas including clinical pharmacology, paediatrics, 
paediatric ethics and legal issues, to provide the framework for the 
preparation of consultation on and general review of paediatric information to 
help ensure consistency and quality.84 
 
1.10.2 European perspective 
 
In Europe, the agency that evaluates medicinal products is the European 
Medicines Agency (EMA) which was formerly known as the European 
Agency for the Evaluation of Medicinal Products (EMEA) and established 
from 1995 to 2004. In 1997, the EMA created the "Note for guidance on 
clinical investigation of medicinal products in the paediatric population" 
describing how and when drugs should be tested in children.21 As the note 
only contained guidelines, new legislation (Regulation [EC] No. 1901/2006 as 
amended) namely the "Paediatric Regulation" governing the development 
and authorisation of medicines for use in children aged zero to less than 18 
years was introduced in the European Union in January 2007.57 By 
establishing a framework of requirements, incentives, obligations and 
rewards for pharmaceutical companies similar to the PREA in the United 
States, the legislation aims to encourage the development of medicines 
appropriately tested, authorised and formulated for use in the paediatric 
population.79, 88 As part of the ''Paediatric Regulation'', companies are 
required to submit a Paediatric Investigation Plan (PIP) to the Paediatric 
Committee (PDCO) of the EMA to reach agreement on proposed studies and 
measures to be undertaken for new medicinal products to provide data to 
enable the assessment of the quality, safety and efficacy in children and the 
benefit/risk profile in the paediatric population. The PDCO may grant a waiver 
from the obligation to undertake studies when medicinal products are 
expected to be unsafe or ineffective in children or where a particular medical 
condition does not occur in children.79 Additionally, as off-patent medicines 
are of little commercial interest to pharmaceutical companies, the Paediatric 
Regulation includes provisions for funding studies into off-patent medicinal 
products. An updated list of priorities was agreed by the PDCO in August 
2013.89 
   36 
1.10.3 WHO Initiatives 
 
Promoting safe and appropriate drugs for children is a global concern. In 
2007, the World Health Organization (WHO) launched the ‘Make medicines 
child size’ campaign to raise awareness among health care professionals, 
pharmaceutical manufacturers, policy makers, researchers and the public. In 
the same year, the first WHO Model List of Essential Medicines for Children 
was released and identified medicines that should be available for use in 
children.90 The list is updated every two years and the current list, the 4th 
WHO Essential Medicines List for Children, was updated in April 2013 and 
revised in October 2013.91 In 2010, the first WHO Model Formulary for 
Children was released allowing medical practitioners worldwide to have 
access to standardised information on how to use over 240 essential 
medicines for treating illness and disease in children.92 
 
1.10.4 Australian perspective 
 
One of the aims of the Australian government is to have equal access to 
medications for all patients. However, in the 1990's, the Australian Drug 
Evaluation Committee found that there was a lack of access to medications 
for children so in 1995 the Working Party on the Registration of Drugs for 
Use in Children was established. Although several recommendations were 
made, the lack of incentives did not encourage their uptake.3 In 1997, the 
Orphan Drug Program was established. The TGA defines an "orphan drug" 
as a medicine, vaccine or in vivo diagnostic agent that is intended to treat, 
prevent or diagnose a rare disease that is not commercially viable to supply 
to treat, prevent or diagnose another disease or condition.93 Although the 
Orphan Drug Program was not specific to children, it aimed to encourage 
drug companies to provide essential products for rare conditions to Australia, 
while ensuring the same level of safety, efficacy and quality as other products 
and involved evaluation fees being waivered for drugs with small patient 
populations (< 2000). As the concerns around paediatric medicines 
continued, the Australian Health Minister's Advisory Council (AHMAC) set up 
a working party to consider issues relating to registration of paediatric 
   37 
pharmaceuticals and appropriate access.3 This led to the establishment of 
the Paediatric Medicines Advisory Group (PMAG) by  the Department of 
Health and Ageing.94 The PMAG has identified a priority list of medicines 
requiring access for paediatric use in Australia, which is reviewed and 
updated at each meeting.3  
 
A list of priority drugs and their clinical need for consideration by the PMAG 
was prepared in one of the initial meetings in October 2007 (Table 1.1).95 As 
a result of the work by the PMAG, by 2008, clarithromycin powder and 
levetiracetam were listed on the Pharmaceutical Benefits Scheme (PBS).96 In 
an outcome statement in June 2012, the PMAG reported that as a result of 
its work, a number of new medicines had been listed on the PBS including 
arthemether with lumefantrine dispersible tablet, clarithromycin powder for 
oral liquid, cefuroxime oral suspension, fluconazole powder for oral 
suspension, lansoprazole tablet (orally disintegrating), levetiracetam oral 
solution, ondansetron syrup, tocilizumab concentrate for injection and 
voriconazole powder for oral suspension. Access to diazoxide oral 
suspension via the Special Access Scheme had improved as a result of the 
PMAG's work and there had also been several amended listings on the PBS, 
including risperidone oral solution, methylphenidate hydrochloride, 
ciprofloxacin ear drops, dornase alfa solution for inhalation, albendazole 
chewable tablets, nevirapine oral suspension, terbinafine, deferasirox 
dispersible tablet, ribavirin with pegylated interferon and atenolol 50mg/10mL 
oral liquid.97 The PMAG continues to liaise with expert paediatric groups and 
pharmaceutical companies to discuss medications on the PMAG's priority 
list. The most recent list, as at October 2012, is shown in Table 1.2.98 
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Table 1.1 - Medicines under PMAG consideration as at October 2007.95 
 
Medicine Clinical Need as agreed by the PMAG 
aciclovir suspension to treat herpes simplex infections/ prevent recurrent 
attacks of herpes simples infections 
atenolol solution beta-blocker used to treat hypertension and angina 
calciferol/ 
cholecalciferol 
vitamin D deficiency 
calcitriol drops renal bone disease 
ciprofloxacin 
suspension 
cystic fibrosis, atypical mycobacterial infections and 
urinary tract infections 
clarithromycin powder pertussis and atypical mycobacterial infections, 
particularly immunosuppressed patients 
clindamycin 
suspension 
Community acquired MRSA and osteomyelitis 
diclofenac dispersible 
tablets 
NSAID used to treat pain and inflammation 
flecainide solution used to treat cardiac arrhythmias 
fusidic acid 
suspension 
anti-infective used to treat MRSA 
gabapentin 
suspension 
used for neuropathic pain and as anticonvulsant 
melatonin tablets sleep disorders 
midazolam oral 
suspension 
sedative 
nitrofurantoin 
suspension 
antibiotic for prophylaxis and treatment of 
complicated urinary tract infections 
spironolactone 
suspension 
congenital heart disease in neonates and chronic 
lung disease 
trimethoprim 
suspension 
antibiotic for prophylaxis and treatment of 
complicated urinary tract infections 
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Another priority of the PMAG was the development of a national paediatric 
prescribing manual. This was achieved with support from the AHMAC, as 
part of the Paediatric Pharmaceuticals Prescribing Resource Project and led 
to the publication of the Australian Medicines Handbook (AMH) Children's 
Dosing Companion in 2013.99 The resource provides detailed dosing 
information for around 230 drugs and will be updated with more drugs every 
six months. Dosages are provided by indications and/or age groupings from 
toddlers to teens. Other specific information relating to each drug's paediatric 
use is included, as well as off-label use and all content is evidence-based 
and peer reviewed. Further, the Australian Medicines Handbook Children's 
Dosing Companion99 makes reference to the proposed framework published 
in the Australian Medical Journal in 2006 as a guide for clinicians and others 
for the off-label use of medicines.77 According to the article, off-label 
prescribing may be considered appropriate if there is high-quality evidence 
supporting its use, within formal research or in exceptional use in an 
individual patient (e.g. if there is a serious underlying disease or condition).77 
 
The recent initiatives in Australia with the availability of an evidence-based 
and peer reviewed paediatric prescribing information resource, the guidelines 
published in the Medical Journal of Australia and the PMAG national 
decision-making framework have led to some improvements in the use and 
access to children's medicines.77 However, despite strong professional 
advocacy on many fronts, there is still a lack of any legislative and regulatory 
reforms addressing paediatric medicines.78, 85  Unlike the United States and 
Europe, there is currently no specific government commitment to give high 
priority to paediatric medicines issues.85   
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Table 1.2 - Medicines under PMAG consideration as at October 2012.98 
 
Medicine Clinical Need as agreed by the PMAG 
abatacept polyarticular juvenile idiopathic arthritis 
adalimumab uveitis related to juvenile idiopathic arthritis, 
enthesitis and Crohn disease 
anakinra systemic juvenile idiopathic arthritis 
bosentan pulmonary hypertension 
calciferol/ 
cholecalciferol 
vitamin D deficiency 
clindamycin 
suspension 
Community acquired MRSA and osteomyelitis 
clobazam tablets resistant epilepsy 
diazepam mixture chronic spasticity 
glycopyrrolate oral 
solution 
drooling 
infliximab ankylosing spondylitis 
Kindergen® medicinal food for older children 
leflunomide juvenile idiopathic arthritis 
leuprorelin precocious puberty 
melatonin sleep disorders particularly those with neurological 
impairment/ cortical blindness 
mycophenolate 
sodium 
nephrotic syndrome 
natalizumab refractory multiple sclerosis 
6-mercaptopurine/ 
thioguanine 
suspension 
acute leukaemia 
tacrolimus suspension organ transplant 
triamcinolone 
hexacetonide 
steroid joint injections for juvenile idiopathic arthritis 
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1.11 Lincomycin 
 
An example of a drug used off-label in children is lincomycin. The safety and 
effectiveness in paediatric patients below the age of one month has not been 
established. Lincomycin injection also contains the preservative benzyl 
alcohol which has caused fatal gasping syndrome in premature infants.30 The 
use of lincomycin reconstituted with various intravenous fluids is considered 
unlicensed since this formulation is unlicensed and current use is non-
evidence based in that there are no data on the stability of these 
formulations. 
 
1.11.1 Antimicrobial activity and indications 
 
Lincomycin, a naturally occurring lincosamide antibiotic obtained as a 
fermentation product of Streptomyces lincolnensis var lincolnensis binds to 
the 50S subunit of bacterial ribosomes to suppress protein synthesis.100 Its 
action may be bactericidal or bacteriostatic depending on the concentration 
of the drug attained at the site of infection and the susceptibility of the 
infecting organism.101 It has a spectrum of activity against Gram positive 
bacteria and most anaerobes, but not Gram negative aerobes.100 It is 
indicated for the treatment of serious infections due to susceptible strains of 
staphylococci, streptococci and pneumococci and is generally reserved for 
patients who are allergic to penicillin.30 Specific indications for lincomycin 
include upper and lower respiratory tract infections, skin and skin structure 
infections such as cellulitis and abscesses, septicaemia, endocarditis, bone 
and joint infections, including osteomyelitis and septic arthritis.30 At PMH, in 
paediatrics, it is frequently used to treat surgical and medical paediatric 
patients with or at risk of non-multiresistant staphylococcal infections or those 
with complicated pneumonia and empyemas. It is also used in those allergic 
to a beta-lactam antibiotic that require empiric gram positive cover, e.g. intra-
abdominal sepsis, pneumonia.100 
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1.11.2 Chemistry  
 
The chemical name of lincomycin is methyl 6-amino-6,8-dideoxy-N-[(2S,4R)-
1-methyl-4-propylprolyl]-1-thio-α-D-erythro-D-galacto-octopyranoside.102 It 
serves as a starting material for the synthesis of clindamycin, which is a 
semisynthetic derivative of lincomycin with a closely related structure (Figure 
1.1).100 The spectrum of activity of lincomycin resembles that of clindamcyin, 
although lincomycin is generally less active against susceptible organisms 
than is clindamycin. There is complete cross-resistance between the two 
antibiotics. Partial cross-resistance has also been reported between 
lincomycin and macrolides (erythromycin).101 
 
 
 
Figure 1-1 - Structure of lincomycin and clindamycin.102 
 
Lincomycin is a basic compound in which the single amine group is tertiary 
with a pKa of 7.6. The free base is soluble in water and most organic solvents 
other than the hydrocarbons. The crystalline hydrochloride salt, which is 
freely soluble in water, soluble in dimethylformamide and very slightly soluble 
in acetone, forms hydrates.30, 103 Lincomycin hydrochloride monohydrate is a 
very stable white or almost white, crystalline powder that is odourless or has 
a faint mercaptan-like odour and a bitter taste.100, 104 Its molecular weight is 
461.0g. A 10% solution in water has an acid pH between 3.0 and 5.5 
therefore incompatibility may be expected with alkaline preparations or with 
drugs unstable at low pH.102 
Lincomycin Clindamycin 
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1.11.3 Pharmacokinetics 
 
Lincomycin is administered orally or parenterally as the hydrochloride. Doses 
are expressed as the base with 1.13g of lincomycin hydrochloride equivalent 
to about one gram of lincomycin.102 The usual adult oral dose is 500 mg three 
to four times daily. Lincomycin is rapidly but only partially absorbed from the 
gastrointestinal tract and an oral 500 mg dose of lincomycin hydrochloride 
reaches peak serum levels of two to three microgram/mL in two to four hours 
and decreases to one microgram/mL in a further four to eight hours. Total 
absorption and peak serum levels are significantly reduced by food.30, 100 In 
Australia, lincomycin is not available as oral dosage forms and is 
administered parenterally by intramuscular injection in a dose of 600 mg 
every 12 to 24 hours, or by slow intravenous infusion in a dose of 600 mg to 
one gram every eight to 12 hours.30 The dose for children over one month of 
age depends on the severity of infection and 10 to 20 mg/kg/day may be 
infused in divided doses.30, 102  
 
Lincomycin is widely distributed in a volume approximating to the total body 
water.100 It reaches insignificant cerebrospinal fluid levels in persons with 
normal meninges and attains concentrations that are approximately 40% of 
those in the blood in cases of meningitis.  
 
A substantial proportion of lincomycin is inactivated in the body, presumably 
in the liver. Bile is an important route of excretion.30 About 40% of an oral 
dose can be recovered from faeces. Less than 5% of an oral dose appears in 
the urine over 24 hours, but up to 60% after intravenous administration, 
mostly in the first four hours.100 The biological half-life of lincomycin after oral, 
intramuscular or intravenous administration is 5.4  1.0 hours.30 In patients 
with severe hepatic dysfunction, the plasma half-life is approximately 
doubled.100 
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1.11.4 Availability in Australia 
 
Lincomycin and clindamycin are both available in Australia as solutions for 
injection but only lincomycin injection (600 mg in 2 mL) is available on the 
PBS.  
 
In a discussion with the Chief Pharmacist and Head of Department of 
Microbiology at PMH, they advised that there was a lack of adequate data on 
the stability of lincomycin in systems used by the hospital. Lincomycin 
injections are extemporaneously prepared so they are currently considered 
unlicensed and there is, at the moment, no stability data available. 
 
This thesis aimed to determine the stability of lincomycin in commonly used 
IV fluids, including 0.9% sodium chloride, Hartman’s solution, 5% glucose 
solution and 10% glucose solution. To achieve this, an appropriate analytical 
technique using a reverse phase high performance liquid chromatography 
(HPLC) - mass spectrometry assay based on a method by Catena et al.105 
was developed. 
 
1.11.5 Stability studies 
 
Few studies on the stability of lincomycin seem to be available in the 
literature although a study published in 1965 reported on the acid stability of 
lincomycin at 37C and 70C to predict the stability of lincomycin in the 
stomach following oral administration.106 Solutions containing 0.4% 
lincomycin hydrochloride with 0.1 M HCl were incubated and samples 
analysed at specific time intervals. Lincomycin hydrochloride in 0.1 M HCl at 
37C showed no degradation for at least 48 hours and at 70C, it degraded 
slowly with a half-life of 39 hours.106 
 
Importantly, when lincomycin is administered intravenously, doses are 
administered on the basis of 1g Lincocin® diluted in not less than 100 mL of 
an appropriate solution and infused over a period of not less than one hour. 
Administration at greater than the recommended concentrations and rate has 
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resulted in severe cardiopulmonary reactions.30 Infusion solutions stated in 
MIMS to be physically compatible with Lincocin® include glucose 5% 
intravenous infusion, glucose 10% intravenous infusion, sodium chloride 
0.9% and glucose 5% intravenous infusion, sodium chloride 0.9% and 
glucose 10% intravenous infusion, compound sodium lactate intravenous 
infusion, sodium lactate 1/6 molar and Dextran 70 intravenous infusion.30  
However, according to MIMS "compatibility determinations of lincomycin in 
these IV fluids are physical observations only and not chemical 
determinations. Adequate clinical evaluation of the safety and efficacy of 
these combinations has not been performed".30  
 
As previously mentioned, intravenous administration of Lincocin® requires 
dilution of the 2 mL ampoule in an appropriate solution. This produces an 
unlicensed product. There is currently no mechanism for inclusion of such 
products in the product information (PI) to render the formulations as 
licensed, therefore giving rise to formulation uncertainty. The next best option 
is to provide scientific information on the compatibility and stability of such 
formulations which goes part of the way to facilitating their clinical use. 
Already lincomycin hydrochloride is reported in the American Hospital 
Formulary Service (2014)101 to be physically compatible for 24 hours at room 
temperature in commonly used intravenous fluids. However, there may be 
instances where prolonged storage of lincomycin in IV solution is required.101 
For example, in case of rural administration, several days supply of 
lincomycin in IV solutions may be needed or in the 'hospital in the home' 
setting, it may be necessary to store lincomycin in IV solution for several 
days. For these reasons, it was decided to investigate the stability of 
lincomycin in different IV solutions over 31 days in order to determine its 
potential stability. 
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Chapter 2 
2Materials and Methods 
 
 
  
   47 
Part 1 
Off-label and unlicensed prescribing 
 
2.1 Patients 
 
Medical records from Princess Margaret Hospital (PMH) from a population of 
145,550 patients seen at the hospital between 1st January 2008 and 31st 
December 2008 were sampled to obtain a random selection of 1200 records 
from Emergency Department admission, inpatients and outpatients. These 
were obtained from 55,591 records of Emergency Department admissions, 
24,425 records from inpatient admissions and 65,534 records from outpatient 
encounters. The ratio of Emergency Department patients to inpatients to 
outpatients were maintained to generate a randomly selected list of 1200 
cases. For the Emergency Department cases, the 55,991 patients were 
arrayed in Excel. Using a Randomisation process, they were randomly 
unsorted and the first 458 displaying cases copied and pasted to a new Excel 
sheet. The process was repeated for inpatients and outpatients to obtain the 
first 202 displaying inpatient cases and the first 458 outpatient cases 
respectively. In the new Excel spreadsheet, the 1200 cases were scrambled 
across the three groups from which to draw subjects and an event date in 
2008 was recorded for each record. Of the 1200 records, data from 1038 
records were collected. The reason for collecting data from this number of 
records was to give a precision of at least 2% for major findings. Each record 
had a unique identifying number that was kept by the Chief Pharmacist at 
PMH in case it was necessary to go back to any record for clarification of the 
data collected. 
 
 
2.2 Ethics 
 
A submission for approval of the project was made to the PMH Ethics 
Committee and the research was reviewed and approved by the relevant 
Hospital Quality Improvement Committee and also by the Executive Director 
for Medical Services in accordance with the National Statement 2007 (Audit 
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103QP - Prescription of off-label or unregistered medications - GEKO 1944) 
(Appendix 2). Human ethics approval was also obtained from the Human 
Research Ethics Committee at Curtin University, approval number PH-13-11 
(Appendix 3). 
 
 
2.3 Data collection 
 
A data collection form was designed and optimised during a pilot phase of 
the study to collect the following data from each medical record: ID number, 
type of patient (inpatient, outpatient or emergency), sex, date of birth, weight, 
height, diagnosis, adverse effects, past medical history, ceased medications 
and reasons for ceasing. Prescribing details of all prescription medications 
were also collected including date of prescription, dosage form, dose, 
strength and frequency of administration. Prescription medications were 
defined as any medication written onto the patient's medication chart. Data 
were entered into a Predictive Analytics SoftWare (PASW) version 19 
spreadsheet (a version of Statistical Package for the Social Sciences 
(SPSS)) for analysis. 
 
 
2.4 Classification of data 
 
2.4.1 Definition of off-label and unlicensed 
 
Following data collection, all prescribed drugs were classified as registered, 
unregistered, off-label or unlicensed according to the 2008 Product 
Information (PI) available from the Therapeutics Goods Administration (TGA) 
website107  or the Monthly Index of Medical Specialties (eMIMS).108 Drugs 
were considered as registered if a PI for the drug was listed on the TGA 
website or in eMIMS. Drugs were considered unregistered (unlicensed) if no 
PI was available.  
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A comparison was made between the PI on the TGA website107 or eMIMS108 
to determine whether prescribed drugs were licensed, unlicensed or off-label. 
Several categories of off-label prescribing were defined according to Turner:  
 
1) Age/ weight - administration of a prescription drug outside the age 
range or weight for which the product is licensed. 
2) Indication - the use for indications not described in the PI. 
3) Route of administration - the use of alternative routes of administration 
other than the approved route for that formulation in the PI. 
4) Dosage including dose frequency - the use of doses or dose 
frequencies other than those stated in the approved PI. 
 
A prescription drug was considered off-label if it met at least one of the above 
four criteria according to the TGA or eMIMS PI.107, 108 If there was any doubt 
as to whether a drug was off-label or not, to err on the side of caution, the 
drug was labelled as licensed. The same applied for uncertainty around 
unlicensed drugs. 
 
The hierarchical approach adopted by Hsien et al.42 was followed in this 
study. According to Hsien et al.42, an off-label prescribed drug cannot be 
classified into more than one classification. Therefore, in keeping with Hsien 
et al. all prescriptions were initially analysed for age so that drugs with no 
paediatric information or those prescribed in an age group for which the drug 
was not licensed were classified as off-label for age. 42 In keeping with Hsien 
et al., the next hierarchical level was indication, then route of administration 
and finally dosage (which included frequency of administration). Where the 
TGA107 or eMIMS108 PI provided a drug dose range (e.g. Painstop® 1-2 yrs 
[10-12kg]: 5-6 mL), dosages administered outside this dose range were 
considered off-label. However, where the dose provided in the TGA107 or 
eMIMS108 PI was prescribed on a weight basis e.g. paracetamol 15mg/ kg/ 
dose, a variation of  10% was accepted to allow for practical dosage 
volumes.  
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Data entry was made into the PASW spreadsheet. Prescribed drugs that 
were off-label for age plus one or more other reasons were classified as off-
label for age as this was considered the most important off-label 
classification. This was then followed by indication, then route of 
administration and finally dosage so that all PASW entries showed only the 
hierarchical off-label classification. 
 
Where a PI was available for a drug but did not include a dose for children, 
the drug was classified as off-label, regardless of whether it was reformulated 
or not. For example, a dose was not included in the PI for carbimazole so it 
was classified off-label.30, 107, 108 However, it was also reformulated to a 
suitable dosage form for a two month old child as no commercial liquid 
formulation was available. One exception was domperidone, which did not 
include a dose for children in the PI.107 However the PI stated that 
extrapyramidal reactions occur rarely in young children which was suggestive 
that it could be used in children despite the absence of a dose in the PI. As 
domperidone was reformulated, it was classified as unlicensed. 
 
A prescription drug was considered unlicensed if it was an unregistered drug, 
an unlicensed formulation of a registered drug, if a non-pharmacological 
substance was prescribed as a medicine or if the drug was obtained through 
the SAS, including drugs awaiting approval in Australia or those registered in 
another country.  Unlicensed drugs included drugs that were not available in 
a paediatric formulation and required modification to either make the drug 
easier to be administered or to obtain a suitable dose size for administration 
to a child. 
 
For all drugs that were reformulated, where the PI was available, this was 
consulted prior to classifying the drug. Some drugs were off-label for 
indication or age and were also reformulated (hence potentially classifying 
them as unlicensed). In these cases, if the PI stated that safety in children 
had not been established or that the drug was not recommended in children, 
then despite being reformulated, the drug was classified as off-label for 
purposes of data entry into the PASW spreadsheet. For other drugs, if a 
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commercially available product such as a tablet or an injectable product was 
reformulated, providing a dose for children was listed in the PI, the drug was 
classified as unlicensed. For example, propranolol is commercially available 
as 10mg, 40mg and 160mg tablets. In one case in this study, a 1 year old 
child was administered 2mg three times daily. The PI in eMIMS provides a 
children’s dose (as 0.25 - 0.5 mg/kg) therefore the drug was not classified as 
off-label. However, to achieve a dose of 2mg, PMH prepared a liquid 
formulation which was not registered and not licensed, hence the drug was 
classified as unlicensed overall. 
 
2.4.2 Patient classification 
 
In analysing the outpatient data, it was found that for 52 patients all of their 
prescribing related to their 2008 inpatient record hence these have been 
recorded as inpatients for this study. None of their current medications had 
been prescribed as an outpatient. 
 
2.4.3 Anatomical Therapeutic Chemical (ATC) classification system 
 
Prescribed drugs were classified according to the organ or system on which 
they act and their pharmacological, therapeutic and chemical properties as 
defined by the World Health Organisation's Anatomical Therapeutic Chemical 
(ATC) classification system.109 Each drug was broadly classified into one of 
the following 14 groups: 
 
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system 
D Dermatologicals 
G Genito-urinary system and sex hormones 
H Systemic hormonal preparations, excluding sex hormones and 
 insulins 
J Anti-infectives for systemic use 
L Antineoplastics and immunomodulating agents 
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M Musculo-skeletal system 
N Nervous system 
P Antiparasitic products, insecticides and repellents 
R Respiratory system 
S Sensory organs 
V Various 
 
 
2.5 Pilot study 
 
Prior to commencement of data collection from the 1038 medical records, a 
pilot study was conducted. The data collection form was used to collect data 
on 20 medical records that were unrelated to this study. The reason for the 
pilot study was to make any required modifications to the data collection form 
to ensure optimisation of data collection. Data collected from the pilot medical 
records were not included in this study as the data collected were not from 
2008. 
 
 
2.6 Preliminary analysis 
 
A preliminary analysis of data from the first 200 medical records from the 
randomised 1200 records was conducted to ensure that the original 
assumptions were still relevant to the cohort. Each medical record was 
assigned an event date in 2008 and the data collected were from that 
specified event date. If the event was for ongoing care, for example a patient 
reviewed as an outpatient following treatment of a fracture on a previous 
occasion in 2008, then data were also collected for the previous event. 
However, if a previous (but related event) occurred in 2007, then these data 
were not collected. Each drug prescribed was classified into its appropriate 
ATC classification. 
 
Where the same drug was prescribed to a patient but in a different dosage 
form (e.g. injection and oral dosage form) these were counted as two 
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separate drugs as this would have required two separate prescriptions to be 
written.  
 
 
2.7 Age classification 
 
All cases were classified according to the European Medicine Agency (EMA) 
age classification of paediatric patients:6  
 
 Preterm newborn infants. 
 Term newborn infants (0 to 27 days) - these have been termed 
neonates in this thesis. 
 Infants and toddlers (28 days to 23 months) - these have been termed 
infants in this thesis. 
 Children ( 2 to 11 years). 
 Adolescents (12 to 18 years). 
 
There were no preterm newborn infants included in this study as they are 
treated at another (maternity) hospital. 
 
 
2.8 Exclusion criteria 
 
Not included in this study were oxygen therapy, standard intravenous (IV) 
replacement solutions, blood products, flushes of NaCl 0.9% or heparin used 
to maintain patency of intravenous (IV) lines and TPN. Anyone aged 19 years 
or older was excluded from the study.  
 
Since this was a retrospective study, for any cases where there was an 
uncertainty as to whether a drug was off-label or unlicensed (for example, if it 
could not be determined whether the drug had been reformulated), then the 
drug was classified as licensed.  
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Although a diagnosis for each patient was available in all medication charts, 
the indications for use of some drugs were not always clear. For example, 
several different dosage forms of ondansetron have TGA marketing approval 
including injections, tablets, wafers, syrup and suppositories. Ondansetron 
injections, tablets, wafers or syrup are licensed for children over four years of 
age for treatment of emetogenic chemotherapy or radiotherapy. However, 
ondansetron injection only is licensed for children aged two to 12 years of 
age for prevention and treatment of post operative nausea and vomiting 
(PONV). Several children of various ages were prescribed ondansetron 
wafers or syrup. Where there was no evidence that a child over four years of 
age prescribed ondansetron wafers or syrup was undergoing chemotherapy 
or radiotherapy, it was assumed the drug was prescribed for PONV and 
classified as off-label for indication. 
 
 
2.9 Analysis of data and statistical evaluation 
 
All data were entered into PASW for analysis. The appropriateness of 
prescribing for each drug was classified based on diagnosis, drug and 
dosage schedules and the drug’s registration status with the TGA, including 
whether it was registered, registered for the indication and route of 
administration, registered for the age group and whether the dosage form 
prescribed was registered.  The use of each drug (‘status of prescribing’) was 
classified as licensed, off-label, and unlicensed according to these various 
criteria. 
 
Simple descriptive statistics were used to summarise the demographic data 
of the patients being studied (frequencies and percentages for categorical 
variables, means, standard deviations and ranges for variables measured on 
a continuous scale).  The data were collected for each patient from medical 
records and included gender, age, type of patient (inpatient, outpatient or 
Emergency Department patient) and the number of drugs prescribed.  
Univariate differences between the proportions of patients prescribed 
licensed, off-label and unlicensed drugs for groups defined by the 
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demographic data (gender, age group, ward, etc) were compared using 
Pearson's chi-squared test (‘person-based’ comparisons). In addition the 
proportions of drugs classified as licensed, off-label and unlicensed in 
different drug classes (ATC codes), and patient demographic profile was 
evaluated in a similar manner (‘drug-based’ comparisons). The drugs most 
commonly prescribed off-label and unlicensed were tabulated.  A p-value of 
0.05 or less was taken to indicate a statistically significant association in all 
tests. 
 
Linear regression analysis was used to determine the range of drugs 
prescribed and to look for variations in terms of age, diagnosis and gender. 
Data were analysed for appropriate prescribing and registration status. In 
addition the status of prescribing within specific drug classes and age groups 
was evaluated using PASW.  
 
The results from the classification of prescribed drugs into off-label and 
unlicensed categories were used to determine the extent of off-label and 
unlicensed prescribing. The extent of off-label and unlicensed prescribing in 
each ATC category was determined and drugs most commonly prescribed 
off-label or unlicensed were identified. 
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Part 2 
Lincomycin stability testing 
 
2.10 Materials 
 
2.10.1 Product investigated 
 
The product investigated for this research was Lincocin® injection containing 
lincomycin hydrochloride 150 mg/mL and benzyl alcohol 9.45 mg/mL. 
 Batch number F04815, expiry Oct 2013, Pfizer, Australia. 
 Batch number G47185, expiry Nov 2013, Pfizer, Australia. 
 Batch number G70495, expiry Sep 2014, Pfizer, Australia. 
 
2.10.2 Standard 
 
Pure analytical grade lincomycin hydrochloride monohydrate, VetranalTM 
analytical standard, expiry 24 Nov 2014, Lot SZB8329XV, Fluka, Germany. 
 
2.10.3 Materials used for buffer solutions 
 
1. Acetic acid glacial, Univar AR, Ajax Chemicals N.S.W., 
Australia 
2. Hydrochloric acid 1 M, freshly prepared. 
3. Orthophosphoric acid 85%, Batch number 10173, Analar 
Grade, Australia. 
4. Citric acid anhydrous BP. Batch number 4184E2, Ramprie, 
Australia 
5. Sodium chloride analytical reagent, Batch number 04090105, 
Lab-Scan Analytical Sciences, Thailand. 
6. Sodium hydroxide, Batch number 09G300017, Analar 
Normapur, VWR BDH Prolabo, Belgium. 
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2.10.4 Materials used for IV fluids 
 
1. 0.9% Sodium chloride, Batch number S58R4, Expiry Jun 2015, 
Baxter, Australia. 
2. Glucose monohydrate 5%, Batch number 12186410, Expiry Apr 
2015, B. Braun Pty Ltd, Australia 
3. Glucose monohydrate 10%, Batch number 14DC7301, Expiry 
Mar 2015, Fresenius Kabi, Germany. 
3. Sodium lactate (Hartmann's solution), Batch number 
122358143, Expiry May 2015, B. Braun Pty Ltd, Australia 
 
2.10.5 Materials used for HPLC mobile phase 
 
1. Acetonitrile, Batch number Lot123662, Fisher Scientific, U.S.A. 
2. 50 mM orthophosphoric acid 85%, Batch number 10173, Analar 
Grade, Australia. 
3. Sodium hydroxide, Batch number 09G300017, Analar 
Normapur, VWR BDH Prolabo, Belgium. 
 
2.10.6 Materials used for stability indicating evaluations 
 
1. Hydrogen peroxide 30%, Analytical Univar reagent, Batch 
number AF412330, Ajax Finechem, Australia. 
2. Hydrochloric acid, Analytical Reagent Grade (32% hydrochloric 
acid), Batch number 1074496, Fisher Scientific, Loughborough, 
UK. 
3. Sodium hydroxide, Batch number 09G300017, Analar 
Normapur, VWR BDH Prolabo, Belgium. 
 
2.10.7 Water 
 
Water was obtained from a Milli-Q Ultrapure water system, Millipore, 
Australia consisting of a 4-bowl ultrapure cartridge kit with conductivity of 
0.05 S.  
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2.11 Chromatographic equipment 
 
2.11.1 HPLC 
 
The High Performance Liquid Chromatography apparatus (HPLC) consisted 
of a Waters 501 HPLC Pump (USA) connected to a Rheodyne Model 7125 
(USA) syringe loading sample injector with 20 L sample loop, an ultraviolet 
detector (Waters 484, Tunable Absorbance Detector, Millipore, USA) and a 
Hewlett-Packard HP 3396 Series II integrator/ printer. Peak area was 
recorded as a measure of concentration and each unit of area was equivalent 
to 1/8 V second. A Prosphere (150 mm x 4.6 mm, particle size 5 ) and 
Apollo C18 (150 mm x 4.6 mm, particle size 5 ) reverse phase HPLC 
column were used in conjunction with a reverse phase guard column as the 
stationary phase.  
 
2.11.2 Water bath 
 
 For temperatures of 25C, a HetoFrig water bath, no 93082469 
(Denmark), with a variable temperature of -40C to 30C and 
variability of  0.1C, was used. 
 For temperatures of 60C and 80C, a Grant water bath model JB1 
(Cambridge), with variable temperature selection of 20C to 90C and 
variability of  0.1C, was used 
 
2.11.3 Thermometer 
 
Zeal thermometer, 76 mm immersion, (England) was used as to monitor the 
temperature in the water bath. 
 
2.11.4 pH meter 
 
Hanna Instruments pH meter, model HI8519N (Singapore) which was 
calibrated with standard buffer solutions according to Section 2.11.5. 
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2.11.5 Standard buffer solutions 
 
1. pH 4 ( 0.02 @ 25C), Date of manufacture 0708, Batch 
number GA1339, BioLab Australia Ltd. 
2. pH 7.00 ( 0.02 @ 25C), Date of manufacture 0209, Batch 
number Lot GH1799, Hurst Scientific Pty Ltd, Armadale, WA 
 
 
2.12 Assay methods 
 
2.12.1 Assay for lincomycin HPLC optimisation 
 
Lincocin® (lincomycin hydrochloride) (1 mL) was diluted to 100 mL with 
milliQ water and assayed by reverse phase HPLC to determine optimum 
conditions for the assay. The mobile phase used was a mixture of 
acetonitrile, 50 mM phosphoric acid and water, adjusted to pH 3.00 with 5 M 
sodium hydroxide. The mobile phase was filtered through a Millipore 0.45 m 
filter. The percentage of acetonitrile for use with an Apollo column ranged 
from 5% to 40% and for a Prosphere column it ranged from 5% to 15%. The 
detection wavelength was 220 nm, the injection volume 20 L and the flow 
rate 1.5 mL/min. All operations were carried out under ambient conditions. 
Possible conditions were informed by an assay for clindamycin.105 
 
2.12.2 Assay validation 
 
A stock solution of 1.0 mg/mL lincomycin hydrochloride was prepared by 
diluting 0.333 mL (measured with a micropipette) of Lincocin to 100 mL 
with milliQ water. From this, standard solutions of 0.1 mg/mL to 1.0 mg/mL 
were freshly prepared and analysed by HPLC. The mobile phase consisted 
of 8% acetonitrile, 92% water, 50 mM phosphoric acid, adjusted to pH 3.00. 
A flow rate of 1.5 mL/min and wavelength of 220 nm were used. A calibration 
curve was produced by plotting the peak area under the curve (which 
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quantitatively represents the concentration of lincomycin in the sample) 
against the concentration of the samples. 
 
Pure analytical grade lincomycin hydrochloride monohydrate was used to 
produce a 1 mg/mL stock solution in milliQ water. From this, standard 
solutions of 0.1 to 0.8 mg/mL were freshly prepared and analysed by HPLC 
to validate the reverse phase HPLC method and to determine the amount of 
lincomycin in a freshly prepared 0.6 mg/mL lincomycin hydrochloride sample 
using the Lincocin® injection. 
 
Inter-day (repeatability) precision of a 0.6 mg/mL stock solution of lincomycin 
hydrochloride (prepared from Lincocin) was determined using six replicate 
samples of stock solution for HPLC analysis. An intra-day (i.e. reproducibility) 
precision assay was determined by comparing the assay of 0.6 mg/mL 
lincomycin hydrochloride on two consecutive days. The results were 
expressed as the relative standard deviation (RSD). 
 
2.12.3 Initial stability indicating assay 
 
A 6 mg/mL lincomycin hydrochloride stock solution was prepared in 0.1 M 
HCl or 0.1 M NaOH respectively. From this, 5 x 5 mL solutions in 10 mL 
volumetric flasks were prepared and placed into a Grant Water bath model 
JB1 (Cambridge) at 60C ( 0.1C). These 5 mL samples were removed from 
the water bath at set time intervals (baseline, 4 hours, 6 hours, 7 hours and 
24 hours for acid solution; baseline, 2 hours, 4 hours, 6 hours and 24 hours 
for base solution). Each 5 mL sample was neutralised with 0.5 mL of 1 M 
NaOH for acid solutions or 0.5 mL of 1 M HCl for base solutions, made to 10 
mL with milliQ water and cooled to room temperature prior to HPLC analysis. 
The mobile phase consisted of 12% acetonitrile, 88% water and was 
adjusted to pH 3 with 50 mM phosphoric acid. A flow rate of 1.5 mL/min and 
wavelength of 220 nm were used. 
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2.12.4 Further stability indicating assays 
 
The stability of lincomycin was tested in 0.1 M HCl, 0.1 M NaOH and 3% 
hydrogen peroxide. Stock solutions of 0.6 mg/mL lincomycin hydrochloride 
were prepared by measuring 0.4 mL of Lincocin, adding 20 mL of 1 M HCl 
or 1 M NaOH respectively, and immediately making to 200 mL volume with 
milliQ water to produce 0.1 M HCl and 0.1 M NaOH solutions respectively. A 
stock solution of 0.6 mg/mL lincomycin hydrochloride in 3% hydrogen 
peroxide was prepared by making 0.4 mL Lincocin up to 200 mL with 3 % 
hydrogen peroxide (prepared from 20 mL 30% hydrogen peroxide made to 
200 mL with milliQ water). All solutions were placed into a Grant Water bath 
model JB1 (Cambridge) at 60C and 5 mL samples removed at time zero and 
twice daily thereafter over a 7 day period. Each 5 mL sample of lincomycin 
hydrochloride in acid or base was neutralised with 0.5 mL of 1 M NaOH or 
0.5 mL of 1 M HCl respectively and made to 10 mL with milliQ water. 
Samples of 5 mL lincomycin hydrochloride in hydrogen peroxide were made 
to 10 mL with milliQ water. Samples were cooled to room temperature prior 
to HPLC analysis. The mobile phase, flow rate and wavelength outlined in 
Section 2.12.3 were used. 
 
2.12.5 Optimisation for resolution of lincomycin break down products 
 
To optimise the resolution of lincomycin breakdown products, a stock solution 
of 0.6 mg/mL lincomycin hydrochloride was prepared by measuring 0.4 mL of 
Lincocin, adding 20 mL of 1 M HCl, and immediately making to 200 mL 
volume with milliQ water. The solution was placed into a Grant Water bath 
model JB1 (Cambridge) at 60C and 5 mL samples removed at time zero and 
every day thereafter for an 18 day period for HPLC analysis. Each 5 mL 
sample was neutralised with 0.5 mL of 1 M NaOH, made to 10 mL with milliQ 
water and cooled to room temperature prior to HPLC analysis. The initial 
assays were performed using the same conditions as outlined in Section 
2.12.3. The effect of reducing the flow rate to 1.0 mL/ min was tested for a 
single run on day 14. On day 18, the effect of changing the mobile phase to 
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10% acetonitrile and 90% water, and later 8% acetonitrile and 92% water, 
was determined, whilst maintaining a flow rate of 1.5 mL/min. 
 
2.12.6 Determination of rate constant 
 
A stock solution of 200 mL was prepared from 0.4mL Lincocin (lincomycin 
hydrochloride) and 20mL 1M HCl  made up to volume with milliQ water and 
placed in a 60C water bath. Samples were taken at time zero (control) and 
at selected time intervals over 12 days. Neutralised 5 mL aliquots taken from 
each sample were analysed by HPLC using the mobile phase, flow rate and 
wavelength outlined in Section 2.12.2. The semi-logarithmic plot of data 
obtained was used to determine the rate constant. 
 
Relationships were generated using Origin® computer software and the 
graphical method was used to confirm the order of the reaction, which was a 
priore assumed to be a first order reaction. Rate constants were obtained 
from the slopes of the log concentration or log percent concentration against 
time plots. The Origin® computer software was used to obtain regression 
analysis of data using unweighted least squares. 
 
A first order reaction can be represented as: 
 
 A  products 
 
The rate of the reaction (dc/dt) is proportional to the concentration of A and 
the rate equation can be written as: 
 
dc = kc 
 dt        (Equation 2.1) 
 
Where  
 k = the first order velocity constant  
 c = the concentration of starting material remaining  
   undecomposed at time t  
   63 
 
If Equation 2.1 is integrated between concentrations co and time t = 0 and 
concentration c and a later time t, this can be mathematically represented as: 
 
    (Equation 2.2) 
  
  ln c  -  ln co = -k (t - 0)    (Equation 2.3) 
 
  ln c   = ln co   -   k t     (Equation 2.4) 
 
 
By converting Equation 2.4 to common logarithms, this yields Equation 2.5: 
 
  log c   = -  log co   -   kt / 2.303  (Equation 2.5) 
 
Which can also be written as: 
 
  k = 2.303 log co    (Equation 2.6) 
        t           c 
 
Written in an exponential form, Equation 2.5 becomes c = coe-kt so that for a 
first order reaction, the concentration of starting material decreases 
exponentially with time (Figure 2.1). If the logarithm of the concentration 
against  time  is  plotted, a  straight line is produced.  The  slope of the line is 
-k/2.303 and from this, the rate constant can be calculated. 
 
 
 
      dc      =  ‐k      dt 
       c ∫ ∫ c co 
t 
0 
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Figure 2-1 - First order reaction linear plot of log concentration versus 
time.110 
 
 
 
 
 
 
The shelf-life, which is taken as the time for decomposition of the initial 10% 
of the active drug to occur, to leave 90% of the activity, is calculated using 
the formula when a first-order reactions occurs (Equation 2.7):  
 
 t90 = 0.105 
      k      (Equation 2.7) 
 
A second order reaction of the form of Equation 2.8 can be rendered pseudo-
first order by maintaining the concentration of B constant using buffers or 
where the concentration of B is in large excess of the concentration of A. 
 
 A + B  products   (Equation 2.8) 
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2.12.7 Stability in IV solutions 
 
2.12.7.1 Accelerated stability testing in IV solutions 
 
To test the stability of lincomycin hydrochloride in 0.9% NaCl and sodium 
lactate (Hartmann’s) intravenous solutions, 0.4mL Lincocin (lincomycin 
hydrochloride) was made to 200 mL with 0.9% sodium chloride or sodium 
lactate (Hartmann’s) solution and placed in a 60C water bath. Samples were 
taken at time zero (control) and several times daily for 8 days for HPLC and 
pH measurements. The mobile phase, flow rate and wavelength outlined in 
Section 2.12.2 were used to analyse 5 mL aliquots taken from each sample. 
 
2.12.7.2 One-month stability testing at room temperature (25C)  
 
Stock solutions were prepared by measuring 0.4mL Lincocin (lincomycin 
hydrochloride) and making up to 200mL with either sodium lactate 
(Hartmann’s) solution, 0.9% sodium chloride solution, 5% glucose solution or 
10% glucose solution. Each stock solution was placed in a 25C water bath. 
Two 5 mL samples were taken at time zero (control), then every third day for 
13 days and finally every fourth day thereafter until 31 days. One 5 mL 
sample was used neat to test pH and the other sample was made up to 10 
mL with milliQ water and repeat analysed by HPLC using conditions outlined 
in Section 2.12.6. Each sample was analysed three times by HPLC. 
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2.12.8 Lincomycin hydrochloride stability in buffer solutions 
 
2.12.8.1 Preparation of buffer solutions 
 
Preparation of buffers used for this research was based on the Henderson-
Hasselbach equation for a weak acid and its salt.110  
 
 pH = pKa + log [salt]   (Equation 2.9)  
           [acid] 
 
where pKa, the negative logarithm of Ka, is the dissociation constant of the 
weak acid.  
 
Buffers were prepared at pH 2.00, 3.10, 4.00, 6.10 and 8.00 to determine the 
effect of the buffer species on degradation of lincomycin hydrochloride. The 
analysis was carried out at each specified pH, 80C and ionic strength of 0.5 
mol/L sodium chloride. In this study, the buffer solutions used were: 
 
 pH 2.00 buffer solution prepared from hydrochloric acid and sodium 
chloride. 
 pH 3.10 buffer solution prepared from citric acid and sodium chloride. 
 pH 4.00 acetate buffer solution prepared from acetic acid, sodium 
chloride and sodium hydroxide. 
 pH 6.10 and 8.00 phosphate buffer solutions prepared from 
orthophosphoric acid, sodium chloride and sodium hydroxide. 
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The amount of sodium chloride required was calculated according to the 
following equation: 
   (Equation 2.10)  
Where: 
  is the ionic strength. 
 ∑ is the summation of the product of cz2 terms for all the ionic species 
 in the  solution, from the first one to the jth species. 
 ci is the concentration in moles/ litre of any of the ions. 
 zi is the valence of the species. 
 
2.12.9 pH measurements 
 
Routine measurements of pH were carried out at room temperature for 5 mL 
samples and buffer solutions using a digital pH meter. Prior to pH 
measurements the instrument was standardised using standard buffer 
solutions. Each pH measurement was made prior to HPLC analysis and was 
taken at precisely 10 minutes using a stop watch.  
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Chapter 3 
3Evaluation of Off-label and Unlicensed prescribing 
at Princess Margaret Hospital 
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3.1 Patient demographics 
 
1038 medical records were reviewed. One case, a 19-year old male, who 
was receiving ongoing care at PMH for cystic fibrosis, was excluded from the 
study due to age. Of the 1037 medical records, 607 (58.5%) were from males 
and 430 (41.5%) from females (Figure 3.1). The age of paediatric patients 
ranged from zero (newborn) up to and including 18 years. The distribution in 
yearly intervals is shown in Figure 3.2.  
 
 
 
 
Figure 3-1 - Number of male and female patients. 
 
 
 
Figure 3.2 shows that there were more patients in the zero to 0.99 years (152 
patients) and 1 - 1.99 years (140 patients) age group than any other age 
group. The least number of patients were in the 18 - 18.99 years age group. 
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Figure 3-2 - Distribution of age. 
 
 
 
 
For ease of analysis, age of patients was classified into four groups 
according to the European Medicines Agency (EMA).6 Figure 3.3 shows that 
the majority of patients were aged between 2 and 11 years (524 patients).   
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Figure 3-3 - Distribution of the four age groups using the EMA age 
classification system.6  
 
 
 
 
 
 
The distribution of patients in each hospital setting (ie inpatient, outpatient 
and Emergency Department) is summarised in Table 3.1. Most records (n = 
403; 38.9%) were from the Emergency Department; 36.6% from outpatients 
(n = 380) and 24.5% from inpatients (n = 254). Figure 3.4 shows that males 
made up a majority in each setting (57.8% in ED, 54.7% outpatients, 65.4% 
inpatients) and this was significant (p = 0.0272). 
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Table 3.1 - Distribution of male and female patients in the Emergency 
Department, inpatient and outpatient settings. 
Gender 
Emergency Inpatient Outpatient 
p (n = 403) 
(%) 
(n = 254) 
(%) 
(n = 380) 
(%) 
Male  
(n = 607; 59%) 
233 57.8 166 65.4 208 54.7 
 
0.0272
Female  
(n = 430; 41%) 
170 42.2 88 34.6 172 45.3 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 - Number of male and female patients in each hospital setting. 
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The single year age distribution of inpatients, outpatients or Emergency 
Department admissions is shown in Figure 3.5. In the Emergency 
Department, the highest numbers of admissions were for patients under 
three years of age with a majority aged between 1 and 1.99 years. 
 
The largest number of inpatients was seen for patients aged less than one 
year (i.e. 0 – 0.99 years). There were no inpatients or Emergency 
Department admissions for anyone aged between 18 and 18.99 years. 
However, there were two outpatients aged between 18 and 18.99 year. The 
greatest numbers of outpatients were aged between one and two years (i.e. 
1 – 1.99 years). There were also a greater number of outpatients aged less 
than one year (i.e. 0 – 0.99 years) and between nine and ten (i.e. 9 - 9.99) 
years of age. 
 
For ease of analysis, the age of patients was grouped into four categories 
according to the EMA classification6 and the distribution in each hospital 
setting recorded. Figure 3.6 shows the distribution of inpatients, outpatients 
and Emergency Department admissions for neonates (zero to 27 days), 
infants (28 days to 23 months), children (two to 11 years) and adolescents 
(12 to 18 years). When patients were grouped in this way, the majority of 
patients in each setting (i.e. inpatients, outpatients and Emergency 
Department patients) were aged between two to 11 years. 
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Figure 3-5 - Distribution of various age groups of patients seen in the Emergency Department, as inpatients and outpatients. 
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Figure 3-6 - Frequency of various age groups of patients seen in the 
Emergency Department, as inpatients and outpatients, according to the EMA 
classification. 
 
 
 
 
 
The youngest patient, a newborn, was admitted as an inpatient and the 
oldest patient (18.4 years) was seen as an outpatient. The average age of all 
patients was 6.6 years ( 5.19 s; range 0.00 - 18.43). The average age of 
patients in the Emergency Department, inpatients and outpatients is shown in 
Table 3.2. The mean age was lowest for Emergency Department admissions 
(5.58  4.83 years) and highest for outpatients (7.82  5.16years). The 
median age was lowest for Emergency Department admissions (3.98 years) 
and highest for outpatients (7.77 years) (Table 3.3). 
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Table 3.2 - Mean age (± 1 standard deviation) of patients in Emergency 
Department admissions, inpatients and outpatients. 
Mean age (years) 
Emergency Inpatient Outpatient 
(n = 403) SD (n = 254) SD (n = 380) SD 
 
5.58 
 
 
± 4.83 
 
6.39 
 
± 5.44 
 
7.82 
 
± 5.16 
 
 
 
The median age was lower than the mean age for Emergency Department 
patients and inpatients but it was slightly higher than outpatients (Table 3.3). 
 
 
Table 3.3 - Median age of patients in Emergency Department admissions, 
inpatients and outpatients. 
Median age (years) 
Emergency Inpatient Outpatient 
(n = 403) (n = 254) (n = 380) 
 
3.98 
(Range: 0 - 17.07) 
 
 
5.36 
(Range:0 - 17.89) 
 
7.77 
(Range: 0.02 - 18.43) 
 
 
 
A comparison of the mean ages between the three types of patients using 
Generalised Linear Model (GLM) analysis produced a significant result (p < 
0.001) (Table 3.4) suggesting that patients seen in the Emergency 
Department were more likely to be younger than patients seen as inpatients 
or outpatients. Similarly, inpatients were more likely to be younger than 
outpatients (p = 0.0003). 
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Table 3.4 - Statistical analysis reported as probability data on age of 
Emergency Department admissions, inpatients and outpatients using GLM 
analysis, with age as a dependent variable. 
 
 
Emergency 
 
 
Inpatient 
 
 
Outpatient 
 
 
Emergency 
 
 0.0491 < 0.0001 
 
Inpatient 
 
0.0491  0.0003 
 
Outpatient 
 
< 0.0001 0.0003  
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3.2 Analysis of prescription drugs 
 
A total of 2654 drugs were prescribed to 699 out of 1037 patients (67.4%). 
The 2654 drugs consisted of 330 different drugs (Appendix 4), which 
included licensed, off-label and unlicensed drugs.  
 
All drugs were classified into the Anatomical Therapeutic Chemical (ATC) 
classification. Table 3.5 shows the frequency of drugs in each ATC category. 
The largest number of the 2654 drugs were classified into the nervous 
system (n = 1034; 39.0%), followed by the alimentary tract (n = 408; 15.4%), 
anti-infective (n = 400; 15.1%) and respiratory system (n = 180; 6.8%). 
 
 
 
Table 3.5 - Frequency of all drugs, including licensed, off-label and 
unlicensed drugs, in each ATC category 
ATC Code 
Frequency 
(n = 2654) % 
Alimentary tract and metabolism 408 15.4 
Blood and blood forming organs 34 1.3 
Cardiovascular system 69 2.6 
Dermatologicals 111 4.2 
Genito-urinary system and sex hormones 19 0.7 
Systemic hormonal preparations excl sex hormones 154 5.8 
Anti-infectives for systemic use 400 15.1 
Antineoplastics and immunomodulating agents 42 1.6 
Musculo-skeletal system 73 2.8 
Nervous system 1034 39.0 
Antiparasitic products, insecticides and repellent 5 0.2 
Respiratory system 180 6.8 
Sensory organs 95 3.6 
Various 30 1.1 
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The age distribution for all drugs prescribed is shown in Figure 3.7. The 
greatest percentage of drugs were prescribed to children (aged 2 to 11 
years), followed by adolescents (aged 12 to 18 years). The least number of 
drugs were prescribed to neonates (aged zero to 27 days). 
 
 
 
 
 
 
 
 
 
Figure 3-7 - Number of drugs prescribed to various age groups of paediatric 
patients. 
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Of the 2654 drugs, the majority (n = 1905, 71.8%) were licensed, 681 
(25.7%) were off-label and 68 (2.6%) unlicensed (Figure 3.8).  
 
 
 
 
Figure 3-8 - Number of drugs that were prescribed licensed, off-label and 
unlicensed. 
 
 
 
 
 
 
 
There were 121 different off-label drugs prescribed (Table 3.6).The most 
commonly prescribed off-label drug was ondansetron, followed by Painstop 
Day® (paracetamol 120 mg, codeine phosphate 5 mg per 5 mL) and 
salbutamol.   
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Table 3.6 - List of 121 off-label prescribed drugs. 
Off-label Drug Frequency Off-label Drug Frequency Off-label Drug Frequency 
Aciclovir 5 Hydralazine 2 Ondansetron 94 
Adrenaline 1 Hydrocortisone 1 Oxybutynin 1
Alfentanil 2 Hydroxyurea 1 Oxycodone 49
Alteplase  2 Hyoscine butylbromide 1 Painstop Day
® 71 
Amitriptyline 1 Ibuprofen 4 Painstop Night® 5
Amlodipine 1 Infliximab 1 Panadeine Forte® 1
Amoxicillin 18 Interferon beta 1 Pantoprazole 2
Aprepitant  3 Ipratropium 12 Paracetamol 48
Atorvastatin 1 Ketamine 1 Parachoc® 1
Augmentin duo® 3 Lactulose 3 Parecoxib 2
Azithromycin 1 Lamotrigine 1 Pizotifen 1
Benzylpenicillin 2 Lansoprazole 2 Potassium chloride 1
Betamethasone 2 Latanoprost 1 Praziquantil  1
Betaxolol 1 Leuprorelin 1 Pregabalin 1
Brimonidine 1 Levetiracetam 2 Promethazine 3
Brinzolamide 1 Lignocaine 1 Propofol 7 
Budesonide/ 
eformoterol 1 Lisinopril 1 Quetiapine 4 
Calcium 
carbonate 1 Loratadine 3 Ranitidine  3 
Captopril  1 Lorazepam  7 Risperidone 1 
Carbimazole 1 Loperamide 1 Salbutamol 51 
Cephalexin 2 Losartan  1 Sertraline 2 
Chloral hydrate 3 Melatonin 1 Sildenafil 2 
Chloramphenicol 4 Meropenem 1 Solifenacin 2 
Clonidine  13 Methotrexate 2 SOOV IT® 1 
Ciprofloxacin 1 Metoclopramide 12 Teicoplanin 1 
Clobazam 3 Metronidazole 3 Temazepam 5 
Codeine 10 Microlax® 2 Terbinafine 1 
Darbapoetin  1 Midazolam 29 
ticarcillin/ 
potassium 
clavulanate 
19 
Dexamethasone 6 Minoxidil 1 Timolol 1 
Dopamine 3 Mirtazapine 1 Tolterodine 1 
Epipen® junior 1 Montelukast 1 Tropisetron 1 
Escitalopram 1 Morphine 3 Tobramycin  7 
Fentanyl 21 Mupirocin 2 Topotecan 2 
Flucloxacillin 18 Natalizumab 1 Tropicamide 1 
Fluorometholone 1 Nifedipine  2 Valaciclovir 1 
Fluorouracil 1 Nitrazepam 1 Valganciclovir 1 
Fluoxetine  4 Octreotide 1 Vancomycin 5 
Gabapentin 2 Ofloxacin 1 Vigabatrin  1 
Gentamicin 8 Olanzapine 2 Vitabdeck® 2 
Glyceryl trinitrate 1 Omeprazole  10 Xalacom® 1 
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All off-label drugs were classified into the appropriate ATC category (Table 
3.7). The majority of off-label drugs (n = 295; 43.3%) were classified into the 
nervous system. This classification included analgesic drugs such as 
Painstop®, oxycodone and paracetamol, which were the most commonly off-
label prescribed nervous system drugs. The next most frequent off-label ATC 
classifications were the alimentary tract (n = 139; 20.4%) and anti-infectives 
(97 i.e. 14.2%).  
 
 
 
 
 
Table 3.7 - Frequency of off-label drugs in each ATC category. 
ATC Code of off-label drugs 
Frequency 
(n = 681) % 
Alimentary tract and metabolism 139 20.4 
Blood and blood forming organs 3 0.4 
Cardiovascular system 28 4.1 
Dermatologicals 7 1.0 
Genito-urinary system and sex hormones 7 1.0 
Systemic hormonal preparations excl sex 
hormones 
3 0.4 
Anti-infectives for systemic use 97 14.2 
Antineoplastics and immunomodulating 
agents 
9 1.3 
Musculo-skeletal system 2 0.3 
Nervous system 295 43.3 
Antiparasitic products, insecticides and 
repellent 
1 0.2 
Respiratory system 71 10.4 
Sensory organs 19 2.8 
Various 0 0 
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The 68 drugs prescribed in an unlicensed manner included 22 different drugs 
(Table 3.8). The most commonly prescribed unlicensed drugs were 
dexamethasone and dilacaine (29.4% and 17.7% respectively).  
 
 
 
 
Table 3.8 - List of 22 different unlicensed drugs 
Unlicensed Drug 
Frequency 
(n = 68) % 
Adrenaline  7 10.3 
Aspirin 2 2.9 
Azathioprine 2 2.9 
Carnitine  3 4.4 
Cephazolin  1 1.5 
Cisretinoic acid  1 1.5 
Dexamethasone 20 29.4 
Dilacaine  12 17.7 
Domperidone 2 2.9 
Gonadorelin  2 2.9 
Magnesium chloride 1 1.5 
Metolazone  1 1.5 
Picibanil (OK 432) 1 1.5 
Potassium chloride 2 2.9 
Propranolol 1 1.5 
Salicyclic acid/ cetylpyridium 
chloride 1 1.5 
Sodium bicarbonate  1 1.5 
Sodium chloride  4 5.9 
Tacrolimus 1 1.5 
Tinidazole 1 1.5 
Tocilizumab 1 1.5 
Trichloracetic acid paste APF 1 1.5 
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All unlicensed drugs were classified into the appropriate ATC category (Table 
3.9). The majority of unlicensed drugs were systemic hormonal preparations 
excluding sex hormones (n = 22, 32.4%) and sensory organ drugs (n = 13, 
19.1%). Alimentary tract and metabolism drugs were also prescribed 
frequently in an unlicensed manner (n = 11; 16.2%) 
 
Since the prevalence of off-label prescribing was 25.7% and the prevalence 
of unlicensed prescribing 2.6%, therefore the overall extent of off-label and 
unlicensed prescribing across the three settings was 28.3%. 
 
 
 
 
 
Table 3.9 - Frequency of unlicensed drugs in each ATC category 
ATC Code of unlicensed drugs 
Frequency 
(n = 68) % 
Alimentary tract and metabolism 11 16.2 
Blood and blood forming organs 3 4.4 
Cardiovascular system 4 5.9 
Dermatologicals 3 4.4 
Genito-urinary system and sex hormones 2 2.9 
Systemic hormonal preparations excl sex 
hormones 
22 32.4 
Anti-infectives for systemic use 1 1.5 
Antineoplastics and immunomodulating agents 5 7.4 
Musculo-skeletal system 0 0.0 
Nervous system 0 0.0 
Antiparasitic products, insecticides and repellent 0 0.0 
Respiratory system 3 4.4 
Sensory organs 13 19.1 
Various 1 1.5 
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3.3 Prescribing trends - considering the patients 
 
Of the 1037 patients involved in the study, the number of patients in each 
setting (inpatients, outpatients, Emergency Department patients) that did not 
receive any drugs or that received some drugs, including licensed, off-label 
and unlicensed drugs, is shown in Figure 3.9. Three hundred and thirty eight 
patients did not receive any drugs and of these 12 were inpatients, 173 were 
outpatients and 153 were Emergency Department patients. In each setting 
more patients received some drugs as opposed to no drugs. When only 
inpatients were considered, 95.3% received some drugs whereas 62.0% of 
Emergency Department patients received some drugs rather than no drugs. 
However, when only outpatients were considered, there was no statistical 
difference difference between outpatients that received no drugs or some 
drugs 45.5% and 54.5% respectively). Overall, the data were significant (p < 
0.0001).  
 
 
 
Figure 3-9 - Number of patients in each hospital setting receiving no drugs 
or some drugs (at least one or more drugs) 
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The number of male and female patients that received no drugs or some 
drugs (including licensed, off-label and unlicensed drugs) is shown in Figure 
3.10. Of the 1037 patients, 189 males (31.1%) and 149 females (34.7%) did 
not receive any drugs. Of the 699 patients that received some drugs, 418 
were males (59.8%) and 281 were females (40.2%).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10 - Gender distribution of patients that received no drugs or some 
drugs. 
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When the drugs administered to patients were grouped into licensed and off-
label/ unlicensed drugs to determine if there was a difference in the number 
of male and female patients that received no drugs, licensed drugs or off-
label/ unlicensed drugs, the percentage of males that were prescribed no 
drugs or licensed drugs (31.1% and 30.0% respectively) was marginally less 
than females (34.7% and 32.3% respectively) but the finding was not 
significant (p = 0.1520) (Table 3.10). The percentage of off-label/ unlicensed 
drugs was also similar for gender (38.9% males, 33.0% females). 
 
 
 
 
Table 3.10 - Gender distribution of the number of patients receiving no 
drugs, licensed drugs or off-label/ unlicensed drugs. 
Gender 
No  
Drugs 
Licensed  
Drugs 
Off-label/  
unlicensed Drugs
(n = 338) (n = 321) (n = 378) 
Male  
(n = 607)(%) 
189 31.1 182 30.0 236 38.9 
Female  
(n = 430)(%) 
149 34.7 139 32.3 142 33.0 
p = 0.1520 
 
 
 
 
Table 3.10 was modified to separate the number of patients receiving off-
label/ unlicensed drugs to determine the number in each classification (Table 
3.11). This showed that more females were prescribed unlicensed drugs 
(4.7% compared to 2.5%) but a greater percentage of males were prescribed 
off-label drugs (36.4% compared to 28.4%). The results were significant (p = 
0.0198). 
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Table 3.11 - Gender distribution of the number of patients prescribed no 
drugs, licensed drugs and off-label or unlicensed drugs. 
Gender 
No Drugs 
Licensed 
Drugs 
Off-label 
Drugs 
Unlicensed 
Drugs 
(n = 338) (n = 321) (n = 343) (n = 35) 
Male   
(n = 607) (%) 189 31.1 182 30.0 221 36.4 15 2.5 
Female   
(n = 430) (%) 149 34.7 139 32.3 122 28.4 20 4.7 
p = 0.0198 
 
 
 
 
 
Figure 3.11 shows the age distribution of patients that were prescribed no 
drugs, licensed, off-label and unlicensed drugs. Of the 20 patients aged zero 
to 27 days, 12 patients (60.0%) were prescribed off-label drugs. This may not 
be representative of all patients in this age group in general as the sample 
size was too small. The highest percentage of off-label prescribing occurred 
in infants (28 days to 23 months) and children (two to 11 years) (31.7% and 
35.9% respectively) and the highest percentage of unlicensed prescribing 
(7.2%) occurred in infants (28 days to 23 months). The results were 
significant (p < 0.0001). 
 
Table 3.12 shows the number of inpatients, outpatients and Emergency 
Department patients that received no drugs, licensed, off-label or unlicensed 
drugs. The highest percentage of off-label drugs were prescribed to 
inpatients (74.4%). The percentage of unlicensed drugs prescribed was the 
similar (3.1%, 3.4% and 3.5%) in each of the three settings. The differences 
in prescribing in the three settings were significant (p < 0.0001). 
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Figure 3-11 - Number of patients in various age groups prescribed no drugs, 
licensed, off-label or unlicensed drugs.  
 
 
Table 3.12 - Number (%) of patients in each setting receiving no drugs, 
licensed, off-label or unlicensed drugs. 
Setting 
(n = 1037) 
No Drugs 
Licensed 
Drugs 
Off-label 
Drugs 
Unlicensed 
Drugs 
(n = 338) (n = 321) (n = 343) (n = 35) 
Inpatient   
(n = 254) (%) 12 4.7 45 17.7 189 74.4 8 3.1 
Outpatient   
(n = 380) (%) 173 45.5 139 36.6 55 14.5 13 3.4 
Emergency   
(n = 403) (%) 153 37.9 137 34.0 99 24.6 14 3.5 
p < 0.0001 
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The data were further classified to determine gender differences in each 
setting (inpatients, outpatients and emergency) (Table 3.13). Of the 403 
Emergency Department admissions, 250 patients received drugs and of 
these, 113 (45.2%) received some off-label/ unlicensed drugs. In considering 
only the 143 male and 107 female Emergency Department patients that 
received drugs, 68 (47.6%) males and 45 (42.1%) females received one or 
more off-label or unlicensed drugs. 
 
 
 
 
 
 
 
 
Table 3.13 - Gender distribution in each setting that were prescribed no 
drugs, licensed and off-label/ unlicensed drugs. 
Setting Gender 
No  
Drugs 
Licensed 
Drugs 
Off-label/ 
unlicensed 
Drugs 
(n = 1037) (n = 338) (n = 321) (n = 378) 
In
pa
tie
nt
 
(n
 =
 2
54
) 
Male      
(n = 166) (%) 8 4.8 29 17.5 129 77.7 
Female      
(n = 88) (%) 4 4.5 16 18.2 68 77.3 
O
ut
pa
tie
nt
 
(n
 =
 3
80
) 
Male      
(n = 208) (%) 91 43.8 78 37.5 39 18.8 
Female      
(n = 172) (%) 82 47.7 61 35.5 29 16.9 
Em
er
ge
nc
y 
(n
 =
 4
03
) 
Male      
(n = 233) (%) 90 38.6 75 32.2 68 29.2 
Female      
(n = 170) (%) 63 37.0 62 36.5 45 26.5 
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Of the 380 outpatients, 207 patients received some drugs and of these, 68 
(32.8%) received some off-label or unlicensed drugs. In considering only the 
117 male and 90 female outpatients that received some drugs, 33.3% of 
males and 32.2% of females received one or more off-label or unlicensed 
drugs.  
 
Table 3.13 shows that the percentages of off-label or unlicensed prescribing 
between male and female inpatients were similar (77.7% for males and 
77.3% for females). However, in considering only the 242 (95.3%) inpatients 
that were prescribed drugs, 197 (81.4%) received some off-label or 
unlicensed drugs. In considering only the 158 male and 84 female inpatients 
that received some drugs, 81.6% of males and 81.0% of females received 
one or more off-label or unlicensed drugs.  
 
To determine if there were gender differences in each setting as well as 
differences in the types of drugs prescribed, the drugs shown in Table 3.13 
as off-label/ unlicensed drugs were separated (Table 3.14). 
 
Table 3.14 shows that a greater percentage of female inpatients and 
outpatients were prescribed unlicensed drugs (5.7% and 5.8% respectively 
compared to 1.8% inpatient males and 1.4% outpatient males)  but a greater 
percentage of Emergency Department males were prescribed unlicensed 
drugs (3.9% compared to 2.9% females). However, a greater percentage of 
inpatient and outpatient males were prescribed off-label drugs (75.9% and 
17.3% respectively compared to 71.6% female inpatients and 11.0% female 
outpatients). The percentage of Emergency Department male and female 
patients prescribed off-label drugs were the same. Differences for male and 
female outpatients were significant (p = 0.0414) but not for inpatients (p = 
0.4056) or Emergency Department patients (p = 0.8103). 
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Table 3.14 - Number of males and females in each setting that were 
prescribed no drugs, licensed, off-label or unlicensed drugs 
Setting Gender 
No drug Licensed 
Drugs 
Off-label 
Drugs 
Un- 
licensed 
Drugs 
p 
(n = 338) (n = 321) (n = 343) (n = 35)   
In
pa
tie
nt
 
(n
 =
 2
54
) Male      
(n = 166) (%) 8 4.8 29 17.5 126 75.9 3 1.8
0.4056 
Female     
(n = 88) (%) 4 4.5 16 18.2 63 71.6 5 5.7
O
ut
pa
tie
nt
 
 (n
 =
 3
80
) 
Male      
(n = 208) (%) 91 43.8 78 37.5 36 17.3 3 1.4
0.0414 
Female     
(n = 172) (%) 82 47.7 61 35.5 19 11.0 10 5.8
Em
er
ge
nc
y 
(n
 =
 4
03
) Male      
(n = 233) (%) 90 38.6 75 32.2 59 25.3 9 3.9
0.8103 
Female     
(n = 170) (%) 63 37.1 62 36.5 40 23.5 5 2.9
 
 
 
 
The age groups of patients in each setting (inpatients, outpatients and 
Emergency Department patients) and the type of drug prescribed is 
summarised in Table 3.15. For inpatients, each of the four age groups were 
prescribed more off-label drugs than licensed drugs. The inpatient age 
groups with the highest percentage of off-label prescribing were children 
aged two to 11 years (85.2%) and neonates aged zero to 27 days (83.3%). 
Only eight of the 254 inpatients (3.1%) were prescribed unlicensed drugs (but 
not any off-label drugs). The age group with the highest percentage of 
unlicensed prescriptions were infants aged 28 days to 23 months (7.5%). The 
differences in the type of drugs prescribed to inpatients in various age groups 
was significant (p = 0.0077). 
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Table 3.15 - Category of drugs prescribed to various age groups of 
inpatients, outpatients and Emergency Department patients. 
Se
tti
ng
 
Age  
group 
No  
drug 
Licensed 
Drugs 
Off-label 
Drugs 
Un- 
licensed 
Drugs 
p 
(n = 338) (n = 321) (n = 343) (n = 35) 
In
pa
tie
nt
 
0 - 27 d 
(n = 12) (%) 1 8.3 1 8.3 10 83.3 0 0 
0.0077
28d - 23 m 
(n =  67) (%) 3 4.5 16 23.9 43 64.2 5 7.5 
2 - 11 y 
(n = 122) (%) 5 4.1 12 9.8 104 85.2 1 0.8 
12 - 18 y 
(n =  53) (%) 3 5.7 16 30.2 32 60.4 2 3.8 
O
ut
pa
tie
nt
 
0 - 27 d 
(n =  2) (%) 0 0 1 50.0 1 50.0 0 0 
0.0004
28d - 23 m 
(n =  78) (%) 35 44.9 21 26.9 13 16.7 9 11.5 
2 - 11 y 
(n = 202) (%) 101 50.0 70 34.7 28 13.9 3 1.5 
12 - 18 y 
(n =  98) (%) 37 37.8 47 48.0 13 13.3 1 1.0 
Em
er
ge
nc
y 
0 - 27 d 
(n =  6) (%) 3 50.0 2 33.3 1 16.7 0 0 
0.2514
28d - 23 m 
(n =  133) (%) 53 39.8 42 31.6 32 24.1 6 4.5 
2 - 11 y 
(n =  200) (%) 74 37.0 62 31.0 56 28.0 8 4.0 
12 - 18 y 
(n =  64) (%) 23 35.9 31 48.4 10 15.6 0 0 
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Significant differences were also found for outpatients. More outpatients aged 
28 days to 23 months and two to 11 years were not prescribed any drugs at 
all (44.9% and 50.0% respectively). There were only two outpatient neonates 
in the study aged zero to 27 days, one of which was prescribed a licensed 
drug and the other an off-label drug. No neonate was prescribed an 
unlicensed drug. More outpatients aged 28 days to 23 months were 
prescribed unlicensed drugs (11.5%). The differences in the type of drugs 
prescribed to outpatients in various age groups was significant (p = 0.0004). 
 
The percentage of Emergency Department patients in the various age groups 
prescribed off-label drugs was similar and ranged from 15.6% (patients aged 
12 to 18 years) to 28.0% (patients aged two to 11 years). No unlicensed 
drugs were prescribed to neonates aged zero to 27 days and adolescents 
aged 12 to 18 years. However, 4.5% of unlicensed drugs were prescribed to 
infants aged 28 days to 23 months and 4.0% to children aged two to 11 
years. No significant differences were found in prescribing trends for 
Emergency Department patients in the various age groups (p = 0.2514). 
 
Table 3.16 shows that the inpatient gender and age groups with the highest 
percentage of off-label or unlicensed prescribing were males aged zero to 27 
days (66.7%) and males aged two to 11 years (58.2%). 
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Table 3.16 - Number of patients in different age groups and in different 
settings prescribed no drugs, licensed, off-label or unlicensed drugs. 
Se
tti
ng
 
Age group Gender 
No 
drugs 
Licensed 
Drugs 
Off-label 
or 
unlicensed 
drugs 
(n = 338) (n = 321) (n = 378) 
  
In
pa
tie
nt
 
0 - 27 d Male  0 0.0 1 8.3 8 66.7 
(n = 12) (%) Female 1 8.3 0 0.0 2 16.7 
28d - 23 m Male 3 4.5 8 11.9 28 41.8 
(n =  67) (%) Female 0 0 8 11.9 20 29.9 
2 - 11 y Male 2 1.6 10 8.2 71 58.2 
(n = 122) (%) Female 3 2.5 2 1.6 34 27.9 
12 - 18 y Male 3 5.7 10 18.9 22 41.5 
 (n =  53) (%) Female 0 0.0 6 11.3 12 22.6 
O
ut
pa
tie
nt
 
0 - 27 d Male 0 0.0 1 50.0 1 50.0  
(n =  2) (%) Female 0 0.0 0 0.0 0 0.0 
28d - 23 m Male 20 25.6 13 16.7 12 15.4 
(n =  78) (%) Female 15 19.2 8 10.3 10 12.8 
2 - 11 y Male 50 24.8 38 18.8 17 8.4 
(n = 202) (%) Female 51 25.2 32 15.8 14 6.9 
12 - 18 y Male 21 21.4 26 26.5 9 9.2 
 (n =  98) (%) Female 16 16.3 21 21.4 5 5.1  
Em
er
ge
nc
y 
0 - 27 d Male 2 33.3 1 16.7 0 0.0 
(n =  6) (%) Female 1 16.7 1 16.7 1  16.7 
28d - 23 m Male 29 21.8 23 17.3 22  16.5 
(n =  133) (%) Female 24 18.0 19 14.3 16  12.0 
2 - 11 y  Male 41 20.5 31 15.5 37  18.5 
(n =  200) (%) Female 33 16.5 31 15.5 27  13.5 
12 - 18 y Male 18 28.1 20 31.2 9  14.1 
 (n =  64) (%)  Female 5  7.8 11 17.2 1  1.6 
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3.4 Further analysis of patients classified as taking ''off-label 
drugs'' 
 
According to the hierarchical classification system defined in Chapter 2 that 
was used to categorise patients into off-label or unlicensed drug categories, 
any patient administered an off-label drug in addition to an unlicensed drug 
was categorised into the off-label group so that each of the 1037 patients 
was categorised only into one single category (Chapter 2 Section 2.4.1). The 
data in Table 3.11 were analysed further to determine the number of patients 
categorised as receiving only off-label drugs and those that received both off-
label and unlicensed drugs (Table 3.17). A comparison of male and female 
patients showed that a greater percentage of males were prescribed off-label 
only drugs (33.3% compared to 27.2% of females) as well as a combination 
of off-label and unlicensed drugs (3.1% compared to 1.2% of females) 
whereas a greater percentage of females were prescribed unlicensed drugs. 
The findings were significant (p = 0.0162). 
 
 
 
 
 
Table 3.17 - Gender distribution of the number of patients prescribed no 
drugs, licensed, off-label, unlicensed or off-label and unlicensed drugs. 
Gender 
No Drugs Licensed 
Drugs 
Off-label 
Drugs  
Unlicensed 
Drugs  
 
Off-label & 
unlicensed 
Drugs 
(n = 338) (n = 321) (n = 319) (n = 35) (n = 24) 
     
Male  
(n = 607) (%) 
189 31.1 182 30.0 202 33.3 15 2.5 19 3.1 
Female  
(n = 430) (%) 149 34.7 139 32.3 117 27.2 20 4.7 5 1.2 
p = 0.0162 
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Figure 3.15 shows that no patients aged zero to 27 days received only 
unlicensed drugs (according to the hierarchical classification system defined 
in the methodology in Chapter 2). To determine if there were any patients 
that were classified as 'off-label 'in this age group that received both off-label 
and unlicensed drugs, patients categorised into the off-label category were 
separated into those that received only off-label drugs and those that 
received both off-label and unlicensed drugs (Table 3.18). 
 
 
 
 
 
 
 
 
Table 3.18 - Different age groups prescribed no drugs, licensed, off-label, 
unlicensed or off-label and unlicensed drugs. 
Age group 
No  
Drugs  
 
(n = 338) 
Licensed 
Drugs  
 
(n = 321) 
Off-label 
Drugs  
 
(n = 319) 
Unlicensed 
Drugs  
 
(n = 35) 
Off-label & 
unlicensed 
Drugs 
(n = 24) 
0 - 27 d 
  
(n = 20) (%) 4 20.0 4 20.0 11 55.0 0 0 1 5.0 
28 d - 23 m    
(n = 278) (%) 91 32.7 79 28.4 77 27.7 20 7.2 11 4.0 
2 - 11 years                   
(n = 524) (%) 180 34.4 144 27.5 178 34.0 12 2.3 10 1.9 
12 - 18 
years                   
(n = 215) (%) 63 29.3 94 43.7 53 24.7 3 1.4 2 1.0 
p < 0.0001 
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Table 3.18 shows that one patient aged zero to 27 days was prescribed both 
unlicensed and off-label drugs. The infant was a two week old male inpatient 
prescribed cephazolin eye drops (unlicensed) and amoxicillin with clavulanic 
acid (off-label for age). Although an injection of cephazolin is available, for 
which the PI states that the safety for use in premature infants and infants 
under one month of age has not been established, no commercial 
formulation of cephazolin eye drops was available so these were 
compounded at the hospital. The PI for amoxicillin with clavulanic acid does 
not provide a dose for children under two months of age so the antibiotic was 
off-label for age. 
 
When the patients classified as receiving off-label drugs in Table 3.12 were 
separated to show how many patients received only off-label drugs and how 
many received a combination of both off-label and unlicensed drugs (Table 
3.19), a higher percentage of inpatients received a combination of off-label 
and unlicensed drugs (5.9%). The differences in the types of drugs 
prescribed with respect to setting was significant (p < 0.0001). 
 
 
 
Table 3.19 - Number of patients in each setting receiving no drugs, licensed, 
off-label drugs only, unlicensed drugs only or off-label and unlicensed drugs. 
Setting 
No Drugs Licensed 
Drugs 
Off-label 
Drugs  
Unlicensed 
Drugs  
Off-label & 
unlicensed 
Drugs 
(n = 338; 
32.6%) 
(n = 321; 
31.0%) 
(n = 319; 
30.8%) 
(n = 35;  
3.4%) 
(n = 24; 
2.3%) 
      
Inpatient 12 4.7 45 17.7 174 68.5 8 3.1 15 5.9 
(n = 254) (%) 
Outpatient 173 45.5 139 36.6 50 13.2 13 3.4 5 1.3 
(n = 380) (%) 
Emergency 153 38.0 137 34.0 95 23.6 14 3.5 4 1.0 
(n = 403) (%) 
p < 0.0001 
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3.5 Prescribing trends - drugs prescribed 
 
The number of drugs prescribed per person, including licensed drugs as well 
as off-label and unlicensed drugs, ranged from zero to twenty-one (Table 
3.20). Almost one-third of patients were prescribed no drug (32.6%) and one 
to two drugs (20.7% and 12.8% respectively) were most frequent. The 
maximum number of drugs prescribed per person (21 drugs) were prescribed 
to seven different patients.  
 
 
Table 3.20 - Number of patients that were prescribed different amounts of 
licensed, unlicensed and off-label drugs 
Number of 
drugs  
Number of patients 
(n = 1037) % 
0 338 32.6 
1 215 20.7 
2 133 12.8 
3 88 8.5 
4 69 6.7 
5 33 3.2 
6 49 4.7 
7 21 2.0 
8 21 2.0 
9 16 1.5 
10 12 1.2 
11 12 1.2 
12 10 1.0 
13 3 0.3 
14 2 0.2 
15 2 0.2 
16 5 0.5 
19 1 0.1 
21 7 0.7 
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Table 3.21 shows the number of drugs prescribed per inpatient, outpatient 
and Emergency Department patients. The majority of outpatients and 
Emergency Department patients were prescribed no drugs or one to two 
drugs. The maximum number of drugs prescribed to outpatients was twelve 
and to Emergency Department patients was sixteen. The results were very 
different for inpatients. The number of drugs prescribed for the 254 inpatients 
ranged from zero to 21 but few inpatients were prescribed no drug (4.7%). 
Frequently inpatients were prescribed three (11.0%), four (13.4%) or six 
(11.8%) drugs. Twenty one drugs were prescribed to seven inpatients. The 
differences in the number of drugs prescribed with respect to setting were 
significant (p < 0.0001). 
 
Table 3.22 shows differences in the number of off-label drugs prescribed per 
person in each setting (inpatients, outpatients, Emergency Department). 
These findings were significant (p < 0.0001). Of the 699 patients that were 
prescribed drugs, 343 were prescribed off-label drugs and 356 were not 
prescribed any off-label drugs (53 inpatients, 152 outpatients and 151 
emergency patients). A greater percentage of outpatients and Emergency 
Department patients were not prescribed any off-label drugs (73.4% and 
60.4% respectively). In each setting, the majority of patients were prescribed 
one or two off-label drugs. The maximum number of off-label drugs was 11, 
prescribed to one inpatient. Of the 356 patients that were not prescribed any 
off-label drugs, 321 were prescribed licensed drugs and 35 were prescribed 
unlicensed drugs. Some patients that were prescribed off-label drugs were 
also prescribed unlicensed drugs. The number of patients prescribed both 
off-label and unlicensed drugs was 24 (19 males and five females - Table 
3.17). 
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Table 3.21 - Number of drugs prescribed per person in each setting, 
including licensed drugs as well as off-label and unlicensed 
Drugs 
per 
person 
Inpatient Outpatient Emergency Total  
(n = 
1037) 
(n = 254) (n = 380) (n = 403) 
 n               n                    n                 
0 (%) 12 3.6 173 51.2 153 45.3 338 
1 (%) 20 9.3 80 37.2 115 53.5 215 
2 (%) 21 15.8 62 46.6 50 37.6 133 
3 (%) 28 31.8 24 27.3 36 40.9 88 
4 (%) 34 49.3 15 21.7 20 29.0 69 
5 (%) 20 60.6 8 24.2 5 15.2 33 
6 (%) 30 61.2 11 22.4 8 16.3 49 
7 (%) 16 76.2 3 14.3 2 9.5 21 
8 (%) 18 85.7 2 9.5 1 4.8 21 
9 (%) 15 93.8 0 0.0 1 6.2 16 
10 (%) 9 75.0 0 0.0 3 25.0 12 
11 (%) 9 75.0 1 8.3 2 16.7 12 
12 (%) 6 60.0 1 10.0 3 30.0 10 
13 (%) 3 100.0 0 0.0 0 0.0 3 
14 (%) 2 100.0 0 0.0 0 0.0 2 
15 (%) 1 50.0 0 0.0 1 50.0 2 
16 (%) 2 40.0 0 0.0 3 60.0 5 
19 (%) 1 100.0 0 0.0 0 0.0 1 
21 (%) 7 100.0 0 0.0 0 0.0 7 
(p < 0.0001) 
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Table 3.22 - Number of patients prescribed different numbers of off-label 
drugs in each setting 
Off-
label 
drugs 
per 
person 
Inpatient Outpatient Emergency Total 
number 
(n = 699) 
 
(n = 242) 
 
(n = 207) 
 
(n = 250) 
n 
% of 
inpatients n 
% of 
outpatients n 
% of 
emergency 
0 53 21.9 152 73.4 151 60.4 356 
1 64 26.5 35 16.9 66 26.4 165 
2 58 24.0 15 7.3 19 7.6 92 
3 39 16.1 2 1.0 3 1.2 44 
4 17 7.0 2 1.0 6 2.4 25 
5 5 2.1 1 0.5 3 1.2 9 
6 4 1.7 0 0.0 2 0.8 6 
8 1 0.4 0 0.0 0 0.0 1 
11 1 0.4 0 0.0 0 0.0 1 
p < 0.0001 
 
 
 
 
 
Table 3.23 shows the average age of patients prescribed no drugs, licensed 
or off-label and unlicensed drugs. The average age of patients that were not 
prescribed any drugs was 6.36 (± 4.89) years (median age = 5.59). The 
number of licensed drugs prescribed ranged from one to 12 and the average 
age of patients prescribed licensed drugs was 7.54 (± 5.52) years (median 
age = 6.97). The number of off-label drugs prescribed ranged from zero to 
eleven and the number of unlicensed drugs ranged from zero to three. 
Patients that were prescribed off-label or unlicensed drugs may also have 
been prescribed licensed drugs so the overall number of drugs they were 
prescribed ranged from one to 21 drugs and their average age was 6.01 (± 
5.07)(median age = 4.72). 
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Table 3.23 - Average age of patients prescribed no drugs, licensed, off-label 
or unlicensed drugs 
Type of  
Drug 
Average age  
( 1 SD) 
Range of 
drugs 
prescribed 
Range of off-
label drugs 
per person 
Range of 
unlicensed 
drugs per 
person 
No drugs 6.36 (4.89) 
(median = 5.59)
0 0 0 
(n = 338) 
Licensed 
drugs 
 
7.54 (5.52) 
(median = 6.97)
 1 - 12 0 0 
(n = 321) 
Off-label or 
unlicensed 
drugs 
6.01 (5.07) 
(median = 4.72)
 1 - 21 0 - 11 0 - 3 
(n = 378) 
 
 
 
 
 
 
 
Table 3.24 summarises the maximum number of drugs prescribed to various 
age groups in Emergency Department admissions, inpatients and 
outpatients. The maximum number of drugs prescribed to individual patients 
was 21 which were prescribed to inpatients in all age groups except infants 
(aged 28 days to 23 months). The maximum number of drugs prescribed to 
infants (aged 28 days to 23 months) was fourteen. For outpatient, the 
maximum number of drugs prescribed was twelve (prescribed to children 
aged two to 11 years) and in the Emergency Department, the maximum 
number of drugs prescribed was sixteen, for both infants (aged 28 days to 23 
months) and children (aged two to 11 years).  
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Table 3.24 - Maximum number of drugs prescribed per patient, including all 
drugs, off-label and unlicensed drugs in various settings according to age 
group 
Patient 
status 
Age group 
Maximum number of drugs 
prescribed per patient 
All drugs Off-label Unlicensed 
Inpatient 0 - 27 days       
(n = 12) 
21 6 1 
 (n = 254) 28 days - 23 
months  
(n = 67) 
14 6 1 
  2 - 11 years  
(n = 122) 
21 11 2 
  12 - 18 years  
(n = 53) 
21 6 1 
Outpatient 0 - 27 days       
(n = 2) 
4 2 0 
  (n = 380) 28 days - 23 
months  
(n = 78) 
8 4 2 
  2 - 11 years  
(n = 202) 
12 5 1 
  12 - 18 years  
(n = 98) 
11 2 2 
Emergency 0 - 27 days       
(n = 6) 
3 1 0 
  (n = 403) 28 days - 23 
months  
(n = 133) 
16 6 3 
  2 - 11 years  
(n = 200) 
16 5 2 
  12 - 18 years  
(n = 64) 
15 4 0 
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The maximum number of off-label drugs was eleven, prescribed to inpatients 
children (aged two to 11 years). In the outpatient setting, the maximum 
number of off-label drugs prescribed was five, prescribed to children (aged 
two to 11 years) and in the Emergency Department it was six, prescribed to 
infants (aged 28 days to 23 months). The lowest maximum was one drug 
prescribed to neonates in the Emergency Department. 
 
The maximum number of unlicensed drugs was three, prescribed in the 
Emergency Department to infants (aged 28 days to 23 months). A maximum 
of two unlicensed drugs was prescribed to inpatient and Emergency 
Department children (aged two to 11 years) and to outpatient infants (aged 
28 days to 23 months) and adolescents (aged 12 to 18 years). 
 
 
3.6 Details of off-label and unlicensed drug usage 
 
Of the 2654 drugs recorded in this study, the number of drugs prescribed in 
each setting is shown in Table 3.25. More drugs were prescribed to 
inpatients (1494) than outpatients (502) or Emergency Department patients 
(658). In considering the number of drugs prescribed in each setting, a higher 
percentage of off-label drugs were prescribed to inpatients (29.0%) and 
Emergency Department patients (25.0%). The least number of off-label drugs 
were prescribed to outpatients (16.7%). However, in considering only the 681 
off-label drugs, the highest percentage (63.6%) were prescribed to inpatients 
and the least (12.3%) were prescribed to outpatients. The differences in the 
categories of drugs prescribed in each setting were significant (p < 0.0001). 
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Table 3.25 - Drug classifications prescribed in each setting 
Setting Licensed Off-label Unlicensed 
(n = 2654) (n = 1905) (n = 681) (n = 68) 
Inpatient  
1036 69.3 433 29 25 1.7 (n = 1494) (%) 
Outpatient  
398 79.3 84 16.7 20 4 (n = 502) (%) 
Emergency  
471 71.6 164 25 23 3.5 (n = 658) (%) 
(p < 0.0001) 
 
 
 
 
 
 
 
 
For each setting, the gender distribution was obtained to determine whether 
there were differences in off-label and unlicensed prescribing in male and 
female patients (Table 3.26). Licensed, off-label and unlicensed prescribing 
trends were similar for male and female inpatients. Female outpatients were 
prescribed more licensed and unlicensed drugs than males (81.5% and 5.9% 
respectively compared to 77.8% and 2.7% respectively for males). Male 
outpatients were prescribed more off-label drugs than female outpatients 
(19.5% compared to 12.7% for females). Licensed prescribing for male and 
female Emergency Department patients were similar (70.2% for males and 
73.5% for females) and off-label prescribing was also similar for both sexes 
(25.1% and 24.7% respectively). There was a higher percent of unlicensed 
prescriptions for Emergency Department males (4.7% compared to 1.8% for 
females).  
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Table 3.26 - Gender distribution showing the number of licensed, off-label 
and unlicensed drugs prescribed in each setting 
 
Setting 
(n = 2654) 
Gender 
Drugs Prescribed 
Licensed Off-label Unlicensed 
(n = 1905) (n = 681) (n = 68) 
Inpatient 
Male  
(n = 1009) (%) 
697 69.1 296 29.3 16 1.6 
(n = 1494) Female  
(n = 485) (%) 
339 69.9 137 28.2 9 1.9 
Outpatient 
Male  
(n = 297) (%) 
231 77.8 58 19.5 8 2.7 
(n = 502) Female  
(n = 205) (%) 
167 81.5 26 12.7 12 5.9 
Emergency 
Male  
(n = 379) (%) 
266 70.2 95 25.1 18 4.7 
(n = 658) Female  
(n = 279) (%) 
205 73.5 69 24.7 5 1.8 
 
 
 
 
 
 
Tables 3.27, 3.28 and 3.29 show off-label and unlicensed drugs prescribed to 
male and female patients in each setting. The most frequently prescribed off-
label drug for inpatients was ondansetron (Table 3.27), for outpatients it was 
midazolam (Table 3.28) and for Emergency Department patients it was 
Painstop Day® (Table 3.29). The most frequently prescribed unlicensed 
drugs for inpatients were both dexamethasone and adrenaline (Table 3.27), 
for outpatients it was dilacaine (Table 3.28) and for Emergency Department 
patients it was dexamethasone (Table 3.29) 
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Table 3.27 - Off-label and unlicensed drugs prescribed to inpatients 
INPATIENTS 
Off-Label 
(n  = 296 males, 137 females) 
Drug Male  Female Drug Male 
 
Female Drug Male 
 
Female Drug Male 
 
Female 
Aciclovir 2 0 Hydralazine  1 0 Nifedipine 1 0 Temazepam 1 3 
Alfentanil 1 0 Hydrocortisone 1 0 Omeprazole  3 1 Terbinafine 1 0 
Alteplase 2 0 Hyoscine 
butylbromide 
1 0 Ondansetron 52 25 Ticarcillin with 
clavulanic acid 
6 4 
Amoxicillin 10 3 Ibuprofen 0 1 Oxybutynin 1 0 Tobramycin 3 1 
Aprepitant 3 0 Interferon beta 1 0 Oxycodone 25 15 Topotecan 1 1 
Atorvastatin 0 1 Ipratropium 2 2 Painstop® 20 17 Tropisetron 1 0 
Amoxicillin with 
clavulanic acid 
2 1 Lactulose 1 0 Painstop night® 3 1 Vancomycin 4 0 
Benzylpenicillin 1 0 Lamotrigine 0 1 Panadeine forte® 1 0 Vigabatrin 0 1 
Calcium carbonate 0 1 Lansoprazole 0 1 Pantoprazole 1 0 Vitabdeck® 0 1 
Chloral hydrate 2 1 Levetiracetam 0 1 Paracetamol 26 9 Unlicensed  
(n = 16 males, 9 females) 
Chloramphenicol 2 0 Lignocaine 1 0 Parachoc® 1 0 Adrenaline 4 0 
Ciprofloxacin 1 0 Lisinopril 0 1 Parecoxib 1 1 Carnitine 0 2 
Clobazam  0 1 Lorazepam 5 1 Pizotifen 0 1 Cephazolin 1 0 
Clonidine 6 3 Losartan 0 1 Potassium chloride 1 0 Cisretinoic acid 1 0 
Codeine 7 3 Melatonin 0 1 Praziquantel 1 0 Dexamethasone 4 0 
Dexamethasone  3 1 Meropenem 1 0 Pregabalin 0 1 Dilacaine 1 1 
Dopamine 2 0 Methotrexate 1 0 Promethazine 3 0 Gonadorelin 0 2 
Escitalopram 1 0 Metoclopramide 7 4 Propofol 6 0 Magnesium chloride 1 0 
Fentanyl 8 2 Metronidazole 0 1 Quetiapine 1 1 Metolazone 0 1 
Flucloxacillin 7 3 Microlax® 1 1 Ranitidine 3 0 Picibanil 1 0 
Fluorouracil 1 0 Midazolam 15 5 Salbutamol 18 7 Potassium chloride 1 0 
Fluoxetine 0 1 Mirtazapine 0 1 Sertraline 0 1 Sodium bicarbonate 1 0 
Gabapentin 0 2 Morphine 2 1 Sildenafil 2 0 Sodium chloride 1 2 
Gentamicin 6 1 Natalizumab 1 0 SOOV IT® 1 0 Tocilizumab 0 1 
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Table 3.28 - Off-label and unlicensed drugs prescribed to outpatients 
OUTPATIENTS 
Off-Label 
(n =  58 males, 26 females) 
Drug Male 
 
Female Drug Male 
 
Female Drug Male 
 
Female Drug Male 
 
Female 
Aciclovir 1 0 Eformoterol/ 
budesonide 
0 1 Minoxidil  0 1 Valaciclovir  1 0 
Amitriptyline 0 1 Epipen jr® 1 0 Nifedipine  1 0 Valganciclovir  1 0 
Amlodipine  1 0 Fentanyl  2 0 Nitrazepam  0 1 Vitabdeck®  1 0 
Amoxicillin 1 2 Fluorometholone  1 0 Octreotide  0 1 Xalacom®  0 1 
Azithromycin 1 0 Fluoxetine  1 1 Ofloxacin  1 0  3 1 
Betamethasone 1 1 Glyceryl trinitrate 1 0 Omeprazole  1 1 Unlicensed 
Betaxolol 1 0 Hydralazine   1 0 Ondansetron  3 0 (n =  8 males, 12 females) 
Brimonidine 1 0 Hydroxyurea  1 0 Painstop®  2 2 Aspirin 1 0 
Brinzolamide 1 0 Infliximab  1 0 Paracetamol  2 0 Azathioprine  2 0 
Captopril 1 0 Lactulose  1 1 Risperidone  0 1 Carnitine  0 1 
Carbimazole  1 0 Lansoprazole  1 0 Salbutamol  2 0 Dilacaine  3 7 
Cephalexin 0 1 Latanoprost  1 0 Sertraline  0 1 Domperidone   0 1 
Chloramphenicol 1 0 Levetiracetam  1 0 Solifenacin  1 1 Propranolol   1 0 
Clobazam 2 0 Loperamide  1 0 Ticarcillin with 
clavulanic acid 
1 0 Salicylic acid/ 
cetylpyridium 
chloride 
0 1 
Clonidine 1 2 Loratadine  0 1 Timolol  1 0 Sodium chloride 1 0 
Darbepoetin alfa 1 0 Methotrexate  0 1 Tobramycin  2 1 Tacrolimus  0 1 
Dexamethasone  2 1 Metoclopramide  
 
1 0 Tolterodine  0 1 Trichloracetic 
acid paste 
0 1 
Dopamine 1 0 Midazolam  4 1 Tropicamide  1 0    
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Table 3.29 - Off-label and unlicensed drugs prescribed to Emergency Department patients 
EMERGENCY PATIENTS 
Off-Label 
(n = 95 males, 69 females) 
Drug Male 
 
Female Drug Male Female Drug Male Female Drug Male Female 
Aciclovir 2 0 Gentamicin 1 0 Olanzapine 1 1 Teicoplanin 0 1
Adrenaline 1 0 Ibuprofen 0 3 Omeprazole 1 3 Temazepam 0 1
Alfentanil 1 0 Ipratropium 6 2 Ondansetron 8 6 Ticarcillin with 
clavulanic acid 
7 1
Amoxicillin 0 2 Ketamine 1 0 Oxycodone 4 5 Vancomycin 1 0
Benzylpenicillin 1 0 
Leuprorelin acetate 0 1 Painstop Day® 14 16 Unlicensed 
(n = 18 males, 5 females) 
Cephalexin 0 1 Loratadine 2 0 Painstop night® 0 1 Adrenaline 3 0
Chloramphenicol 1 0 Lorazepam 1 0 Pantoprazole 1 0 Aspirin 1 0
Clonidine 0 1 Metronidazole 1 1 Paracetamol 5 6 Dexamethasone 11 5
Fentanyl 6 3 Midazolam 3 1 Propofol 0 1 Domperidone 1 0
Flucloxacillin 5 3 Montelukast 1 0 Quetiapine 2 0 Potassium Chloride 1 0
Fluoxetine 1 0 Mupirocin 2 0 Salbutamol 15 9 Tinidazole 1 0
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To determine differences in prescribing trends with age, the distribution of 
licensed, off-label and unlicensed drugs for the four age groups is shown in 
Table 3.30. The highest percentages of licensed drugs were prescribed to 
children aged two to 11 years (46.7%). This was also the age group 
prescribed the highest percentage of off-label drugs (56.8%). The highest 
percentage of unlicensed prescribing was in infants aged 28 day to 23 
months (52.9%). The smallest percentage of licensed prescribing was in 
neonates aged zero to 27 days (3.3%). This age group also had the smallest 
percentage of off-label and unlicensed prescribed drugs (4.4% and 1.5% 
respectively). 
 
 
Table 3.30 - Distribution of the type of drug prescribed to the various age 
groups 
Type  
of  
Drug 
Age group of patients 
0 - 27 days 
28 days - 23 
months 
2 - 11 years 
12 - 18 
years 
(n = 94) (n = 533) (n = 1302) (n = 725)
Licensed 63 3.3 333 17.5 890 46.7 619 32.5 
(n = 1905) (%)   
Off-label 30 4.4 164 24.1 387 56.8 100 14.7 
(n = 681) (%)   
Unlicensed 1 1.5 36 52.9 25 36.8 6 8.8 
(n = 68) (%)                 
 
 
 
When all of the 2654 drugs prescribed were categorised according to their 
ATC code and separated into licensed, off-label and unlicensed drugs (Table 
3.31), the majority of licensed and off-label drugs were classified into the 
nervous system (n = 1034; 39.0%). There were no unlicensed drugs in this 
category. The categories with the highest percentage of unlicensed drugs 
were systemic hormonal preparations excluding sex hormones (n = 22; 
14.4%) and sensory organ drugs (n = 13; 13.7%). 
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Table 3.31 - Frequency of licensed, off-label and unlicensed drugs 
prescribed in each ATC category. 
ATC Licensed Off-label Unlicensed 
(n = 1905) (n = 681) (n = 68) 
Alimentary tract and 
metabolism (n = 408) (%) 
258 63.2 139 34.1 11 2.7 
Blood and blood forming 
organs (n = 34) (%) 
28 82.4 3 8.8 3 8.8 
Cardiovascular system  
(n = 69) (%) 
37 53.6 28 40.6 4 5.8 
Dermatologicals (n = 111) (%) 101 91.0 7 6.3 3 2.7 
Genito-urinary system and 
sex hormones (n = 19) (%) 
10 52.6 7 36.8 2 10.5 
Systemic hormonal 
preparations excl sex 
hormones (n = 154) (%) 
129 83.8 3 1.9 22 14.3 
Anti-infectives for systemic 
use (n = 400) (%) 
302 75.5 97 24.3 1 0.2 
Antineoplastics and 
immunomodulating agents 
(n = 42) (%) 
28 66.7 9 21.4 5 11.9 
Musculo-skeletal system  
(n = 73) (%) 
71 97.3 2 2.7 0 0.0 
Nervous system  
(n = 1034) (%) 
739 71.5 295 28.5 0 0.0 
Antiparasitic products, 
insecticides and repellent  
(n = 5) (%) 
4 80.0 1 20.0 0 0.0 
Respiratory system  
(n = 180) (%) 
106 58.9 71 39.4 3 1.7 
Sensory organs   
(n = 95) (%) 
63 66.3 19 20.0 13 13.7 
Various (n = 30) (%) 29 96.7 0 0.0 1 3.3 
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Table 3.32 lists the thirty most commonly prescribed drugs overall in 
descending order, indicating whether they were prescribed in a licensed, off-
label or unlicensed manner. The ten most commonly prescribed drugs were 
paracetamol, ibuprofen, ondansetron, Painstop Day®, morphine, oxycodone, 
amoxicillin, dexamethasone, salbutamol and prednisolone.  
 
Table 3.32 shows that of the ten most commonly prescribed drugs overall, 
several were prescribed in an off-label manner more frequently than in a 
licensed manner including ondansetron (74.6%), Painstop Day® (88.8%), 
oxycodone (66.2%) and salbutamol (87.9%). Other drugs that were 
prescribed in an off-label manner more frequently than in a licensed manner 
included fentanyl (53.8%), midazolam (93.5%), ticarcillin/ clavulanic acid 
(Timentin®) (95.0%) and omeprazole (55.6%). Some drugs, including 
prednisolone, Emla® cream, hydrocortisone, NovoRapid® insulin, 
Panadeine® and ceftriaxone, were not prescribed in either an off-label or 
unlicensed manner. 
 
Dexamethasone, which is marketed in a number of dosage forms including 
tablets, injection and eye drops, was prescribed in a licensed, off-label and 
unlicensed manner. In the six cases where the drug was used in an off-label 
manner, eye drops were administered to patients despite the safety and 
efficacy in paediatric patients not having been established. All twenty 
unlicensed uses of dexamethasone were due to reformulation.  
 
The ten most commonly prescribed drugs to different age groups are shown 
in Table 3.33 (including licensed, unlicensed and off-label drugs). Prescribing 
trends for different age groups varied, especially drugs prescribed to 
neonates (aged zero to 27 days) since these included mainly anti-infectives 
such as amoxicillin, gentamicin, cefotaxime, nystatin, aciclovir, amoxicillin 
with clavulanic acid (Augmentin Duo®) and vancomycin. The most commonly 
prescribed drugs to infants (aged 27 days to 23 months) included analgesics 
(paracetamol and ibuprofen), respiratory drugs (salbutamol) and anti-
infectives (amoxicillin, flucloxacillin and amoxicillin/ clavulanic acid). 
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Table 3.32 - The 30 most common drugs prescribed overall. 
Drug Licensed Off-label Unlicensed Total
  n % n % n %   
Paracetamol 265 84.7 48 15.3 0 0.0 313
Ibuprofen  196 98 4 2.0 0 0.0 200
Ondansetron 32 25.4 94 74.6 0 0.0 126
Painstop Day® (paracetamol/ 
codeine) 
9 11.2 71 88.8 0 0.0 80 
Morphine 76 96.2 3 3.8 0 0.0 79
Oxycodone 25 33.8 49 66.2 0 0.0 74
Amoxicillin 41 68.3 18 31.7 0 0.0 59
Dexamethasone 32 55.2 6 10.3 20 34.5 58
Salbutamol 7 12.1 51 87.9 0 0.0 58
Prednisolone 48 100 0 0.0 0 0.0 48
Flucloxacillin 23 56.1 18 43.9 0 0.0 41
Fentanyl  18 46.2 21 53.8 0 0.0 39
Augmentin duo® 
(amoxicilin/ clavulanic acid) 
30 90.9 3 9.1 0 0.0 33 
Midazolam  2 6.5 29 93.5 0 0.0 31
Propofol 22 75.9 7 24.1 0 0.0 29
Emla® (lignocaine/ prilocaine) 26 100 0 0.0 0 0.0 26
Loratadine 23 88.5 3 11.5 0 0.0 26
Metoclopramide 14 53.8 12 46.2 0 0.0 26
Chloramphenicol 18 81.8 4 18.2 0 0.0 22
Cephalexin 19 90.5 2 9.5 0 0.0 21
Gentamicin 13 61.9 8 38.1 0 0.0 21
Lactulose 18 85.7 3 14.3 0 0.0 21
Panadeine forte 20 95.2 1 4.8 0 0.0 21
Hydrocortisone 20 100 0 0.0 0 0.0 20
NovoRapid® (insulin aspart) 20 100 0 0.0 0 0.0 20
Timentin® (ticarcillin/ clavulanic acid) 1 5.0 19 95.0 0 0.0 20
Metronidazole 16 84.2 3 15.8 0 0.0 19
Panadeine® (paracetamol/ codeine) 19 100 0 0.0 0 0.0 19
Omeprazole 8 44.4 10 55.6 0 0.0 18
Ceftriaxone 16 100 0 0.0  0 0.0 16
      
115
Table 3.33 - The ten most common drugs, including licensed, off-label or unlicensed drugs, to various age groups. 
Drugs prescribed for  
0 - 27 days 
Drugs prescribed for  
27 days - 23 months 
Drugs prescribed for  
2 - 11 years 
Drugs prescribed for  
12 - 18 years 
(n = 94 drugs) (n = 533 drugs) (n = 1302 drugs) (n = 725 drugs) 
Drugs Frequency % Drugs Frequency % Drugs Frequency % Drugs Frequency % 
Amoxicillin  12 12.8 Paracetamol 91 17.1 Paracetamol 163 12.5 Paracetamol 51 7 
Gentamicin  10 10.6 Ibuprofen 46 8.6 Ibuprofen 108 8.3 Ibuprofen 45 6.2 
Paracetamol  8 8.5 Salbutamol 26 4.9 Ondansetron  79 6.1 Ondansetron  33 4.6 
Cefotaxime  4 4.3 Dexamethasone 17 3.2 
Painstop Day® 
(paracetamol/ 
codeine) 
65 5 Oxycodone 30 4.1 
Nystatin  4 4.4 Amoxicillin 14 2.6 Morphine 43 3.3 Morphine 23 3.2 
Aciclovir  3 3.2 Flucloxacillin 14 2.6 Oxycodone 40 3.1 
Panadeine 
Forte® 
(paracetamol/ 
codeine) 
18 2.5 
Amoxicillin/ 
clavulanic acid 
3 3.2 Ondansetron  14 2.6 Dexamethasone 32 2.5 
Panadeine® 
(paracetamol/ 
codeine) 
17 2.3 
Morphine  3 3.2 Prednisolone  14 2.6 Amoxicillin 29 2.2 Fentanyl 12 1.7 
Omeprazole  3 3.2 Dilacaine  11 2.1 Fentanyl 26 2.0 Prednisolone 11 1.5 
Vancomycin  3 3.2 
Amoxicillin/ 
clavulanic acid 
10 1.9 Salbutamol 26 2.0 Glargine insulin 10 1.4 
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Children aged two to 11 years were prescribed mainly analgesics (paracetamol, 
ibuprofen, Painstop Day®, morphine, oxycodone and fentanyl) and alimentary 
tract drugs (ondansetron). Adolescents (aged 12 to 18 years) were also 
prescribed mainly analgesics and alimentary tract drugs but instead of Painstop 
Day®, they were prescribed Panadeine Forte® and Panadeine®. 
 
Considering only drugs prescribed in an off-label manner, the twenty most 
frequently prescribed off-label drugs are shown in Table 3.34. Off-label drugs 
shown in Table 3.34 include the alimentary tract drugs ondansetron, nervous 
system drugs including Painstop Day®, oxycodone, paracetamol, midazolam 
and fentanyl, the respiratory system drug salbutamol, as well as the anti-
infectives ticarcillin with clavulanic acid, amoxicillin and flucloxacillin. 
Ondansetron was the most frequently prescribed off-label drug. 
 
The ten most commonly prescribed off-label drugs prescribed to the various age 
groups are shown in Table 3.35. Off-label prescribing trends varied for the 
different age groups. Six of the ten most common drugs prescribed to neonates 
(aged zero to 27 days) were anti-infectives including amoxicillin, gentamicin, 
aciclovir, amoxicillin with clavulanic acid (Augmentin Duo®), meropenem and 
metronidazole.  The most commonly prescribed drug to infants aged 27 days to 
23 months was the respiratory drug salbutamol. Other drugs included analgesics 
(paracetamol, Painstop Day® and codeine), alimentary tract drugs (ondansetron 
and omeprazole), anti-infectives (amoxicillin and flucloxacillin) and other drugs 
affecting the nervous system (midazolam and propofol). The most commonly 
prescribed drug to children aged two to 11 years was Painstop Day®. Other 
analgesics included oxycodone, paracetamol and fentanyl. The second most 
common drug prescribed to children aged two to 11 years was ondansetron. 
Ondansetron was the most common drug prescribed to adolescents aged 12 to 
18 years. Other drugs included drugs affecting the nervous system (fentanyl, 
lorazepam, oxycodone, temazepam, midazolam and quetiapine) and anti-
infectives (ticarcillin/ clavulanic acid and tobramycin). 
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Table 3.34 -  The twenty most common off-label drugs and their frequencies 
 
Off-label drug Frequency Percent ATC Category 
Ondansetron 94 13.8 Alimentary Tract  
Painstop Day® 71 10.4 Nervous system  
Salbutamol 51 7.5 Respiratory System  
Oxycodone 49 7.2 Nervous system  
Paracetamol 48 7.1 Nervous system  
Midazolam 29 4.3 Nervous system  
Fentanyl 21 3.1 Nervous system 
Ticarcillin/ clavulanic acid 19 2.8 Anti-infective 
Amoxicillin 18 2.6 Anti-infective 
Flucloxacillin 18 2.6 Anti-infective 
Clonidine 13 1.9 Cardiovascular 
System 
Ipratropium 12 1.8 Respiratory System 
Metoclopramide 12 1.8 Alimentary Tract  
Codeine 10 1.5 Nervous system 
Omeprazole 10 1.5 Alimentary Tract 
Gentamicin 8 1.2 Anti-infective 
Lorazepam 7 1.0 Nervous system 
Propofol 7 1.0 Nervous system 
Tobramycin 7 1.0 Nervous system 
Dexamethasone 6 0.9 Sensory Organs 
 
 
 
 
 
 
Table 3.36 lists all off-label drugs prescribed in each ATC category and shows 
the frequency of each drug. 
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Table 3.35 - The ten most common off-label drugs prescribed to different age groups 
Drugs prescribed for 
0 - 27 days 
Drugs prescribed for 
28 days - 23 months 
Drugs prescribed for 
2 - 11 years 
Drugs prescribed for 
12 - 18 years 
(n = 94 drugs) 
 
(n = 533 drugs) 
 
(n = 1302 drugs) 
 
(n = 725 drugs) 
 
Drugs Freq % Drugs Freq % Drugs Freq % Drugs Freq % 
Amoxicillin  9 30.0 Salbutamol 25 15.2 Painstop Day® 60 15.6 Ondansetron 23 23.0 
Gentamicin  4 13.3 Ondansetron  14 8.5 Ondansetron  57 14.7 Fentanyl 7 7.0 
Aciclovir 3 10.0 Paracetamol 13 7.9 Oxycodone 40 10.3 Lorazepam 5 5.0 
Omeprazole  3 10.0 Painstop Day® 10 6.1 Paracetamol 34 8.8 Oxycodone 5 5.0 
Augmentin Duo® 2 6.7 Amoxicillin 7 4.3 Salbutamol 23 5.9 Temazepam 5 5.0 
Dopamine 2 6.7 Flucloxacillin  7 4.3 Midazolam 16 4.1 
Ticarcillin/ 
clavulanic 
acid 
5 5.0 
Midazolam 2 6.7 Midazolam 7 4.3 Fentanyl 13 3.4 Fluoxetine 4 4.0 
Hydrocortisone 1 3.3 Omeprazole  7 4.3 Clonidine 11 2.8 Midazolam 4 4.0 
Meropenem 1 3.3 Codeine 6 3.7 Flucloxacillin  11 2.8 Quetiapine 4 4.0 
Metronidazole 1 3.3 Propofol 5 3.1 Metoclopramide 10 2.6 Tobramycin 4 4.0 
 
  
    
119
Table 3.36 - Details of off-label drugs prescribed in each ATC category with their respective frequencies 
Alimentary tract and metabolism (n = 139) Genito-urinary system and sex hormones 
(n = 7) 
Nervous system (n = 295) Antineoplastic and immunomodulating 
agents (n = 9) 
Ondansetron  94 Sildenafil 2 Painstop Day® 71 Methotrexate 2 
Metoclopramide 12 Solifenacin 2 Oxycodone 49 Topotecan 2 
Omeprazole  10 Leuprorelin acetate 1 Paracetamol 48 5-fluorouracil 1 
Aprepitant  3 Oxybutynin 1 Midazolam 29 Hydroxyurea 1 
Lactulose  3 Tolterodine 1 Fentanyl 21 Infliximab 1 
Ranitidine  3 Dermatologicals (n = 7) Codeine 10 Interferon beta 1 
Lansoprazole  2 Mupirocin 2 Lorazepam  7 Natalizumab 1 
Microlax® 2 Betamethasone 2 Propofol 7 Respiratory System (n = 71) 
Pantoprazole 2 SOOV® 1 Painstop Night 5 Salbutamol 51 
Vitabdeck 2 Glyceryl trinitrate 1 Temazepam 5 Ipratropium  12 
Calcium carbonate 1 Minoxidil 1 Fluoxetine  4 Loratidine 3 
Hyoscine butylbromide 1 Anti-infective (n = 97)   Ibuprofen 4 Promethazine 3 
Loperamide 1 Ticarcillin/ clavulanic acid 19 Quetiapine 4 Eformoterol/ budesonide 1 
Paraffin liquid (Parachoc®) 1 Flucloxacillin 18 Chloral hydrate 3 Montelukast 1 
Potassium chloride 1 Amoxicillin 18 Clobazam 3 Sensory Organs (n = 19) 
Tropisetron 1 Gentamicin 8 Morphine 3 Dexamethasone 6 
Blood and blood forming organs (n = 3) Tobramycin  7 Alfentanil 2 Chloramphenicol 4 
Alteplase  2 Aciclovir 5 Gabapentin 2 Betaxolol 1 
Darbepoetin alfa 1 Vancomycin 5 Levetiracetam 2 Brimonidine 1 
Cardiovascular System (n = 28) Amoxicillin/ clavulanic acid 3 Olanzapine 2 Brinzolamide 1 
Clonidine  13 Metronidazole 3 Sertraline 2 Fluorometholone 1 
Dopamine 3 Benzylpenicillin 2 Amitriptyline  1 Latanoprost 1 
Hydralazine 2 Cephalexin 2 Escitalopram 1 Latanoprost/ timolol 1 
Nifedipine  2 Azithromycin 1 Ketamine 1 Ofloxacin 1 
Adrenaline 1 Ciprofloxacin 1 Lamotrigine 1 Timolol 1 
Amlodipine  1 Meropenem 1 Melatonin 1 Tropicamide 1 
Atorvastatin 1 Teicoplanin 1 Mirtazapine 1 Systemic hormonal preparations, excl 
sex hormones (n = 3) 
Captopril  1 Terbinafine 1 Nitrazepam 1 Carbimazole 1 
Epipen junior 1 Valaciclovir 1 Paracetamol/ codeine 1 Hydrocortisone 1 
Lignocaine 1 Valganciclovir 1 Pizotifen 1 Octreotide 1 
Lisinopril 1 Musculoskeletal system (n = 2) Pregabalin 1 Antiparasitic products, insecticides and 
repellent (n = 1) Losartan  1 Parecoxib 2 Risperidone 1 
      Vigabatrin  1 Praziquantil  1 
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As outlined in Chapter 2, a hierarchical approach was used in assigning reasons 
for off-label prescribing. This was done so that each drug was assigned only to 
one single category. The order of allocations was age, indication, route of 
administration and dose (including inappropriate frequency). Therefore, a drug 
off-label for dose and age would be classified as off-label for age. Similarly, for a 
drug administered at an inappropriate frequency where the age was within the 
marketing authorisation, the reason for off-label prescribing would be recorded 
as dosage. However, where a drug not marketed for a particular age group was 
administered at an inappropriate frequency, the reason for off-label prescribing 
would be due to age. Hence, there may have been more dosages which were 
off-label but where age as the primary factor may have rendered it off-label, then 
the dosage was not evaluated. The same applied to the other reasons. 
 
Table 3.37 shows that the most common reasons for off-label prescribing were 
due to age and dosage (43.2% and 47.4% respectively). When considering that 
some drugs, where dose was a factor, were likely to be combined with those 
where age was a factor, indicates that dosage was clearly the primary factor 
leading to off-label prescribing. The least common reason for off-label 
prescribing was due to indication. 
 
Table 3.37 - Reasons for off-label prescribing showing the hierarchical 
classification used 
Reason for off-label prescribing Frequency Percentage 
(n = 681) 
Age 294 43.2 
Indication 29 4.3 
Route of administration 35 5.1 
Dosage (including inappropriate 
frequency) 
323 47.4 
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When the reasons for off-label prescribing were determined for each ATC code 
(Table 3.38), in the alimentary system the majority of drugs were off-label due to 
dosage (51.8%). With respect to the nervous system, a large percentage of 
drugs were off-label due to age (44.4%) and dosage (44.1%). 
 
The most commonly prescribed unlicensed drugs were dexamethasone (20/ 68), 
dilacaine (12/ 68) and adrenaline (7/ 68). All unlicensed drugs were categorised 
into the appropriate ATC category (Table 3.39). The ATC category with the 
majority of unlicensed drugs were systemic hormonal preparations excluding 
sex hormones (n = 20, 29.4%) and sensory organ drugs (n = 13, 19.1%). The 
most commonly prescribed unlicensed systemic hormonal preparation excluding 
sex hormones was dexamethasone and the most commonly prescribed 
unlicensed sensory organ drug was dilacaine. Dexamethasone was 
reformulated from tablets into a liquid dosage form suitable for administration. 
Dilacaine mydriatic eye drops were formulated at PMH since no commercial 
preparation was available. Each 1 mL of dilacaine eye drops contained 
proxymetacaine 1.25 mg, cyclopentolate 2.5 mg, tropicamide 2.5 mg and 
phenylephrine 25 mg. The eye drops were intended to be instilled into the eye 
one hour prior to examination and the formulation was for individual patient use 
only. There were no unlicensed drugs in a number of ATC categories including 
the musculoskeletal system, nervous system and antiparasitic products, 
insecticides and repellent. 
 
Table 3.40 shows the most commonly prescribed unlicensed drugs to different 
age groups. The only unlicensed drug prescribed to a neonate aged zero to 27 
days was cephazolin which was formulated as an eye drop. Only six unlicensed 
drugs were prescribed to adolescents aged 12 to 18 years which included two 
topical preparations for eczema.  
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Table 3.38 - Reasons for off-label prescribing in each ATC category 
Off-label Age Indication 
Route of 
admin. 
Dosage 
(n = 294) (n = 29) (n = 35) (n = 323) 
Alimentary tract  
(n = 139) (%) 
54 
(38.9) 
13 
(9.4) 
0 
(0.0) 
72 
 (51.8) 
Blood and blood forming 
products (n = 3) (%) 
3 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Cardiovascular system  
(n = 28) (%) 
24 
(85.7) 
2 
(7.1) 
2 
(7.1) 
0 
(0.0) 
Dermatologicals  
(n = 7) (%) 
7 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Genitourinary system & sex 
hormones (n = 7) (%) 
7 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Systemic hormonal 
preparations (n = 3) (%) 
3 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Anti-infective 
(n = 97) (%) 
32 
(33.0) 
3 
(3.1) 
4 
(4.1) 
58 
(59.8) 
Antineoplastics  
(n = 9) (%) 
5 
(55.6) 
2 
(22.2) 
0 
(0.0) 
2 
(22.2) 
Musculo-skeletal system  
(n = 2) (%) 
2 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Nervous system  
(n = 295) (%) 
131 
(44.4) 
5 
(1.7) 
29 
(9.8) 
130 
(44.1) 
Antiparasitic products, 
insecticides and repellent 
(n = 1) (%) 
1 
(100.0)
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Respiratory system  
(n = 71) (%) 
10 
(14.1) 
0 
(0.0) 
0 
(0.0) 
61 
(85.9) 
Sensory organs  
(n = 19) (%) 
15 
(78.9) 
4 
(21.1) 
0 
(0.0) 
0 
(0.0) 
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Table 3.39 - Listing of the 68 unlicensed drugs in appropriate ATC categories 
 
ATC category Drugs Frequency 
% 
(n = 68) 
Alimentary tract  
(n = 11) (%) 
Sodium chloride 4 36.4 
Carnitine  3 27.3 
Domperidone  2 18.2 
Magnesium chloride  1 9.1 
Potassium chloride 1 9.1 
Blood and blood forming 
products (n = 3) (%) 
Aspirin  2 66.7 
Sodium bicarbonate 1 33.3 
Cardiovascular system  
(n = 4) (%) 
Adrenaline 2 50.0 
Metolazone  1 25.0 
 Propranolol  1 25.0 
Dermatologicals  
(n = 3) (%) 
Sal acid/ cetylpyridinium  1 33.3 
Tacrolimus  1 33.3 
Trichloracetic acid paste  1 33.3 
Genitourinary system & 
sex hormones (n = 2) (%) 
Gonadorelin  2 100.0
Systemic hormonal 
preparations (n = 20) (%) 
Dexamethasone 20 100.0
   
Anti-infective (n = 1) (%) Tinidazole  1 100.0
Antineoplastics and 
immunomodulating 
agents 
(n = 5) (%) 
Azathioprine  2 40.0 
Picibanil (OK 432) 1 20.0 
Cisretinoic acid 1 20.0 
Tocilizumab  1 20.0 
Respiratory system  
(n = 5) (%) 
Adrenaline  5 100.0
Sensory organs  
(n = 13) (%) 
Dilacaine  12 92.3 
Cephazolin  1 7.7 
Various (n = 1) (%) Potassium chloride 1 100.0
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Table 3.40 - The ten most commonly prescribed unlicensed drugs (where available) prescribed to various age groups 
 
Drugs prescribed for Drugs prescribed for Drugs prescribed for Drugs prescribed for 
0 - 27 days 28 days - 23 months 2 - 11 years 12 - 18 years 
(n = 94 drugs) (n = 533 drugs) (n = 1302 drugs) (n = 725 drugs) 
Drugs Freq % Drugs Freq % Drugs Freq % Drugs Freq % 
Cephazolin 1 1.1 Dilacaine 11 2.1 Dexamethasone 11 0.8 Cisretinoic acid 1 0.1 
  Dexamethasone 9 1.7 Adrenaline 3 0.2 Gonadorelin 1 0.1 
    Adrenaline 4 0.8 Carnitine 2 0.1 
Salicylic acid/ 
cetylpyridinium  1 0.1 
  Sodium chloride 3 0.6 Picibanil 1 0.1 Sodium chloride 1 0.1 
  Aspirin 2 0.4 Azathioprine 1 0.1 Tocilizumab 1 0.1 
    Domperidone 2 0.4 Dilacaine 1 0.1 
Trichloracetic acid 
paste  1 0.1 
  Azathioprine 1 0.2 Gonadorelin 1 0.1   
    Carnitine 1 0.2 
Magnesium 
chloride 1 0.1     
    Propranolol 1 0.2 Metolazone 1 0.1     
      Tinidazole 1 0.2 Tacrolimus 1 0.1       
 
 
125 
In summary, the rates identified in the study of prescribing off-label and 
unlicensed medicines are as shown in Table 3.41. 
 
 
 
 
Table 3.41- Overall rates of off-label and unlicensed prescribing 
Classification Rate per 1000 
Off-label Unlicensed 
 
Patients admitted 
 
 
331 
 
34 
Patients admitted and 
prescribed drugs 
 
491 
 
 
50  
Patients admitted as 
inpatients and 
prescribed drugs 
 
781 
 
33  
Patients classified as 
outpatients and 
prescribed drugs 
 
 
266 
 
 
 
63 
 
Patients admitted as 
emergency cases and 
prescribed drugs 
 
 
396 
 
 
 
56 
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Chapter 4 
4Lincomycin Results 
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4.1 Analytical methods 
 
4.1.1 Assay for lincomycin hydrochloride HPLC optimisation 
 
Results for the retention times of HPLC analysis of Lincocin® (which contains 
lincomycin hydrochloride and benzyl alcohol) using either a Prosphere® or 
Apollo® C18 columns with different ratios of acetonitrile and water in the 
mobile phase, as indicated in Section 2.11.1, are summarised in Table 4.1. 
 
Separation of lincomycin hydrochloride and benzyl alcohol peaks was 
achieved with the Prosphere® column using a mobile phase containing either 
8%, 10% and 15% acetonitrile, a flow rate of 1.5 mL/min and wavelength of 
220nm (Figure 4.1). At each of these concentrations of acetonitrile, 
lincomycin hydrochloride was eluted before benzyl alcohol.  
 
A mobile phase containing 5 % acetonitrile did not produce acceptable peak 
separation and peaks were of poor shape. There was also a reversal of 
lincomycin hydrochloride and benzyl alcohol elution times where benzyl 
alcohol eluted before lincomycin (Figure 4.2). 
 
Superior separation of peaks was obtained using the C18 reverse phase 
Apollo® column. The results showed that 40% acetonitrile and 60% water 
containing 50 mM phosphoric acid at a flow rate of 1.5 mL/min and 
wavelength of 220 nm produced good benzyl alcohol and lincomycin peaks 
but the peaks were too close together (Figure 4.3a). At these conditions 
benzyl alcohol, which was also injected as a separate solution (Figure 4.3b), 
gave a clear peak at 2.374 minutes, with baseline separation of benzyl 
alcohol from lincomycin. 
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Table 4.1 - Results for lincomycin hydrochloride and benzyl alcohol HPLC 
analyses to determine optimum conditions using Prosphere® and Apollo® 
C18 columns and different ratios of acetonitrile and water in the mobile phase 
Column Acetonitrile 
(%) 
Lincomycin 
hydrochloride 
retention  
time  
(minutes) 
Benzyl 
alcohol 
retention 
time 
(minutes) 
Result 
Prosphere® 15 1.7 3 Both peak shapes 
acceptable 
Prosphere® 10 2.7 4.3 Both peak shapes 
acceptable 
Prosphere® 8 3.7 5 Both peak shapes 
acceptable 
Prosphere® 5 7.6 7 Lincomycin showed 
poor peak shape; 
benzyl 
alcohol showed 
acceptable peak 
shape. 
Apollo®  40 ~ 1.0 2.4 Both peak shapes 
acceptable 
Apollo®  25 1.5 4 Both peak shapes 
acceptable 
Apollo®  15 2.5 7.8 Both peak shapes 
acceptable 
Apollo®  12 3.8 10.7 Both peak shapes 
acceptable 
Apollo®  5 >20 >20 Lincomycin showed 
poor peak shape; 
benzyl alcohol 
showed poor peak 
shape. 
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(a) 15% acetonitrile and 85% water. 
 
 
 
 
 
 
 
 
(b) 10% acetonitrile and 90% water. 
 
 
 
 
 
 
(c) 8% acetonitrile and 92% water. 
 
 
Figure 4-1 - HPLC traces showing the separation of lincomycin 
hydrochloride and benzyl alcohol using a Prosphere® column and different 
concentrations of acetonitrile and water in the mobile phase. Concentrations 
of (a) 15%, (b) 10% and (c) 8% acetonitrile are shown. A flow rate of 1.5 
mL/min and wavelength of 220 nm were used. 
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Figure 4-2 - Separation of lincomycin hydrochloride and benzyl alcohol 
peaks using a Prosphere® column and mobile phase of 5% acetonitrile and 
95% water. The flow rate was 1.5 mL/min and wavelength 220 nm.  
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(a) Separation of lincomycin and benzyl alcohol peaks. 
 
 
 
 
 
 
 
 
 
(b) Benzyl alcohol elution at 2.374 minute. 
 
 
Figure 4-3 - Diagram (a) shows separation of lincomycin hydrochloride and 
benzyl alcohol peaks using a 1 in 100 dilution of Lincocin® and a C18 reverse 
phase Apollo® column, with a mobile phase of 40% acetonitrile and 60% 
water containing 50 mM phosphoric acid at a flow rate of 1.5 mL/min and 
wavelength of 220 nm; (b) shows pure benzyl alcohol. 
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Changing the mobile phase to 25% acetonitrile and 75% water containing 50 
mM phosphoric acid at pH 3 (flow rate 1.5 mL/min, wavelength 220 nm) 
produced two peaks that were separated satisfactorily however, lincomycin 
hydrochloride was eluted at the solvent front, which was not satisfactory 
(Figure 4.4a). Using the same mobile phase but a wavelength of 260 nm, a 
peak for benzyl alcohol only was produced (without lincomycin hydrochloride) 
thereby confirming the maximum absorption of benzyl alcohol at this 
wavelength (Figure 4.4b). 
 
A mobile phase consisting of 15% acetonitrile and 85% water containing 50 
mM phosphoric acid at pH 3 and wavelength of 220 nm produced two good 
peaks separating lincomycin hydrochloride and benzyl alcohol (Figure 4.5). 
An attenuation of 6, which had been used for all previous traces, was 
maintained but the peaks produced were too large. Hence the attenuation 
was changed to 10 which produced peaks on a suitable scale. However as 
can be seen in Figure 4.5, the lincomycin hydrochloride peak was still close 
to the solvent front. 
 
Using a mobile phase consisting of 5% acetonitrile and 95% water containing 
50 mM phosphoric acid at pH 3 did not produce a good result as the peaks 
were too close together and too distant from the solvent front.  
 
A mobile phase of 12% acetonitrile and 88% water containing 50 mM 
phosphoric acid at pH 3 produced the optimum conditions on the C18 reverse 
phase Apollo® column (Figure 4.6). This was used for further analysis 
including stability of lincomycin hydrochloride at 60C in acid (HCl), base 
(NaOH) and hydrogen peroxide.  
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(a) Separation of lincomycin and benzyl alcohol. 
 
 
 
(b) Benzyl alcohol elution at 4.018 minutes. 
 
Figure 4-4 - Diagram (a) shows lincomycin hydrochloride and benzyl alcohol 
peaks using a 1 in 100 dilution of Lincocin® and a C18 reverse phase Apollo® 
column, with a mobile phase of 25% acetonitrile and 75% water containing 
50 mM phosphoric acid at a flow rate of 1.5 mL/min and wavelength of 220 
nm; (b) shows pure benzyl alcohol at a wavelength of 260 nm. 
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Figure 4-5 - Separation of lincomycin hydrochloride and benzyl alcohol 
peaks using a C18 reverse phase Apollo® column, with a mobile phase of 
15% acetonitrile and 85% water containing 50 mM phosphoric acid at a flow 
rate of 1.5 mL/min and wavelength of 220 nm. 
 
 
 
 
Figure 4-6 - Separation of lincomycin hydrochloride and benzyl alcohol 
peaks using a C18 reverse phase Apollo® column, with a mobile phase of 
12% acetonitrile and 88% water containing 50 mM phosphoric acid at a flow 
rate of 1.5 mL/min and wavelength of 220 nm.  
  
135 
4.1.2 Assay validation 
 
4.1.2.1 Calibration curve of Lincocin® 
 
The linearity of the detector response for a range of Lincocin® (lincomycin 
hydrochloride) concentrations was determined to validate the reverse phase 
HPLC method. The assay was found to produce a linear relationship 
between the peak area and concentrations of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 
and 1.0 mg/mL lincomcyin hydrochloride with a regression coefficient (R2) of 
0.9993 as shown in Figure 4.7. 
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Figure 4-7 - Lincomycin hydrochloride calibration curve using solutions of 
Lincocin®. 
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4.1.2.2 Calibration curve of pure analytical grade lincomycin 
 
The linearity of the detector response for a range of pure analytical grade 
lincomycin hydrochloride monohydrate concentrations was determined to 
validate the reverse phase HPLC method and to determine the amount of 
lincomycin in a freshly prepared 0.6 mg/mL lincomycin hydrochloride sample 
using Lincocin® injection. The assay was found to produce a linear 
relationship between the peak area and concentrations of lincomcyin 
hydrochloride monohydrate with a regression coefficient (R2) of 0.9999 as 
shown in Figure 4.8. 
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Figure 4-8 - Calibration curve prepared from analytical grade lincomycin 
hydrochloride monohydrate standard. 
. 
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The above calibration curve was used to determine the amount of lincomycin 
base in the 0.6 mg/mL lincomycin hydrochloride sample prepared from 
Lincocin® and was found to contain 0.629 mg/mL lincomycin. This was 
equivalent to 104.9% of the stated amount. According to the British 
Pharmacopeia (BP) 2013,36 the specifications for the content of lincomycin in 
lincomycin injection is 92.5 to 107.5% of the stated amount. The calculated 
quantity of lincomycin in Lincocin® injections (104.9%) meets the 
specifications of the BP. 
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4.1.2.3 Inter- and intra-day variability 
 
Table 4.2 shows the results obtained when six separate injections of 0.6 
mg/mL lincomycin hydrochloride (Lincocin®) were analysed consecutively on 
two separate days. The minimum and maximum HPLC results, mean, 
standard deviation, variance and coefficient of variation percentage are 
shown in Table 4.3. The coefficient of variation for both day one and two was 
identical at 0.63%. 
 
Table 4.2 - HPLC results obtained on two separate days after six individual 
injections of a standard 0.6 mg/mL lincomycin hydrochloride (Lincocin®) 
solution 
Sample Day 1 
(Peak area) 
Day 2 
(Peak area) 
1 13186480 12823912 
2 13408640 12926984 
3 13183768 13053792 
4 13235680 12852992 
5 13259464 12928080 
6 13292888 12813832 
 
 
Table 4.3 - The minimum and maximum HPLC values, mean, standard 
deviation, variance and coefficient of variation percentage of 0.6 mg/mL 
lincomycin hydrochloride tested on two days 
Analysis Day 1 Day 2 
Minimum (Peak area) 13183768 12813832 
Maximum (Peak area) 13408640 13053792 
Mean (Peak area) 13261153 12899932 
Standard deviation 83637 90102 
Variance 7.0 x 109 8.11 x 109 
Coefficient of Variation (%) 0.63 0.63 
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4.1.3 Stability indicating HPLC method 
 
To determine the stability indicating nature of the assay, lincomycin 
hydrochloride was subjected to forced degradation in acid and base solutions 
at 60C.  
 
4.1.3.1 Initial acid and alkali degradation 
 
Results for the initial stability indicating test of 6 mg/mL lincomycin 
hydrochloride in 0.1 M HCl or 0.1 M NaOH solutions over 24 hours at 60C 
are shown in Table 4.4 and Table 4.5. The results indicated that lincomycin 
hydrochloride underwent a slow degradation process but degradation 
occurred more rapidly in base solutions than acid solutions. This is evidenced 
by a lower area under the curve value at 24 hours in sodium hydroxide 
solution. 
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Table 4.4 - HPLC area under the curve results of 6 mg/mL lincomycin 
hydrochloride indicating its degradation over a 24 hour period in 0.1 M HCl 
solution at 60C 
Time of 
sampling 
(hours) 
Peak Area under curve Peak height 
 
(%) (mm) (%) 
0.0 48670592 100.0 137.0 100.0 
2.0 - -   
4.0 54803360 112.6 141.5 103.3 
6.0 52338144 107.5 139.5 101.8 
7.0 52366976 107.6 138.5 101.1 
24.0 48792640 100.3 131.0 95.6 
 
 
 
Table 4.5 - HPLC area under the curve results of 6 mg/mL lincomycin 
hydrochloride indicating its degradation over a 24 hour period in 0.1 M NaOH 
solution at 60C 
Time of 
sampling 
(hours) 
Peak Area under curve Peak height 
 
(%) (mm) (%) 
0.0 50392320 100.0 134.0 100.0 
2.0 49080448 97.4 136.0 101.5 
4.0 48243392 95.7 134.0 100.0 
6.0 47010624 93.3 131.0 97.8 
7.0 - -   
24.0 39324096 78.0 115.0 85.8 
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4.1.3.2 Further stability testing in acid and alkali 
 
The results from seven day stability testing of 0.6 mg/mL lincomycin 
hydrochloride in 0.1 M hydrochloric acid and 0.1 M sodium hydroxide solution 
at 60C are shown in Table 4.6. As can be seen, lincomycin hydrochloride 
showed less rapid degradation in acid than in base solutions with 48.8% 
lincomycin remaining in the acid solution after 7 days compared to 8.0% 
remaining in base solution after the same time. Figure 4.9 shows the initial 
and final HPLC traces of lincomycin hydrochloride in 0.1 M HCl. Figure 4.10 
shows the initial and final traces of lincomycin hydrochloride in 0.1 M NaOH.  
 
Table 4.6 - HPLC results showing the degradation of lincomycin 
hydrochloride in 0.1 M HCl and 0.1 M NaOH solutions at 60C over 7 days 
Time of  
Sampling 
Lincomycin 
hydrochloride in 
0.1 M HCl 
Lincomycin 
hydrochloride in 
 0.1 M NaOH 
Area under curve Area under curve 
(hours) (days) (Peak area) (%) (Peak area) (%) 
0.0 0.0 6532634 100.0 6418883 100.0 
6.0 0.3 6537232 100.1 6083315 93.8 
24.0 1.0 6728099 103.0 4918394 76.6 
30.0 1.3 5817482 89.1 4196714 65.4 
48.0 2.0 5612877 85.9 3224552 50.2 
54.0 2.3 5508173 84.3 2939918 45.8 
72.0 3.0 4953027 75.8 2253712 35.1 
78.0 3.3 4167718 63.8 2043185 31.8 
96.0 4.0 3631354 55.6 1485735 23.1 
102.0 4.3 3650494 55.9 1411459 22.0 
120.0 5.0 3475410 53.2 964804 15.0 
126.0 5.3 3384413 51.8 910042 14.2 
144.0 6.0 3179478 48.7 685628 10.7 
168.0 7.0 3186080 48.8 512264 8.0 
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(a) Baseline peak of lincomycin hydrochloride in 0.1 M HCl solution 
 
 
 
 
 
 
(b) Degradation of lincomycin hydrochloride in 0.1 M HCl solution 
after 7 days 
 
Figure 4-9 - HPLC traces showing lincomycin peak at baseline (day zero) 
and after seven day treatment of 0.6 mg/mL lincomycin hydrochloride with 
0.1 M HCl (a) and after seven days at 60C (b). A flow rate of 1.5 mL/min 
was used and wavelength of 220 nm. 
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(a) Baseline peak of lincomycin hydrochloride in 0.1 M NaOH 
solution 
 
 
 
 
(b) Degradation of lincomycin hydrochloride in 0.1 M NaOH solution 
after 7 days 
 
Figure 4-10 - HPLC traces showing lincomycin peak at baseline (day zero) 
after treatment of 0.6 mg/mL lincomycin hydrochloride with 0.1 M NaOH (a) 
and after seven days at 60C (b). A flow rate of 1.5 mL/min was used and 
wavelength of 220 nm 
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4.1.3.3 Hydrogen peroxide degradation 
 
The results for the stability test of lincomycin hydrochloride in hydrogen 
peroxide at 60C over 60 minutes are shown in Table 4.7. Lincomycin 
hydrochloride was shown to degrade most rapidly in 3% hydrogen peroxide 
compared to acid and base conditions. Figure 4.11 shows the exponential 
degradation of lincomycin hydrochloride in 3% hydrogen peroxide over 60 
minutes. When the logarithm of peak area was plotted against time, the 
following linear relationship was produced: 
 
 Log10 Peak Area = -(0.03968 x hrs) + 7.0225 
 
with a correlation coefficient (R2) of 0.98333 (Figure 4.11). 
 
Table 4.7 - HPLC results for lincomycin hydrochloride in 3% hydrogen 
peroxide solutions at 60C over 60 minutes 
 
Time of 
Sampling 
(minutes) 
Peak Area of Lincomycin hydrochloride 
in Hydrogen peroxide 
(Peak area) (%) 
0.0 7178880 100.0 
5.0 5863210 81.7 
10.0 4349565 60.6 
15.0 2831058 39.4 
20.0 1871485 26.1 
25.0 1256313 17.5 
30.0 801870 11.2 
35.0 525966 7.3 
40.0 343733 4.8 
45.0 190615 2.7 
50.0 114585 1.6 
55.0 67297 0.9 
60.0 25187 0.4 
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Figure 4-11 - Log peak area versus time for the degradation of 0.6 mg/mL 
lincomycin hydrochloride in 3% hydrogen peroxide 
 
 
 
 
 
From Figure 4.11, the rate constant for the degradation of 0.6 mg/mL 
lincomycin hydrochloride in 3% hydrogen peroxide was calculated as 9.14 x 
10-2 min-1 which corresponds to a shelf-life of 1.15 hours, suggesting that 
lincomycin hydrochloride readily undergoes oxidation.  
 
HPLC traces showing the baseline chromatogram of lincomycin 
hydrochloride in 3% hydrogen peroxide and final HPLC tracing are shown in 
Figure 4.12. Only 0.4% lincomycin hydrochloride remained in the solution 
after 60 minutes.  
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(a) Baseline peak of lincomycin. 
 
 
 
 
(b) Degradation of lincomycin after 60 minutes. 
 
Figure 4-12 - HPLC traces showing lincomycin hydrochloride peak at 
baseline after treatment of 0.6 mg/mL lincomycin hydrochloride with 3% 
hydrogen peroxide (a) and after 60 minutes at 60C (b). A flow rate of 1.5 
mL/min was used and wavelength of 220 nm were used. 
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4.2 Optimisation for resolution of lincomycin breakdown products  
 
When 0.6 mg/mL lincomycin hydrochloride was prepared in 0.1 M HCl and 
stored at 60C, evidence of the lincomycin hydrochloride breakdown product 
after 48 hours was seen in the HPLC trace (Figure 4.13.a). The breakdown 
product appeared as a lincomycin hydrochloride 'shoulder peak' at 4.168 
minutes. After 72 hours (3 days) the breakdown product was much more 
evident (Figure 4.13b) and was eluted as a 'shoulder peak' at 4.169 minutes. 
After 96 hours (4 days), a small "shoulder peak'' on lincomycin hydrochloride 
was seen at 3.987 minutes but was less evident (Figure 4.13c) and after 264 
hours the ''shoulder peak'' was almost not visible. 
 
 
 
 
 
 
 
 
(a) Evidence of breakdown product after 48 hours. 
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(b) Evidence of breakdown product after 72 hours. 
 
(c) Evidence of breakdown product after 96 hours (4 days). 
 
 
(d) Evidence of breakdown product after 264 hours (11 days). 
Figure 4-13 - Evidence of lincomcyin hydrochloride breakdown products after 
48 hours (a), 72 hours (b), 96 hours (c) and 264 hours (d). 
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After 18 days, a sharp ''shoulder peak'' was again visible as part of the 
lincomycin hydrochloride peak at 4.150 minutes (Figure 4.14). To optimise 
the separation of lincomycin hydrochloride and the lincomycin hydrochloride 
breakdown product, a mobile phase consisting of 10% acetonitrile and 90% 
water was employed (Figure 4.15). This produced clear separation of peaks. 
The early sharp peak was eluted at 2.423 minutes, the ''shoulder peak'' at 
4.301 minutes, lincomycin hydrochloride at 6.384 minutes and benzyl alcohol 
at 11.677 minutes. However, superior separation of peaks was achieved 
using an unused Apollo C18 column and a mobile phase consisting of 8% 
acetonitrile and 92% water (Figure 4.16) and all subsequent HPLC analysis 
was carried out using these concentrations. Decreasing the flow rate to 1.0 
mL/min did not optimise results. 
 
 
 
 
 
Figure 4-14 - Evidence of a lincomycin hydrochloride breakdown product 
after 18 days. 
 
150 
 
Figure 4-15 - Separation of lincomycin hydrochloride and lincomycin 
hydrochloride breakdown product peaks using a mobile phase of 10% 
acetonitrile and 90% water. 
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Figure 4-16 - Separation of lincomycin hydrochloride and lincomycin 
hydrochloride breakdown product peaks using a new Apollo® column and 
mobile phase of 8% acetonitrile and 92% water. 
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4.3 Stability indicating tests in IV fluids 
 
4.3.1 Stability indicating test of 0.6 mg/mL lincomycin hydrochloride in 
0.9% NaCl and sodium lactate (Hartmann’s) solution  
 
The pH of 0.6 mg/mL lincomycin hydrochloride in 0.9% NaCl solution and 
sodium lactate solution was determined over a period of 7 days at 60C. The 
pH of sodium lactate (Hartmann's) solution and 0.9% NaCl solution was 5.9 
and 5.79 respectively prior to the addition of lincomycin hydrochloride. A 
slight change in pH was observed at time zero after the addition of 0.6 
mg/mL lincomycin hydrochloride to each IV solution. However, Table 4.8 
shows that lincomycin hydrochloride in 0.9% sodium chloride and sodium 
lactate (Hartmann's) solution was very stable and there was no measurable 
change in concentration for a period of time. We can conclude that the shelf-
life of lincomycin hydrochloride in 0.9% sodium chloride or sodium lactate 
(Hartmann's) solution at 60C is at least 7 days. 
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Table 4.8 - pH obtained for lincomycin hydrochloride in sodium lactate and 
0.9% sodium chloride solution over 7 days at 60C 
 
Sampling 
Time 
(hours) 
pH of 0.6 mg/mL 
lincomycin hydrochloride 
in sodium lactate 
(Hartmann's) solution 
pH of 0.6 mg/mL 
lincomycin hydrochloride 
in 0.9% NaCl solution 
0.0 5.81 5.70 
2.0 5.86 6.07 
4.0 5.91 6.03 
24.0 6.01 6.01 
26.0 5.91 5.99 
48.0 5.99 6.03 
50.0 6.01 6.10 
54.0 6.03 6.16 
72.3 6.03 6.13 
76.0 6.01 6.07 
100.0 6.04 6.18 
143.0 6.07 6.28 
145.0 6.08 6.30 
168.0 6.07 6.35 
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4.3.2 Stability testing of 0.6 mg/mL lincomycin hydrochloride at room 
temperature (25C)  
 
The stability of lincomycin hydrochloride was tested in IV solutions including 
sodium lactate (Hartmann's) solution, 0.9% sodium chloride solution, 5% 
glucose solution and 10% glucose solution. 
 
Lincomycin hydrochloride was found to be stable in sodium lactate 
(Hartmann's) solution with only a small proportion degrading over the 31 day 
period at 25C (Table 4.9). 
 
Lincomycin hydrochloride was found to be more stable in 0.9% sodium 
chloride solution than in sodium lactate (Hartmann's) solution, with less than 
2% lincomycin hydrochloride degrading over the 31 day period at 25C 
(Table 4.10).  
 
Lincomycin hydrochloride was found to be more stable in 5% glucose 
solution than in sodium lactate (Hartmann's) solution, but less stable than in 
0.9% NaCl solution with less than 5% lincomycin hydrochloride degrading 
over the 31 day period at 25C (Table 4.11).  
 
Lincomycin hydrochloride showed similar stability in 10% glucose compared 
to 5% glucose solution. It was more stable than in sodium lactate 
(Hartmann's) solution, but less stable than in 0.9% NaCl solution with less 
than 5% lincomycin degrading over the 31 day period at 25C (Table 4.12).  
 
As can be seen from the results in Tables 4.9 to 4.12, lincomycin 
hydrochloride was very stable in sodium lactate (Hartmann’s) solution, 0.9% 
sodium chloride solution, 5% glucose solution and 10% glucose solutions. All 
samples had a shelf-life of 744 hours or 31 days. 
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Table 4.9 - Results for the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 25C in sodium lactate (Hartmann's) solution over 31 days 
Time 
(hours) 
pH 
Sodium 
lactate 
Peak Area 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 6.28 6297749 6.7992 100.0 2.0000 
24.0 6.26 6141936 6.7883 97.5 1.9890 
96.0 6.22 6298190 6.7992 100.0 2.0000 
168.0 6.23 6271727 6.7974 99.6 1.9983 
264.0 6.30 6307764 6.7999 100.2 2.0009 
336.0 6.27 6409389 6.8068 101.8 2.0078 
409.7 6.35 6189187 6.7916 98.3 1.9926 
575.5 6.34 6168075 6.7901 97.9 1.9908 
744.0 6.44 6266224 6.7970 99.5 1.9978 
 
Table 4.10 - Results for the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 25C in 0.9% sodium chloride solution over 31 days 
Time 
(hours) 
pH 
0.9% NaCl 
Peak Area 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC  
Log10 
Percentage 
of baseline 
AUC 
0.0 5.87 6426908 6.8080 100.0 2.0000 
24.0 5.75 6193777 6.7920 96.4 1.9841 
96.0 5.80 6384620 6.8051 99.3 1.9970 
168.0 5.87 6341349 6.8022 98.7 1.9943 
264.0 5.97 6429204 6.8082 100.0 2.0000 
336.0 5.75 6442411 6.8090 100.2 2.0009 
410.8 5.68 6419509 6.8075 99.9 1.9996 
575.5 5.80 6345487 6.8025 98.7 1.9943 
744.0 5.79 6263480 6.7968 97.5 1.9890 
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Table 4.11 - Results for the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 25C in 5% glucose solution over 31 days 
Time 
(hours) 
pH 
5% 
Glucose 
Peak Area 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC  
Log10 
Percentage 
of baseline 
AUC 
0.0 3.49 6569197 6.8175 100.0 2.0000 
24.0 3.51 6245656 6.7956 95.1 1.9782 
96.0 3.52 6435503 6.8086 98.0 1.9912 
168.0 3.60 6366680 6.8039 96.9 1.9863 
264.0 3.53 6474652 6.8112 98.6 1.9939 
336.0 3.50 6250465 6.7959 95.1 1.9782 
410.8 3.47 6565427 6.8173 99.9 1.9996 
575.5 3.37 6424328 6.8078 97.8 1.9903 
744.0 3.45 6458256 6.8101 98.3 1.9926 
 
Table 4.12 - Results for the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 25C in 10% glucose solution over 31 days 
 
Time 
(hours) 
pH 
10% 
Glucose 
Peak Area 
Log 10 
Peak Area 
Percentage 
of baseline 
AUC  
Log10 
Percentage 
of baseline 
AUC 
0.0 3.73 6427563 6.8080 100.0 2.0000 
24.0 3.67 6345394 6.8025 98.7 1.9943 
96.0 3.73 6429390 6.8082 100.0 2.0000 
168.0 3.65 6364180 6.8037 99.0 1.9956 
264.0 3.61 6462238 6.8104 100.5 2.0022 
336.0 3.62 6312479 6.8002 98.2 1.9921 
410.8 3.63 6526265 6.8147 101.5 2.0065 
575.7 3.55 6281076 6.7980 97.7 1.9899 
744.0 3.52 6395738 6.8059 99.5 1.9978 
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4.4 Lincomycin stability studies  
 
4.4.1 Stability studies of lincomycin in acid at 60C over 12 days to 
 determine the rate constant  
 
The stability of a 0.6 mg/mL stock solution of lincomycin hydrochloride in 0.1 
M HCl at 60C was evaluated by HPLC analysis using a mobile phase 
consisting of 8% acetonitrile and 92% water. The degradation of lincomycin 
hydrochloride follows first order kinetics as is shown in Figure 4.17. 
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Figure 4-17– Degradation of lincomycin hydrochloride in 0.1 M HCl at 60C 
over 12 days. 
 
 
The equation of the degradation curve in Figure 4.17 was used to calculate a 
rate constant of 5.90  0.03.x 10-3 hr-1. 
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4.4.2 Lincomycin stability in buffer solutions 
 
Table 4.13 shows the HPLC data of 0.6 mg/mL lincomycin hydrochloride 
obtained at pH 2.00. The degradation of lincomycin hydrochloride at pH 2.00 
is shown graphically in Figure 4.18, which shows log10 area versus time and 
log10 percent of lincomycin hydrochloride. 
 
 
 
 
 
 
Table 4.13 - HPLC data on the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 80C at pH 2.00 
Time 
(hours) 
pH 
Peak Area of 
lincomycin 
hydrochloride 
at pH 2.00 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 1.99 6811984 6.8333 100.0 2.0000 
19.0 2.01 4884208 6.6888 71.7 1.8555 
23.0 1.88 4927843 6.6927 72.3 1.8591 
43.0 1.88 3642618 6.5614 53.5 1.7284 
48.5 1.88 3375061 6.5283 49.5 1.6946 
67.0 2.01 2769046 6.4423 40.6 1.6085 
91.0 1.96 2106157 6.3235 30.9 1.4900 
139.0 1.92 1242386 6.0943 18.2 1.2601 
163.0 1.98 950851 5.9781 14.0 1.1461 
187.0 1.91 738960 5.8686 10.8 1.0334 
211.0 1.95 570899 5.7566 8.4 0.9243 
235.0 1.95 437606 5.6411 6.4 0.8062 
259.0 1.95 324447 5.5111 4.8 0.6812 
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Figure 4-18 - Degradation of 0.6 mg/mL lincomycin hydrochloride at 80C at 
pH 2.00 (I = 0.5). 
 
 
 
 
Table 4.14 shows the HPLC data of 0.6 mg/mL lincomycin hydrochloride 
obtained at pH 3.10. The degradation of lincomycin hydrochloride at pH 3.10 
is shown graphically in Figure 4.19, which shows log10 area versus time and 
log10 percent of lincomycin hydrochloride. 
 
Table 4.15 shows the HPLC data of 0.6 mg/mL lincomycin hydrochloride 
obtained at pH 4.00. The degradation of lincomycin hydrochloride at pH 4.00 
is shown graphically in Figure 4.20, which shows log10 area versus time and 
log10 percent of lincomycin hydrochloride. 
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Table 4.14 - HPLC data showing the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 80C at pH 3.10 
Time 
(hours) 
pH 
Peak Area of 
lincomycin 
hydrochloride 
at pH 3.10 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 3.11 6246531 6.7956 100.0 2.0000 
24.0 3.11 6243854 6.7955 100.0 1.9998 
47.8 3.08 6012065 6.7790 96.3 1.9834 
122.5 3.04 5472902 6.7382 87.6 1.9426 
141.0 3.08 5172219 6.7137 82.8 1.9180 
167.0 3.11 4783645 6.6798 76.6 1.8841 
192.0 3.10 4598690 6.6626 73.6 1.8670 
211.5 3.10 4526065 6.6557 72.5 1.8601 
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Figure 4-19 - Degradation of 0.6 mg/mL lincomycin hydrochloride at 80C at 
pH 3.10 (I = 0.5). 
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Table 4.15 - HPLC data on the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 80C at pH 4.00 
Time 
(hours) 
pH 
Peak Area of 
lincomycin 
hydrochloride 
at pH 4.00 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 3.93 6531376 6.8150 100.0 2.0000 
24.0 3.95 6365779 6.8039 97.5 1.9890 
48.0 3.98 6250963 6.7959 95.7 1.9809 
77.0 4.00 6189162 6.7916 94.8 1.9768 
96.0 3.99 5908979 6.7715 90.5 1.9566 
120.0 3.98 5976058 6.7764 91.5 1.9614 
167.0 3.98 5416733 6.7337 82.9 1.9186 
216.0 4.00 5387098 6.7314 82.5 1.9165 
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Figure 4-20 - Degradation of 0.6 mg/mL lincomycin hydrochloride at 80C at 
pH 4.00 (I = 0.5). 
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Table 4.16 shows the HPLC data of 0.6 mg/mL lincomycin hydrochloride 
obtained at pH 6.10. The degradation of lincomycin hydrochloride at pH 6.10 
is shown graphically in Figure 4.21, which shows log10 area versus time and 
log10 percent of lincomycin. 
 
Table 4.17 shows the HPLC data of 0.6 mg/mL lincomycin hydrochloride 
obtained at pH 8.00. The degradation of lincomycin hydrochloride at pH 8.00 
is shown graphically in Figure 4.22, which shows log10 area versus time and 
log10 percent of lincomycin. 
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Table 4.16 - HPLC data on the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 80C at pH 6.10 
Time 
(hours) 
pH 
Peak Area of 
lincomycin 
hydrochloride 
at pH 6.10 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 6.09 7203789 6.8576 100.0 2.0000 
24.0 6.07 6831139 6.8345 94.8 1.9768 
48.0 6.10 5780173 6.7619 80.2 1.9042 
72.0 6.14 5464064 6.7375 75.8 1.8797 
96.0 6.14 4881498 6.6886 67.8 1.8312 
119.0 6.10 4669754 6.6693 64.8 1.8116 
142.5 6.12 3834850 6.5837 53.2 1.7259 
216.0 6.12 3098224 6.4911 43.0 1.6335 
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Figure 4-21 - Degradation of 0.6 mg/mL lincomycin hydrochloride at 80C at 
pH 6.10 (I = 0.5). 
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Table 4.17 - HPLC data on the degradation of 0.6 mg/mL lincomycin 
hydrochloride at 80C at pH 8.00 
Time 
(hours) 
pH 
Peak Area of 
lincomycin 
hydrochloride 
at pH 8.00 
Log10 Peak 
Area 
Percentage 
of baseline 
AUC 
Log10 
Percentage 
of baseline 
AUC 
0.0 7.89 6794621 6.8322 100.0 2.0000 
24.0 7.89 6256170 6.7963 92.1 1.9643 
48.0 7.93 5369299 6.7299 79.0 1.8976 
72.0 7.93 4704771 6.6725 69.2 1.8401 
96.0 7.92 4191389 6.6224 61.7 1.7903 
119.0 7.92 3841709 6.5845 56.5 1.7521 
142.5 7.92 3423270 6.5344 50.4 1.7024 
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Figure 4-22 - Degradation of 0.6 mg/mL lincomycin hydrochloride at 80C at 
pH 8.00 (I = 0.5). 
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Figure 4.18 to 4.22 show graphic representations of lincomycin hydrochloride 
degradation at pH 2.00, 3.10, 4.00, 6.10 and 8.00. The calculated rate 
constant and shelf-life of lincomycin hydrochloride at each pH tested is 
summarised in Table 4.18. The results show that lincomycin hydrochloride 
had the greatest stability at pH 4.00 when stored at 80C, with a calculated 
shelf-life of 4.59 days. It was least stable at pH 2.00, with a calculated shelf-
life of 0.38 hours. 
 
Figure 4.23, which shows the log k: pH profile of lincomycin hydrochloride, 
also shows that lincomycin hydrochloride was most stable at pH 4.00. Since 
lincomycin is a basic compound in which the single amine group is tertiary 
with a pKa of 7.6103 at low pH (i.e. pH 2 to 3), it undergoes acid catalysed 
degradation of the deprotonated form. At higher pH values, from pH 6.10 to 
8.00, there is some hydroxyl ion catalysis limited by the protonation occurring 
in that pH range. 
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Table 4.18 - Data for lincomycin showing the gradient of equations, 
correlation coefficient, rate constant and shelf-life obtained at pH 2.00, 3.10, 
4.00, 6.10 and 8.00 at 80C. 
pH Graph 
Type 
Gradient 
(m x 10-3) 
Error 
(x 10-5 ) 
Coefficient 
of 
determination
(R2 ) 
k  
(x 10-3 
hour-1) 
t90 
(hours) 
t90 
(days) 
2.00 
Log10 
Peak 
Area 
-4.94 6.048 0.99836 11.4 9.23 0.38 
Log10 % 
AUC 
-4.94 6.065 0.99834 11.4 9.23 0.38 
3.10 
Log10 
Peak 
Area 
-0.72 5.118 0.97058 1.66 63.32 2.64 
Log10 % 
AUC 
-0.72 5.12 0.97054 1.66 63.32 2.64 
4.00 
Log10 
Peak 
Area 
-0.41 4.144 0.94323 0.95 110.2 4.59 
Log10 % 
AUC 
-0.41 4.18 0.94239 0.95 110.1 4.59 
6.10 
Log10 
Peak 
Area 
-1.75 8.884 0.98484 4.03 26.05 1.09 
Log10 % 
AUC 
-1.75 8.901 0.98477 4.03 26.05 1.09 
8.00 
Log10 
Peak 
Area 
-2.14 6.488 0.99543 4.93 21.31 0.89 
Log10 % 
AUC 
-2.14 6.544 0.99534 4.93 21.31 0.89 
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Table 4.19 - Rate constant and log k for lincomycin hydrochloride at pH 
2.00, 3.10, 4.00, 6.10 and 8.00 at 80C 
pH Rate constant (k) log k 
2.00 1.14 x 10-2 -1.943 
3.10 1.66 x 10-3 -2.780 
4.00 9.53 x 10-4 -3.021 
6.10 4.03 x 10-3 -2.395 
8.00 4.93 x 10-3 -2.307 
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Figure 4-23 - Log k: pH profile of 0.6 mg/mL lincomycin hydrochloride at 
80C. 
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5.1 Methodology 
 
This is the first randomised 12 month study of all paediatric patients across 
three hospital settings (inpatients, outpatients and Emergency Department 
admissions) in Australia and internationally. Other studies have evaluated 
specific hospital settings, including several in inpatients including a census 
sample as they presented to the hospital4, 20, 22, 24, 42, 46, 51 and randomly 
selected patients only in that setting55 or another single setting.69 No previous 
study has randomly selected patients across all three settings. In this study, 
data for 1200 records were randomly selected from a total population of 
145,550 patients which included 458 patients from 55,591 Emergency 
Department admissions, 202 patients from 24,425 inpatients and 540 
patients from 65,534 outpatients. The reason 1200 random cases were 
generated was in case some patient files were not available (which was likely 
for child protection cases and patients being seen at the hospital, as their file 
would have been in use). The study was powered to identify a two percent 
difference in major parameters. 
 
This study is the first study undertaken at PMH since that reported by Turner 
in 1999.24 Unlike Turner's five week study which involved only a sample of 
200 consecutive inpatients (100 from a medical ward and 100 from a surgical 
ward), this one-year retrospective study involved 1037 randomly selected 
patients across three hospital settings (inpatients, outpatients and 
Emergency Department patients).  
 
 
5.2 Definitions of off-label and unlicensed and their classification 
 
The definitions proposed by Turner for off-label, with some modification to the 
unlicensed definition, were adopted for this study.24 The hierarchical 
classification system for off-label drugs by Hsien et al.42 was adopted and the 
approach taken was that an off-label drug cannot be identified in more than 
one classification. All prescription drugs were initially analysed for age so that 
drugs with no paediatric information or those prescribed in an age group for 
170 
which the drug was not licensed were classified as off-label for age.42 In 
keeping with Hsien et al.42, the next hierarchical level was indication, then 
route of administration and finally dosage (which included frequency of 
administration). A hierarchical approach has also been reported in other 
studies. For example, Ribeiro et al.69 who only considered drugs for 
outpatient care, used a mutually exclusive graded approach based on 
indication, then age, then dose and frequency and finally route of 
administration. If there was no information regarding its use in the product 
information, the drug was classified as off-label, most likely due to age similar 
to Hsien, as only the four classifications of indication, age, dose/ frequency 
and route of administration were used, although this was not clearly 
specified.69 
 
For ease of analysis, each patient was also classified into either an off-label 
or unlicensed category. Patients prescribed only off-label drugs and those 
prescribed both off-label and unlicensed drugs were classified as 'off-label' 
patients. Patients prescribed only unlicensed drugs were classified as 
''unlicensed''.  
 
Initially, the age classification in the AMH 2008111, which includes neonates 
(zero to 28 days), young infants (one to three months), infants (three months 
to two years) and children (two to 12 years) was considered for use. Notably, 
this has been changed recently in the AMH 2014112 to include only three age 
categories: neonates (zero to 28 days), infants (one month to two years) and 
children (two to 12 years). Other age classification systems were also 
considered48, 54, 57, 61, 64, 68, 113 but the internationally recognised classification 
system of the European Medicines Agency (EMA)6 (term newborn infants/ 
neonates 0 – 27 days, infants and toddlers 28 days - 23 months, children 2 - 
11 years, adolescents 12 - 18 years), used by Hsien et al. and other 
researchers42, 50, 55, 69 was adopted for this study. Some researchers used the 
EMA age classification but further divided the 2-11 years group into 2-5 years 
(preschool) and 6-11 years (school children) as they reported it reflects more 
accurately a child's ability to take solid drug formulations.67 This was not 
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adopted for the current study as the EMA classification provides the best 
option for standardisation and is harmonised with the TGA. 
 
 
5.3 Factors influencing off-label and unlicensed prescribing in 
 Australia 
 
The majority of patients included in this study (58.5%) were males, which 
was similar to previous findings at PMH by Turner24 who reported 61.5% of 
males (i.e. 58% in surgical ward and 65% in medical ward) and another 
Australian study in Tasmania which reported 56% of males.62 The age of 
paediatric patients ranged from zero (newborn) to 18 years (mean 6.6  5.2 
years). The youngest patient was a newborn admitted as an inpatient and the 
oldest patient, aged 18.4 years, was an outpatient. The mean and median 
ages varied across the three settings (Emergency Department patients 5.6 / 
4.0 years, inpatients 6.4 / 5.4 years, outpatients 7.8 / 7.8 years respectively), 
with Emergency Department patients generally younger than outpatients (p = 
0.0003).  In Turner's study24 the age ranged from 49 days to 18 years 
(median 6 years). The median age of inpatients in this study (5.4 years) was 
comparable to that reported by Turner .24  
 
Of the three hospital settings investigated, the majority of patients (38.9%) 
were Emergency Department admissions. In each setting there were more 
males than females.  The highest numbers of admissions in the Emergency 
Department were for patients under three years of age and inpatients less 
than one year of age. The age distribution of outpatients did not show peaks 
as seen for emergency patients and inpatients, although there were a greater 
percentage of patients less than two years of age and also between nine and 
ten years.  
 
There were 2654 prescribed drugs of which 1905 (71.8%) were licensed, 681 
(25.7%) were off-label and 68 (2.6%) were unlicensed, hence the overall 
extent of off-label and unlicensed prescribing was 28.3%. In comparison to 
other Australian studies, this was higher than the 16.2% reported by Turner 
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in the 1999 PMH study24 but lower than the 47% reported by O'Donnell.1 The 
extent of off-label and unlicensed prescribing was slightly higher in inpatients 
in the current study (30.7%) compared to Turner and was similar to a recent 
inpatient study in Tasmania which reported the extent of off-label prescribing 
as 31.8%.62 The study by O'Donnell was conducted in an Australian neonatal 
intensive care unit and involved patients with a gestational age of 22.7 to 
41.4 weeks.1 The difference in the age of patients in O'Donnell's study and 
other Australian studies involving older patients, such as Turner's study (in 
which the age ranged from 49 days to 18 years), Ballard's study (in which the 
age ranged from one day to 11 years) and the current study (age zero to 18.4 
years), makes a direct comparison erroneous.1, 24, 62 However, in the current 
study, when only inpatient neonates aged zero to 27 days were considered, 
despite some being slightly older than in O'Donnell's study, the extent of off-
label prescribing was 83.3% (Table 3.15) which was considerably higher than 
the overall study result. Although the number of inpatients in this group was 
small (n = 12), the finding suggests that by targeting specific patient groups, 
including specific age groups, the extent of off-label prescribing reported can 
increase considerably. In addition, by limiting age range to lower age groups 
will give a higher likelihood of off-label classification, especially with respect 
to age. 
 
Inpatients were prescribed between zero and 21 drugs (emergency patients 
between zero and 16 drugs and outpatients between zero and 12 drugs). The 
median number of drugs prescribed was one drug for both emergency 
patients and outpatients and five drugs for inpatients (overall study median 
was one drug). One reason for a higher median number of drugs for 
inpatients was that very few patients were prescribed no drugs (4.7%) 
compared to Emergency Department patients (38.0%) and outpatients 
(45.5%). This was similar to Ballard's inpatient study in Tasmania, in which 
only 20 of 300 patients (6.7%) were prescribed no drugs. The difference in 
the number of drugs prescribed in each setting was significant (p < 0.0001). 
The overall median in this study was lower than the median of four drugs 
reported by Turner. However, Turner's study was conducted on inpatients 
and in this study, when only inpatients were considered, the median number 
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of drugs (five) was slightly higher than reported by Turner (four).24 A 
contributing factor to these differences may be that Turner's study involved 
only two wards (a surgical and medical ward) whereas in this study, patients 
were randomly selected from all inpatient wards at PMH. 
 
Overall, 699 (67.4%) patients were prescribed drugs, which included 321 
(31.0%) patients prescribed licensed drugs and 378 (36.5%) that were 
prescribed off-label or unlicensed drugs. Three hundred and thirty eight 
patients (32.6%) were not prescribed any drugs. The percentage of patients 
prescribed off-label or unlicensed drugs (36.5%) was similar to Turner's study 
which reported that 36% of patients received off-label or unregistered 
drugs.24 In the current study, when patients who were not prescribed drugs 
were excluded, the extent of off-label and unlicensed prescribing would have 
been 54.1% (i.e. 378 / 699). However, in the current study, when only 
inpatients were considered, the number of patients prescribed off-label or 
unlicensed drugs increased significantly to 77.6% (77.8% for males and 
77.3% for females). The percentages were much lower for Emergency 
Department patients (29% of males and 27% of females) and outpatients 
(19% of males and 17% of females). The differences in the number of 
patients prescribed off-label and unlicensed drugs in different settings was 
significant (P < 0.0001). The extent of off-label and unlicensed prescribing to 
inpatients in the current study was higher than in Ballard's retrospective 
inpatient study which reported that 57.3% of patients received at least one 
off-label medicine. One reason is that Ballard's study only considered off-
label drugs and not unlicensed drugs.62 Another possible reason is that 
Ballard's study included patients aged one day to 11 years whereas the 
current study included paediatric patients aged zero to 18 years.62 Ballard 
also excluded unscheduled over-the-counter (OTC) medications which were 
not excluded in the current study. Although paracetamol is an OTC 
medication, this was included in Ballard's study contradicting the exclusion 
criteria set for that study. 
 
In the current study, there were 330 different drugs which included 121 
different off-label drugs and 22 different unlicensed drugs. In considering only 
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inpatients, 82 different off-label drugs and 14 different unlicensed drugs were 
prescribed. Turner reported that 86 different drugs were used in the surgical 
ward (of which 22 drugs were off-label or unlicensed) and 118 different drugs 
in the medical ward (of which 35 drugs were off-label or unlicensed).24 Turner 
does not specify whether prescribed drugs, including off-label and unlicensed 
drugs, were similar on both wards (i.e. whether there was overlap) or whether 
they were entirely different drugs. There is insufficient information provided 
by the author to enable this to be further analysed.24 However, the number of 
different off-label or unlicensed drugs prescribed in the current study was 
higher than reported by Turner.24 It was also higher than the findings in 
Tasmania62 where researchers reported that out of 887 drug prescriptions, 
there were 51 different off-label drugs (out of 106 different drugs). A reason 
for reporting fewer different off-label drugs in Ballard's study may be that 
unscheduled products were excluded which may have contributed to a 
decrease in the range of medications. A likely reason for a greater number of 
different off-label drugs reported in the current study compared to the 
previous PMH study is that drugs used off-label across all wards were 
identified rather than findings reported for only two wards, as in Turner's 
study. 
 
The ten most commonly prescribed drugs were paracetamol, ibuprofen, 
ondansetron, Painstop Day®, morphine, oxycodone, amoxicillin, 
dexamethasone, salbutamol and prednisolone, half of which are analgesics/ 
antipyretics from the nervous system ATC code (paracetamol, ibuprofen, 
Painstop Day®, morphine and oxycodone). Prednisolone was not used in an 
off-label or unlicensed manner on any occasion. The two most commonly 
prescribed drugs (paracetamol and ibuprofen) were the same as reported in 
Ballard's study but unlike Ballard who reported oxycodone as the third most 
commonly prescribed drug, in this study the third most commonly prescribed 
drug was ondansetron (which was also the most commonly prescribed off-
label drug).62 Turner reported that paracetamol was also commonly 
prescribed on both the medical and surgical ward but not ibuprofen. Other 
drugs commonly prescribed on the medical ward in Turner's study included 
salbutamol, ceftriaxone, prednisolone and on the surgical ward, morphine, 
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metronidazole and ceftriaxone.24 In the current study, morphine, salbutamol 
and prednisolone were also most commonly prescribed but not ceftriaxone 
and metronidazole.  
 
The 10 most commonly prescribed off-label drugs overall were ondansetron, 
Painstop Day®, salbutamol, oxycodone, paracetamol, midazolam, fentanyl, 
ticarcillin with clavulanic (Timentin®), amoxicillin and flucloxacillin. Most of 
these drugs were nervous system drugs (Painstop Day®, oxycodone, 
paracetamol, midazolam, fentanyl) and anti-infectives (Timentin®, amoxicillin, 
flucloxacillin). Turner reported the most commonly prescribed off-label and 
unlicensed drugs were metoclopramide, Colonlytely®, ondansetron, clonidine 
and chloral hydrate, although there were differences on the wards.24 On the 
surgical ward, the drugs were metoclopramide, Colonlytely®, ondansetron, 
clonidine and on the medical ward they were chloral hydrate, aspirin, 
ciprofloxacin and sodium bicarbonate. Despite considerable differences 
between Turner's findings and those reported in the current study, 
ondansetron was commonly prescribed off-label in both studies.24 However, 
in Turner's study, ondansetron was reported off-label for indication but in the 
current study it was off-label for indication, age and dosage although age was 
the first factor employed for the classification.24   
 
Ballard et al reported the most commonly used off-label drugs as oxycodone, 
salbutamol, paracetamol, ondansetron and amoxicillin, with oxycodone used 
off-label more frequently than any other drug.62 Although these drugs are in 
the top five most commonly prescribed off-label drugs in the current study, 
unlike Ballard, ondansetron was the most commonly prescribed off-label 
drug. It was prescribed a total of 126 times of which 94 prescriptions (74.6%) 
were off-label. Reasons for off-label prescribing included dosage (65; 69.2%), 
age (16; 17.0%) and indication (13; 13.8%).  
 
Several different dosage forms of ondansetron have TGA marketing approval 
including injections, tablets, wafers, syrup and suppositories. All dosage 
forms are approved for the prevention and treatment of nausea and vomiting 
induced by cytotoxic chemotherapy or radiotherapy. The injection is also 
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approved for prevention and treatment of postoperative nausea and vomiting 
(PONV). Ondansetron suppositories are not recommended for children and 
in this study there were no prescriptions for ondansetron suppositories. For 
emetogenic chemotherapy or radiotherapy, ondansetron injection, tablets, 
wafers or syrup are licensed for children over four years of age at a dose of 5 
mg/ m2, followed by oral therapy at doses of 4 mg twice daily up to five days. 
For prevention and treatment of PONV, ondansetron injection only is licensed 
for children aged two to 12 years of age at a dose of 0.1 mg/ kg up to a 
maximum of 4 mg. Although not specified in the PI, at 12 years of age it is 
assumed the adult dose is used.30  
 
In this study, several children were prescribed ondansetron for PONV to be 
administered three to four times a day and often on a ''when required'' basis 
despite MIMS stating that repeat dosing has not been studied in paediatric 
patients.30, 108 In a few cases, oral forms of ondansetron were prescribed for 
PONV instead of the approved injection. None of the oral forms (tablets, 
wafers, syrup) are approved for PONV. 
 
Although not indicated for children under two year of age because the clinical 
safety in this age group has not been established,30, 108 ondansetron was 
prescribed to 13 children under two years of age with the youngest two 
infants three months old. Ondansetron syrup, which is only licensed for 
cytotoxic chemotherapy and radiotherapy induced nausea and vomiting in 
children older than 4 years, was prescribed to three other children aged two 
and three years. The diagnosis in the medical records was cystic swelling to 
the neck and infective exacerbation for a two year old child, dental trauma 
and extraction for another two year old child and spinal fracture for a three 
year old child. As there was no indication that any of the children were 
undergoing cytotoxic chemotherapy or radiotherapy, ondansetron was most 
likely used for PONV, also rendering it off-label for indication. According to 
the hierarchical classification outlined in Chapter two in section 2.4.1, for 
these children ondansetron syrup was classified off-label for age, although it 
was also off-label for indication. In some countries, ondansetron is approved 
for use in children from one month of age for both PONV and chemotherapy 
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induced nausea and vomiting (CINV).65 Recently the TGA listing in Australia 
for Zofran® (which contains the single ingredient ondansetron), was updated 
with information stating that the IV form can be administered to children from 
one month onwards for PONV107 but at the time of writing, MIMS 2014 had 
not been updated to reflect this information.30 The fact that ondansetron can 
be used for PONV and CINV in some overseas countries but in Australia, 
only the injection can be used in children over one month of age for PONV 
highlights the inconsistency in PIs on an international platform. 
 
Painstop Day®, which contains a combination of 120mg paracetamol and 5 
mg codeine phosphate per 5 mL, was the second most commonly prescribed 
off-label drug. It was off-label for 89% of cases due to higher doses of 
Painstop Day® prescribed than recommended by the approved license. In the 
majority of cases, the increase in dose ranged from 17% to 75%. A few 
obese children were prescribed higher doses than this. In one case, an eight 
year old Emergency Department male patient weighing 42.9 kg, with an 
infection and inflammation of the little toe and boil like lesions on the inner 
aspects of the thigh, was prescribed double the normal dose for age (i.e. 30 
mL rather than 13 to 15 mL recommended for children aged eight to nine 
years). The average weight for boys aged eight years is 25.8 kg and for boys 
aged nine years, it is 28.7 kg,37 so it is likely that this 42.9 kg child was 
overweight, although it was not possible to calculate the BMI as height was 
not recorded in the medication chart. A dose of 30 mL Painstop Day® 
provides 720 mg paracetamol and 30 mg codeine. If the paracetamol dose 
was calculated based on 15 mg/kg and the child's weight of 42.9 kg, then the 
dose would have been 644 mg. If the paracetamol dose was calculated 
based on ideal body weight for a child eight years of age (i.e. 25.8 kg), then 
the dose would have been 387 mg paracetamol. However, the child was 
prescribed 720 mg paracetamol which is considerably greater than 
recommended.30  
 
In another case involving a nine year old female with a slipped femoral 
epiphysis and weighing 44.4 kg, a dose of 35 mL was administered despite 
the manufacturer's recommended dose of 15 mL for children aged nine to 10 
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years. This child received more than double the recommended dose. All 
doses for Painstop Day® specified in MIMS30 are for children of certain ages 
and corresponding weights [i.e. Children 1-2 years (10-12kg) 5-6mL; 2-3 
years (12-14kg) 6-7mL; 3-4 years (14-16kg) 7-9mL; 4-5 years (16-18kg) 9-
10mL; 5-6 years (18-20kg) 10-11mL; 6-7 years (20-22kg) 11-12mL; 7-8 years 
(22-24kg) 12-13mL; 8-9 years (25-28kg) 13-15mL; 9-10 years (28-32kg) 
15mL]. Although it may be challenging for a health practitioner to adhere to 
the recommended dose for obese patients, especially if they are in 
considerable pain, obesity does not necessarily translate to a more active 
liver to detoxify drugs or more active kidneys to aid elimination.  
 
Ballard did not report off-label use associated with Painstop Day® but this 
may be because the researchers excluded over-the-counter (OTC) 
medication in their study.62  
 
Paracetamol was also commonly prescribed off-label - it was the fifth most 
commonly prescribed off-label drug. The standard dose of 15 mg/kg/dose in 
the accepted license30 was exceeded in 15.3% of prescriptions (dose range 
17 mg/kg/dose to 30 mg/kg/dose). The extent of off-label use of paracetamol 
was similar to the 10% reported by Ballard in which paracetamol was used at 
approximately 20 mg/kg/dose. In the current study, it was found that the 
maximum daily dose prescribed was up to 81 mg/kg/day. This was also 
comparable to Ballard's study which reported that up to 80 mg/kg/day 
paracetamol was prescribed.62 Although doses above 15 mg/kg/dose are not 
listed in the approved paracetamol license, standard references such as the 
Paediatric Pharmacopoeia (Royal Children's Hospital, Melbourne)114 and the  
AMH111, 112 state that up to 90 mg/kg/day can be used under medical 
supervision, to be reviewed at 48 hours. The AMH specifies that this dose 
recommendation is for children older than three months.111, 112 However, 
there are reports in the literature of hepatic failure in children when doses 
greater than 75 mg/kg/day were administered.115 There are currently no 
published case-control or population based studies of repeated 
supratherapeutic doses of paracetamol and this should prompt an organised 
study to be considered to determine definitive recommendations.115 
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Both the AMH and Paediatric Pharmacopoeia reflect current best practice in 
Australia but include many recommendations that involve the use of off-label 
medicines when compared to the manufacturer's product information. There 
clearly needs to be a mechanism by which the product license is updated 
regularly, especially for children, with evidence based professional 
recommendations. 
 
Salbutamol was prescribed 58 times and was off-label 51 times (87.9%) 
because it was prescribed at doses or frequencies greater than that stated in 
the approved license (one to two inhalations repeated four hourly if needed). 
In many cases, the prescribed dose was six inhalations at various dose 
intervals, in some cases including every 20 minutes. Ballard also reported 
that salbutamol was commonly off-label due to higher dosages than those 
approved.62  The National Asthma Council's First Aid Protocol and the 
Asthma Management Handbook116, as well as other references,111, 112 
support the use of  increased dosages of salbutamol, despite not being 
reflected in the PI.  
 
There were 74 prescriptions for oxycodone, of which 49 (66%) were 
classified off-label. This is less than reported in Ballard's study where it was 
found that oxycodone was used off-label in all cases. Although Ballard 
reported that the PI of both oxycodone liquid and tablet dosage forms stated 
that ''the drug should not be used in patients under 18 years of age'' there 
was no evidence found in the approved license to support this.62 In the 
current study, it was found that the PI for oxycodone (OxyNorm®) capsules, 
liquid and injection stated it should not be used in patients under 18 years of 
age whereas the controlled release tablets (OxyContin®) were not 
recommended in children under 12 years of age.30 As Ballard's study 
excluded children aged 12 years or older, regardless of which oxycodone 
dosage form was administered in the Tasmanian study, it would have been 
classified as off-label due to age.62 
 
In the current study, most children prescribed oxycodone were aged under 
12 years with the youngest, both a male and a female, aged 10 months. 
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There are reports in the literature that oxycodone may provide superior pain 
relief to some other analgesics.117, 118 Several studies have investigated the 
pharmacokinetics of oxycodone in children. One study in children aged six 
months to seven years reported that a weight-based dose without adjustment 
for age between six months and seven years was valuable119 while another 
study that investigated the pharmacokinetics of oxycodone in infants aged 
zero to six months, reported pronounced variability in clearance and half-life 
in the young children and recommended that routine dosing of oxycodone in 
young children may be dangerous.120 Although oxycodone has been in 
clinical use for 90 years, the PI does not include directions for use in children. 
A large clinical study should be undertaken involving various paediatric age 
groups and the PI updated to reflect appropriate dosage guidelines for 
children. 
 
Midazolam was commonly prescribed in an off-label manner which was a 
finding not reported in other Australian studies.1, 24, 62 It was prescribed 31 
times and of these, 29 (93.5%) prescriptions were off-label. Following the 
hierarchy discussed in Chapter two (section 2.5.1), 20 midazolam 
prescriptions were off-label for age because the drug was prescribed to 
children under the age of eight years, the youngest being a newborn. MIMS 
states that the ''safety and effectiveness of midazolam in children below the 
age of eight have not been established''. The other nine prescriptions were 
off-label for route of administration, since midazolam solution for injection 
was administered buccally to children older than eight years of age. Although 
according to the classification system used in this study based on Hsien that 
a drug can only be classified into one off-label category, if further 
classifications had been used in this study, then of the 20 prescriptions that 
were off-label for age, 11 prescriptions were also off-label for route of 
administration since midazolam solution for injection was administered 
buccally.  
 
Fentanyl, an opioid with a rapid onset of action and short duration of action, 
is available as solution for injection or patch for transdermal delivery. It was 
prescribed 39 times of which 21 (53.8%) were off-label. In one case, fentanyl 
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was prescribed to a one-year old child and hence was off-label for age 
because MIMS states that ''the safety of fentanyl in children younger than two 
years of age has not been established".30, 108 For the other 20 cases, fentanyl 
was off-label due to route of administration since the solution for injection 
was administered intranasally. There is no information in the PI to support 
this route of administration. However, the AMH recommends an intranasal 
dose for children aged one to 12 years and advises that if the 100 mcg/2 mL 
injection solution is used, that the dose should be divided between nostrils to 
minimise swallowing and effects such as sneezing.111, 112 Fentanyl is not 
available as an oral dosage form and while the intravenous and 
intramuscular routes are effective, they require painful placement of 
intravenous lines or injections. Advantages of fentanyl are that it has fewer 
cardiovascular effects than other opioids and does not cause histamine 
release.121 Several randomised controlled trials have shown that intranasal 
fentanyl is equivalent or superior to fentanyl administered parenterally or 
morphine administered parenterally or orally in providing analgesia for 
various painful procedures and conditions in children. Evidence for the use of 
intranasal fentanyl in children has been available since 1999 yet despite this, 
the PI has not been updated to reflect this.121 
 
Timentin® (ticarcillin with clavulanic acid) was prescribed 19 times and was 
off label for age in 95.0% of prescriptions. MIMS states that ''the efficacy and 
safety of Timentin® has not been established in infants and children under 
the age of 14''. The youngest child prescribed Timentin® was a 10 month old 
male. Timentin® was not reported to be commonly prescribed off-label (in the 
top 10 drugs) in any other Australian study. 
 
The two most commonly prescribed unlicensed drugs were dexamethasone 
and dilacaine. PMH produces hospital formulations of dilacaine eye drops 
and dexamethasone oral solution (1mg/mL). Dilacaine eye drops contain 
proxymetacaine HCl 1.25mg, cyclopentolate HCl 2.5mg, tropicamide 2.5mg, 
phenylephrine HCl 25mg and are used as mydriatic and anaesthetic eye drop 
for examination of the fundus of the eye. Dexamethasone, a synthetic 
glucocorticoid with anti-inflammatory or immunosuppressive actions, is also 
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used in neonates for respiratory insufficiency and oedema with acute non-
infectious laryngospasm. Neither of these drugs were reported off-label in 
Turner's or O'Donnell's study. As Ballard's study involved only off-label drugs, 
no unlicensed drugs were included.62 
 
 
5.4 Variations in prescribing with age 
 
Neither Turner nor Ballard identified drugs commonly prescribed to different 
age groups. In this study, the 10 most commonly prescribed drugs overall 
were different for various age groups. Seven out of 10 drugs for neonates 
aged zero to 27 days were from the ATC anti-infective classification and 
included amoxicillin, gentamicin, cefotaxime, nystatin, aciclovir, Augmentin 
Duo® and vancomycin whereas only three anti-infectives were included in the 
10 most commonly prescribed drugs for infants aged 27 days to 23 months 
(amoxicillin, flucloxacillin and Augmentin Duo®), one for children aged two to 
11 years (amoxicillin) and none for adolescents. Seven out of the 10 most 
common drugs for adolescents aged 12 to 18 years were from the ATC class 
nervous system (paracetamol, ibuprofen, oxycodone, morphine, Panadeine 
Forte®, Panadeine® and fentanyl) and alimentary tract (ondansetron). Six of 
the most common drugs prescribed for children aged two to 11 were the 
same as those prescribed for adolescents except instead of Panadeine 
Forte® and Panadeine®, Painstop Day® was more commonly prescribed. 
 
 
5.5 Variations in off-label and unlicensed prescribing with age 
 
There were also variations in the 10 most commonly prescribed off-label 
drugs for various age groups. For example, newborn infants aged zero to 27 
days were prescribed more anti-infectives than any other age group with 
seven out of 10 drugs from the ATC anti-infective classification. The most 
commonly prescribed off-label anti-infectives to newborn infants were 
amoxicillin, gentamicin, and aciclovir.  
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For age groups other than neonates, more nervous system drugs were 
prescribed off-label. Differences were noted for the types of nervous system 
drugs prescribed off-label to the different age groups. Infants (27 days to 23 
months) and children (two to 11 years) were prescribed mainly off-label 
analgesics but adolescents were prescribed more diverse nervous system 
drugs including off-label analgesics, sedatives, hypnotics and other 
psychotherapeutic drugs including fluoxetine and quetiapine.  
 
Turner reported that metoclopramide and clonidine were commonly 
prescribed off-label (metoclopramide for dose and clonidine for indication).24 
Although these two drugs were not in the ten most commonly prescribed off-
label drugs in the current study, they were in the top 10 off-label drugs 
prescribed to children aged two to 11 years, but not for any other age group. 
In this study, as in Turner's study, clonidine was off-label for indication.24 
However, unlike Turner's study, in the current study, metoclopramide was off-
label for age. MIMS states the use of metoclopramide should be restricted in 
children and young adults less than 20 years of age to severe intractable 
vomiting of known cause, vomiting associated with radiation therapy or 
intolerance to cytotoxic drugs and to assist in small bowel intubation30, 108 and 
since there was no evidence that any of the patients met these criteria, 
metoclopramide was classified off-label for age. It could, however, have been 
classified as off-label for indication but as a result of the hierarchical 
approach used in this study and since all children prescribed metoclopramide 
were under the age of 20 years, metoclopramide was classified off-label for 
age. 
 
 
5.6 Specific prescribing issues in neonates 
 
Amoxicillin was the most commonly prescribed off-label drug to neonates 
aged zero to 27 days. The dose for amoxicillin specified in eMIMS for 
children less than 20 kg is 20 to 40mg/kg/day in divided doses every six to 
eight hours. For the majority of patients, a greater dose was prescribed than 
specified in the PI. In one case, amoxicillin was prescribed at a higher dose 
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for possible viral meningitis, so it was off-label for dose and indication, 
although using the hierarchical approach, it was classified off-label for 
indication. 
 
Aciclovir was prescribed to two newborn infants and one four week old infant 
despite no dosage listed in eMIMs.30 Two of the infants had suspected viral 
meningitis. The notes for the third infant did not specify why aciclovir was 
prescribed, but the diagnosis of hypoxic ischaemic neonatal encephalopathy 
with meconium aspiration and seizures could suggest that it was used 
prophylactically to prevent viral infection. Intravenous dosing information is 
provided in eMIMs for children aged one to 12 years for the treatment of 
herpes simplex encephalitis but not for its prevention.30 The recommended 
dose for children aged one to 12 years of age with herpes simplex infections 
(except herpes simplex encephalitis) or varicella zoster infections is 250 mg/ 
m2 of body surface area (equivalent to 5 mg/ kg in adults) and for herpes 
simplex encephalitis is 500 mg/ m2 of body surface area (equivalent to 10 
mg/ kg in adults). No dose is provided for children less than one year of 
age.30 Indications of aciclovir listed in the AMH include treatment as well as 
prevention of herpes simplex infections. Notably, a dose for infants less than 
three months for herpes simplex (based on body weight (20 mg/ kg IV every 
8 or 12 to 24 hours depending on whether the infant is preterm or term)) is 
provided in the AMH 2013 but not AMH 2014.112, 122 The dose for children 
aged three months to 12 years for herpes simplex encephalitis in both 
references is 500 mg/ m2 every eight hours.112, 122 However, the Therapeutic 
Guidelines (Antibiotics) recommends a dose of 20 mg/ kg aciclovir for 
suspected or proven herpes simplex encephalitis, administered IV, eight 
hourly for 21 days with the dose adjusted for renal function.123 For babies 
under three months, the Paediatric Pharmacopoeia provides a dose of 20 
mg/ kg 12 to 24 hourly (preterm) and eight hourly for term infants.114 The new 
AMH Children's Dosing Companion 2013 lists the same dose for infants from 
birth (term) to three months although the dose provided for encephalitis is 
500 mg/ m2 every eight hours.99 
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Gentamicin, an aminoglycoside antibiotic, was also commonly prescribed off-
label for neonates aged zero to 27 days. The dose for gentamicin specified in 
the PI for life threatening infections is five to 7.5 mg/ kg/ day administered in 
two to three divided doses.30 Three cases were off-label due to frequency of 
administration of the dose - for two cases the dose was administered once 
daily and for the other case, the dose was initially administered every two 
days and then once daily. For the other case, the dose administered was 21 
mg every 2.5 hours which equated to 45 mg/kg/day, thereby exceeding the 
recommended dose.  
 
In Ballard's study, gentamicin was always used in an off-label manner which 
was not the finding in the current study.62 However, as outlined in Chapter 
two, where there was any uncertainty with respect to dosing, frequency of 
dosing or indication, a conservative approach was adopted and the drug 
classified as licensed. There may have been more off-label gentamicin cases 
in the current study but the frequency of administration and indication was 
not always clear on the medication chart so it is likely that the extent of off-
label use has been under reported. The PI in eMIMS only details divided 
daily doses and in Ballard's study it was found single daily doses were 
administered.30, 62 Administration of single daily dosing has been supported in 
the literature for over 15 years as it may decrease the likelihood of 
nephrotoxicity and ototoxicity in children, but despite this, the PI has not been 
updated. 
 
In one study in the UK, researchers reported that gentamicin was commonly 
used off-label in many neonatal centres. They reported that if twice daily 
doses were used as recommended by the manufacturer, premature infants 
would be exposed to excessive serum concentrations. The reason for this is 
that the drug is renally excreted and at birth renal function in limited due to 
immaturity of the kidney, hence in these infants, gentamicin is usually 
administered at 18 or 24 hour intervals.43 
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5.7 Comparison with international studies 
 
The proportion of off-label and unlicensed prescribing in this study (25.7% 
and 2.6% respectively) was lower than that reported in several overseas 
studies in the United Kingdom43 (55% and 10%), in the United Kingdom, 
Sweden, Italy, Germany, Netherlands124 (39% and 7%), in the Netherlands54 
(44% and 28%), Switzerland55 (25% and 24%), in France44 (63% and 10%), 
in Israel45 (59% and 16%) and in Malaysia56 (34% and 27%). However, the 
percentage of off-label prescribing was similar to that reported by Hsien et al. 
in Germany, who reported off-label prescribing as 30.5%.42 Several other 
studies have reported a low incidence of off-label or unlicensed prescribing 
including a study in Israel66 (26% and 8%), in the United Kingdom22 (18% 
and 7%) and in Croatia57(12% and 13%). A contributing factor to the lower 
percentages of off-label and unlicensed prescribing reported in the current 
study may be that data were collected and combined across all settings at 
PMH. Most studies, including studies in Australia, have been conducted in 
one particular setting e.g. Emergency Department patients64, 65, 69, medical or 
surgical wards22, 24, 25, 49, 124 or ICU1, 42, 43, 45, 56, 59 or outpatients66, 67. This 
renders the comparisons above inappropriate because of the various natures 
of the patient groups and sites chosen for evaluation. This is an important 
issue in the reporting of these data. 
 
 
5.8 Prescribed drugs overseas 
 
Several of the drugs commonly prescribed in the current study were also 
commonly prescribed in overseas studies including paracetamol4, 20, 22, 25, 49, 
51, 53, 55, 69, 125, ibuprofen4, 25, 49, 69, morphine22, 49, 51, 55, oxycodone20 and 
salbutamol69, 124. In a study across five European countries, Conroy et al.124 
reported that paracetamol was the most widely prescribed drug in four of the 
five centres included in their study and salbutamol was also a commonly 
prescribed drug, both of which are in keeping with the current study. 
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In studies conducted overseas, several of the most commonly prescribed 
drugs were also prescribed in an off-label manner, including paracetamol63, 69 
and salbutamol63, 69. This is similar to the current study. For example, in a 
study by Conroy et al. involving five European countries, paracetamol was 
commonly used in an off-label manner in three of the centres investigated 
and salbutamol was commonly used off-label in four of the centres 
investigated.124 Although the reason for the off-label use of paracetamol was 
not specified in Conroy's study, salbutamol was reported off-label because it 
was used more frequently than recommended in the approved license. In the 
current study, paracetamol, which was the most commonly prescribed drug 
overall, was prescribed off-label in 48 (15.3%) out of 313 prescriptions. 
However, salbutamol, which was the ninth most commonly prescribed drug, 
was used off label in 51 (87.9%) of 58 prescriptions. All off-label cases of 
salbutamol related to dosage, which was similar to Conroy. Paracetamol was 
also off-label due to dose. Paracetamol25, 49, 54and other drugs commonly 
prescribed off-label in overseas studies included ondansetron48, 55, 65, 
salbutamol54, 66, 67, 69, morphine49, 53, 124, oxycodone125, midazolam64, 125 and 
fentanyl.125 In one study, researchers did not specify which drugs were 
commonly prescribed in an off-label or unlicensed manner so it was not 
possible to make drug-based comparisons.56 
 
Similar to the findings reported by Hsien et al.42, in the current study the four 
most frequently prescribed drug groups were analgesics and antipyretics (i.e. 
nervous system drugs), drugs for the alimentary tract and metabolism, anti-
infectives and drugs for the respiratory system.  
 
 
5.9 Reasons for off-label and unlicensed prescribing in overseas 
studies 
 
Hsien et al.42 reported the most common reason for off-label prescribing was 
dose (39%) which was also found in the current study (47.6%). Other 
reasons for off-label prescribing reported by Hsien et al.42 included indication 
(31%) and age (30%). Hsien et al.42 did not report any drugs as off-label for 
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route of administration. In the current study, fewer drugs were off-label due to 
indication (7.9%) but more drugs were off-label due to age (38.5%) and some 
drugs were off-label due to route of administration (6.0%). 
 
Many other researchers also reported that the most common reason for off-
label prescribing was dose and/ or dose frequency including a recent study in 
Tasmania.25, 43, 46, 49, 53, 54, 59, 62, 63, 66, 69, 124 Although in the current study the 
percentage of off-label prescribing due to dose or dose frequency was 
47.6%, this percentage may have been higher but since the hierarchical 
classification by Hsien et al. 42 was used, once drugs were classified into a 
category above dosage (i.e. age, indication and route of administration) they 
were then not considered for another category. Other categories of off-label 
prescribing in the current study included age (38.5%), indication 7.9%) and 
route of administration (6.0%) 
 
Some researchers have reported dose and dose frequency as two separate 
categories. For example, Ribeiro et al.69 reported that the main reason for off-
label prescribing was dosage (28.2%), followed by age (27.8%), indication 
(23.1%) and frequency of drug use (20.9%). In the current study, as with 
other studies62 dosage was defined as including the frequency of drugs 
administration as well as the dosage given. Following this definition, off-label 
prescribing in Ribeiro's study equates to 49.1%.69 However, it is the 
variations in definition of the term off-label that makes a direct comparison 
between studies often inappropriate. 
 
Several studies have reported the main reason for off-label prescribing as 
age.48, 56 In a study in Malaysia56 medicines prescribed outside the licensed 
age range were reported as the most common reason for off-label 
prescribing (37.1%), followed by dose (21.3%) and indication (19.9%). In this 
eight week study, which included preterm babies to patients aged under 18 
years admitted to a NICU, paediatric ICU, and paediatric high dependency 
unit, the median age was two years and the highest percentage of off-label 
and unlicensed prescriptions was for patients in NICU (i.e. patients with a 
gestational age less than 37 weeks and up to 27 days). It is not surprising 
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that the most common reason for off-label prescribing in the study was due to 
age since few medicines are licensed for use in neonates. The results of the 
study also highlight that the age of the study population can influence 
reasons for off-label and unlicensed prescribing since the researchers also 
reported that children younger than two years of age were more likely to 
receive an unlicensed medicine compared to older children. 
 
Age was also the main reason for off-label prescribing in a recent study in 
Spain.48 Researchers reported that in 82.7% of cases, the age range was not 
covered by the PI (which in Spain is called the SPC i.e. Summary of Product 
Characteristics) - either by not being directly included in the indication 
wording or indirectly through the inclusion of specific age-adapted posology 
recommendations. The other reason for off-label prescribing related to 
dosage (17.3%) with higher or lower doses prescribed than those 
recommended.48 
 
Due to different definitions of off-label and unlicensed prescribing used in 
various studies, in another study59 researchers reported that the most 
frequent reason for unlicensed medications was that ''safety and efficacy 
have not been established in children''. Most other researchers have 
classified this situation as off-label rather than unlicensed. 
 
 
5.10 Differences in study design 
 
The percentage of off-label and unlicensed prescribing varies widely between 
studies, ranging from 16 to 75% of prescriptions and reaching a prevalence 
of up to 100% when patients that received at least one off-label or unlicensed 
drug are considered. This variability may be explained by differences in study 
design, including the selection of different age groups, settings (inpatients, 
outpatients and Emergency Department patients), the duration of the study, 
whether the study was retrospective or prospective, different definitions of 
off-label and unlicensed drugs, different countries and different authorisation 
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status of drugs in different countries. Some of these differences make a 
direct comparison between studies inappropriate.  
 
Some studies were retrospective47, 61, 62, 64-69 but most were prospective 
studies that varied in the way patients were selected.1, 4, 11, 22-25, 42, 43, 45, 46, 49-
51, 53, 55-57, 59, 60, 63, 124 In many studies data were collected for prescription 
records of all patients admitted to the study ward within a specified time 
frame over several consecutive weeks.11, 22, 42, 46, 53, 54, 56, 60, 63, 124 In a few 
studies however, data were collected intermittently over a period of time. For 
example, Palcevski et al.57 collected data on one predetermined day each 
month during a 12 month period, Craig et al.25 collected data on one day 
each week over a two month period and in a four month study by Barr et al. 
45 medications were reviewed every two weeks. In a study in the Netherlands 
54, drugs prescribed to children on four different wards were studied for one 
day each week for five consecutive weeks but on a different day each week. 
Very few studies were randomised, with most prospective studies collecting 
data as patients presented to the setting where the study occurred. However, 
in a randomised study involving five different hospital wards in Switzerland55, 
medications prescribed to 60 randomly chosen paediatric patients were 
studied over a 24 hour period. In a retrospective study in Portugal, Ribeiro et 
al.69 randomly selected 700 children for inclusion in the study. It is unknown 
whether knowledge that a prospective study was occurring affected 
prescribing. 
 
The length of studies varied considerably. Some were of two weeks 
duration20, 125, some four weeks44, 49, 124, 30 days64, 5 weeks24, 53, two months/ 
eight weeks25, 56, 66, 10 weeks1, 12 weeks63, 13 weeks22, 23, 43, four months45, 
51, six months, eight months50, 10 months48, 69, one year61, two years4, three 
years68 and four years65. The number of patients included in studies also 
varied considerably from 3411 to 355409,61 although one study did not 
provide information on the number of patients included in the study.49 
 
The frequency of off-label and unlicensed prescribing for children was 
reported for various settings including various intensive care units (NICU, 
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paediatric ICU), surgical or medical wards, general paediatric medical wards, 
respiratory and cardiology wards, oncology wards, gastroenterology 
outpatient departments, Emergency Departments and others. Some studies 
focused on patients in specific age groups (e.g. neonates) or with specific 
conditions such as oncology, paediatric pain management or adverse drug 
reactions associated with off-label and unlicensed drug use. 
 
The age of patients included in the studies varied, with some studies 
including only neonates1, 11, 43, 45, others including children aged up to 11 
years62, up to 13 years25, less than or up to 14 years55, 63, less than 15 
years51, less than or up to 16 years48, 59, less than or up to 17 years47, 65, up 
to 18 years4, 23, 56, 64, less than 19 years67 and less than or up to 20 years22, 57. 
In several studies, the youngest child was one month old or one year old.63, 66 
59 In studies conducted exclusively in neonates the extent of off-label and 
unlicensed prescribing reported has been higher than in some other hospital 
settings so by not including children under one month or one year of age, this 
may impact considerably on the actual extent of off-label or unlicensed 
prescribing.  
 
Several different age classifications were used by researchers and these 
varied considerably. Examples of age classification included those used by 
'tJong et al.54 (0 to < 1 month, 1 to < 6 months, 6 months to < 2 years, 2 to < 
6 years, 6 to < 12 years, 12 years and older), Shah et al.61 (≤ 28 days, 29 
days to one year, 2 - 5 years, 6 - 12 years, 13 - 17 years), Bazzano et al.68 
(infant < 1 year, toddler 1 to < 2 years, preschool 2 to < 6 years, school age 6 
to < 12 years, adolescent 12 to < 18 years), Palcevski et al.57 [neonates (0-
28 days), infants (29 days - 1 yr), toddlers (1-2 yrs), preschool children (3-6 
yrs), school children (7-11 yrs), adolescents (12-19yrs), McKinzie et al.64 
(zero to 2 years, three to 1 years, 12 to 17 years) and Ruiz-Antoran et al.48 
(infants younger than two years, children between two and 10 years, 
adolescents 11 years and older). However, a number of researchers used 
the European Medicines Agency (EMA)6 age classification including Hsien et 
al. and others42, 50, 55, 69 (term newborn infants/ neonates aged zero to 27 
days, infants and toddlers aged 28 days to 23 months, children aged two to 
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11 years, adolescents aged 12 to 18 years) so this internationally accepted 
classification was adopted for the current study.  
 
5.10.1 Exclusions 
 
Possible selection bias may have resulted from the exclusion of certain 
patients and drugs. For example, McKinzie et al.64 excluded paediatric 
patients who presented exclusively for psychiatric evaluation.  The exclusion 
criteria of drugs varied with studies. Several studies excluded standard IV 
replacement solutions, blood products, oxygen therapy and flushes of sodium 
chloride 0.9% or heparin used to maintain patency of intravenous lines22, 24, 
124 whereas others excluded over-the-counter drugs or unscheduled 
medications62, 64, immunisations/ vaccinations62, 64 total parenteral nutrition 
(TPN)53, 54, 56, 62, eye drops, ear drops, nasal preparations, gargles and topical 
creams56. Other studies included all prescription and non-prescription 
medications in the evaluation. 60 
 
In some studies, patients who did not receive any medications were excluded 
from the study.56 By including only patients prescribed medications, the 
percentage of patients prescribed off-label or unlicensed drugs would be 
higher than if all patients, including those that did not receive medications, 
were included. 
 
In the current study, the exclusion criteria included oxygen therapy, standard 
intravenous (IV) replacement solutions, blood products, flushes of NaCl 0.9% 
or heparin used to maintain patency of IV lines and total parenteral nutrition 
(TPN). Most of these are not directly related to drug treatment and their 
omission was based on them not being directly used as drug therapy. Some 
would have influenced the number of unlicensed items prescribed. 
Procedures that did not involve the administration of agents for therapeutic 
effect, such as flushes to maintain patency of IV lines would also not have 
influenced the extent of off-label or unlicensed prescribing. Although TPN is 
not an active drug treatment, if it had been included in the study, it would 
have been classified as an unlicensed product. It is noteworthy that drugs 
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can be added to TPN and as this would have been recorded on the 
medication chart, such drugs would have been included in the current study.  
 
In considering the different exclusion criteria in various studies and the 
differences in reporting, a set of standard exclusions should be devised to 
allow accurate comparisons to be made between studies. It would be useful if 
the standardised parameters were set by the WHO as part of its role as a 
leader in global health matters and shaping the health research agenda, 
including setting norms and standards. 
 
5.10.2 Variations in off-label and unlicensed definitions 
 
Considerable variation in the extent of off-label and unlicensed prescribing is 
reported from different studies. This may be explained in part by the various 
definitions that have been used to describe off-label and unlicensed drugs. 
Thus the results are not directly comparable but provide an overall view of 
the issue. For example, some studies considered only one type of off-label 
use, such as McKinzie et al.64 who conducted a study in the Emergency 
Department in which off-label drug use was based solely on age-specific 
prescribing guidelines without considering indication, route of administration 
or dosage. In a study in the US outpatient setting, Bazzano et al.68 used only 
age and indication to determine off-label status whereas Lass et al.67 defined 
off-label as lack of paediatric information or contraindication to the use of the 
drug as well as age. Bajcetic et al.4 defined off-label drug use with respect to 
age, dose and route of administration but not indication.  
 
Many studies adopted the definition for off-label prescribing outlined by 
Turner et al. 22, 23 which describes off-label use as the use of drugs outside 
the manufacturer's approved license with regard to age, dose, route of 
administration and different indication or contraindication.25, 43, 46, 47, 50, 54, 66. 
Some researchers included a separate off-label category for drugs with no 
information for paediatric use 11, 55, 56, 69 while other researchers 42 classified 
drugs with no paediatric information as off-label for age. Some researchers 
considered up to eight types of off-label categories including lack of 
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paediatric information, age, lower than licensed dose, higher than licensed 
dose, indication, route of administration, less frequent than licensed 
frequency and more frequent than licensed frequency.56  
 
The definitions of unlicensed drugs also varied. Turner et al. defined 
unlicensed drugs as follows: modification to licensed drugs (e.g. crushing 
tablets to produce a suspension), licensed medicines in a modified 
formulation manufactured under a special manufacturing license (e.g. when 
an adult formulation is not suitable for use in children and a smaller dose 
must be formulated), new medicines under a special manufacturing license 
(e.g. caffeine injections for apnoea of prematurity), medicines used before a 
license has been granted, imported medicines or chemicals used as 
medicines.22  Several researchers used this classification system.47, 50 
However, other researchers defined unlicensed drugs as ''modified'' or ''home 
label'' preparations 53 without any further classifications. Lee et al.56 classified 
unlicensed drugs as extemporaneous preparations or unregistered products. 
Palcevski et al. classified drugs not approved for use in Croatia or those 
approved for use in Croatia but not for use in children, as unlicensed.57 
These researchers classified off-label drugs as drugs approved for use in 
children but for other indications or routes or age groups.57 Gavrilov et al. 
defined unlicensed use only as modification of a licensed drug.66 Lass et al 
defined unlicensed as a drug with no official marketing authorisation in 
Estonia.67 Bajcetic et al. classified unlicensed as an unapproved formulations 
(e.g. crushing tablets to make a syrup).4 'tJong et al. defined unlicensed 
drugs as drugs that were manufactured or modified by the hospital 
pharmacy, those that had an information text without dosage guidelines in 
children and drugs that were contraindicated for use in children.54 
 
A different definition was used by Santos et al. who defined unlicensed drugs 
as extemporaneous preparations that were a) manufactured (home-label 
medications) or b) modified by the hospital or nurse. These researchers also 
classified drugs as unlicensed if the safety and efficacy in the paediatric 
population were not established or if the drug was contraindicated for use in 
children. Where there was a discrepancy with the license information for age 
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(or weight), dose (or frequency), route of administration or formulation, these 
drugs were classified as off-label medicines.59 These researchers reported 
that the most frequent reason for unlicensed medications was that ''safety 
and efficacy have not been established in children''. 
 
Many researchers assigned more than one classification for off-label drugs 
and classified some drugs as off-label for multiple reasons. However,  Hsien 
et al.42 stated that an off-label drug cannot be classified in more than one 
classification.42 The different definitions of off-label and unlicensed medicines 
used by various researchers' categorisation make comparisons between 
studies difficult or impossible. A standardised definition of ''off-label'' and 
''unlicensed'' should be adopted internationally and could perhaps be initiated 
by the WHO. 
 
Most studies reported both off-label and unlicensed prescribing 1, 4, 11, 20, 22, 24, 
25, 43, 46, 47, 49-51, 53, 54, 56, 57, 59, 66, 124 with a few reporting only on off-label 
prescribing.42, 56, 60-65, 67-69 Reporting of off-label prescribing in patients varied 
with different studies. For example, by excluding patients that were not 
prescribed medicines 56 a higher percentage of off-label prescribing in 
patients is likely to be reported. Some studies included patients that did not 
receive medicines but when they reported the percentage of patients that 
received off-label medicines, they only considered patients that were 
prescribed medicines. For example, in a recent study in Spain involving 695 
children, 207 received medicines of which 47.3% received off-label 
medicines.48 If the number of patients receiving off-label drugs was reported 
in relation to all patients in the study (i.e. 695 children) the percentage would 
be much less (i.e. 14.1% i.e. 98 / 695).  
 
Similar reported data occurred in a study in Croatia which involved 691 
paediatric patients.57 Of these, 531 received drugs, and of these, 254 
received either off-label or unlicensed drugs. The researchers reported the 
percentage of patients receiving off-label or unlicensed drugs as 47.8% (i.e. 
254/531) but if the percentage had been reported as a percentage of the total 
study population, then 36.8% (i.e. 254/691) of patients would have been 
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reported as receiving an off-label or unlicensed drug which would have been 
closer to the findings reported in the current study. By contrast, in a recent 
Portuguese study involving 700 children of whom 427 were prescribed drugs 
of which 197 were prescribed off-label drugs, researchers reported that 
28.1% of all children received one off-label prescription. These researchers 
reported the finding based on the whole study population.69 
 
In the current study, 378 patients out of 1037 patients were prescribed off-
label or unlicensed drugs and 338 patients did not receive any drugs. The 
percentage of patients receiving off-label or unlicensed drugs in this study 
was reported as 36.5% in relation to all patients. However, if patients not 
prescribed drugs were excluded, the percentage of patients prescribed off-
label or unlicensed drugs would be 54.0% (i.e. 378 / 699). Therefore reported 
percentages can be manipulated depending on how the findings are 
reported. 
 
The percentage of patients reported as receiving off-label or unlicensed 
drugs in the current study, which was calculated as 36.5% by considering the 
whole study population, was similar to those reported by studies in the UK, 
Israel and Ireland.22, 25, 66 However, it is difficult to make direct comparisons 
between studies as the UK and Ireland studies were inpatient studies and the 
study in Israel was an outpatient study. Further, the age of patients included 
in the studies was different with the UK study including patients less than 20 
years, the Ireland study including patients less than 13 years and the Israel 
study including patients from one month to 18 years.  
 
 
5.11 What is happening overseas 
 
Since 1997, legislation was introduced in the United States, including the 
Paediatric Rule Regulation 1998, Best Pharmaceutical for Children Act 
(BPCA) 2002 and the Paediatric Research Equity Act (PREA) 2003, to 
ensure that high quality safe and effective drugs, that were ethically 
researched, were approved and made available for use in children.126, 127 For 
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drugs where paediatric studies are required, the PREA requires 
pharmaceutical companies to conduct paediatric studies in the same drug 
that is approved for adults use.126 The BPCA provides an incentive for 
pharmaceutical companies to conduct paediatric studies requested by the 
FDA by providing an additional six months of marketing exclusivity.127 Prior to 
BPCA and PREA becoming law, more than 80% of drugs approved for use in 
adults were being use off-label in children despite a lack of safety and 
efficacy data. Since the introduction of the new legislation, the number of 
adult drugs used in children without adequate safety and efficacy data has 
decreased to 50% during the past 15 years.85, 106 
 
Following the experience in the US, the Paediatric Regulation was 
implemented by the European Union in January 2007. This established a 
framework of requirements, incentives, obligations and rewards for 
pharmaceutical companies similar to the PREA in the United States. The 
central instrument of the Paediatric Regulation is the Paediatric Investigation 
Plan (PIP) which aims to obtain relevant data through clinical trials without 
subjecting children to unnecessary trials. PIPs are approved by the 
Paediatric Committee (PDCO) established within the EMA and all 
pharmaceutical companies are required to submit a PIP when a new drug is 
marketed (unless a waiver has been granted).128 Reflecting on the successes 
of the Paediatric Regulation after five years since its implementation in 2007, 
the EMA recently reported that more high quality research in paediatric 
medicines was taking place, better information on the use of medicines in 
children had become available (221 changes about safety and efficacy, from 
submission of old or new studies and 89 additions to dosing information for 
children as a result of PIPs) and there were more medicines for children with 
age appropriate dosage forms.129  
 
On the world front,  in 2007 the WHO launched the ''Make medicines child 
size" campaign and established the Model List of Essential Medicines for 
Children, which is now in its fourth version.90, 91 Further, the EMA and the 
FDA in the United States have agreed on principles to interact and exchange 
information on paediatric matters, to foster the global development of 
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medicines for children. Collaboration with other regulators outside the 
European Union and with the WHO are also ongoing.130  
 
 
5.12 What is happening in Australia 
 
Since the mid-1990s, initiatives addressing issues related to paediatric 
medicines have been proposed through professional and government bodies, 
including paediatric medicines research to ensure quality use of medicines 
(QUM) which is part of the National Medicines Policy.85 Despite some recent 
initiatives such as the availability of an evidence based and peer reviewed 
paediatric prescribing information resource, guidelines for off-label 
prescribing published in the Medical Journal of Australia and the ongoing 
work of the Paediatric Medicines Advisory Group (PMAG), there is still a lack 
of any legislative and regulatory reforms addressing paediatric medicines in 
Australia.77, 94, 99 
 
Both the current Western Australian study and the recent Tasmanian study 
reported that a high percentage of patients receive off-label drugs and that 
many medicines are used in an off-label manner because of the lack of 
appropriate safety and efficacy data.62 In addition it is evident that many 
medicines have been used off-label for decades. The initiatives by the US 
and Europe show a strong commitment by governments and society as a 
whole to stimulate development and study of drugs used in paediatrics and 
provide important scientific data for improvement of paediatric therapy but 
there is currently no specific government commitment in Australia to give 
high priority to paediatric medicines issues. 
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5.13 Patient related issues 
 
5.13.1 Informed consent 
 
In the current study, no documentation was found in any of the paediatric 
medical records documenting parent or carer's informed consent when off-
label or unlicensed drugs were prescribed to a patient. As the study was 
retrospective, it was not possible to verify if an oral parent or carer's informed 
consent was obtained and there was no evidence of this in the medical 
records. Other researchers have also reported a lack of informed consent 
documents.48, 62  
 
The benefits and risks associated with off-label or unlicensed prescribed 
drugs should be discussed with parents or carers and consent obtained, 
preferably with documentation of a signed consent form, especially when 
high quality evidence for use of a medicine is lacking. Further,  Ballard et al. 
suggest that in the latter case, approval of a hospital drug committee should 
be obtained.62 
 
5.13.2 Patient safety and ethical issues 
 
Since the study conducted by Turner at PMH in 1999,24 the current study 
suggests that the percentage of inpatients prescribed off-label and 
unlicensed drugs has increased, especially patients prescribed off-label 
drugs. The individual percentages of off-label or unlicensed drugs cannot be 
compared as only a combined value of 16% off-label and unlicensed drugs 
were reported in Turner's study. However, the percentage reported in the 
current study is higher suggesting that the rate of prescriptions for off-label 
and unlicensed use has increased in the last decade.  
 
Other comparative studies have also reported an increase in the rate of off-
label prescribing, especially in newborns. In a recent study in Finland 
researchers compared prescribing trends between 2001 and 2011. They 
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reported that despite the implementation of the European Paediatric 
Regulation in 2007, the number of patients prescribed at least one off-label or 
unauthorised (unlicensed) drug had increased from 58% in 2001 to 79% in 
2011.125 However, they added that the four year period that the regulation 
had been in force might be too short for significant changes.125 
 
One of the assumed consequences of off-label and unlicensed prescribing is 
the potential for an ADR. A ten year study in Denmark that analysed 
spontaneous reporting of ADRs in children aged zero to 17 years reported 
that 17% of ADRs were associated with off-label use and that 60% of these 
were severe.74 In another study, researchers reported that ADRs related to 
off-label use was lower than the rate for drugs with approved (licensed) 
uses.131 Although these findings are conflicting, in a recent 12 month 
prospective study of ADRs involving 6020 children admitted to a paediatric 
hospital in the UK, researchers reported that off-label and unlicensed 
medicines were more likely to be implicated in an ADR than authorised 
medicines (relative risk 1.67, 95% CI 1.38, 2.02, p < 0.001).132 This was due 
to the fact that many of the ADRs related to off-label and unlicensed use of 
drugs in oncology patients. 
 
In the current study, reporting of ADRs related to off-label or unlicensed drug 
use was not well recorded in patient medication records. This made it 
impossible to determine whether the level of ADRs was greater with off-label 
and unlicensed drugs compared to licensed drugs. Whether the lack of 
reporting was due to litigation fears or just simple omissions was not able to 
be determined. Although off-label and unlicensed prescribing is not illegal, it 
has been reported previously that physicians and hospitals can be wary of 
using medicines in this way for fear of litigation.133 If ADRs were suspected of 
being a major factor associated with off-label and unlicensed prescribing at 
PMH, a study should be conducted collecting data prospectively. The only 
concern would be as to whether the same level of off-label and unlicensed 
prescribing would be maintained once awareness of the study emerged and 
could influence the reporting of ADRs as these may require verbal enquiry. 
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In Australia, ADRs can be reported either online or via the ''Blue Card'' and 
this probably involves mainly licensed (or on-label) drug use. ADRs 
associated with off-label and unlicensed drugs are likely to be underreported, 
not only in the current study but also other studies.48 Therefore monitoring, 
pharmacovigilance and documentation of ADRs associated with off-label and 
unlicensed drug use should be improved. 
 
Drugs are registered to demonstrate efficacy, safety and toxicity including 
ADRs to ensure that when a drug is prescribed to a patient that the patient is 
likely to benefit from the drug and not have untoward effects above an 
acceptable level. The use of off-label and unlicensed drugs raises some 
important ethical issues as to whether the drug used in an unapproved 
manner should be considered as an experimental use that warrants patient 
or parent consent prior to administration.  
 
With respect to off-label drugs, neither the benefit nor the risk has been 
demonstrated either for that indication, dose or in that age group. However, 
by allowing off-label prescribing, it gets around the need for a sponsor to 
demonstrate efficacy in those categories. For unlicensed drugs there is no 
information for the general population but for one person it may be 
acceptable. The availability of unlicensed drugs for one person provides 
access to an individual who would like access to the product but does not 
expose the community to the risk. But since off-label prescribing is so highly 
prevalent, the community is exposed to the risk, especially children. 
 
Recently, in a meeting of experts that included experts in drug development 
and formulation, neonatal intensive care, paediatric clinical pharmacology 
and others, more than 80% advised that poor formulation of a drug was 
occasionally associated with an untoward effect such as prolonged 
hospitalisation or cause of a new condition. Further, nearly 40% believed that 
lack of a properly formulated parenteral drug occasionally contributed to 
death.134 Hence the underlying ethical issues are whether off-label drugs and 
unlicensed drugs should be permitted and the level of risk in its acceptance. 
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In addition, if it was not permitted there would be an issue as to whether 
sponsors would carry out studies in children as they are a small market. 
 
In Australia, as a result of the support of the Australian Health Ministers' 
Advisory Council (as part of the Paediatric Pharmaceuticals Resource 
project) the AMH Children's Dosing Companion was recently introduced.99 
This publication was prepared from the best available evidence to support 
the recommendations and is a welcome resource for professionals who 
devote their efforts to provide high quality care for children. For example, 
although the approved license for midazolam is for the injection solution to be 
administered IV or IM, the AMH Children's Dosing Companion provides 
doses for oral, buccal and intranasal administration, all of which are off-label 
for route of administration. Under the heading "Off-label use" it states that the 
PI does not include doses for seizures, or for oral, buccal or intranasal use. It 
does not provide further information to justify off-label use by different routes 
of administration to those in the accepted license. This is similar for other 
drugs that are also used off-label such as clonidine for which the approved 
license does not include preoperative sedation and analgesia. However, the 
AMH Children's Dosing Companion provides doses for children aged one to 
18 years.99 
 
Considering that the prevalence of off-label and unlicensed prescribing in this 
study was almost one third of all patients and given that the prevalence of off-
label and unlicensed prescribing in other countries has also been reported to 
be high, especially in some settings (e.g. inpatients) and some patient age 
groups (e.g. neonates), governments around the world need to be aware of a 
potential public health hazard. A government sponsored group of experts, 
perhaps even the WHO, should consolidate and evaluate the quality of 
evidence for the prescribing of drugs for children. This could be achieved 
through systematic reviews including meta-analyses, to identify whether 
there is sufficient evidence for the off-label or unlicensed prescribing 
including the dose and range of age groups of children where 
pharmacokinetics could have an impact. Where notable deficiencies are 
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reported, studies should be sponsored to provide an adequate evidence-
base for their prescribing.  
 
 
5.14 Lincomycin 
 
In Australia, the use of parenteral lincomycin in hospitals, including ICUs, 
exceeds parenteral clindamycin usage.135 This preference of lincomycin over 
clindamycin may have been partly due to the lower acquisition cost of 
lincomycin, although there have been recent changes in the cost of these 
agents, so they now both cost the same. This may have an impact on future 
prescribing trends. However, lincomycin is currently the only injectable 
lincosamide available on the PBS.136 Further, the Australian Therapeutic 
Guidelines (Antibiotics) presents both drugs as equivalent treatments for 
serious infections resulting from Staphylococcus aureus, Streptococcus 
pyogenes and Streptococcus agalactiae. 123 
 
Lincocin® (which contains lincomycin hydrochloride) can be administered by 
direct intramuscular injection every 12 to 24 hours at a dose of 10 mg/kg/day 
of lincomycin. Alternatively, intravenous doses can be administered on the 
basis of one gram Lincocin® (lincomycin as the hydrochloride) diluted in not 
less than 100 mL of appropriate IV solution and infused over at least one 
hour.30 Lincocin® is commonly used in an unlicensed manner by adding the 
drug to various IV solutions including sodium lactate, 0.9% sodium chloride, 
5% glucose and 10% glucose solutions. Current stability information on 
lincomycin in these IV solutions is limited to the compatibility of lincomycin in 
these IV fluids which are physical determinations rather than chemical 
determinations.30 Physical compatibility has been reported only for 24 hours 
at room temperature.101 However, the expiry dates for many stable 
compounds can be extended when prepared aseptically thus potentially 
reducing wastage. Further, more patients are being treated at home so less 
home visits to obtain additional doses from an attending nurse may increase 
convenience.  
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This study investigated the stability of Lincocin® in sodium lactate 
(Hartmann’s), 0.9% sodium chloride, 5% glucose and 10% glucose solutions 
over 31 days. An initial investigation was carried out to ensure that the 
Lincocin® sample met the BP 2013 specifications for the content of 
lincomycin in the lincomycin injection, which should be 92.5 to 107.5% of the 
stated amount.36 The amount of lincomycin base in a 0.6 mg/mL lincomycin 
hydrochloride sample prepared from Lincocin® was found to contain 0.629 
mg/mL lincomycin, equivalent to 104.9% of the stated amount. Hence the 
calculated quantity of lincomycin in Lincocin® injections (104.9%) met the 
specifications of the BP. 
 
Stability studies testing the degradation of 0.6 mg/mL lincomycin in 0.1 M 
hydrochloric acid solution, 0.1 M sodium hydroxide solution and 3% hydrogen 
peroxide solution at 60C showed that lincomycin degradation occurred most 
rapidly in hydrogen peroxide suggesting that lincomycin hydrochloride readily 
undergoes oxidation. Less rapid degradation was observed in acid solution 
with 48.8% lincomycin hydrochloride remaining in acid solution after seven 
days compared to 8.0% remaining in base solution after the same time. In a 
study investigating the stability of 0.4% lincomycin hydrochloride in 0.1 N 
hydrochloric acid solution at 37C and 70C, it was reported that lincomycin 
showed no degradation for at least 48 hours at 37 C and degraded slowly 
(half-life 39 hours) at 70C.106 
 
The stability of lincomycin was tested over four weeks at 25C in the four 
different IV solutions stated above (sodium lactate (Hartmann's Solution), 
0.9% sodium chloride solution, 5% glucose solution and 10% glucose 
solution). Lincomycin was very stable in all four IV solutions and showed very 
little degradation over time. All samples had a shelf-life of 744 hours or 31 
days at 25C. In a study investigating the stability of clindamycin in 5% 
dextrose and 0.9% sodium chloride at 4C and at room temperature (23C) 
over 21 days, researchers reported that the degradation of clindamycin was 
slow with less than 5% loss occurring at various concentrations of 
clindamycin in each diluent and at each temperature. This is similar to 
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findings on lincomycin in the current study although a single concentration 
(0.6 mg/mL) was used in each IV solution.137  
 
The degradation of lincomycin hydrochloride at 80C at pH 2.00, 3.00, 4.00, 
6.10 and 8.00 was also investigated. The rate constant was lowest at pH 
4.00. The results showed that lincomycin had the greatest stability at pH 
4.00, with a calculated shelf-life of 4.59 days. It was least stable at pH 2.00, 
with a calculated shelf-life of 0.38 hours. 
 
Lincomycin hydrochloride (Lincocin®) is only available as a 2 mL ampoule. 
When lincomycin hydrochloride is required in an appropriate IV solution, this 
necessitates that the required amount is transferred into the IV infusion via a 
syringe. Aseptic technique is essential for this and usually requires a hospital 
pharmacy environment. Once prepared, however, the solution could be used 
outside the hospital environment. 
 
 
5.15 Study limitations 
 
There were several limitations to this study. There were few neonates 
included in this study as they are usually treated at another hospital unless 
they require treatment after discharge. There was a smaller percentage of 
inpatients (24.5%) in this study than outpatients (36.6%) or Emergency 
Department patients (38.9%). However, for some outpatients, all of their 
prescribing related to their admission in 2008 as an inpatient. For these 
patients, their prescribing details were recorded and they were classified as 
an inpatient for the study. The transfer from outpatient to inpatient may have 
decreased the level of prescribing attributed to the outpatient category. 
 
Some medical records were not available as patients had either been 
readmitted to the hospital so their medical chart was in use on the ward or 
they had recently been discharged so their medication chart was still waiting 
to be filed. It was expected that more patients prescribed psychotherapeutic 
drugs would have been identified but it could be that their medical records 
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were amongst those difficult to obtain which could have occurred for child 
protection cases or where they were being used on the ward. The study 
however accessed medical records at least 86.5% of the time after the end of 
2008. 
 
There were limitations with the hierarchical classification system because in a 
number of cases, if a hierarchical approach had not been used, drugs could 
have been classified into a number of categories. The classification system 
may have lowered the number of unlicensed drugs reported. In some 
categories there were low levels of unlicensed prescribing and hence an 
even larger sample would be necessary to ensure adequate power in that 
subgroup to make comparisons. The hierarchical system used classifies 
medicines as off-label or unlicensed with the same frequency as recording all 
possible reasons, however the number of reasons for which an item could 
have been classified would be lower in this study. 
 
 
5.16 Conclusion 
 
This study provides the first data on the prevalence of off-label and 
unlicensed prescribing from a random sample of patients from a major 
paediatric hospital which gave an overall off-label and unlicensed prevalence 
of 28.3%, of which 25.7% accounted for off-label prescribing and 2.6% 
accounted for unlicensed prescribing. The percentage of patients prescribed 
at least one off-label or unlicensed drug was 36.5% with the highest 
percentage of off-label prescribing associated with nervous system drugs and 
the highest percentage of unlicensed prescribing with systemic hormonal 
preparations excluding sex hormones. Most drugs were used in an off-label 
manner rather than in an unlicensed manner. The ten most commonly 
prescribed off-label drugs were ondansetron, Painstop Day®, salbutamol, 
oxycodone, paracetamol, midazolam, fentanyl, ticarcillin/ clavulanic acid, 
amoxicillin and flucloxacillin. The most commonly prescribed unlicensed 
drugs were dexamethasone and dilacaine.  
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Of the inpatients that were prescribed drugs, 78% were prescribed off-label 
drugs. Further, children aged between two and 11 years were prescribed the 
highest percentage of off-label drugs (85%). The highest percentage of 
unlicensed drugs were prescribed to outpatient infants aged 28 days to 23 
months (17%). 
 
These findings indicate that almost one-third of patients are being exposed to 
medicines for indications that are unregistered and/or doses that are 
unregistered. This situation is a potential public health hazard especially for 
inpatients and children aged two to eleven years since off-label prescribing 
was found to be highest in these groups.  Children are considered a 
vulnerable group of patients and governments around the world need to be 
made aware of a potential public health disaster from the current system. 
 
As a first step, a government sponsored group of experts should consolidate 
and evaluate the quality of evidence for the prescribing of drugs in paediatric 
populations. Where there are notable deficiencies then studies should be 
sponsored to provide an adequate evidence-base for their prescribing. 
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5.17 Recommendations  
 
 To allow international studies to be comparable, guidelines should be 
provided outlining an optimum study design including clear definitions 
of the terms off-label and unlicensed and age groups. The definitions 
provided by Turner et al. have been used by a number of researchers 
as they are comprehensive and unambiguous. It is recommended that 
a major organisation, such as the WHO, provide a universal definition 
of the terms off-label and unlicensed prescribing and propose 
international study guidelines to provide better consistency so data 
can be comparable.  
 A system for monitoring off-label and unlicensed prescribing in 
children across Australia is recommended. 
 All off-label and unlicensed prescribing should require a mandatory 
consent form. This may increase awareness among health 
professionals that they are prescribing a drug in an off-label or 
unlicensed manner and would ensure that parents/ carers were 
appropriately informed. 
 The current study describes the findings of off-label and unlicensed 
prescribing in the major children's hospital in WA. A major study at a 
national level involving several major paediatric hospitals in Australia 
would be valuable to determine the robustness of the findings in the 
current study. 
 A committee to establish evidence based paediatric data from 
published studies should be established, possibly at the level of the 
WHO, so that vital information on safety and efficacy of drugs could be 
available and accessible for all health practitioners in the world for the 
benefit of children. 
 It is proposed to publish the lincomycin hydrochloride stability data in a 
well regarded journal so that this information is widely available to the 
pharmacy community. In the current climate of off-label and 
unlicensed products, this seems to be the only option available. 
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Appendix 1 -  Summary of studies reporting off-label and unlicensed drugs prescriptions.  
Country  Study 
Study 
type 
Length 
of 
study 
Type of patients or study 
wards 
Number 
of 
patients 
Age of 
patients 
Total 
prescriptions/ 
prescription 
episodes 
Percentage 
prescriptions 
off-label (OL) 
Percentage 
prescriptions 
unlicensed 
(UL) 
Percentage 
prescriptions 
OL or UL 
Patients 
receiving 
OL or UL 
drugs 
UK 
Turner S 
et al. 51 
P 
4 
months 
Paediatric intensive care unit 166 
1 day - 15 
yrs 
862 Not reported Not reported 31% 70% 
US  
McKinzie 
et al. 64 
R 30 days  
Emergency Department 
patient charts 
359 
4 days - 
17 years 
Not reported Not reported Not reported Not reported 43 % OL 
UK 
Turner et 
al. 22 
P 
13 
weeks  
Medical & surgical paediatric 
wards 
609 
4 days - 
20 years 
2013 18% 7% 25% 36% 
UK 
Conroy et 
al. 43 
P 
13 
weeks  
Neonatal intensive care unit 70 neonates 455 55% 10% 65% 90% 
UK 
Turner et 
al. 23 
P 
13 
weeks  
5 different wards e.g. 
surgical, medical, neonatal 
surgical 
1046 
1 day - 18 
yrs  
4455 Not reported Not reported 35% 48% 
Australia 
Turner et 
al. 24 
P 
5 
weeks  
Medical ward & surgical ward 
(100 patients from each) 
200 
49 days - 
18 years  
735 Not reported Not reported 16% 36% 
Across 
Europe 
Conroy et 
al. 58 
P 
4 
weeks  
General paediatric medical 
wards in 5 hospitals 
624 
4 days - 
16 years 
2262 39% 7% 46% 67% 
France 
Avenel et 
al. 44 
P 
4 
weeks 
Neonatal intensive care unit 40 Neonates 257 63% 10% 73% 
Not 
reported 
Israel 
Gavrilov 
et al. 66 
R 
2 
months 
Outpatients in the General 
Paediatric Ambulatory Unit 
132 
1 month - 
18 years 
222 26% 8% 34% 42% 
UK 
Conroy et 
al. 49 
P 
4 
weeks 
Children's hospital acute 
medical & acute surgical 
ward 
not 
provided 
Not 
reported 
715 33% 0% 33% 
Not 
reported 
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Country  Study 
Study 
type 
Length 
of 
study 
Type of patients or study 
wards 
Number 
of 
patients 
Age of 
patients 
Total 
prescriptions/ 
prescription 
episodes 
Percentage 
prescriptions 
off-label (OL) 
Percentage 
prescriptions 
unlicensed 
(UL) 
Percentage 
prescriptions 
OL or UL 
Patients 
receiving 
OL or UL 
drugs 
Ireland 
Craig et 
al. 25  
P 
2 
months  
Paediatric medical ward 74 
1 week - 
13 years 
237 19% 3% 22.00% 43% 
Netherlands 
t Jong et 
al. 53 
P 
5 
weeks 
3 ICUs and one medium care 
unit 
237 
0 days - 
17 years 
2139 18% 48% 66% 90% 
Israel 
Barr et al. 
45 
P 
4 
months  
Neonatal intensive care unit 105 Neonates 525 59% 16% 75% 
93% off 
label 
Australia 
O'Donnell 
et al. 1 
P 
10 
weeks  
Neonatal intensive care unit 97 Infants 1442 47% 11% 58% 80% 
Italy 
Pandolfini 
et al. 63 
P 
12 
weeks  
Paediatric wards from 9 
participating Italian hospitals 
1461 
1 month - 
14 years 
4265 60% 0.2% 60.2% 82% 
Netherlands 
t Jong et 
al. 54 
P 
5 
months 
Paediatric ward & 
neonatology unit 
293 
0 days to 
16.7 
years 
1017 44% 28% 72% 92% 
UK 
Conroy et 
al. 46 
P 
4 
weeks 
Oncology inpatients and 
outpatients 
51 
0.6 - 16.3 
years 
569 26% 19% 45% 100% 
UK 
Dick et al. 
47 
R 
6 
months 
Paediatric gastroenterology 
outpatient department 
308 
20 days - 
17 years 
777 37% 12% 49% 
Not 
reported 
Germany 
Neubert 
et al. 50 
P 
8 
months. 
Paediatric isolation ward 178 
5 days - 
17 years 
740 26.4% 0.4% 26.8% 52% 
Belgrade 
Bajcetic 
et al. 4 
P 2 years  Paediatric cardiology ward 544 
4 hours - 
18 years 
2037 47% 11% 58% 76% 
Switzerland 
DiPaolo 
et al. 55 
P 
6 
months  
Various wards e.g. neonatal, 
paediatric, intensive care 
60 
3 days - 
14 years 
483 25% 24% 49% 100% 
  
224
Country  Study 
Study 
type 
Length 
of 
study 
Type of patients or study 
wards 
Number 
of 
patients 
Age of 
patients 
Total 
prescriptions/ 
prescription 
episodes 
Percentage 
prescriptions 
off-label (OL) 
Percentage 
prescriptions 
unlicensed 
(UL) 
Percentage 
prescriptions 
OL or UL 
Patients 
receiving 
OL or UL 
drugs 
US  
Eiland & 
Knight 60 
P 
6 
months 
Clinic, the emergency dept or 
the paediatric ICU 
403 
3 days - 
18 years 
1383 31% Not reported Not reported 
Not 
reported 
Italy 
Dell'Aera 
et al. 11 
P 
2 
months  
Neonatology intensive care 
unit 
34 neonates 176 51% 12% 63% 51% 
US  
Shah et 
al. 61 
R 1 year  
31 tertiary care paediatric 
hospitals  
355409 
≤ 18 
years  
Not provided Not reported Not reported Not reported 78.7% OL 
Brazil 
Santos et 
al. 59 
P 
5 
months  
Ward with several different 
paediatric specialities  
272 
1 - 16 
years 
1450 39.6% 5.5% 45.1% 83% 
Germany 
Hsien et 
al. 42 
P 
6 
months 
Pneumology & cardiology 
ward 
417 
1 day - 40 
years 
1812 31% Not reported Not reported 61% OL 
US  
Bazzano 
et al. 68 
R 3 years 
National Ambulatory Medical 
Care Surveys data 
7901 OP 
visits 
0 - 17 
years 
312 million 
visits 
62% Not reported Not reported 59% OL 
Finland 
Lindell-
Osuagwu 
et al. 20 
P 
2 
weeks 
NICU, general and surgical 
ward 
141 
< 18 
years 
629 36 % 13 % 49 % 76 % 
Estonia 
Lass et al. 
67 
R 1 year  Outpatients 151476 
< 19 
years 
467334 31% 0.1% 31.1% 
Not 
reported 
Italy 
Zanon et 
al. 65 
R 4 years 
8 pediatric emergency 
departments 
19879 
0 - 17 
years 
19879 doses 
of antiemetic 
30% Not reported Not reported 
Not 
reported 
Croatia 
Palcevski 
et al. 57 
P 
12 
months  
Hospitalised children in the 
Department of paediatrics 
691 
1 day - 20 
years 
1643 12% 13.3% 25% 48% 
Portugal 
Ribeiro et 
al. 69 
R 
10 
months 
Paediatric emergency unit 700 
4 days - 
18 years 
724 32.2% Not reported Not reported 28.1% OL 
Spain 
Ruiz-
Antoran 
R 
10 
months 
Pediatric gastroenterology 
outpatient clinic  
695 
22 days - 
15.6 yrs 
331 33.2% Not reported Not reported 47% 
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Country  Study 
Study 
type 
Length 
of 
study 
Type of patients or study 
wards 
Number 
of 
patients 
Age of 
patients 
Total 
prescriptions/ 
prescription 
episodes 
Percentage 
prescriptions 
off-label (OL) 
Percentage 
prescriptions 
unlicensed 
(UL) 
Percentage 
prescriptions 
OL or UL 
Patients 
receiving 
OL or UL 
drugs 
et al. 48 
Australia 
Ballard et 
al 62 
R 
4 
months  
General paediatric ward 300 
1 day - 11 
years 
887 32% Not reported Not reported 57% OL 
Malaysia 
Lee et al 
56 
P 
8 
weeks 
3 Intensive care units 194 
1 day - 16 
years 
1295 34.1 27.3 61.4% 92.4% 
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Appendix 3 - Ethics approval Curtin University 
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Appendix 4 -  List of all 330 prescribed drugs (licensed, off-label and 
unlicensed) included in the study and their frequencies 
 
Drug Name Frequency Drug Name Frequency
Acetylcysteine 3 Azathioprine 4 
Aciclovir 7 Azithromycin 9 
Actrapid 6 Baclofen 1 
Adrenaline 11 Benzathine penicillin 1 
Albey bee venom 2 Benzocaine/ phenazone  2 
Alfentanil 2 Benzylpenicillin 9 
Allopurinol 1 Betamethasone 11 
Alpha-keri  1 Betaxolol 1 
Alprostadil 1 Bisacodyl 2 
Alteplase 2 Botulinum toxin 5 
Aminophylline 1 Brimonidine 1 
Amitriptyline 3 Brimonidine/ timolol 1 
Amlodipine 1 Brinzolamide 1 
Amoxicillin 59 Budesonide/ eformoterol  2 
Amphotericin B 1 Bupivacaine 1 
Aprepitant 3 Buscopan 1 
Aspart insulin 22 Calamine 1 
Aspirin 7 Calcitriol 1 
Atenolol 2 Calcium carbonate 4 
Atomoxetine 1 Calcium folinate 1 
Atorvastatin 1 Captopril 1 
Atovaquone/ proguanil  2 Carbamazepine 4 
Atracurium 9 Carbimazole 2 
Atropine 1 Carnitine 3 
Augmentin Duo® 36 Cefepime 3 
Augmentin Duo Forte® 7 Cefotaxime 10 
Ceftazidime 1 Creon  9 
Ceftriaxone 16 Cromoglycate 2 
Cephalexin 21 Crotamiton 1 
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Drug Name Frequency Drug Name Frequency
Cephazolin 15 Cyclopentolate 15 
Cetaphil® cleanser 1 Cyclophosphamide 5 
Cetylpyridinum chloride 1 Cyclosporin 1 
Chloral hydrate 7 Cyproheptadine 1 
Chloramphenicol  24 Darbapoetin alfa 1 
Chlorhexidine 14 Demazin® 1 
Chlorhexidine/ 
lignocaine 
1 Dermeze® 5 
Choline salicylate 4 Desmopressin 5 
Ciclesonide 1 Detemir insulin  2 
Ciprofloxacin 6 Dexamethasone 58 
Ciproxin® HC 7 Dexchlorpheniramine 2 
Cisplatin 1 Diazepam 8 
Cisretinoic acid 1 Diclofenac 2 
Clindamycin 4 Digoxin 1 
Clobazam 3 Dilacaine 12 
Clonazepam 7 Docusate 4 
Clonidine 14 Domperidone 2 
Clotrimazole 2 Dopamine 3 
Codeine 12 Dornase alfa 3 
Colecalciferol 5 Doxorubicin 1 
Cophenylcaine 2 Doxycycline 1 
Coenzyme Q10 1 Emla 26 
Colonlytely® 1 Enalapril 3 
Coloxyl with senna 5 Entonox 1 
Cotrimoxazole 1 Epipen junior 5 
Epipen  7 Griseofulvin 1 
Escitalopram 1 Heparin 3 
Esomeprazole 1 Hep B vaccine 3 
Etonogestrel 1 Homatropine 1 
Ectoposide 1 Humalog® 11 
Erythromycin 2 Humulin® NPH 4 
  230 
Drug Name Frequency Drug Name Frequency
Fentanyl 39 Hyaluronidase 1 
Ferrous sulfate 8 Hydralazine 2 
Fess 1 Hydrochlorothiazide 1 
Filgrastim 2 Hydrocortisone 20 
Flucloxacillin 41 Hydroxyurea 1 
Fluconazole 7 Hydrozole® 1 
Fludrocortisone 2 Hyoscine butylbromide 3 
Fluorometholone 1 Ibuprofen 201 
Fluorouracil  1 Indomethacin 1 
Fluoxetine 4 Infliximab 2 
Fluticasone 7 Interferon beta 1 
Folic acid 4 Ipratropium 14 
Frusemide 7 Kenacomb® 4 
Gabapentin 2 Ketamine 3 
Gentamicin 21 Lactulose 21 
Glargine insulin 11 Lamotrigine 12 
Glucagon 4 Lansoprazole 3 
Glucose 1 Latanoprost 2 
Glycerin  5 Leuprorelin  1 
Glyceryl trinitrate 2 Levonorgestrel  1 
Glycopyrrolate 1 Levonorgestrel/ 
ethinyloestradiol  
2 
Gonadorelin 2 Levetiracetam 7 
Levocabastine 1 Mixtard® insulin 1 
Lignocaine  9 MMR, MenCCV and Hib 1 
Liquid paraffin 5 Mometasone 16 
Lisinopril 2 Montelukast 8 
Locacorten® ear drops 1 Morphine 80 
Loperamide 1 Movicol®  10 
Loratadine 26 Moxifloxacin 1 
Lorazepam 10 Mupirocin 8 
Losartan 1 Mycophenolate  1 
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Drug Name Frequency Drug Name Frequency
Magnesium chloride 2 Mycostatin 1 
Mannitol 1 Mylanta 3 
Melatonin 1 Naproxen 6 
Mercaptopurine 1 Natalizumab 1 
Meropenem 5 Nemdyn® 1 
Mesalazine 2 Nifedipine 2 
Mesna 2 Nitrazepam 1 
Metformin 1 Nitric oxide 4 
Methotrexate 4 Normal immunoglobulin 4 
Methylphenidate 4 Normal saline 7 
Methylprednisolone 11 Nurofen Plus® 1 
Metoclopramide 26 Nystatin 10 
Metolazone 1 Octreotide 1 
Metoprolol 1 Oestradiol 1 
Metronidazole 19 Ofloxacin 2 
Microlax 5 Oily glycerol 1 
Midazolam 31 Olanzapine 2 
Minoxidil 1 Olopatadine 3 
Mirtazapine 1 Omeprazole 18 
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Drug Name Freq Drug Name Freq 
Ondansetron 126 Polyvinyl alcohol 2
Oxcarbazepine 6 Potassium chloride 4
Oxybutynin 3 Praziquantel 2
Oxycodone 74 Prednefrin forte® 2
Painstop Day® 80 Prednisone 1
Painstop Night 9 Prednisolone 48
Panadeine 19 Pregabalin 1
Panadeine Forte 21 Prochlorperazine 1
Pancuronium 1 Promethazine 13
Pantoprazole 2 Propranolol 2
Paracetamol 314 Propofol 29
Parachoc 10 Propylthiouracil 1
Parecoxib 2 Protaphane® 9
Pegfilgrastim 3 Psyllium 2
Pentavite® 4 Quetiapine 4
Perindopril 1 Ranitidine 11
Pethidine 11 Rectinol® 2
Phenobarbitone 8 Rifampicin 1
Phenoxymethylpenicillin 10 Risperidone 1
Phenylephrine 1 Ropivacaine 1
Phenytoin 4 Roxithromycin 5
Phosphate 1 Salbutamol 58
Picibanil 1 Salicylic acid/ 
cetylpyridinum  
1
Pimecrolimus 1 Senna 2
Piperacillin 1 Seretide® 9
Piroxicam 1 Sertraline 2
Pizotifen 7 Sildenafil 2
Poloxamer 4 Sodium bicarbonate 4
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Drug Name Frequency Drug Name Frequency
Sodium chloride 7 Tocilizumab 1
Sodium phosphate  3 Tolteridone 1
Sodium valproate 13 Topiramate 7
Solifenacin 2 Topotecan 2
Sofradex® 3 Tramadol® 3
Somatropin 4 Tranexamic acid 1
SOOV 1 Tretinoin 1
Sorbolene and paw paw  1 Triamcinolone 2
Spironolactone 1 Trichloracetic acid paste  1
Sumatriptan 1 Trimethoprim/ 
sulfamethoxazole 
17
Suxamethonium 2 Tropisetron 6
Tacrolimus 3 Tropicamide 2
Teicoplanin 1 Valaciclovir 2
Temazepam 6 Valganciclovir 2
Terbinafine 1 Vancomycin 14
Terbutaline 2 Vecuronium 2
Testosterone 1 Vigabatrin 1
Tetanus booster 1 Vincristine 2
Tetanus vaccine 1 VitABDeck® 5
Tetracosatrin 2 Vitamin D3 2
Thalidomide 1 Vitamin E 1
Thioguanine 1 Vitamin K 4
Ticarcillin/ clavulanic 
acid 
20 Voriconazole 1
Timolol 1 Warfarin 2
Tinidazole 2 Xalacom 1
Thyroxine 13 Xylocaine viscous 1
Tobramycin 10 Xylometazoline 6
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Appendix 5 -  Calculation of lincomycin content in Lincocin® injection 
solution 
 
The lincomycin content in Lincocin® injection solution was calculated using 
the equation from the calibration curve: 
 
Peak Area   = 17.832x + 0.24572 
 
12.974856  = 17.832x + 0.24572 
  x = 0.7138 mg/mL 
 
molecular weight of lincomycin hydrochloride monohydrate = 461.02 
molecular weight of lincomycin base    = 406.54 
 
weight of lincomycin in  
0.6 mg/mL sample    =    0.7138 mg/mL (406.54 / 461.02) 
      =    0.629 mg 
 
Hence 0.6294806 mg would have been in 1 mL 
 
so in 200 mL, there would have been 125.8961 (which was actually initially in 
the 0.4 mL) 
 
So 125.8961 in 0.4 mL = 31.474 mg/ 0.1 mL  = 314.74 mg/mL 
 
Each Lincocin® injection is stated to contain 300mg lincomycin base per mL, 
so percentage error   
   = 14.74  x 100 
    300 
    
   = 4.91344% 
 
   = 4.9% or 104.9% of lincomycin 
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Appendix 6 -  Details of off-label and unlicensed cases included in the study.  
(ID = identification; IP = inpatient; OP = outpatient; ED = Emergency Department patient; Reg = registered; Lic = licensed; OL = off-label; UL = unlicensed). 
Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
61 19 
d 
3.72 M IP Possible viral meningitis. 
Red rash on forehead, 
stomach & legs 
aciclovir 77mg tds IV IV yes no OL Age MIMS/ TGA: No dosage given for children < 
1 year 
372 4 w 4.33 M OP Review of possible viral 
meningitis.  
aciclovir 93mg tds IV IV yes no OL Age MIMS/ TGA: No dosage given for children < 
1 year 
714 0 d 3.18 M IP Hypoxic ischaemic neonatal 
encephalopathy with 
meconium aspiration and 
seizures                                   
aciclovir 65 mg tds IV  IV yes no OL Age MIMS/ TGA: No dosage given for children < 
1 year 
945 10 
m 
8.6 M ED Impetigo aciclovir 100 mg IV IV yes no OL Age MIMS/ TGA: No dosage given for children < 
1 year 
949 4 y   M ED Diarrhoeal illness, 
hypoglaecemic episode, 
ulcers on buccal surface 
and palate                               
aciclovir 200 mg 5x / 
day 
Tab PO yes no OL Age MIMS: Safety and effectiveness in children 
have not been established 
63 2 y 14.1 M IP Bronchiectasis (confirmed 
on a CT scan). Recently 
moved to Australia from 
Tanzania. PMH includes 2 
episodes of pneumonia and 
mannose binding lectin 
(MBL) deficiency. 
adrenaline 0.75mL 
inhaled 
resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
78 15 
y 
  M ED Possible capillary 
hemangioma                           
adrenaline  1.5 mL 
diluted to 20 
mL applied 
topically 
IV Topical yes no OL ROA Solution for injection used topically. MIMS 
states indication as adjunctive use in the 
management of cardiac arrest. 
98 1 y 
8 
m 
  M ED Possible croup (marked 
stridor and recession)              
adrenaline  0.5mL 
inhaled 
resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
418 1.5 
y 
  M ED Viral induced wheeze. 
(Patient unwell for 2 days 
and has runny nose, cough, 
difficulty breathing and no 
stridor at that time)                  
adrenaline  0.6mL 
inhaled 
resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
429 2 y 11.5 M ED Croup. R upper lobe 
anterior segment 
bronchomalacia,bronchiecta
sis. Presented with a day's 
Hx of URTI Sx and stridor. 
CXR demonstrated patchy 
changes consistent with 
viral LRTI. 
adrenaline nebulised resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      adrenaline 0.4ml twice resp sol Inhaled no  no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
797 5 y 18.65 M IP Allergic reaction adrenaline 1% resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
880 1 y   M IP Severe croup, asthma; 
transferred from JHC               
adrenaline 5 mg resp sol Inhaled no no UL Formulation PMH formulation - Adrenaline 1% 
Respirator Solution 15 mL 
1 9 y   M IP Injury - fell off a push bike 
and lost 200ml of blood. 
Patient was taken to theatre 
for wound exploration and 
repair. 
alfentanil 1mg injection IV yes no OL Age MIMS: Adequate data to support the use of 
alfentanil in children under 12 years of age 
are presently not available. 
414 7 y 47.85 M ED Appendicitis. Patient was 
admitted for laparoscopic 
appendectomy. 
alfentanil 1mg IV IV yes no OL Age MIMS: Adequate data to support the use of 
alfentanil in children under 12 years of age 
are presently not available. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
alteplase 1 mL IV IV yes no OL Age MIMS: Safety and effectiveness of Actilyse 
in children have not been established. 
Therefore, treatment of such patients is not 
recommended 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
alteplase 0.5 mg IV IV yes no OL Age MIMS: Safety and effectiveness of Actilyse 
in children have not been established. 
Therefore, treatment of such patients is not 
recommended 
936 17 
y 
55.55 F OP Major depressive disorder, 
chronic costochondritis            
amitriptylline 25 mg nocte tab PO yes no OL Age MIMS: The safety and efficacy of Endep for 
the treatment of depression or other 
psychiatric disorders in children and 
adolescents aged less than 18 years has 
not been satisfactorily established. Endep 
should not be used in this age group for the 
treatment of depression 
1137 1 y 
3 
m 
9.6 M OP Review for liver 
transplanted                            
amlodipine 1.6 ml daily liquid PO yes no OL Age MIMS: Safety and effectiveness have not 
been established in children. Also, no oral 
liquid formulation available so PMH 
prepared formulation 
61 19 
d 
3.72 M IP Possible viral meningitis. 
Red rash on forehead, 
stomach & legs 
amoxicillin 220mg tds IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
185 2 
m 
4.02 F IP Gastroenteritis (Vomiting 
and diarrhoea and patient 
treated for presumed 
sepsis) 
amoxicillin 200mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
186 27 
d 
4.34 M OP Possible of sepsis                   amoxicillin 215mg IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
205 5 y 19.75 M IP Adenoidectomy and cautery 
of turbinates 
amoxicillin 1.5g IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
257 1.5 
y 
  F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
amoxicillin 315mg q8h IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
371 20 
d 
3.57 M IP Possible sepsis - admitted 
for a septic screen including 
blood cultures, and CXR.  
amoxicillin 175mg IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
371 20 
d 
3.57 M IP Possible sepsis - admitted 
for a septic screen including 
blood cultures, and CXR.  
amoxicillin 180mg QID IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
372 6 d 4.33 M IP Possible viral meningitis.  amoxicillin 233mg tds IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
438 5 y 19 F IP Post-tonsillectomy bleed - 
adenotonsilectomy 
conducted 16 days ago. 
amoxicillin 300mg QID IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
527 1 
m 
3.04 M IP Complex congenital 
cyanotic heart disease, 
pulmonary hypertension          
amoxicillin 180 mg qid  NGT NGT yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
635 1 
m 
5 d 
3.3 F IP Gastroschisis                           amoxicillin 150 mg tds 
= 136 
mg/kg/day 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
689 27 
d 
3.31 F IP Abdominal distension (likely 
secondary to air 
swallowing) 
amoxicillin 165mg once IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
769 3 d 4.43 M IP Mildly dilated ascending 
aorta, biventricular 
hypertrophy, 
laryngomalacia with 
laryngeal reflux                        
amoxicillin 235 mg tds IV IV yes  no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
858 1 y 
8 
m 
  F ED Mild pneumonia                       amoxicillin 150 mg tds 
7/7 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
amoxicillin 105 mg bd  IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
1024 4 d 2.77 M IP Trachoesophageal fistula 
repair, GORD                          
amoxicillin 129 mg tds IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
1073 4 y   F OP Sacral agenesis L5/S1 
nerve roots; UTI 
prophylaxis, urinary 
continence                               
amoxicillin 250 mg 
nocte 
liquid   yes no OL Indication MIMS: Not registered for UTI prophylaxis 
1199 1 y 
10 
m 
11.9 M IP Neck abscess, drainage          amoxicillin 300 mg tds 
7/7  
tds PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 20kg: 20-40mg/kg/day in 
divided doses every 6-8 hours.  
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
591 17 
y 
75.2 M IP High risk T-cell ALL                 aprepitant 80 mg tab PO yes  no OL Age MIMS: Safety and effectiveness of Emend 
in paediatric patients have not been 
established. The pharmacokinetics of 
Emend have not been evaluated in patients 
below 18 years. 
 
804 14 
y 
  M IP Burkitt's lymphoma aprepitant 80 mg tab PO yes no OL Age MIMS: Safety and effectiveness of Emend 
in paediatric patients have not been 
established. The pharmacokinetics of 
Emend have not been evaluated in patients 
below 18 years. 
1197 13 
y 
44.1 M IP Nasopharyngeal carcinoma, 
PEG insertion                          
aprepitant 80 mg tab PO yes  no OL Age MIMS: Safety and effectiveness of Emend 
in paediatric patients have not been 
established. The pharmacokinetics of 
Emend have not been evaluated in patients 
below 18 years. 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses included 
pneumothorax, gardia and 
thrombocytosis.  
aspirin 30mg oral PO no no UL Formulation No oral liquid formulation available; hospital 
formulation. 
1137 1 y 
3 
m 
9.6 M OP Review for liver 
transplanted                            
aspirin  1.3 ml daily liquid PO no no UL Formulation No oral liquid formulation available; hospital 
formulation. 
725 8 y 26.6 F IP Chronic nephropathy atorvastatin 20 mg daily tab PO yes no OL Age MIMS: Treatment experience in a 
paediatric population is limited. 
Pharmacokinetic studies have not been 
conducted in the paediatric population. 
665 2 w   M IP Conjunctivitis amoxicillin and 
clavulanic acid 
100 mg bd 
7/7 
liquid PO yes no OL Age MIMS: No dosage given for children < 2 
months 
944 1 y 8.68 F IP Bronchiolitis, LRTI amoxicillin and 
clavulanic acid 
225 mg bd 
1/52 
liquid PO yes no OL Dose Greater dose than specified in MIMS. 
MIMS: Children 2 mths - 12 yrs < 40 kg 
(mod-severe infection): 45 mg/kg/day in 2 
divided doses. 
1148 27 
d 
4.15 M IP UTI amoxicillin and 
clavulanic acid 
96 mg bd liquid PO yes no OL Age MIMS: No dosage given for children < 2 
months 
844 9 y   M OP Renal transplant, 
hypertension, epilepsy, 
chronic diarrhoea, 
metaphysical dysplasia           
azathioprine 15 mg daily  
(10mg/mL) 
liquid PO no no UL Formulation No oral liquid formulation available; hospital 
formulation. 
1137 1 y 
3 m 
9.6 M OP Review for liver 
transplanted                            
azathioprine 1.35 ml 
daily 
liquid PO no no UL Formulation No oral liquid formulation available; hospital 
formulation. 
532 13 
y 
50.5 M OP Cystic fibrosis, pancreas 
insufficiency and 
bronchiectasis 
azithromycin 250 mg 
daily 
tab PO yes no OL Indication MIMS: Azithromycin should not be used in 
patients with pneumonia who are judged to 
be inappropriate for outpatient oral therapy 
because of moderate to severe illness or 
risk factors such as any of the following: 
patients with cystic fibrosis. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
527 1 
m 
3.04 M IP Complex congenital 
cyanotic heart disease, 
pulmonary hypertension          
benzylpenicillin        120 mg tds IV IV yes no OL Dosage MIMS: Neonates: 30-60 mg every 12 
hours; children < 3 years: 60 mg 6 hourly. 
945 10 
m 
8.6 M ED Impetigo. benzylpenicillin        520 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children < 3 years minimum dose of 
60 mg 6 hourly; children 3 - 10 years: 150 
to 300 mg 6 hourly. 
73 8 y   F OP Alopecia areata. Eczema 
around eyes and elbows. 
betamethasone  daily ointment Topical yes no OL Age MIMS: Diprosone OV is not recommended 
for use in children under 12 years of age. 
306 9 y   M OP Eczema - severe on palms 
and localized areas such as 
soles. 
betamethasone  apply 
sparingly 
daily to 
hands and 
feet 
ointment Topical yes no OL Age MIMS: Diprosone OV is not recommended 
for use in children under 12 years of age. 
333 9 y   M OP Traumatic mydriasis and 
scleral perforation. Had 
stick thrown in R eye; 
injured orbit. 
betaxolol 1 drop bd eye 
drops 
Eye 
drops 
yes no OL Age MIMS: Clinical studies to establish the 
safety and efficacy in children have not 
been performed 
333 9 y   M OP Traumatic mydriasis and 
scleral perforation. Had 
stick thrown in R eye; 
injured orbit. 
brimonidine  Dose not 
specified 
eye 
drops 
Eye 
drops 
yes no OL Age Mims: Safety and effectiveness of 
brimonidine in paediatric patients has not 
been established.  
333 9 y   M OP Traumatic mydriasis and 
scleral perforation. Had 
stick thrown in R eye; 
injured orbit. 
brinzolamide 1 drop bd eye 
drops 
Eye 
drops 
yes no OL Age MIMS: The safety and effectiveness of 
Azopt eye drops in paediatric patients have 
not been established 
1170 7 y 24.2 F OP Asthma, allergic rhinitis           budesonide/ 
eformoterol 
2 puffs bd; 
100/6 mcg 
puffs Inhaled yes no OL Age MIMS: Symbicort is not recommended for 
children below 12 years of age. 
725 8 y 26.6 F IP Chronic nephropathy calcium 
carbonate 
600 mg bd tab PO yes no OL Age MIMS: No children's dosage listed. 
844 9 y   M OP Renal transplant, 
hypertension, epilepsy, 
chronic diarrhoea, 
metaphysical dysplasia           
captopril 2.5 mg tds tab PO yes no OL Age MIMS: Safety and effectiveness in children 
have not been established. 
896 2 
m 
  M OP Neonatal hypothyroidism 
due to maternal antibodies      
carbimazole  1 mg tds liquid PO yes no OL Age MIMS/TGA: No paediatric dosage listed; 
hospital formulated capsules? 
642 4 y   F OP CP, glutaric aciduria type I, 
OSA, GORD                            
carnitine 450 mg liquid PO no no UL Formulation Carnitine liquid not registered in Australia. 
746 1 
m 
  F IP Glutamic aciduria                     carnitine 70 mg tds liquid PO no no UL Formulation Carnitine liquid not registered in Australia. 
812 6 y 25 F IP Epilepsy, seizure with 
cyanotic episode, admitted 
after seen in ED; deceased 
9/5/2010 (apnoea following 
LRTI and seizure)     
 
 
                                                
carnitine 300 mg bd liquid PO no no UL Formulation Carnitine liquid not registered in Australia. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
257 1.5 
y 
12.7 F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
cephalexin 250mg QID oral PO yes no OL Dose Greater dose than specified in MIMS. 
MIMS: The usual recommended daily dose 
for children is 25-50mg/kg in divided doses. 
Child 10kg: 5-10mL bd of 125mg/5mL 
suspension.  
1073 4 y   F OP Sacral agenesis L5/S1 
nerve roots; UTI 
prophylaxis, urinary 
continence                               
cephalexin 200 mg 
nocte 
liquid PO yes no OL Indication MIMS: Not registered for UTI prophylaxis.  
665 2 w   M IP Conjunctivitis cephazolin 1 drop to 
RE q2h 
eye drop Eye 
drops 
no no UL Formulation Hospital formulation. 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      chloral hydrate 350 mg qid 
prn 
liquid PO yes  no OL Indication MIMS: Only indicated for preop sedation 
and short-term treatment of insomnia (< 2 
wks); Chloral Hydrate Mixture is not 
recommended in infants and children when 
repetitive dosing would be necessary 
880 1 y   M IP Severe croup, asthma; 
transferred from JHC               
chloral hydrate 80 mg qid 
prn 
liquid PO yes no OL Indication MIMS: Only indicated for preop sedation 
and short-term treatment of insomnia (< 2 
wks); Chloral Hydrate Mixture is not 
recommended in infants and children when 
repetitive dosing would be necessary 
1116 3 
m 
4.84 F IP Cleft lip repair                          chloral hydrate 300 mg  liquid PO yes no OL Dose MIMS: Children: 30-50mg/kg or 1.5g/m2, 
max 1g. 
281 3 y   M IP Biopsy of a lesion on 
forehead under general 
anaesthesia 
chloramphenicol apply 
sparingly for 
7 days daily 
eye 
ointment 
Topical yes no OL Indication MIMS: Chloramphenicol eye ointment is 
only indicated for ocular bacterial infections 
caused by organisms susceptible to 
chloramphenicol.  
516 2 y 9.6 M OP Replantation of left thumb chloramphenicol 10 mg/g qid 
to left thumb 
eye 
ointment 
Topical yes no OL Indication MIMS: Chloramphenicol eye ointment is 
only indicated for ocular bacterial infections 
caused by organisms susceptible to 
chloramphenicol.  
543 10 
m 
  M ED Balanitis  chloramphenicol 10 mg/g 
topical 
eye 
ointment 
Topical yes no OL Indication MIMS: Chloramphenicol eye ointment is 
only indicated for ocular bacterial infections 
caused by organisms susceptible to 
chloramphenicol.  
819 1 y 11.65 M IP Eyebrow laceration 
(infected), finger infection        
chloramphenicol 10 mg/g qid 
to wound 
eye 
ointment 
Topical yes no OL Indication MIMS: Chloramphenicol eye ointment is 
only indicated for ocular bacterial infections 
caused by organisms susceptible to 
chloramphenicol.  
1101 2 y 11.7 M IP Hydronephrosis, iron 
deficiency anaemia                 
ciprofloxacin  110 mg bd IV IV yes no OL Age MIMS: Ciprofloxacin is not recommended 
for use in prepubertal children, except for 
use in inhalational anthrax (postexposure). 
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased           
 
                                                
cisretinoic acid     IV     UL SAS Not registered in Australia 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
789 9 y   M OP Cognitive impairment, 
epilepsy, significant 
behavioural problems, non-
verbal                                       
clobazam 5 - 7.5 mg 
bd 
tab PO yes no OL Age MIMS: Not recommended for children 
884 1 y 
3 
m 
12.8 F IP Hyponatraemia, seizures, 
left ventricular cyst (VP 
shunt), panhypothyroidism, 
diabetes insipidus, septo-
optic dysplasia                         
clobazam 2.5 mg liquid PO yes no OL Age MIMS: Not recommended for children. No 
liquid formulation available - hospital 
formulation 
1001 2 y   M OP Epilepsy, strabismus               clobazam 2.5 mg (1/4 
tab) prn 
clusters 
tab PO yes no OL Age MIMS: Not recommended for children 
104 2 y 15 M IP Dentinogenesis imperfecta 
(Patient admitted for dental 
restoration and extraction) 
clonidine 30mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
115 15 
y 
35.9 M OP Epilepsy, aggressive 
behaviour and learning 
problems.  
clonidine   IV IV yes no OL Indication MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis. Not indicated for 
aggressive behaviour or attention deficit 
disorder 
132 5 y 18.2 F IP Adenotonsillectomy clonidine 20mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
390 6 y 20 F IP Adenotonsillectomy clonidine 15mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
399 7 y 42.2 M IP Myringotomy, insertion of 
grommets and 
adenoidectomy 
clonidine 30mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
458 9 y 37.3 F IP Tonsillectomy  clonidine 40mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
523 1 y   M IP Subcoronal hypospadias 
repair 
clonidine 45 mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
572 11 
y 
47.2 M IP Excision of congenital 
melanocytic nevus on left 
posterior thigh 
clonidine 120 mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
815 10 
y 
  F ED Autistic disorder, severe 
behavioural disturbance          
clonidine 100 mcg bd IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
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833 8 y 22.8 M IP Mosaic down syndrome, left 
tibial osteotomy and fibular 
epiphyseodesis, 
constipation                             
clonidine 80 mcg IV IV yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
1090 10 
y 
  F OP ADHD clonidine 100 mcg 
nocte 
tab PO yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis. Not indicated for 
aggressive behaviour or attention deficit 
disorder 
1091 12 
y 
  F OP ADHD clonidine 100 mcg 
nocte 
tab PO yes no OL Indication MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis. Not indicated for 
aggressive behaviour or attention deficit 
disorder 
1095 5 y 20.3 M IP Left-sided cochlear implant, 
seasonal allergic rhinitis          
clonidine 100 mcg tab PO yes no OL Age MIMS: Hypertension. Injection indicated for 
acute hypertensive crisis - no suggestion 
that it can be used in this age group. Used 
here for sedation/anaesthesia 
183 1 y 10.1 F IP Left upper limb injury, finger 
trapped and nail avulsed.  
codeine 5-10mg q4h 
prn 
liquid PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
218 5 
m 
6.5 M IP Possible bronchiolitis  codeine  5mg liquid PO yes no OL Age MIMS: No children's dose. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
codeine 8-16 mg liquid PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      codeine  2 mg liquid PO yes  no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
814 6 
m 
9.35 M IP Removal of bilateral 
preauricular skin tags and 
removal anterior tongue 
cyst                                          
codeine 4-8 mg q4h 
prn 
liquid PO yes no  OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
832 12 
y 
43 F IP Intrinsic brain stem glioma; 
deceased 17.12.08                  
codeine 30 mg qid 
prn 
liquid PO yes no OL Indication MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu.  
862 7 
m 
9.9 M IP Vomiting, fever, irritability,       codeine 2.5 mg qid liquid PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
886 3 y   M IP Adenotonsillectomy codeine 10-15 mg 
q4h prn 
liquid PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
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960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
codeine 15-30 mg tab PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
1116 3 
m 
4.84 F IP Cleft lip repair                          codeine 2 mg qid 
prn 
liquid PO yes no OL Age MIMS: Codeine linctus is indicated for an 
unproductive, dry and intractable cough 
associated with colds and flu. No children's 
dose. 
844 9 y   M OP Renal transplant, 
hypertension, epilepsy, 
chronic diarrhoea, 
metaphysical dysplasia           
darbepoetin alfa 60 mcg 
fortnightly 
SC SC yes no OL Age MIMS: The safety and efficacy of Aranesp 
(darbepoetin alfa) in paediatric patients 
have not been established. 
63 2 y 14.1 M IP Bronchiectasis (confirmed 
on a CT scan). Recently 
moved to Australia from 
Tanzania. PMH includes 2 
episodes of pneumonia and 
mannose binding lectin 
(MBL) deficiency. 
dexamethasone 2.25mg 
daily for 2 
days 
oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
98 1 y 
8 
m 
  M ED Possible croup (marked 
stridor and recession)              
dexamethasone 1.7mg oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
138 2 y 
5 
m 
  M ED Possible croup                         dexamethasone 2.25mg oral PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
164 2 y 11.3 M ED Respiratory distress - croup. 
Hx of asthma 
dexamethasone 1.65mg  oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
227 5 y 
8 
m 
34.6 M ED Respiratory symptoms - 
sore throat, fever, painful 
swallowing                               
dexamethasone 4mg  oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
278 7 y   M IP Croup (Symptoms included 
sore throat, fever and not 
being able to breathe)             
dexamethasone 3.2mg  oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
415 9 
m 
  M IP Croup (Respiratory distress)   dexamethasone 1.6mg  oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
418 1.5 
y 
  M ED Viral induced wheeze. 
(Patient unwell for 2 days 
and has runny nose, cough, 
difficulty breathing and no 
stridor at that time)                  
dexamethasone 7.2mg oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
429 2 y 11.5 M ED Croup. R upper lobe 
anterior segment 
bronchomalacia and 
bronchiectasis. Day's Hx of 
URTI Sx and stridor. CXR 
demonstrated patchy 
changes consistent with 
viral LRTI. 
dexamethasone 1.65mg oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
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444 10 
m 
  M ED Viral URTI (dry cough, 
runny nose)                             
dexamethasone 1.2mg oral 
liquid 
PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
548 1 y 
10 
m 
  M ED Croup, respiratory distress      dexamethasone 1.9 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
727 7 y   F ED Fever, cough, sore throat, 
croupy cough, viral URTI         
dexamethasone 3.6 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
741 1 y 
5 
m 
  F ED Respiratory distress, croupy 
cough, stridor                          
dexamethasone 2 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
895 8 
m 
  F ED Viral illness dexamethasone 1.4 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
901 4 y   M ED Viral illness, respiratory 
distress, croup                         
dexamethasone 4.2 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
1004 2 y 13.76 M ED Cough, asthma, URTI, viral 
illness                                      
dexamethasone 2 mg daily 
2/7 
liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
1011 3 y   F ED Viral croup                               dexamethasone 1.5 mg daily 
prn 
liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
1028 1 y 
9 
m 
  M IP Croup dexamethasone 2 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
1080 4 y   M ED Croup, rash                              dexamethasone 3 mg liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
1138 1 y   F ED Croup dexamethasone 1.8 mg daily 
2/7 
liquid PO no no UL Formulation PMH formulation - Dexamethasone Oral 
Solution 1mg/mL 
333 9 y   M IP Traumatic mydriasis and 
scleral perforation. Had 
stick thrown in R eye; 
injured orbit. 
dexamethasone 1 drop qid  eye 
drops 
Eye 
drops 
yes no OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
637 5 y   F OP Allergic rhinoconjunctivis.        dexamethasone 1 drop tds 
BE; 1 mg/ml 
eye drop Eye 
drops 
yes no  OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
695 2 y   F IP Bilateral esotropia                   dexamethasone 1 drop 1 
mg/ml tds 
BE 
eye 
drops 
Eye 
drops 
yes no OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
976 10 
y 
  M IP Bilateral epiblepharon repair   dexamethasone 1 mg/ml qid 
BE 
eye 
drops 
Eye 
drops 
yes no OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
1105 1 y 
8 
m 
13.7 M IP Right 4th nerve palsy, 
oblique myectomy                   
dexamethasone 1 mg/ml qid 
right eye 
eye drop Eye 
drops 
yes no  OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
1185 4 
m 
  M OP Glaucoma, left exotropia         dexamethasone 1 mg/ml tds 
BE 
eye 
drops 
Eye 
drops 
yes no  OL Age MIMS/ TGA: The safety and effectiveness 
of Maxidex eye drops in paediatric patients 
have not been established 
264 3 
m 
  F OP Possible retinopathy of 
prematurity 
dilacaine 1 drop eye drop Eye 
drops 
 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
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370 7 
m 
  F OP Primary lymphoedema 
(Miliary syndrome)  
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
524 11 
m 
  F OP Retinopathy exam, 
bronchiolitis 
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
526 3 
m 
5.08 F OP Beckwith-Wiedemann 
syndrome, cutaneous 
heamangioma, hepatic 
haemangioma 
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
629 6 
m 
  F OP Pre-term ophthalmic review    dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
630 6 
m 
  M IP Facial bruising 
(observation) 
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
648 7 y   M OP Ophthalmic clinic review          dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
743 5 
m 
  F OP Ophthalmic review dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
744 3 
m 
  M OP Ophthalmic review dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
807 7 
m 
5.26 F IP CP, seizures and spasms, 
lissencephaly                           
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
1050 1 y   M OP Buthalmus, right sided 
proptosis, hypoglobus 
lagophthalmus                         
dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
1114 10 
m 
  F OP Squint both eyes                     dilacaine 1 drop eye drop Eye 
drops 
no no UL Formulation PMH formulation - Dilacaine Eye Drops 
538 1 y 
3 
m 
8.22 F OP Gastric reflux, feeding 
difficulties 
domperidone 2 mg bd liquid PO no no UL Formulation PMH formulation - Domperidone Oral 
Suspension 
1112 8 
m 
5.34 M ED Bronchiolitis                             domperidone 1 mg tds liquid PO no no UL Formulation PMH formulation - Domperidone Oral 
Suspension 
485 1 y   M OP Review of coarction repair 
and duct litigation.  
dopamine 1mL / hour IV IV yes  no OL Age MIMS: It is not recommended for use in 
children as safety and efficacy in this age 
group have not been established. 
714 ne
wb
orn 
3.18 M IP Hypoxic ischaemic neonatal 
encephalopathy with 
mecorium aspiration and 
seizures                                   
dopamine 190 mg IV  IV yes no OL Age MIMS: It is not recommended for use in 
children as safety and efficacy in this age 
group have not been established. 
1024 4 d 2.77 M IP Trachoesophageal fistula 
repair, GORD                          
dopamine 79 mg daily 
3/7 
IV IV yes no OL Age MIMS: It is not recommended for use in 
children as safety and efficacy in this age 
group have not been established. 
514 2 y 11.3 M OP Multiple food allergies epipen jr. 0.15 mg prn IM IM yes no OL Age MIMS: EpiPen Jr is intended for children 
with body weight of 15 to 30 kg 
114 14 
y 
55 M IP Injury after playing football. 
Also suicidal ideation and 
worsening depression. 
escitalopram 20mg daily oral PO yes  no OL Age MIMS: The efficacy and safety of 
escitalopram have not been established in 
children and adults less than 18 years of 
age.  
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88 1 y 11.4 F ED Injury-left upper limb. 
(patient was admitted for 
exploration and repair) 
fentanyl Dose: 15-
10-10 
solution Intranasal yes no OL Age MIMS: Safety of fentanyl in chn younger 
than 2 years of age has not been 
establishes. Also, fentanyl IV fluid is 
administered intranasally 
205 5 y 19.75 M IP Adenoidectomy and cautery 
of turbinates 
fentanyl 30mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
332 3 y 16.05 M OP Injury. Right upper limb and 
thumb fractured 
fentanyl 15mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
357 6 y   M IP Otitis media and nasal 
obstruction 
fentanyl 25mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
358 6 y 26.45 M ED Injury - closed fracture fentanyl 40 mcg - 
one dose in 
ED 
solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
404 15 
y 
  M ED Injury - fractured hand and 
swollen 2nd MCP joints           
fentanyl 110 mcg - 
one dose in 
ED 
solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
413 11 
y 
  M ED Fractured left wrist (swelling 
and pain of forearm)                
fentanyl 45 mcg - 
one dose in 
ED 
solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
420 15 
y 
  F IP Cerebral palsy (patient 
admitted for Botox 
injections)                                
fentanyl 100 mcg - 
one dose in 
ED 
solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
545 15 
y 
  M OP Fractured left ankle fentanyl 105 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
601 11 
y 
  M IP Cerebral palsy, mild spastic 
dysplegia, focal epilepsy 
(btx-injections)                         
fentanyl 50 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
602 10 
y 
  F ED Abdominal pain, central, 
radiating to back                      
fentanyl 44 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
703 13 
y 
  M IP Laceration to perianal area, 
wound infection                       
fentanyl 75 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
fentanyl 70 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
719 11 
y 
  M ED Injury, left lower leg fracture    fentanyl 50 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
831 10 
y 
38.4 F IP Chronic recurrent multifocal 
osteomyelitis, pain 
management                           
fentanyl 55 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only. 
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836 16 
y 
  M IP Orbital floor fracture, eye 
trauma, dizzy, nausea             
fentanyl 100 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
909 4 y   F ED Vulva laceration                       fentanyl 31 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
918 13 
y 
62.3 M IP Fractured left distal radius 
and ulna                                  
fentanyl 250 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
926 11 
y 
  M ED Fracture distal radius and 
ulna                                          
fentanyl 90 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
1039 8 y   M ED Eye injury, swelling                  fentanyl 50 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
1100 4 y 17.15 M IP Supracondylar elbow 
fracture                                    
fentanyl 26 mcg solution Intranasal yes no OL ROA Fentanyl IV fluid was administered 
intranasally. MIMS: Fentanyl injection is for 
intramuscular or intravenous injection only.  
127 8 y 42.9 M ED Infection/inflammation of 
little toe - swelling, and boil 
like lesions on the inner 
aspects of leg-thigh. 
flucloxacillin 2000mg six 
hourly for 1 
day 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
155 5 y 20 M ED Acute lymphadenitis 
(presented with a 3 day 
history of limited neck 
movement and pain) 
flucloxacillin 300mg QID 
for 1 week 
was 
changed 
after 2 days 
to 500mg 
QID 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: 250 mg every 6 hours; 
children 2-10 yrs: 1/2 adult dose. 
257 1.5 
y 
  F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
flucloxacillin 550mg six 
hourly 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
flucloxacillin 500mg six 
hourly 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
587 6 y 20.7 F ED Right-sided pneumonia with 
pleural effusion.                       
flucloxacillin 1g QDS IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
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605 8 y 34.5 F IP Cellulitis to ear. flucloxacillin 1.7g QDS IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
819 1 y 11.65 M IP Eyebrow laceration 
(infected), finger infection.       
flucloxacillin 275 mg qid 
7/7 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: 250 mg every 6 hours; 
children 2-10 yrs: 1/2 adult dose. 
819 1 y 11.65 M IP Eyebrow laceration 
(infected), finger infection.       
flucloxacillin 500 mg qid  IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
824 4 y 15.5 M IP Periorbital cellulitis, 
laceration to eye glued on 
Sunday, swelling started 
Monday. 
flucloxacillin 750 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
900 4 y   M IP Orbital cellulitis, chronic 
runny nose, right 
pansinusitis.                            
flucloxacillin 720 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
945 10 
m 
8.6 M ED Impetigo. flucloxacillin 430 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
958 5 y 17 M ED Head injury, laceration of 
forehead. 
flucloxacillin 850 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
1025 5 y   F IP Right tibia, low trauma 
fracture, skin lesions.              
flucloxacillin 275 mg qid 
7/7 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: 250 mg every 6 hours; 
children 2-10 yrs: 1/2 adult dose. 
1025 5 y   F IP Right tibia, low trauma 
fracture, skin lesions.              
flucloxacillin 1000 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
1126 4 y 15.9 F ED Acute OM, cellulitis finger. flucloxacillin 400 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: 250 mg every 6 hours; 
children 2-10 yrs: 1/2 adult dose. 
 
 
 
 
  
 
249
Case 
ID 
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(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
1166 8 y 29.4 M IP Right post septal abscess 
secondary to sinogesic 
source (nose).                         
flucloxacillin 1000 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
1199 1 y 
10 
m 
11.9 M IP Neck abscess, drainage.         flucloxacillin 600 mg qid IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: IVI 250mg-1g every 6 hours. 
Severe infections may double dose. 
Children 2-10 yrs: 1/2 adult dose. Children 
< 2 yrs: 1/4 adult dose. 
1199 1 y 
10 
m 
11.9 M IP Neck abscess, drainage.         flucloxacillin 300 mg qid oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults: 250 mg every 6 hours; 
children 2-10 yrs: 1/2 adult dose. 
283 3 y   M OP HSV ulceration of the 
cornea. Pain/sensitive to 
light - patient treated for 
blepharitis for many 
months. 
fluorometholone  1 drop QID gutt Eye 
drops 
yes no OL Age MIMS: Safety and effectiveness in children 
have not been established. 
1197 13 
y 
44.1 M IP Nasopharyngeal carcinoma, 
PEG insertion                          
5-fluorouracil           1400 mg IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Admin based on patients actual 
bodyweight (use ideal weight if obese, 
oedema); max 1 g/day.  
65 17 
y 
  F OP Eating disorder and 
exercise obsession.                 
fluoxetine 40mg daily caps PO yes no OL Age MIMS: The safety and efficacy of fluoxetine 
for the treatment of children and 
adolescents less than 18 years of age have 
not been established 
193 14 
y 
42 F IP Post-traumatic disorder. 
Showed depressive 
features and multi-sensory 
hallucinations.  
fluoxetine 20mg caps PO yes no OL Age MIMS: The safety and efficacy of fluoxetine 
for the treatment of children and 
adolescents less than 18 years of age have 
not been established 
313 14 
y 5 
m 
  M OP Drug misuse, social 
isolation and behavioural 
issues                                      
fluoxetine 40mg daily caps PO yes no OL Age MIMS: The safety and efficacy of fluoxetine 
for the treatment of children and 
adolescents less than 18 years of age have 
not been established 
835 17 
y 
  M ED Non-epileptic seizures, 
migraine, anxiety disorder       
fluoxetine 20 mg bd caps PO yes no OL Age MIMS: The safety and efficacy of fluoxetine 
for the treatment of children and 
adolescents less than 18 years of age have 
not been established 
673 13 
y 
  F IP Left-sided facio-auriculo 
vertebral spectrum, 
complex congenital heart 
disease, end stage cardiac 
failure with cachexia; 
deceased 07/02/09, at 
home     
 
 
                                                
gabapentin 100 mg 
daily 
tab PO yes no OL Age MIMS: Neuropathic pain: Safety and 
effectiveness in children below the age of 
18 years have not been established. 
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Case 
ID 
Age  Weight 
(kg) 
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or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
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923 15 
y 
  F IP Spondylo-epiphyseal 
dysplasia tarda 
pseaudorheumatoid 
arthritis; scoliosis, spinal 
fusion                                       
gabapentin 300 mg 
nocte 10/7 
tab PO yes no OL Age MIMS: Neuropathic pain: Safety and 
effectiveness in children below the age of 
18 years have not been established. 
91 7 y 26 M IP Acute appendicitis with 
perforation, admitted for 
laparoscopic 
appendectomy.  
gentamicin 195mg daily 
once 
IV IV yes  no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
498 16 
y 
  M IP Hodgkin Lymphoma 
(diagnosed in 2006)                
gentamicin 330mg 
single daily 
dose 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
500 11 
y 
47.2 M ED Severe abdominal pain. 
Patient was diagnosed with 
acute appendicitis and 
underwent urgent 
appendectomy.  
gentamicin 350mg daily 
once 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
667 8 
m 
9.95 M IP UIT, E.coli gentamicin 68 mg once 
daily 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
689 27 
d 
3.31 F IP Abdominal distension (likely 
secondary to air 
swallowing) 
gentamicin 23 mg once 
daily 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
769 3 d 4.43 M IP Mildly dilated ascending 
aorta, biventricular 
hypertrophy, 
laryngomalacia with 
laryngeal reflux                        
gentamicin 21 mg 
q2.5h 
IV IV yes  no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
1024 4 d 2.77 M IP Trachoesophageal fistula 
repair, GORD                          
gentamicin 11.6 mg - 
first every 2 
days then 
once daily 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
1148 27 
d 
4.15 M IP UTI gentamicin   30 mg once 
daily 
IV IV yes no OL Dosage MIMS: Children. Admin in 2-3 divided 
doses;  Life threatening infection: initially 5-
7.5 mg/kg/day 
533 15 
y 
  M OP Cold-induced vasculopathy 
of the digits                              
glyceryl trinitrate      2 mg/g prn ointment Topical yes no OL Age MIMS: Safety and effectiveness of 
Rectogesic® (glyceryl trinitrate) in children 
and adolescents under 18 years of age 
have not been established. Not indicated 
for cold-induced vasculopathy. 
612 5 y 46.3 F IP Precocious puberty                 gonadorelin 100 mcg IV IV no no UL Formulation Not registered in Australia. 
671 14 
y 
  F IP Short stature, obesity, 
obstructive sleep apnoea, 
nocturnal enuresis, 
acenthosis nigricans, 
pseudo-
pseudohypoparathyroidism  
                                                
gonadorelin 100 mcg IV IV no no UL Formulation Not registered in Australia. 
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or ED 
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156 4 y 20.55 M IP Swollen face, was urinating 
blood, decreased urine 
today, unwell. Asthmatic, 
recent tonsillitis. BP 150/90. 
Principal diagnosis: post 
streptococcal 
glomerulonephritis, pre-
renal impairment, 
secondary hypertension, 
proteinuria 
hydralazine 15mg bd oral PO yes no OL Age MIMS: Safety and efficacy of hydralazine 
have not been established in children. 
844 9 y   M OP Renal transplant, 
hypertension, epilepsy, 
chronic diarrhoea, 
metaphysical dysplasia           
hydralazine 25 mg tds  liquid PO yes no OL Age MIMS: Safety and efficacy of hydralazine 
have not been established in children.  
714 ne
wb
orn 
3.18 M IP Hypoxic ischaemic neonatal 
encephalopathy with 
mecorium aspiration and 
seizures                                   
hydrocortisone 32mg QID IV  IV yes no OL Age TGA/ MIMS: No dose given for newborn 
infants - this child was born today. AMH 
2008 also does not supply a dose for < 1 
month old 
1139 11 
m 
8.8 M IP Jejunal atresia, bowel 
obstruction, vomiting               
hyoscine 
butylbromide           
4 mg tds 
prn 
IV  IV yes no OL Age MIMS: Dose for adults and children > 6 
years: 20 - 40 mg. No dose for children < 6 
years. 
553 11 
y 
  M OP Sickle cell disease, vitamin 
D deficiency                             
hydroxyurea 1d daily oral PO yes no OL Age MIMS: Safety and efficacy have not been 
established in children 
246 9 y 44.35 F ED Slipped femoral epiphysis. 
Pain on ambulation; there 
was obvious deformity and 
swelling. 
ibuprofen 500mg 
single dose 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 5-10mg/kg 3 to 4 times per day.  
246 9 y 44.35 F ED Slipped femoral epiphysis. 
Pain on ambulation; there 
was obvious deformity and 
swelling. 
ibuprofen 500mg tds 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 5-10mg/kg 3 to 4 times per day.  
257 1.5 
y 
  F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
ibuprofen 150mg QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 5-10mg/kg 3 to 4 times per day.  
944 1 y 8.68 F IP Bronchiolitis, LRTI ibuprofen 100 mg tds 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 5-10mg/kg 3 to 4 times per day.  
963 11 
y 
  M OP Juvenile idiopathic arthritis      infliximab 250 mg 6 
weekly 
IV IV yes no OL Indication MIMS: Not registered for juvenile idiopathic 
arthritis  
917 14 
y 
  M IP Multiple sclerosis, 
exacerbation                            
interferon beta 62.5 mcg 3 
weekly 
IM IM yes no OL Age MIMS: Safety and effectiveness in those 
below 18 years of age have not been 
established in clinical trials. 
272 4 y 16.9 M ED Viral pneumonitis (patient 
was pale, tachypnoeic and 
moderate intercostal muscle 
recession. (CXR showed no 
consolidation but bilateral 
infiltrates) 
ipratropium 4 puffs - 3 
doses every 
20 min in 
ED 
inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
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or ED 
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UL 
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 OL or UL 
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335 7 y   F ED Worsening asthma 
secondary to LRTI 
(Wheezing at home and 
appear cyanosed) 
ipratropium 8 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
541 1 y   M ED Respiratory distress, 
vomiting                                   
ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
724 8 y   M IP Asthma exacerbation, viral      ipratropium 8 puffs 
thrice 
inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
750 2 y   M ED Asthma exacerbation, viral      ipratropium 4 puffs 
thrice 
inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1004 2 y 13.76 M ED Cough, asthma, URTI, viral 
illness                                      
ipratropium 4 puffs prn inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1013 5 y   F IP Asthma exacerbation ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1026 1 y 
3 
m 
  M ED Asthma, viral wheeze              ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1130 5 y 
5 
m 
  F IP Asthma (new onset) ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1132 1 y 
9 
m 
  M ED Asthma exacerbation              ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1187 6 y   F ED Asthma, mild exacerbation      ipratropium 4 puffs inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff three 
times daily.  
1193 13 
y 
  M IP Asthma, allergic rhinitis, 
exacerbation                            
ipratropium 6 puffs prn inhaler Inhalation yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 6-12 yrs: 1 or 2 puff three 
to four times daily; < 6 yrs: 1 puff tds.  
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
ketamine 10 mg daily IV IV yes no OL Indication Not indicated as analgesic. MIMS: Non-
barbiturate IV and IM anaesthetic 
especially for short procedures; induction 
prior to other general anaesthetics;  
supplement to low potency agents. 
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700 2 y   F OP Hyperinsulaemic 
hypoglyceamia of infancy, 
exocrine pancreatic 
insufficiency                             
lactulose 20 mg daily liquid PO yes no  OL Dosage Greater dose than specified in MIMS. 
MIMS: Children (maintenance) < 12 
months: 3-5 mL; 1-6 years: 5-10 mL; 7-14 
years: 10 mL; daily. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
lactulose 15 ml bd 
prn 
liquid PO yes  no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children (maintenance) < 12 
months: 3-5 mL; 1-6 years: 5-10 mL; 7-14 
years: 10 mL; daily. 
964 12 
y 
  M OP Constipation, vitamin D 
deficient congestion                
lactulose 25-30 ml liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Constipation adults: initially 15-30 
mL daily until response (3 days) then 10-25 
mL daily.  
807 7 
m 
5.26 F IP CP, seizures and spasms, 
lissencephaly                           
lamotrigine 25 mg daily tab PO yes no OL Age TGA: Lamotrigine is not recommended in 
children less than 2 years of age 
554 3 
m 
6.13 M OP GORD lansoprazole 15 mg daily granules  PO yes no OL Age MIMS: No dose for children < 1 year of age. 
899 2 
m 
  F IP GORD                                      lansoprazole 15 mg daily granules  PO yes no OL Age MIMS: No dose for children < 1 year of age. 
333 9 y   M OP Traumatic mydriasis and 
scleral perforation. Had 
stick thrown in R eye. 
latanoprost 1 drop night eye 
drops 
Eye 
drops 
yes no OL Age MIMS: Xalatan® (latanoprost) is not 
recommended for use in children. Use in 
children has not been studied. 
531 4 y   F OP Congenital glaucoma latanoprost/ 
timolol 
(Xalacom®) 
5/0.05mg/ml 
nocte BE        
eye drop Eye 
drops 
yes no OL Age MIMS: Not recommended for use in 
children. Safety and effectiveness in 
children have not been established. 
542 11   F ED Precocious puberty leuprorelin 
acetate                    
22,5 mg IM IM yes  no OL Age MIMS: Safety and effectiveness in children 
have not been established. Contraindicated 
in paediatrics. 
884 1 y 
3 
m 
12.8 F IP Hyponatraemia, seizures, 
left ventricular cyst (VP 
shunt), panhypothyroidism, 
diabetes insipidus, septo-
optic dysplasia                         
levetiracetam 100 mg bd  liquid PO yes no OL Age MIMS: There are insufficient data to 
recommend the use of levetiracetam in 
children under 4 years of age. 
1001 2 y   M OP Epilepsy, strabismus               levetiracetam 3 ml mane, 
4 ml nocte; 
100 mg/ml 
liquid PO yes no OL Age MIMS: There are insufficient data to 
recommend the use of levetiracetam in 
children under 4 years of age. 
1064 3 y 15.15 M IP Spinal fracture lignocaine 40 mg liquid PO yes no OL ROA Lignocaine IV solution was administered 
sublingually 
725 8 y 26.6 F IP Chronic nephropathy lisinopril 7.5 mg daily tab PO yes no OL Age MIMS: Safety and effectiveness of lisinopril 
in children have not been established 
844 9 y   M OP Renal transplant, 
hypertension, epilepsy, 
chronic diarrhoea, 
metaphysical dysplasia           
loperamide 2 mg tds caps  PO yes no OL Age MIMS: Imodium is contraindicated in 
children under the age of 12 years 
146 8 
m 
10.9 M ED Viral illness (cough for 3 
days, but no wheeze). 
Patients’ PMH includes 
atopic dermatitis. 
loratadine 2mg oral PO yes no OL Age MIMS: No dosage given for children < 1 
year. Claratyne Syrup (1 mg/mL): Children 
2-12 years > 30kg: 10 mL daily; less than 
or equal to 30 kg: 5 mL daily. Children 1-2 
years: 2.5 mL daily. 
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903 11 
m 
  F OP Eczema loratadine 10 mg prn liquid PO yes  no OL Age MIMS: No dosage given for children < 1 
year. Claratyne Syrup (1 mg/mL): Children 
2-12 years > 30kg: 10 mL daily; less than 
or equal to 30 kg: 5 mL daily. Children 1-2 
years: 2.5 mL daily. 
945 10 
m 
8.6 M ED Impetigo loratadine 2.5 mg daily liquid PO yes no OL Age MIMS: No dosage given for children < 1 
year. Claratyne Syrup (1 mg/mL): Children 
2-12 years > 30kg: 10 mL daily; less than 
or equal to 30 kg: 5 mL daily. Children 1-2 
years: 2.5 mL daily. 
193 14 
y 
42 F IP Post-traumatic disorder. 
Showed depressive 
features and multi-sensory 
hallucinations.  
lorazepam 05 - 1 mg 
daily PRN 
for severe 
agitation 
oral PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
lorazepam 1mg tds prn oral PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
lorazepam 0.5 mg daily tab PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
804 14 
y 
  M IP Burkitt's lymphoma lorazepam 1 mg prn for 
nausea 
tab PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
1085 11 
y 
  M ED Dysthemia, anxiety 
disorder, suicide attempt, 
hallucinations                          
lorazepam 0.5-1 mg 
tds prn 
tab PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
1177 12 
y 
  M IP T-Cell ALL lorazepam 1-2 mg bd 
prn 
tab PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
1197 13 
y 
44.1 M IP Nasopharyngeal carcinoma, 
PEG insertion                          
lorazepam 1-2 mg bd 
prn 
tab PO yes no OL Age MIMS: The safety and effectiveness of 
lorazepam have not been established in 
children less than 16 years of age 
725 8 y 26.6 F IP Chronic nephropathy losartan 25 mg daily tab PO yes no OL Age MIMS: Safety and effectiveness in children 
have not been established 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
magnesium 
chloride 
5 ml/5 mmol liquid PO no no UL Formulation PMH formulation 
812 6 y 25 F IP Epilepsy, seizure with 
cyanotic episode, admitted 
after seen in ED; deceased 
9/5/2010 (apnoea following 
LRTI and seizure)                    
melatonin 5 mg nocte tab PO yes no OL Age TGA: Circadin® (melatonin) is not 
recommended for use in children and 
adolescents below 18 years of age due to 
insufficient data on safety and efficacy 
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
meropenem 42 mg bd IV IV yes no OL Age MIMS: Efficacy and tolerability in infants 
under 3 months of age have not been 
established; therefore, meropenem is not 
recommended for use below this age 
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963 11 
y 
  F OP Juvenile idiopathic arthritis      methotrexate 15 mg 
weekly 
tab PO yes no OL Indication MIMS: Not registered for juvenile idiopathic 
arthritis   
1177 12 
y 
  M IP T-Cell ALL methotrexate 5060 mg IV IV yes no OL Dosage MIMS: Lymphoblastic leukaemia. 
Maintenance: 30 mg/m2 IMI twice wkly or 
2.5 mg/kg IVI every 14 days 
18 5 y 30   IP Possible appendicitis 
(abdominal pain). Patient 
admitted for appendectomy     
metoclopramide 4.5mg prn IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
399 7 y 42.2 M IP Myringotomy and insertion 
of grommets and 
adenoidectomy 
metoclopramide 6mg QID 
prn 
IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
409 7 y 32.45 M IP Phimosis (elective 
admission). Patient was 
commenced on IV 
ondansetron 3mg QID prn. 
metoclopramide 6mg tds IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
516 2 y 9.6 M OP Replantation of left thumb metoclopramide 2mg tds IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
561 12 
y 
    IP Right gastroenemius 
release 
metoclopramide 6 mg tds 
prn 
IV IV yes  no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
607 8 y 20.6 M IP Cerebral palsy, spasticity, is 
receiving BTX-A injection        
metoclopramide 4 mg tds 
prn 
IV IV yes  no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
653 7 y 29.8 M IP Hemithyroidectomy                  metoclopramide 6 mg tds 
prn 
IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
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678 10 
y 
20 F IP Adenotonsillectomy metoclopramide 4 mg qid 
prn 
IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
761 15 
y 
    IP Spine injury, fracture L5 
following MVA                          
metoclopramide 10 mg tds 
prn 
IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
816 9 y     IP Circumcision (phimosis), 
asthma                                     
metoclopramide  4 mg qid 
prn 
IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
999 8 y 39.65   IP Adenotonsillectomy                 metoclopramide 8 mg prn IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
1095 5 y 20.3 M IP Left-sided cochlear implant, 
seasonal allergic rhinitis          
metoclopramide 4 mg tds IV IV yes no OL Age MIMS: In children and young adults < 20 
years: restricted use to severe intractable 
vomiting of known cause, vomiting 
associated with radiation therapy or 
intolerance to cytotoxic drugs, assist in 
small bowel intubation. 
725 8 y 26.6 F IP Chronic nephropathy metolazone 5 mg 
alternate 
days 
tab PO no no UL Not 
registered 
Not registered in Australia 
446 10 
y 
41.3 F ED Appendectomy. metronidazole 500mg - 
single dose 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children under 12 years: 8 hourly as 
for adults but the single IV dose is based 
on metronidazole 7.5mg/kg.  
500 11 
y 
47.2 M ED Severe abdominal pain. 
Patient was diagnosed with 
acute appendicitis and 
underwent urgent 
appendectomy.  
metronidazole 500mg  IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children under 12 years: 8 hourly as 
for adults but the single IV dose is based 
on metronidazole 7.5mg/kg.  
689 27 
d 
3.31 F IP Abdominal distension (likely 
secondary to air 
swallowing) 
metronidazole 50mg once IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children under 12 years: 8 hourly as 
for adults but the single IV dose is based 
on metronidazole 7.5mg/kg.  
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
656 1 y 
3 
m 
  F IP Bronchiolitis microlax 1 enema enema Rectal yes no OL Dosage MIMS: Children < 3 yrs: insert 1/2 length of 
nozzle 
1101 2 y 11.7 M IP Hydronephrosis, iron 
deficiency anaemia                 
microlax 1 enema enema Rectal yes no OL Dosage MIMS: Children < 3 yrs: insert 1/2 length of 
nozzle 
3 13 
y 
54.6 M IP Injury. Patient fell off a 
motor bike. Pain in the right 
clavicle and wrist, hit head 
but was wearing a helmet 
midazolam 15mg  injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
131 6 y   M OP Guillian Barre syndrome. 
PMH includes possible post 
viral neuropathy, post 
pituitary cyst, bronchiolitis 
and hyperactivity and 
vitamin D deficiency.  
midazolam 5mg daily injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
262 7 
m 
  F IP Possible parietal skull 
fracture - fell off the bed. 
midazolam 2.4mg  injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
midazolam 1mg IV IV yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
361 4 y   M ED Foreign body in left nostril. midazolam 7.5 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
456 11 
y 
24.5 M IP Neurological Symptoms - 
seizure/ fitting. Had seizure 
for 30 seconds which self 
resolved. Has recently been 
unwell with viral infection. 
Refusing oral intake. PMH 
of epilepsy, cerebral palsy, 
deafness, blindness 
midazolam 5mg  injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
485 1 y   M OP Review of coarction repair 
and duct litigation.  
midazolam 11mg  injection 
solution 
Buccal yes  no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
591 17 
y 
75.2 M IP High risk T-cell ALL                 midazolam 15 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
601 11 
y 
  M IP Cerebral palsy, mild spastic 
dysplegia, focal epilepsy 
(btx-injections)                         
midazolam 12 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
607 8 y 20.6 M IP Cerebral palsy, spasticity.       midazolam 10 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
 
 
  
 
258
Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
646 2 y   M IP Brachial plexus injury              midazolam 8 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
683 11 
y 
  M OP Idiopathic generalised 
epilepsy                                   
midazolam 5 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
690 1 y   F ED Generalised tonic clonic 
seizure, otitis media                
midazolam 5 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
690 1 y   F ED Generalised tonic clonic 
seizure, otitis media                
midazolam 3.5 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
692 3 y   F IP Repair of ostium premium 
defect and left AV valve 
regurgitation, small 
pericordial effusion.                 
midazolam 6 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
698 3 y   M IP Right orchidopexy testes         midazolam 10 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
714 ne
wb
orn 
3.18 M IP Hypoxic ischaemic neonatal 
encephalopathy with 
mecorium aspiration and 
seizures                                   
midazolam 19 mg IV  IV yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
midazolam 3 mg prn injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      midazolam 0.50 mg IV IV yes  no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
797 5 y 18.65 M IP Allergic reaction midazolam 4 mg IV IV yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
807 7 
m 
5.26 F IP Cerebral palsy, seizures 
and spasms, lissencephaly     
midazolam 1.5 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
812 6 y 25 F IP Epilepsy, seizure with 
cyanotic episode, admitted 
after seen in ED; deceased 
9/5/2010 (apnoea following 
LRTI and seizure)                    
midazolam 5 mg prn 
seizures 
injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
873 2 y 
6 
m 
16.05 M IP Total colonic Hirschsprungs 
disease; closure of 
ileostomy                                 
midazolam 8 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
876 3 y   F IP Right hip dysplasia, salter 
osteotomy with wound 
infection                                   
midazolam 9 mg injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
920 11 
y 
  M IP Cerebral palsy, right 
hemiparesis, GMFCS level 
1                                              
midazolam 10 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
943 3 y   M ED Epileptic seizure, vomiting, 
febrile                                       
midazolam 2.5 mg prn 
buccal for 
seizures 
injection 
solution 
Buccal yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
midazolam 200 mcg IV IV yes no OL Age MIMS: Safety and effectiveness of 
midazolam in children below the age of 8 
have not been established 
1161 15 
y 
60 F OP Epilepsy midazolam 10 mg prn injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
1177 12 
y 
  M IP T-Cell ALL midazolam 15 mg injection 
solution 
Buccal yes no OL ROA MIMS: Midazolam is not available as an 
oral liquid - IV injection solution 
administered buccally. 
73 8 y   M OP Alopecia areata. Eczema 
around eyes and elbows. 
minoxidil 5% daily topical Topical yes no OL Age MIMS: Safety and efficacy in patients under 
18 years of age have not been established. 
1175 14 
y 
  F IP Paracetamol overdose            mirtazapine 15 mg nocte tab PO yes no OL Age MIMS: The safety and efficacy of 
mirtazapine for the treatment of depression 
or other psychiatric disorders in children 
and adolescents aged less than 18 years 
have not been satisfactorily established 
865 3 
m 
7.21 M ED Bronchiolitis (recurrent)           montelukast 2.5 mg daily 
2/52 
tab PO yes no OL Age MIMS: Safety and effectiveness in 
paediatric patients younger than 6 months 
of age have not been studied 
91 7 y 26 M IP Acute appendicitis with 
perforation, admitted for 
laparoscopic 
appendectomy.  
morphine 13mg  IV IV yes no OL Dosage MIMS: dose in children is 0.1-0.2mg/kg 
every four hours. 26 x 0.2 = 5.2mg - in this 
case dose was 13mg 
390 6 y 20 F IP Adenotonsillectomy morphine 25mg IV IV yes no OL Dosage MIMS: Children - 0.05-0.1mg/kg slow IVI; 
0.1-0.2mg/kg IM or SC. In this case greater 
than the 0.1mg/kg was administered IV 
549 1 y 
8 
m 
17.4 M IP Burns to face, chin, neck, 
chest, right arm (8% BSA), 
admitted for 18 days, skin 
graft                                         
morphine 5-11mg q4h 
prn 
oral PO yes no OL Dosage MIMS: Children: 0.1-0.2mg/kg every 4 
hours (should be 1.74mg - 3.48mg) 
625 1 y 
6 
m 
  M ED Viral illness, eczematous 
rash to face                             
mupirocin 20 mg/g cream Topical yes no OL Age MIMS: The safety and efficacy of 
Bactroban cream has not been established 
in children less than 2 years of age 
945 10 
m 
8.6 M ED Impetigo mupirocin 20 mg/g tds 
12/7 
cream Topical yes no OL Age MIMS: The safety and efficacy of 
Bactroban cream has not been established 
in children less than 2 years of age 
917 14 
y 
  M IP Multiple sclerosis, 
exacerbation                            
natalizumab 300 mg 
monthly 
IV IV yes no OL Age MIMS: Tysabri® (natalizumab) is not 
indicated for use in paediatric and 
adolescent patients less than 18 years 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
156 4 y 20.55 M IP Swollen face, was urinating 
blood, decreased urine 
today, unwell. Asthmatic, 
recent tonsillitis. BP 150/90. 
Principal diagnosis: post 
streptococcal 
glomerulonephritis, pre-
renal impairment, 
secondary hypertension, 
proteinuria 
nifedipine 2.5mg prn oral PO yes no OL Age MIMS: Does not specify a paediatric dose. 
TGA: The safety and efficacy of ADALAT in 
children below 18 years has not been 
established 
533 15 
y 
  M OP Cold-induced vasculopathy 
of the digits                              
nifedipine 5 mg daily tab PO yes no OL Age TGA: The safety and efficacy of ADALAT in 
children below 18 years has not been 
established; not indicated for cold-induced 
vasculopathy 
1161 15 
y 
60 F OP Epilepsy nitrazepam 7.5 mg bd, 
10 mg nocte 
tab PO yes no OL Indication MIMS: only indicated for insomnia 
700 2 y   F OP Hyperinsulaemic 
hypoglyceamia of infancy, 
exocrine pancreatic 
insufficiency                             
octreotide 10 mg 3 
weekly 
IV IV yes no OL Age MIMS: Experience with octreotide in 
children is very limited. 
283 3 y   M OP HSV ulceration of the 
cornea. Pain/sensitive to 
light - patient treated for 
blepharitis for many 
months. 
ofloxacin 1 drop QID gutt Eye 
drops 
yes no OL Age MIMS: Adequate clinical studies of the 
safety of topical ophthalmic treatment with 
ofloxacin have not been conducted. 
Ocuflox should be avoided in children who 
have not attained joint maturity. 
962 2 y 17.65 M IP Cystic swelling to neck, 
infective exacerbation             
picibanil                  9 ml/1 U IM IM no no UL SAS Not registered in Australia 
815 10 
y 
  F ED Autistic disorder, severe 
behavioural disturbance          
olanzapine 5 mg prn tab 
(wafer) 
PO yes no  OL Age MIMS: Zyprexa has not been studied in 
patients under 18 years of age 
1036 12 
y 
60 M ED Chemical intoxication 
(vodka, cologne)                      
olanzapine 5 mg tab 
(wafer) 
PO yes no OL Age MIMS: Zyprexa has not been studied in 
patients under 18 years of age 
112 4 
m 
4.58 F ED Feeding difficulties. PMH 
includes GORD, 
constipation and poor 
weight gain. 
omeprazole 10mg tds tab 
(dispers
ed) 
PO yes no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
151 1 
m 
3.47 F ED Gastro-oesophageal reflux 
disorder. Patient was 
commenced on omeprazole 
2.5mg daily for 2 months.  
omeprazole 2.5mg daily tab 
(dispers
ed) 
PO yes no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
538 1 y 
3 
m 
8.22 F OP Gastric reflux, feeding 
difficulties 
omeprazole 8 mg bd tab 
(dispers
ed) 
PO yes no OL Dosage MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime.  
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ID 
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(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
626 8 
m 
9.91 M OP Benign macrocephaly, 
recurrent vomiting, 
recurrent cough                       
omeprazole 10 mg tab 
(dispers
ed) 
PO yes  no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
768 3 
m 
6.05 F IP Bronchiolitis, RS Virus 
detected                                  
omeprazole 5 mg nocte tab 
(dispers
ed) 
PO yes  no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
769 3 d 4.43 M IP Mildly dilated ascending 
aorta, biventricular 
hypertrophy, 
laryngomalacia with 
laryngeal reflux                        
omeprazole 5 mg daily tab 
(dispers
ed) 
PO yes  no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
862 7 
m 
9.9 M IP Vomiting, fever, irritability,       omeprazole 6 mg bd via 
PEG 
tab 
(dispers
ed) 
PO yes no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
omeprazole 5 mg daily tab 
(dispers
ed) 
PO yes no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
1020 2 w   F ED Unsettled, silent reflux?           omeprazole 5 mg daily tab 
(dispers
ed) 
PO yes no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
1112 8 
m 
5.34 M ED Bronchiolitis                             omeprazole 2.5 mg (1/4 
tab) 
tab 
(dispers
ed) 
PO yes  no OL Age MIMS: For children weighing 10 to 20 kg 
the recommended dose is Losec Tablets 
10 mg once daily; this child weighs less 
than 10 kg and is on a bd regime. No 
dosage given for children < 1 year 
3 13 
y 
54.6 M IP Injury. Patient fell off a 
motor bike. Pain in the right 
clavicle and wrist, hit head 
but was wearing a helmet 
ondansetron 4mg QID 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
18 5 y 30 F IP Possible appendicitis 
(abdominal pain). Patient 
admitted for appendectomy     
ondansetron 3mg six 
hourly 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
70 9 y   M IP Fractured forearm ondansetron 3mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
88 1 y 11.4 F ED Injury. Left upper limb. 
(patient was admitted for 
exploration and repair) 
ondansetron 2mg PONV IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established 
91 7 y 26 M IP Acute appendicitis with 
perforation, admitted for 
laparoscopic 
appendectomy.  
ondansetron 2mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
100 8 y 27.82 F IP Left supracondylar fracture ondansetron 2.7mg q6h 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
106 11 
y 
35 F ED Appendicitis. (Patient 
underwent laparoscopic 
appendectomy) 
ondansetron 4mg TDS 
prn 
postoperativ
ely 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
120 12 
y 
51.9 M IP Removal of plate and 
screws from previous left 
radius fracture 
ondansetron 4mg tds prn IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
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ID 
Age  Weight 
(kg) 
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or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
161 3 y 15 M ED Facial lip laceration (patient 
admitted, wound was 
cleaned and sutured) 
ondansetron 2mg q6h IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
163 7 y 26.65 M IP Burn to left upper thigh and 
dorsal penis from hot 
noodles. (mild difficulties 
voiding, mild discomfort) 
ondansetron 4mg tds prn oral 
liquid 
  yes no OL Indication MIMS: Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting 
207 17 
y 
16.6 F IP Lipomeningocele-sacrum 
region. (Liposuction lumbar-
sacral region, surgery 
complicated by drainage 
and there were some 
concerns that this may have 
been CSF) 
ondansetron 4mg q6h 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
208 17 
y 
65 F IP Dental extraction and 
restoration 
ondansetron 4mg qid IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
209 16 
y 
  M IP Tonsillectomy and cautery 
of turbinates 
ondansetron 8mg tds prn IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
253 2 y 13.05 M IP Dental abscess. Admitted 
for dental extraction under 
general anaesthesia 
ondansetron 1mg every 6 
hrs 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
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Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
316 12 
y 
34.25 M ED Acute appendicitis (Patient 
admitted and underwent 
laparoscopic 
appendectomy) 
ondansetron 4mg bd IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
332 3 y 16.05 M OP Injury. Right upper limb and 
thumb fractured 
ondansetron 1.5mg tds 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
358 6 y 26.45 M ED Injury - closed fracture ondansetron  3mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
390 6 y 20 F IP Adenotonsillectomy ondansetron 2mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
399 7 y 42.2 M IP Myringotomy and insertion 
of grommets and 
adenoidectomy 
ondansetron 3mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
409 7 y 32.45 M IP Phimosis (elective 
admission). Patient was 
commenced on IV 
ondansetron 3mg QID prn. 
ondansetron 3mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
414 7 y 47.85 M ED Appendicitis. Patient was 
admitted for laparoscopic 
appendectomy. 
ondansetron 4mg eight 
hrly prn 
oral 
liquid 
  yes no OL Indication MIMS: Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting. 
458 9 y 37.3 F IP Tonsillectomy  ondansetron 3.7mg q6h IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
476 4 
m 
  M IP Posterior encephalocele 
(Patient admitted for MRI of 
brain and spine under GA)      
ondansetron 1mg QID 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established 
493 3 y   M IP Follow-up of MRI to assess 
progress of left cerebral 
lesion. (Acute onset left 
sided squint July 2008, 
patient noted to be clumsy). 
CT performed and showed 
mild abnormality of left 
hemisphere. 
ondansetron 4mg 8 hrly IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
498 16 
y 
  M IP Hodgkin Lymphoma 
(diagnosed in 2006)                
ondansetron 8mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
500 11 
y 
47.2 M ED Severe abdominal pain. 
Patient was diagnosed with 
acute appendicitis and 
underwent urgent 
appendectomy.  
ondansetron 7mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
516 2 y 9.6 M OP Replantation of left thumb ondansetron 1mg IV QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
523 1 y   M IP Subcoronal hypospadias 
repair 
ondansetron 1mg QID IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
528 5 y 26.3 F IP Biopsy scalp lesion, right 
forearm lesion 
ondansetron 2.6mg tds IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
549 1 y 
8 
m 
17.4 M IP Burns to face, chin, neck, 
chest, right arm (8% BSA), 
admitted for 18 days, skin 
graft                                         
ondansetron 1.5 mg tds 
prn 
liquid PO yes no OL Age MIMS: Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting. The clinical safety of 
ondansetron in children under 2 years has 
not been established. 
561 12 
y 
  M IP Right gastroenemius 
release 
ondansetron 4 mg qid 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
571 8 y 25.8 F ED Facial laceration ondansetron 2.5mg tds 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
572 11 
y 
47.2 M IP Excision of congenital 
melanocytic nevus on left 
posterior thigh 
ondansetron 4mg bd IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
577 11 
y 
35.8 M IP Irritable bowel syndrome, 
constipation, weight loss 
ondansetron 3mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
587 6 y 20.7 F ED Right-sided pneumonia with 
pleural effusion                        
ondansetron 3mg every 8 
hrs prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
593 15 
y 
  M IP Crohn's disease ondansetron 4mg QID 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
643 9 y 33.7 F IP Diabetes Mellitus type 1, 
hypoglycaemia                        
ondansetron 4 mg tds 
prn 
liquid    yes no OL Indication MIMS: Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting. The clinical safety of 
ondansetron in children under 2 years has 
not been established. 
652 4 y 19.85 M IP Dental trauma, extraction ondansetron 2mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms 
after ondansetron treatment". 
653 7 y 29.8 M IP Hemithyroidectomy                  ondansetron 3mg q4h 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms 
after ondansetron treatment". 
676 10 
y 
  M IP Admitted for abdominal pain 
- colonoscopy, endoscopy, 
laparotomy, ceacal 
adhesion                                  
ondansetron 2mg bd prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms 
after ondansetron treatment". 
678 10 
y 
20 F IP Adenotonsillectomy ondansetron 2.5 mg tds 
prn 
liquid   yes no OL Indication MIMS: Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting. The clinical safety of 
ondansetron in children under 2 years has 
not been established. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
679 11 
y 
40.05 F IP Diabetes Mellitus type I, 
hypoglycaemic seizure 
ondansetron 4mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
684 1 y 
2 
m 
  F IP Recurrent OM and insertion 
grommets 
ondansetron 1 mg tds 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
687 3 y   F IP Adenotonsillectomy ondansetron 2mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
695 2 y   F IP Bilateral esotropia                   ondansetron 2mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
703 13 
y 
  M IP Laceration to perianal area, 
wound infection                       
ondansetron 4mg tds prn IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
706 10 
y 
  F IP Adenotonsillectomy                 ondansetron 4mg tds  IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
ondansetron 6mg tds prn IV IV yes no OL Dosage For the control of chemotherapy or 
radiotherapy induced emesis or nausea in 
adults, a single dose of 8 mg should be 
administered by injection. To protect 
against delayed emesis after the first 24 
hours, ondansetron should be continued 
orally at a dosage of 8 mg twice daily for up 
to five days. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
720 10 
y 
44.1 M IP Right testicular hydratid 
torsion 
ondansetron 4mg QID 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
740 1 y 
8 
m 
10.35 M IP Insertion of grommets ondansetron 1,5 mg qid 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
749 2 y 12.55 M ED Split lower lip, croup                ondansetron 2 mg qid IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
754 11 
y 
39.3 M IP Injury to big toe, stubbed, 
swelling not improving             
ondansetron 4 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
761 15 
y 
  M IP Spine injury, fracture L5 
following MVA                          
ondansetron 8 mg tds 
prn 
tab 
(wafer) 
PO yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting 
761 15 
y 
  M IP Spine injury, fracture L5 
following MVA                          
ondansetron 4 mg tds 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
 
779 17 
y 
  M IP Correction of anterior open 
bite                                           
ondansetron 4 mg tds 
prn 
tab 
(wafer) 
PO yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
786 13 
y 
  M ED Appendicitis ondansetron 4mg qid prn IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
793 9 y   M IP Right torted hydatid of 
Morgagni excision                   
ondansetron 4 mg tds tab 
(wafer) 
PO yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting 
793 9 y   M IP Right torted hydatid of 
Morgagni excision                   
ondansetron 4 mg qid IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
816 9 y   M IP Circumcision (phimosis), 
asthma                                     
ondansetron 6 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
818 2 y 15.7 F ED Foreign body left nostril, 
removed under GA 
ondansetron 2 mg tds 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
830 8 y 28.6 M IP Esotropia, squint repair           ondansetron 3 mg tds 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
831 10 
y 
38.4 F IP Chronic recurrent multifocal 
osteomyelitis, pain 
management                           
ondansetron 4 mg prn 
1/12 
tab 
(wafer) 
PO yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
832 12 
y 
43 F IP Intrinsic brain stem glioma; 
deceased 17.12.08                  
ondansetron 8 mg tds IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
836 16 
y 
  M IP Orbital floor fracture, eye 
trauma, dizzy, nausea             
ondansetron 8 mg tab 
(wafer) 
PO yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting 
843 10 
y 
  M IP Spastic quadriplegia, test 
for intrathecal baclofen            
ondansetron 2 mg tds IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
862 7 
m 
9.9 M IP Vomiting, fever, irritability,       ondansetron 0.5 mg tds 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
892 8 y 26.2 M IP Constipation: ACE-
procedure, appendectomy       
ondansetron 4 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
904 6 y 22.95 M IP Burn to left foot, skin grafts     ondansetron 2.5 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
907 3 
m 
4.59 F IP Bilateral inguinal hernia 
repair                                       
ondansetron 0.5 mg qid IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
913 14 
y 
45.2 F IP Excision of granulated 
tissue right nostril 
ondansetron 4 mg qid 
prn 
IV IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
915 16 
y 
  M OP Single dysplastic kidney, 
renal failure, dialysis. 
Abdominal pain after 
dialysis.                                    
ondansetron 4 mg  tab PO yes no OL Indication MIMS: Ondansetron tablets are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting. 
922 10 
y 
39.1 F IP Fracture left forearm ondansetron 4 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
923 15 
y 
  F IP Spondylo-epiphyseal 
dysplasia tarda 
pseaudorheumatoid 
arthritis; scoliosis, spinal 
fusion                                       
ondansetron 3 mg tds 
prn 
tab 
(wafer) 
  yes no OL Indication MIMS: Ondansetron wafers are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting. 
924 10 
y 
33.5 F ED Throat infection, vomiting, 
post-op 
ondansetron 4 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
947 4 y 14.55 M IP Persistent neck lesion, 
excision 
ondansetron 1.5 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
958 5 y 17 M ED Head injury, laceration of 
forehead 
ondansetron 2 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
ondansetron 8 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
962 2 y 17.65 M IP Cystic swelling to neck, 
infective exacerbation             
ondansetron 2 mg qid 
prn 
liquid PO yes no OL Age Off-label for age and indication. MIMS 
states ''Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting in children > 4 years''. 
974 10 
y 
37.09 F IP Excision of nose lesion and 
polydactyl left 5th toe 
ondansetron 4 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
988 3 y 14.35 F IP Facial laceration, sutured        ondansetron 1.5 mg tds 
prn 
IV  IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
1003 12 
y 
41.45 M IP Residual left central 
perforation (repair), right 
pinhole perforation                  
ondansetron 4 mg qid 
prn 
IV  IV yes no OL Dosage Greater dose frequency than stated in 
MIMS: For prevention of postoperative 
nausea and vomiting in adults, a single 
dose of 4mg may be administered by 
injection at induction of anaesthesia. For 
treatment of established postoperative 
nausea and vomiting, a single dose of 4 mg 
by injection is recommended and if 
necessary, the dose may be increased to 8 
mg. 
1008 1 y   M IP Removal of duplicated left 
thumb                                      
ondansetron 1 mg tds 
prn 
IV  IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
1029 3 y 17.2 M IP Foreign body in nose               ondansetron 2 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
1057 2 y 14.1 M IP Dental trauma, extraction ondansetron 1.5 mg qid liquid PO yes no OL Age Off-label for age and indication. MIMS 
states ''Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting in children > 4 years''. 
1064 3 y 15.15 M IP Spinal fracture ondansetron 2 mg tds tab PO yes no OL Age Off-label for age and indication. MIMS 
states ''Ondansetron syrup is only licensed 
for cytotoxic chemo/radiotherapy induced 
nausea and vomiting in children > 4 years''. 
1068 4 y 17.2 M IP Upper lip laceration, 
admitted after ED 
ondansetron 2 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
1095 5 y 20.3 M IP Left-sided cochlear implant, 
seasonal allergic rhinitis          
ondansetron 2 mg qid IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
1105 1 y 
8 
m 
13.7 M IP Right 4th nerve palsy, 
Oblique myectomy                   
ondansetron 1.5 mg tds 
prn 
IV  IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
1110 5 
m 
5.11 F IP Bilateral hernias, right ovary 
and fallopial tube prolapse 
ondansetron 0.5 mg qid 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
1116 3 
m 
4.84 F IP Cleft lip repair                          ondansetron 0.5 mg tds 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
1162 15 
y 
106 M IP Right hip injury, removal of 
screw                                       
ondansetron 4 mg tds 
prn 
tab PO yes  no  OL Indication MIMS: Ondansetron tablets are only 
licensed for cytotoxic chemotherapy and 
radiotherapy induced nausea and vomiting. 
1166 8 y 29.4 M IP Right post septal abscess 
secondary to sinogesic 
source (nose)                          
ondansetron 3 mg qid 
prn 
IV IV yes no OL Dosage More than one dose per day. MIMS states: 
'' Repeat dosing has not been studied in 
paediatric patients who experience nausea 
and/or vomiting despite 
receiving ondansetron prophylaxis or who 
continue to experience symptoms after 
ondansetron treatment". 
1175 14 
y 
  F IP Paracetamol overdose            ondansetron 4 - 8 mg bd 
prn 
IV IV yes no OL Indication MIMS: Indicated for nausea and vomiting 
induced by cytotoxic therapy and 
radiotherapy; prevention & treatment of 
PONV.  
1199 1 y 
10 
m 
11.9 M IP Neck abscess, drainage          ondansetron 1.5 mg qid 
prn 
IV IV yes no OL Age MIMS: The clinical safety of ondansetron in 
children under 2 years has not been 
established. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
1101 2 y 11.7 M IP Hydronephrosis, iron 
deficiency anaemia                 
oxybutynin 2 mg tds tab PO yes no OL Age MIMS: As there is insufficient clinical data 
for children under age 5, Ditropan is not 
recommended for this age group. 
18 5 y 30 F IP Possible appendicitis 
(abdominal pain). Patient 
admitted for appendectomy     
oxycodone  5mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
46 7 y 20.9 F IP Possible appendicitis and 
mild dehydration.  
oxycodone 2-4mg q4h oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
91 7 y 26 M IP Acute appendicitis with 
perforation, admitted for 
laparoscopic 
appendectomy.  
oxycodone  3mg QID 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
106 11 
y 
35 F ED Appendicitis. (Patient 
underwent laparoscopic 
appendectomy) 
oxycodone 3.5-7mg 
QID prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
132 5 y 18.2 F IP Adenotonsillectomy oxycodone 3mg every 4 
hrs prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
205 5 y 19.75 M IP Adenoidectomy and cautery 
of turbinates 
oxycodone 3-6mg 
every 4 hrs 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
219 10 
y 
44 M IP Adenoidectomy without 
tonsillectomy and 
cauterisation of nasal 
turbinates. 
oxycodone  4mg QID 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
246 9 y 44.35 F ED Slipped femoral epiphysis 
(pain on ambulation and 
there was obvious deformity 
and swelling, patient was 
admitted for hip pinning) 
oxycodone IR  5mg q4h 
prn 
tabs PO yes no OL Age MIMS: Oxycodone tablets: should not be 
administered to children. 
316 12 
y 
34.25 M ED Acute appendicitis (Patient 
admitted and underwent 
laparoscopic 
appendectomy) 
oxycodone 3.5-7mg 
q3h  
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
399 7 y 42.2 M IP Myringotomy and insertion 
of grommets and 
adenoidectomy 
oxycodone 3-6mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
414 7 y 47.85 M ED Appendicitis. Patient was 
admitted for laparoscopic 
appendectomy. 
oxycodone 5mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
446 10 
y 
41.3 F ED Appendectomy. oxycodone 4-6mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
458 9 y 37.3 F IP Tonsillectomy  oxycodone 3.7 mg tds 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
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Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
498 16 
y 
  M IP Hodgkin Lymphoma 
(diagnosed in 2006)                
oxycodone 
(OxyNorm®) 
5mL q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
500 11 
y 
47.2 M ED Severe abdominal pain. 
Patient was diagnosed with 
acute appendicitis and 
underwent urgent 
appendectomy.  
oxycodone 
(Endone®) 
5mg q4h tabs PO yes no OL Age MIMS: Oxycodone tablets: should not be 
administered to children. 
600 12 
y 
  F IP Patello femoral ligament 
reconstruction, cerebral 
palsy, epilepsy                         
oxycodone  5 mg qid 
prn 
caps PO yes  no  OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
602 10 
y 
  F ED Abdominal pain, central, 
radiating to back                      
oxycodone 5 mg tabs PO yes  no  OL Age MIMS: Oxycodone tablets: should not be 
administered to children. 
605 8 y 34.5 F IP Cellulitis to ear oxycodone 3-6 mg q4h 
prn 
oral 
liquid 
PO yes  no  OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
650 2 y   M IP Shunted hydrocephalus 
(blocked shunt), epilepsy, 
congenital aquaductal 
stenosis                                   
oxycodone 1 mg oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
653 7 y 29.8 M IP Hemithyroidectomy                  oxycodone 3-5 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
676 10 
y 
  M IP Admitted for abdominal pain 
- colonoscopy, endoscopy, 
laparotomy, ceacal 
adhesion                                  
oxycodone 2-4 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
678 10 
y 
20 F IP Adenotonsillectomy oxycodone 1.9 mg tds 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
706 10 
y 
  F IP Adenotonsillectomy                 oxycodone 3.8 mg oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
720 10 
y 
44.1 M IP Right testicular hydratid 
torsion 
oxycodone 4-6mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
oxycodone 5mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      oxycodone 0.5 mg q3-4 
h 
oral 
liquid 
PO yes  no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
754 11 
y 
39.3 M IP Injury to big toe, stubbed, 
swelling not improving             
oxycodone 4-8 mg q4h 
prn 
oral 
liquid 
PO yes  no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
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ID 
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Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
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 OL or UL 
Explanation for classification 
762 10 
m 
6.72 F IP Bilateral open hip surgery       oxycodone 0.5 mg q4-
6h 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
830 8 y 28.6 M IP Esotropia, squint repair           oxycodone 3 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
831 10 
y 
38.4 F IP Chronic recurrent multifocal 
osteomyelitis, pain 
management                           
oxycodone 3-8 mg oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
832 12 
y 
43 F IP Intrinsic brain stem glioma; 
deceased 17.12.08                  
oxycodone 5 mg qid 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
873 2 y 
6 
m 
16.05 M IP Total colonic Hirschsprungs 
disease; closure of 
ileostomy                                 
oxycodone 1 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
876 3 y   F IP Right hip dysplasia, salter 
osteotomy with wound 
infection                                   
oxycodone 1.8 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
886 3 y   M IP Adenotonsillectomy oxycodone 1.5 mg q4h oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
892 8 y 26.2 M IP Constipation: ACE-
procedure, appendectomy       
oxycodone 2-5 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
904 6 y 22.95 M IP Burn to left foot, skin grafts     oxycodone 4 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
924 10 
y 
33.5 F ED Throat infection, vomiting, 
post-op 
oxycodone 4 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
926 11 
y 
  M ED Fracture distal radius and 
ulna                                          
oxycodone 5-10 mg 
q4h 
tabs PO yes no OL Age MIMS: Oxycodone tablets: should not be 
administered to children. 
962 2 y 17.65 M IP Cystic swelling to neck, 
infective exacerbation             
oxycodone 2 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
999 8 y 39.65 F IP Adenotonsillectomy                 oxycodone 3.5 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1003 12 
y 
41.45 M IP Residual left central 
perforation (repair), right 
pinhole perforation                  
oxycodone 4-8 mg q4h 
prn  
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1008 1 y   M IP Removal of duplicated left 
thumb                                      
oxycodone 1 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1015 7 y   F IP Hearing loss, left 
cholesteatoma                         
oxycodone 2-4 mg q4h oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
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1025 5 y   F IP Right tibia, low trauma 
fracture, skin lesions               
oxycodone 2.20 mg qid 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1029 3 y 17.2 M IP Foreign body in nose               oxycodone 1.5-2 mg 
q4h prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1083 11 
y 
38 M IP Laceration to lower leg            oxycodone 2.5 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1100 4 y 17.15 M IP Supracondylar elbow 
fracture                                    
oxycodone 3 mg oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1166 8 y 29.4 M IP Right post septal abscess 
secondary to sinogesic 
source (nose)                          
oxycodone 3-6 mg q4h 
prn 
oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
1199 1 y 
10 
m 
11.9 M IP Neck abscess, drainage          oxycodone 1.5 mg q4h oral 
liquid 
PO yes no OL Age MIMS: Oxycodone capsules, liquid and 
injection should not be used in patients 
under 18 years of age. 
18 5 y 30 F IP Appendectomy                        Painstop Day® 16mL six 
hourly prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
21 2 y   F ED Inflamed/infected little finger Painstop Day® 8mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
46 7 y 20.9 F IP Possible appendicitis and 
mild dehydration.  
Painstop Day® 16mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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 OL or UL 
Explanation for classification 
70 9 y   M IP Fractured forearm Painstop Day® 24 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
88 1 y 11.4 F ED Injury. Left upper limb. 
(patient was admitted for 
exploration and repair) 
Painstop Day® 6.5 mL 
orally 4-6 
hourly 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
100 8 y 27.82 F IP Left supracondylar fracture Painstop Day® 20mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
106 11 
y 
35 F ED Appendicitis. (Patient 
underwent laparoscopic 
appendectomy) 
Painstop Day® 28mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
118 11 
y 
  F OP Mild lid oedema and mild 
generalized conjunctiva 
infection.  
Painstop Day® 30mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
127 8 y 42.9 M ED Infection/inflammation of 
little toe - swelling, and boil 
like lesions on the inner 
aspects of leg-thigh. 
Painstop Day® 30 mL (one 
dose in ED) 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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UL 
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 OL or UL 
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130 6 y 30 F ED Gradual onset of ear pain 
but no discharge; itchy ear, 
throat sl red; possible otitis 
externa. 
Painstop Day® 24mL - one 
dose in ED 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
132 5 y 18.2 F IP Adenotonsillectomy Painstop Day® 14mL every 
6 hrs when 
needed 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
163 7 y 26.65 M IP Burn to left upper thigh and 
dorsal penis from hot 
noodles. (patient had mild 
difficulties voiding and was 
in mild discomfort) 
Painstop Day® 21mL q6h 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
181 7 y 26.25 M IP Fractured radius and ulna 
following a fall at school. 
Obvious deformity observed 
Painstop Day® 21mL (1 
dose) 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
221 3 y 13.6 M ED Lacerated right little toe and 
had febrile convulsion and 
otitis media 
Painstop Day® 10.5 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
246 9 y 44.35 F ED Slipped femoral epiphysis 
(pain on ambulation and 
there was obvious deformity 
and swelling, patient was 
admitted for hip pinning) 
Painstop Day® 35mL - one 
dose in ED 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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257 1.5 
y 
  F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
Painstop Day® 11.8 mL six 
hourly 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
327 6 y 19 F ED Herpes stomatitis (multiple 
mouth ulcers on lips and 
tongue) 
Painstop Day® 15mL - one 
dose in ED 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
358 6 y 26.45 M ED Injury - closed fracture Painstop Day® 20mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
390 6 y 20 F IP Adenotonsillectomy Painstop Day® 16 mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
400 8 y 34.85 F IP Patient complained of 
severe abdominal pain and 
was admitted (in-patient) for 
overnight observation.  
Painstop Day® 27mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
402 7 y 29.75 M IP Bilateral scrotal exploration 
for excision of hydatid. 
Painstop Day® 23mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
  
 
282
Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
434 1 y 10.16 M ED URTI and otitis media 
(Cough, blocked nose and 
head tilted towards ear 
that's paining and fever) 
Painstop Day® 8mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
452 9 y   M IP Possible vasculitis (Patient 
admitted for investigation 
and treatment of possible 
polyarteritis nodosum) 
Painstop Day® 25mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
474 4 y 16.9 M ED Balanitis (inflammation of 
glans penis) - difficulty 
voiding and also suffered 
pain while micturating. It 
then progressed to inability 
to pass urine 
Painstop Day® 14mL - one 
dose in ED 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
490 1 y   F IP Left 2nd toe doctylitis. 
Aspiration and injection of 
left 2nd toe. 
Painstop Day® 7mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
503 10 
y 
33.8 F IP Abdominal pain, possible 
appendicitis 
Painstop Day® 26mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
528 5 y 26.3 F IP Biopsy scalp lesion, right 
forearm lesion 
Painstop Day® 20mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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539 1 y 10.5 M OP Head injury, bruise to face 
and graze to head 
Painstop Day® 8 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
549 1 y 
8 
m 
17.4 M IP Burns to face, chin, neck, 
chest, right arm (8% BSA), 
admitted for 18 days, skin 
graft                                         
Painstop Day® 8 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
552 9 y 26.9 F OP Fracture left upper thumb, 
seen in ED at 08.08.08 
Painstop Day® 16 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
568 11 
y 
41 F ED Central abdominal pain Painstop Day® 32mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
571 8 y 25.8 F ED Facial laceration Painstop Day® 20 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
580 7 y 27.2 M ED Post-tonsillectomy, woke 
with blood around mouth 
and over sheets 
Painstop Day® 20mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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586 6 y   F ED Injury-Left upper limb burnt 
because of a car cigarette 
lighter 10 minutes earlier. 
Placed in cold water at 
triage 
Painstop Day® 16 mL liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
587 6 y 20.7 F ED Right-sided pneumonia with 
pleural effusion                        
Painstop Day® 16mL q6h 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
605 8 y 34.5 F IP Cellulitis to ear Painstop Day® 27.5mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
639 5 y 22.5 M ED Central abdominal pain, 
pain to shoulders 
Painstop Day® 18mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
676 10 
y 
  M IP Admitted for abdominal pain 
- colonoscopy, endoscopy, 
laparotomy, ceacal 
adhesion                                  
Painstop Day® 18mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
688 6y   M OP Fractured arm Painstop Day® 16mL q6h 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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691 3 y 16.4 M IP Laceration to lip Painstop Day® 12mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
695 2 y   F IP Bilateral esotropia                   Painstop Day® 12mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
698 3 y   M IP Right orchidopexy testes         Painstop Day® 12mL QID 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
749 2 y 12.55 M ED Split lower lip, croup                Painstop Day® 9 mL qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
765 2 y 18 M ED Muscular injury to neck Painstop Day® 14.5 mL 
once 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
792 8 y 25.05 F ED Bilateral eye problem, 
swelling and redness, 
allergic reaction 
Painstop Day® 20 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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793 9 y   M IP Right torted hydatid of 
Morgagni excision                   
Painstop Day® 30 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
831 10 
y 
38.4 F IP Chronic recurrent multifocal 
osteomyelitis, pain 
management                           
Painstop Day® 30 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
833 8 y 22.8 M IP Mosaic down syndrome, left 
tibial osteotomy and fibular 
epiphyseodesis, 
constipation                             
Painstop Day® 18 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
922 10 
y 
39.1 F IP Fracture left forearm Painstop Day® 32 mL q4h liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
924 10 
y 
33.5 F ED Throat infection, vomiting, 
post-op 
Painstop Day® 25 mL tds 
5/7 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
933 5 y 20 M IP Mastoiditis, grommets 
placed 
Painstop Day® 16 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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969 4 y 30.4 M ED Painful left hip/thigh Painstop Day® 12 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
975 10 
y 
  M IP Foreskin adhesion, asthma, 
rhinitis 
Painstop Day® 18 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
988 3 y 14.35 F IP Facial laceration, sutured        Painstop Day® 11 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
998 6 y 25.25 M ED Fracture left arm Painstop Day® 20 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1002 6 y 18.8 F OP Elbow fracture Painstop Day® 14 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1005 2 y 14.55 M OP Thermal burn right forearm Painstop Day® 12 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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1012 1 y 10.2 M ED Viral illness Painstop Day® 8 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1015 7 y   F IP Hearing loss, left 
cholesteatoma                         
Painstop Day® 18.5 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1052 8 y 23.7 F ED URTI, cough Painstop Day® 18 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1053 8 y 32.15 F IP Congenital adrenal 
hyperplasia; 
adenotonsillectomy 
Painstop Day® 25 mL qid 
5/7 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1054 7 y 36.24 M IP Knee deformity and pain Painstop Day® 25 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1060 8 
m 
6.14 M IP Caudal dysplasia sequence 
with imperforate anus 
Painstop Day® 4 mL qid  liquid PO yes no OL Age MIMS: Do not use in infants under 12 
months of age. 
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1064 3 y 15.15 M IP Spinal fracture Painstop Day® 12 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1068 4 y 17.2 M IP Upper lip laceration, 
admitted after ED 
Painstop Day® 12 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1083 11 
y 
38 M IP Laceration to lower leg            Painstop Day® 30 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1095 5 y 20.3 M IP Left-sided cochlear implant, 
seasonal allergic rhinitis          
Painstop Day® 16 mL tds 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1111 1 y 11.9 M IP Laceration right hand, 
dehisced 
Painstop Day® 10 mL qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1121 6 y 26.9 F ED Fracture right distal radius 
and ulna 
Painstop Day® 21 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
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1127 4 y 30.1 M ED Scalp laceration Painstop Day® 15 mL once liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
1136 1 y 11 F ED Tonsillitis, dehydration, 
admitted after seen in ED 
Painstop Day® 8 mL qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL.  
486 7 
m 
  F ED Unsettled and irritable 
during the day.  
Painstop Night® 4ml oral PO yes no OL Age MIMS: Not for children under 2 years of 
age. 
692 3 y   F IP Repair of ostium premiun 
defect and left AV valve 
regurgitation, small 
pericordial effusion                  
Painstop Night® 9.5mL QID 
prn 
oral PO yes no OL Dosage MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL. Dose 
administered higher than recommended by 
MIMS  
819 1 y 11.65 M IP Eyebrow laceration 
(infected), finger infection        
Painstop Night® 8 mL once liquid PO yes no OL Age MIMS: Not for children under 2 years of 
age. 
824 4 y 15.5 M IP Periorbital cellulitis, 
laceration to eye glued on 
Sunday, swelling started 
Monday 
Painstop Night® 12 mL qid 
prn 
liquid PO yes no OL Dosage MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL. Dose 
administered higher than recommended by 
MIMS  
1100 4 y 17.15 M IP Supracondylar elbow 
fracture                                    
Painstop Night® 14 mL qid 
prn 
liquid PO yes no OL Dosage MIMS: Children 1-2 years (10-12kg) 5-6mL; 
2-3 years (12-14kg) 6-7mL; 3-4 years (14-
16kg) 7-9mL; 4-5 years (16-18kg) 9-10mL; 
5-6 years (18-20kg) 10-11mL; 6-7 years 
(20-22kg) 11-12mL; 7-8 years (22-24kg) 
12-13mL; 8-9 years (25-28kg) 13-15mL; 9-
10 years (28-32kg) 15mL. Dose 
administered higher than recommended by 
MIMS  
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816 9 y   M IP Circumcision (phimosis), 
asthma                                     
Panadeine Forte® 1 qid prn tab PO yes no OL Dosage MIMS: Children: 7-12 years: 1/2 tab; max 3 
tabs/ day 
910 8 
m 
  M ED Reflux, vomiting                       pantoprazole 16 mg/day granules PO yes no OL Age MIMS: To date there is insufficient 
experience with treatment in children under 
5 years to justify a general 
recommendation. 
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
pantoprazole 5 mg daily IV IV yes no OL Age MIMS: To date there has been no 
experience with treatment in children 
18 5 y 30 F IP Possible appendicitis 
(abdominal pain). Admitted 
for appendectomy                   
paracetamol 500mg qid oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
32 5 
m 
8.9 M ED Viral illness paracetamol 150mg oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
100 8 y 27.82 F IP Left supracondylar fracture paracetamol 540mg QID 
prn 
oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
132 5 y 18.2 F IP Adenotonsillectomy paracetamol 550mg - 
one dose 
only 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
181 7 y 26.25 M IP Fractured radius and ulna 
following a fall at school. 
Obvious deformity observed 
paracetamol 500mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
219 10 
y 
44 M IP Adenoidectomy without 
tonsillectomy and 
cauterisation of nasal 
turbinates. 
paracetamol 1000mg - 
one dose 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
246 9 y 44.35 F ED Slipped femoral epiphysis 
(pain on ambulation and 
there was obvious deformity 
and swelling, patient was 
admitted for hip pinning) 
paracetamol 660mg QID oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
257 1.5 
y 
  F ED Cellulitis (MRSA); 12 hours 
of fever, vomit, rash to 
abdomen. Ringworm found 
around buttock 
paracetamol 220mg q6h oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
332 3 y 16.05 M OP Injury. Right upper limb and 
thumb fractured 
paracetamol 300mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
paracetamol 250mg (one 
dose) 
oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
358 6 y 26.45 M ED Injury - closed fracture paracetamol 500mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
409 7 y 32.45 M IP Phimosis (elective 
admission). Patient was 
commenced on IV 
ondansetron 3mg QID prn. 
 
paracetamol 600mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
  
 
292
Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
428 2 y 15.9 M ED Viral illness (Fever, watery 
eyes, runny nose and sores 
in the mouth) 
paracetamol 270mg oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
431 6 y 21.48 F ED Ingested a 10cent coin and 
was admitted for endoscopy 
and removal of foreign body 
paracetamol 400mg QID 
prn 
oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
446 10 
y 
41.3 F ED Appendectomy. paracetamol 800mg QID 
prn 
oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
458 9 y 37.3 F IP Tonsillectomy  paracetamol 740mg q6h  oral  PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
516 2 y 9.6 M OP Replantation of left thumb paracetamol 200mg QID oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
536 3 y 11.7 F ED Viral illness, nausea paracetamol 220mg QID oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
556 4 y 22.92 F ED Tonsillitis paracetamol 450mg oral 
liquid 
PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
572 11 
y 
47.2 M IP Excision of congenital 
melanocytic nevus on left 
posterior thigh 
paracetamol 700mg QID tab PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
577 11 
y 
35.8 M IP Irritable bowel syndrome, 
constipation, weight loss 
paracetamol 600mg qid 
prn 
tab PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
605 8 y 34.5 F IP Cellulitis to ear paracetamol 690mg QID 
prn 
tab PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
607 8 y 20.6 M IP Cerebral palsy, spasticity, is 
receiving BTX-A injection        
paracetamol 400mg QID 
prn 
tab PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
643 9 y 33.7 F IP Diabetes Mellitus type 1, 
hypoglycaemia                        
paracetamol 600mg QID 
prn 
liquid  PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
653 7 y 29.8 M IP Hemithyroidectomy                  paracetamol 500mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
705 6 
m 
  M IP Bronchiolitis                             paracetamol 150mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
720 10 
y 
44.1 M IP Right testicular hydratid 
torsion 
paracetamol 800mg QID 
prn 
oral PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
740 1 y 
8 
m 
10.35 M IP Insertion of grommets paracetamol  200mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
749 2 y 12.55 M ED Split lower lip, croup                paracetamol 240 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
754 11 
y 
39.3 M IP Injury to big toe, stubbed, 
swelling not improving             
paracetamol 80 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
814 6 
m 
9.35 M IP Removal of bilateral 
preauricular skin tags and  
anterior tongue cyst                 
paracetamol 180 mg qid 
prn 
liquid PO yes no  OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
833 8 y 22.8 M IP Mosaic down syndrome, left 
tibial osteotomy and fibular 
epiphyseodesis, 
constipation                             
paracetamol 40 mg qid 
prn 
liquid PO yes no  OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
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892 8 y 26.2 M IP Constipation: ACE-
procedure, appendectomy       
paracetamol 500 mg q6h 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
904 6 y 22.95 M IP Burn to left foot, skin grafts     paracetamol 450 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
944 1 y 8.68 F IP Bronchiolitis, LRTI paracetamol 150 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
paracetamol 1000 mg qid 
prn 
tab PO yes no  OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
962 2 y 17.65 M IP Cystic swelling to neck, 
infective exacerbation             
paracetamol 350 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
988 3 y 14.35 M IP Facial laceration, sutured        paracetamol 280 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
994 2 d 2.04 M IP Necrotising enterocolitis, 
short bowel syndrome             
paracetamol 53 mg = 26 
mg/kg 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Neonates < 10 days: 7.5mg/kg up to 
4 times daily. 
1029 3 y 17.2 M IP Foreign body in nose               paracetamol 300 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1057 2 y 14.1 M IP Dental trauma, extraction paracetamol 280 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1060 8 
m 
6.14 M IP Caudal dysplasia sequence 
with imperforate anus 
paracetamol 125 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1095 5 y 20.3 M IP Left-sided cochlear implant, 
seasonal allergic rhinitis          
paracetamol 400 mg qid  liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1101 2 y 11.7 M IP Hydronephrosis, iron 
deficiency anaemia                 
paracetamol 200 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1110 5 
m 
5.11 F IP Bilateral hernias, right ovary 
and fallopial tube prolapse 
paracetamol 100 mg qid 
prn 
liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1111 1 y 11.9 M IP Laceration right hand, 
dehisced 
paracetamol 200 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1139 11 
m 
8.8 M IP Jejunal atresia, bowel 
obstruction, vomiting               
paracetamol 150 mg qid 
prn 
IV  IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
1186 3 
m 
6.97 F IP RVS bronchiolitis paracetamol 125 mg qid liquid PO yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: 15mg/kg 4 hrly up to 4x/day. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
parachoc 20 ml bd liquid PO yes no OL Dosage MIMS: Children 12 mnths-6 yrs: 10-15 mL 
daily 
132 5 y 18.2 F IP Adenotonsillectomy parecoxib 20mg IV IV yes no OL Age MIMS: Has not been studied in patients 
under 18 years old.. Therefore its use is not 
recommended in these patients. 
205 5 y 19.75 M IP Adenoidectomy and cautery 
of turbinates 
parecoxib 40mg IV IV yes no OL Age MIMS: Has not been studied in patients 
under 18 years old.. Therefore its use is not 
recommended in these patients. 
643 9 y 33.7 F IP Diabetes Mellitus type 1, 
hypoglycaemia                        
pizotifen 0.5 mg 
nocte 
tab PO yes no OL Age MIMS/TGA: Experience in children is still 
limited. 
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339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
potassium 
chloride 
5mmol daily oral PO no no UL Formulation PMH formulation 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
potassium 
chloride 
1 tab bd tab PO yes no OL Age MIMS: safety and effectiveness have not 
been established for use in children under 
12 
960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
potassium 
chloride 
20 mmol liquid PO no no UL Formulation PMH formulation 
669 8 y   M IP Malaria, schistosomiasis, 
tinea capitis, raised ALT          
praziquantel 450 mg q4h 
for 3 doses 
tab PO yes no OL Age MIMS: Safety in children has not been 
established 
812 6 y 25 F IP Epilepsy, seizure with 
cyanotic episode, admitted 
after seen in ED; deceased 
9/5/2010 (apnoea following 
LRTI and seizure)                    
pregabalin 75 mg bd tab PO yes no OL Age MIMS: The safety and effectiveness of 
pregabalin has not been established in 
patients below the age of 18 years 
549 1 y 
8 
m 
17.4 M IP Burns to face, chin, neck, 
chest, right arm (8% BSA), 
admitted for 18 days, skin 
graft                                         
promethazine 5.5 mg qid 
prn 
liquid PO yes no  OL Age MIMS: promethazine should not be used in 
children under 2 years of age due to the 
potential for fatal respiratory depression. 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      promethazine 1.5 mg liquid PO yes  no OL Age MIMS: This product should not be used in 
children under 2 years of age due to the 
potential for fatal respiratory depression. 
797 5 y 18.65 M IP Allergic reaction promethazine 45 mg IM IM yes no OL Age MIMS: This product should not be used in 
children under 2 years of age due to the 
potential for fatal respiratory depression. 
63 2 y 14.1 M IP Bronchiectasis (confirmed 
on a CT scan). Recently 
moved to Australia from 
Tanzania. PMH includes 2 
episodes of pneumonia and 
mannose binding lectin 
(MBL) deficiency. 
propofol 100 mcg injection IV yes no OL Age MIMS: According to the manufacturer, 
propofol injection is not recommended in 
children under 3 years of age.  
88 1 y 11.4 F ED Injury. Left upper limb. 
(patient was admitted for 
exploration and repair) 
propofol 20 mcg injection IV yes no OL Age MIMS: According to the manufacturer, 
propofol injection is not recommended in 
children under 3 years of age.  
104 2 y 15 M IP Dentinogenesis imperfecta 
(Patient admitted for dental 
restoration and extraction) 
propofol 30 mcg injection IV yes no OL Age MIMS: According to the manufacturer, 
propofol injection is not recommended in 
children under 3 years of age.  
266 3 
m 
  M IP Elective left inguinal hernia 
repair (symptoms included 
vomiting and loose motions)   
propofol 20 mcg injection IV yes no OL Age MIMS: According to the manufacturer, 
propofol injection is not recommended in 
children under 3 years of age.  
341 1 y   M IP Lesion in liver  propofol 30 mg injection IV yes no OL Age MIMS: According to the manufacturer, 
propofol injection is not recommended in 
children under 3 years of age.  
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476 4 
m 
  M IP Posterior encephalocele 
(Patient admitted for MRI of 
brain and spine under GA)      
propofol 20 mg injection IV yes no OL Age MIMS: According to the manufacturer of 
Propofol Sandoz, propofol injection is not 
recommended in children under 3 years of 
age.  
880 1 y   M IP Severe croup, asthma; 
transferred from JHC               
propofol 40 mg IV IV yes no OL Age MIMS: There are no clinical trials to support 
the use of propofol for the sedation of 
children with croup or epiglottitis receiving 
intensive care. MIMS: According to the 
manufacturer of Propofol Sandoz, injection 
is not recommended in children under 3 
years of age.  
485 1 y   M OP Review of coarction repair 
and duct litigation.  
propranolol 2mg tds oral PO yes  no UL Formulation Hospital formulation. 
114 14 
y 
55 M IP Injury after playing football. 
Also suicidal ideation and 
worsening depression. 
quetiapine 50mg  oral PO yes no OL Age MIMS: The safety and efficacy have not 
been established in patients under 18 years 
of age. 
193 14 
y 
42 F IP Post-traumatic disorder. 
Showed depressive 
features and multi-sensory 
hallucinations.  
quetiapine 50mg oral PO yes no OL Age MIMS: The safety and efficacy have not 
been established in patients under 18 years 
of age. 
464 16 
y 
64 M ED Hit by a car travelling at 
50km/hr. Mild headaches, 
blurred vision and vomiting 
(possible splenic injury). 
Patient’s PMH includes 
behavioural issues. Was 
observed to be suicidal.  
quetiapine 25mg daily oral PO yes no OL Age MIMS: The safety and efficacy have not 
been established in patients under 18 years 
of age. 
1036 12 
y 
60 M ED Chemical intoxication 
(vodka, cologne)                      
quetiapine 25 mg tab PO yes no OL Age MIMS: The safety and efficacy have not 
been established in patients under 18 years 
of age. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
ranitidine 50 mg bd liquid PO yes no OL Age MIMS: Experience in children is limited and 
such use has not been fully evaluated in 
clinical studies. Ranitidine, has however, 
been used successfully in children aged 8 
to 18 years in doses up to 150mg twice 
daily 
797 5 y 18.65 M IP Allergic reaction ranitidine 18 mg IV PO yes no OL Age MIMS: Experience in children is limited and 
such use has not been fully evaluated in 
clinical studies. Ranitidine, has however, 
been used successfully in children aged 8 
to 18 years in doses up to 150mg twice 
daily 
887 1 y   M IP Viral induced wheeze ranitidine 2 mL (30 
mg) 
liquid PO yes no  OL Age MIMS: Experience in children is limited and 
such use has not been fully evaluated in 
clinical studies. Ranitidine, has however, 
been used successfully in children aged 8 
to 18 years in doses up to 150mg twice 
daily 
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925 14 
y 
58.2 F OP Epilepsy, psychosis, vitamin 
D deficiency 
risperidone 1 mg daily tab PO yes no OL Age MIMS: Experience is lacking in children 
with schizophrenia less than 15 years 
28 1 y   F ED Possible bronchiolitis salbutamol 6 puffs via 
spacer 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
62 1 y   M ED Virus induced wheeze 
(difficulty breathing and 
patient passed out and was 
floppy)                                      
salbutamol 6 puffs QID inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
97 2 y   M IP Asthma (worsening 
shortness of breath, cough) 
salbutamol 
nebules 
6 puffs 
inhaled 
every 1/2 - 
2 hourly 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
97 2 y   M IP Asthma (worsening 
shortness of breath, cough) 
salbutamol 6 puffs 
inhaled 
every 1/2 - 
2 hourly 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
136 3 y   M ED Cough, wheezing; 
diagnosed with moderate-
severe asthma. 
salbutamol 4 puffs 
inhaled 
every 1 - 2 
hours as 
needed 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
144 11 
m 
  M ED Respiratory distress was 
seen yesterday morning 
and diagnosed with 
bronchiolitis. Overnight 
increased respiratory effort 
and wheeze 
salbutamol 6 puffs 
every 20 
min 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
160 6 y   M ED Worsening asthma and 
cough 
salbutamol 6 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
272 4 y 16.9 M ED Viral pneumonitis (patient 
was pale, tachypnoeic and 
moderate intercostal muscle 
recession. (CXR showed no 
consolidation but bilateral 
infiltrates) 
salbutamol 6 puffs - 3 
doses every 
20 min in 
ED 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
278 7 y   M IP Croup (Symptoms included 
sore throat, fever and not 
being able to breathe)             
salbutamol 6 puffs in 
ED 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
288 10 
m 
  F ED Viral URTI (3 day history of 
cough, rhinorrhea and 
vomiting)                                  
salbutamol 6 puffs - 1 
dose in ED 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
335 7 y   F ED Worsening asthma 
secondary to LRTI 
(Wheezing at home and 
appear cyanosed) 
salbutamol 12 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
397 7 
m 
7.76 F IP Bronchiolitis (2-3 days of 
rhinorrhea, cough and 
wheeze)  
salbutamol 6 puffs 3-4 
hrly 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
  
 
297
Case 
ID 
Age  Weight 
(kg) 
Sex IP, OP 
or ED 
Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
418 1.5 
y 
  M ED Viral induced wheeze. 
(Patient unwell for 2 days 
and has runny nose, cough, 
difficulty breathing and no 
stridor at that time)                  
salbutamol 6 puffs 
every 20 
minutes prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
432 2 y   M IP Viral induced wheeze and 
when in hospital patient was 
diagnosed with asthma. 
(Symptoms - cough, 
vomiting, patient became 
very distressed and was 
using accessory muscles) 
salbutamol 6 puffs 
every 2-3 
hours 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
449 6 
m 
  F ED Viral URTI (Bronchiolitis, 
wheezing cough but has no 
respiratory distress) 
salbutamol 6 puffs  - 2 
doses in 
one hour 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
482 3 y   F IP Unwell with cough, flu but 
the symptoms got worse 
and patient had CXR which 
showed bilateral changes.  
salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
512 3 y   F IP LRTI salbutamol 6 puffs 
q0.5-2h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
521 1 y   F ED Respiratory distress, cough, 
fever, pneumonia 
salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
523 1 y   M IP Subcoronal hypospadias 
repair 
salbutamol 2-6 puffs 
q4-6h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
535 1 y   M IP Viral pneumonitis salbutamol 6 puffs q2h 
prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
541 1 y   M ED Respiratory distress, 
vomiting                                   
salbutamol 2-6 puffs 
prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
623 1 y 
6 
m 
  F ED Wheeze, cough, unsettled       salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
656 1 y 
3 
m 
  F IP Bronchiolitis salbutamol 6 puffs q0.5 
- 4 h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
670 17 
y 
  M OP Cystic fibrosis, chest 
crackles                                   
salbutamol 6 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
687 3 y   F IP Adenotonsillectomy salbutamol 2-6 puffs 
prn with 
spacer 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
705 6 
m 
  M IP Bronchiolitis                             salbutamol 6 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
718 11 
y 
  M ED Persistent asthma                    salbutamol 12 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
724 8 y   M IP Asthma exacerbation, viral      salbutamol 12 puffs 
every 90 
minutes 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
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734 4 y   M IP Viral wheeze salbutamol 6 puffs q2-
4h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
750 2 y   M ED Asthma exacerbation, viral      salbutamol 6 puffs 
thrice 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
816 9 y   M IP Circumcision (phimosis), 
asthma                                     
salbutamol 4-6 puffs qid inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
839 13 
y 
32.8 M ED Asthma, infrequent 
exacerbations, epilepsy           
salbutamol 2-6 puffs 
prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
858 1 y 
8 
m 
  F ED Mild pneumonia                       salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
865 3 
m 
7.21 M ED Bronchiolitis (recurrent)           salbutamol 6 puffs q4-
6h prn             
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
880 1 y   M IP Severe croup, asthma; 
transferred from JHC               
salbutamol 
nebules 
6 puffs 
q0.5-2h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
887 1 y   M IP Viral induced wheeze salbutamol 6 puffs 
q0.5-2h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
995 4 y   M OP Asthma salbutamol 2-6 puffs 
prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1004 2 y 13.76 M ED Cough, asthma, URTI, viral 
illness                                      
salbutamol 6 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1013 5 y   F IP Asthma exacerbation salbutamol 6 puffs 
q0.5-1h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1026 1 y 
3 
m 
  M ED Asthma, viral wheeze              salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1052 8 y 23.7 F ED URTI, cough salbutamol 6 puffs  inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1103 2 y   M IP Asthma exacerbation              salbutamol 6 puffs 
q0.5-4h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1130 5 y 
5 
m 
  F IP Asthma (new onset) salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1132 1 y 
9 
m 
  M ED Asthma exacerbation              salbutamol 6 puffs q1-
3h via 
spacer 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1144 8 
m 
9.36 M IP Bronchiolitis, rhinovirus           salbutamol 2.5 mg q2-
4h 
nebules Inhalation yes no OL Age MIMS: no dosage given for children < 4 
years 
1144 8 
m 
9.36 M IP Bronchiolitis, rhinovirus           salbutamol 6 puffs q2-
4h prn 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1145 9 
m 
9.34 M IP Bronchiolitis salbutamol 27 mcg IV IV yes no OL Age TGA: No dosage listed for children < 2 year 
1145 9 
m 
9.34 M IP Bronchiolitis salbutamol 6 puffs prn inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1146 11 
m 
10.8 M ED Tonsillitis, viral illness, 
wheeze                                    
salbutamol 4 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
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1187 6 y   F ED Asthma, mild exacerbation      salbutamol 6 puffs inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1193 13 
y 
  M IP Asthma, allergic rhinitis, 
exacerbation                            
salbutamol 12 puffs 
q0.5-4h 
inhaler Inhalation yes no OL Dosage MIMS: children: 1-2 inhalations, may repeat 
every 4 hrs 
1047 13 
y 
  F OP Psoriasis salicylic 
acid/cetylpyridiniu
m chloride                
nocte scalp 
and flexures 
30/30 mg/g     
cream Topical no no UL Formulation Hospital formulation. 
193 14 
y 
42 F IP Post-traumatic disorder. 
Showed depressive 
features and multi-sensory 
hallucinations.  
sertraline 50mg tab PO yes no OL Age MIMS: Sertraline should not be used in 
children and adolescents below the age of 
18 years for the treatment of major 
depressive disorder 
936 17 
y 
55.55 F OP Major depressive disorder, 
chronic costochondritis            
sertraline 125 mg 
mane 
tab PO yes no OL Age MIMS: Sertraline should not be used in 
children and adolescents below the age of 
18 years for the treatment of major 
depressive disorder 
527 1 
m 
3.04 M IP Complex congenital 
cyanotic heart disease, 
pulmonary hypertension          
sildenafil 1.5 mg qid oral PO yes no OL Age MIMS: Safety and effectiveness in 
paediatric pulmonary hypertension patients 
have not been established (Revatio). 
2mg/mL solution prepared by hospital 
pharmacy. 
527 1 
m 
3.04 M IP Complex congenital 
cyanotic heart disease, 
pulmonary hypertension          
sildenafil 1 mg qid oral PO yes no OL Age MIMS: Safety and effectiveness in 
paediatric pulmonary hypertension patients 
have not been established (Revatio). 
2mg/mL solution prepared by hospital 
pharmacy. 
156 4 y 20.55 M IP Swollen face, was urinating 
blood, decreased urine 
today, unwell. Asthmatic, 
recent tonsillitis. BP 150/90. 
Principal diagnosis: post 
streptococcal 
glomerulonephritis, pre-
renal impairment, 
secondary hypertension, 
proteinuria 
sodium 
bicarbonate 
10 mL bd oral PO no yes UL Formulation MIMS: No commercial oral preparation 
available. PMH prepare a 8.4% oral 
solution (1 mmol/mL) 
827 3 
m 
  F IP CF, pancreas insufficiency      sodium chloride 7 % solution 
tds 
nebules Inhalation no no UL Formulation Not registered in Australia 
934 16 
y 
  M IP CF, constipation (8 days no 
stool)                                        
sodium chloride 7% solution 
daily 
nebules Inhalation no no UL Formulation Not registered in Australia 
946 9 
m 
  M OP CF, pancreas insufficiency, 
bronchiolitis                             
sodium chloride 7% solution; 
2.5 ml tds 
nebules Inhalation no  no UL Formulation Not registered in Australia 
961 3 
m 
  F IP CF, pancreas insufficient         sodium chloride 7% solution; 
1 ml qid 
nebules Inhalation no  no UL Formulation Not registered in Australia 
1088 9 y   F OP Enuresis, constipation             solifenacin 5 mg daily tab PO yes no OL Age MIMS: Safety and effectiveness in children 
have not yet been established. Therefore, 
Vesicare should not be used in children. 
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Diagnosis Drug(s) Dosage Form Route Reg Lic OL/ 
UL 
Reason 
 OL or UL 
Explanation for classification 
1089 10 
y 
  M OP Nocturnal enuresis solifenacin 5 mg daily tab PO yes no OL Age MIMS: Safety and effectiveness in children 
have not yet been established. Therefore, 
Vesicare should not be used in children. 
523 1 y   M IP Subcoronal hypospadias 
repair 
SOOV IT® 5/50 mg/g ointment Topical yes no OL Age CMI: not intended for use in children below 
2 years of age 
579 8 y   F OP Eczema tacrolimus 0.3 mg/gl lotion Topical no no UL Formulation tacrolimus lotion not registered in Australia 
587 6 y 20.7 F ED Right-sided pneumonia with 
pleural effusion                        
teicoplanin 200 mg 
daily 
IV IV yes no OL Age TGA: No children's dosage listed. 
193 14 
y 
42 F IP Post-traumatic disorder. 
Showed depressive 
features and multi-sensory 
hallucinations.  
temazepam  10mg oral PO yes no OL Age According to MIMS, safety and 
effectiveness has not been established in 
children less than 16 years of age.  
567 14 
y 
59.7 F ED Goitre, tremor, tachycardia, 
thyrotoxicosis                           
temazepam 10 mg daily 
5/7 
tab PO yes no OL Age MIMS: The safety and efficacy of 
temazepam have not been established in 
children less than 16 years of age 
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
temazepam 10 mg nocte 
prn 
tab PO yes no OL Age MIMS: The safety and efficacy of 
temazepam have not been established in 
children less than 16 years of age 
804 14 
y 
  F IP Burkitt's lymphoma temazepam 20 mg tab PO yes no OL Age MIMS: The safety and efficacy of 
temazepam have not been established in 
children less than 16 years of age 
923 15 
y 
  F IP Spondylo-epiphyseal 
dysplasia tarda 
pseaudorheumatoid 
arthritis; scoliosis, spinal 
fusion                                       
temazepam 10 mg tab PO yes no OL Age MIMS: The safety and efficacy of 
temazepam have not been established in 
children less than 16 years of age 
669 8 y   M IP Malaria, schistosomiasis, 
tinea capitis, raised ALT          
terbinafine 125 mg 
daily 
1/2 tab PO yes no OL Age MIMS: There is no experience with 
terbinafine in children and its use cannot be 
recommended 
18 5 y 30 F IP Possible appendicitis 
(abdominal pain). Admitted 
for appendectomy                   
ticarcillin with 
clavulanic acid 
1000mg IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
18 5 y 30 F IP Possible appendicitis 
(abdominal pain). Admitted 
for appendectomy                   
ticarcillin with 
clavulanic acid 
1500mg bd IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
63 2 y 14.1 M IP Bronchiectasis (confirmed 
on a CT scan). Recently 
moved to Australia from 
Tanzania. PMH includes 2 
episodes of pneumonia and 
mannose binding lectin 
(MBL) deficiency. 
ticarcillin with 
clavulanic acid 
1200mg tds IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
91 7 y 26 M IP Acute appendicitis with 
perforation, admitted for 
laparoscopic 
appendectomy.  
 
ticarcillin with 
clavulanic acid 
1300mg 
QID 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14. 
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UL 
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302 13 
y 
  M ED Laparoscopic 
appendectomy.  
ticarcillin with 
clavulanic acid 
1000mg IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
316 12 
y 
34.25 M ED Acute appendicitis (Patient 
admitted and underwent 
laparoscopic 
appendectomy) 
ticarcillin with 
clavulanic acid 
1500mg 
during 
anaesthesia 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
316 12 
y 
34.25 M ED Acute appendicitis (Patient 
admitted and underwent 
laparoscopic 
appendectomy) 
ticarcillin with 
clavulanic acid 
1500mg 
QID 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
ticarcillin with 
clavulanic acid 
1000mg 
(one dose in 
ED) 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
400 8 y 34.85 F IP Patient complained of 
severe abdominal pain and 
was admitted (in-patient) for 
overnight observation.  
ticarcillin with 
clavulanic acid 
1700mg 
QID 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14. In hospital, 
patient was commenced on Timentin 
1700mg QID. Timentin was classified as 
unlicensed and the reason for it was the 
indication for which it was prescribed.  
Patient was discharged the following day 
because symptoms were not consistent 
with appendicitis and analgesia was 
sufficient.  
414 7 y 47.85 M ED Appendicitis. Patient was 
admitted for laparoscopic 
appendectomy. 
ticarcillin with 
clavulanic acid 
2500mg 
q6h 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14 
446 10 
y 
41.3 F ED Appendectomy. ticarcillin with 
clavulanic acid 
2000mg 
QID 
IV IV yes no OL Age MIMS: safety and efficacy of Timentin has 
not been established in children under the 
age of 14.  
500 11 
y 
47.2 M ED Severe abdominal pain. 
Patient was diagnosed with 
acute appendicitis and 
underwent urgent 
appendectomy.  
ticarcillin with 
clavulanic acid 
2350mg 
QID 
IV IV yes no OL Age MIMS: The efficacy and safety of Timentin 
has not been established in infants and 
children under the age of 14  
516 2 y 9.6 M OP Replantation of left thumb ticarcillin with 
clavulanic acid 
450 mg qid IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
703 13 
y 
  M IP Laceration to perianal area, 
wound infection                       
ticarcillin with 
clavulanic acid 
2850 mg qid IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
742 10 
m 
7.47 M IP Metopic craniosynosthosis      ticarcillin with 
clavulanic acid 
375 mg qid IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
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786 13 
y 
  M ED Appendicitis ticarcillin with 
clavulanic acid 
2.5 mg qid IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
873 2 y 
6 
m 
16.05 M IP Total colonic Hirschsprungs 
disease; closure of 
ileostomy                                 
ticarcillin with 
clavulanic acid 
750 mg qid IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
1074 11 
y 
34.5 M IP Appendectomy                        ticarcillin with 
clavulanic acid 
2000mg 
QID 
IV IV yes  no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
1116 3 
m 
4.84 F IP Cleft lip repair                          ticarcillin with 
clavulanic acid 
250 mg IV IV yes no OL Age MIMS: The efficacy and safety have not 
been established in infants and children 
under the age of 14 
1185 4 
m 
  M OP Glaucoma, left exotropia         timolol 2.5 mg/ml 
daily BE 
eye 
drops 
Eye 
drops 
yes no OL Age MIMS: Safety and effectiveness in children 
have not been established by adequate 
and well controlled studies. 
339 1 y 9.6 M ED Osteomylitis and 
pneumonia (staph aureus). 
Other diagnoses includes 
pneumothorax, gardia and 
thrombocytosis.  
tinidazole 200mg oral PO yes no UL Formulation PMH formulation 
532 13 
y 
50.5 M OP Cystic fibrosis, pancreas 
insufficiency and 
bronchiectasis 
tobramycin 80 mg bd nebules Inhalation yes no OL ROA MIMS: Tobramycin solution for injection 
may be given IM or IV. In this case, used 
for inhalation. 
544 8 
m 
  M OP CF tobramycin 80 mg bd nebules Inhalation yes no OL ROA MIMS: Tobramycin solution for injection 
may be given IM or IV. In this case, used 
for inhalation. 
584 3 y 14.25 F IP Pre-B ALL tobramycin 180 mg 
daily 
IV IV yes no OL Dosage Greater than dose specified in MIMS. 
MIMS: Adult dose for serious infections is 
3mg/kg/day in 3 doses given every 8 hours. 
Life threatening infections: 5mg/kg/day 
641 3 y   F OP CF tobramycin 80 mg bd nebules Inhalation yes no OL ROA MIMS: Tobramycin solution for injection 
may be given IM or IV. In this case, used 
for inhalation. 
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
tobramycin 450mg daily IV IV yes no OL Dosage Greater than dose specified in MIMS. 
MIMS: Adult dose for serious infections is 
3mg/kg/day in 3 doses given every 8 hours. 
Life threatening infections: 5mg/kg/day 
934 16 
y 
  M IP CF, constipation (8 days no 
stool)                                        
tobramycin 500 mg 
daily = 8.16 
mg/kg/day 
IV IV yes no OL Dosage Greater than dose specified in MIMS. 
MIMS: Adult dose for serious infections is 
3mg/kg/day in 3 doses given every 8 hours. 
Life threatening infections: 5mg/kg/day 
934 16 
y 
  M IP CF, constipation (8 days no 
stool)                                        
tobramycin 80 mg bd nebules Inhalation no no OL ROA MIMS: Tobramycin solution for injection 
may be given IM or IV. In this case, used 
for inhalation. 
867 12 
y 
32.8 F IP Lymphoproliferative 
disease, Castleman's 
disease                      
                                                
tocilizumab              600 mg 3 
weekly 
IV IV no no UL Not 
registered 
Not registered in Australia 
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1088 9 y   F OP Enuresis, constipation             tolterodine 2 mg bd tab PO yes no OL Age MIMS: The safety and effectiveness of 
Detrusitol in paediatric patients have not 
been established 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
topotecan 0.52 mg; 
0.75 mg/m2 
IV IV yes no OL Age MIMS: The use of topotecan in children is 
not recommended as only limited data are 
available 
948 4 y 17.3 F IP Abdominal neuroblastoma; 
deceased 1/5/2010                  
topotecan 0.52 mg; 
0.75 mg/m2 
IV IV yes no OL Age MIMS: The use of topotecan in children is 
not recommended as only limited data are 
available 
1099 4 y   M OP Right exotropia, right high 
myopia, left emmetropia          
tropicamide 1 drop BE; 
10 mg/ml 
eye 
drops 
Eye 
drops 
yes no  OL Age MIMS: Tropicamide has been reported to 
be inadequate for cycloplegia in children. 
Avoid use in children. 
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
tropisetron 5 mg daily IV IV yes no OL Age MIMS: Since experience with Navoban in 
children is still limited, its use cannot be 
recommended. 
1047 13 
y 
  F OP Psoriasis Upton's Paste ASA 60%, 
TCAA 10%, 
glycerol 
20%; prn to 
warts              
ointment Topical no no UL Formulation not a registered product; hospital 
formulation 
283 3 y   M OP HSV ulceration of the 
cornea. Pain/sensitive to 
light - patient treated for 
blepharitis for many 
months. 
valaciclovir  280mg tds 
for 2 
months 
oral PO yes no OL Age MIMS: Safety and effectiveness in children 
have not been established. Dose in 
children: No data available. 
1137 1 y 
3 
m 
9.6 M OP Review for liver 
transplanted                            
valganciclovir 2.7 ml daily liquid PO yes no OL Age MIMS: Safety and efficacy have not been 
established in this patient population. The 
use of Valcyte in children is not 
recommended because the 
pharmacokinetic characteristics of Valcyte 
have not been established in this patient 
population.  
498 16 
y 
  M IP Hodgkin Lymphoma 
(diagnosed in 2006)                
vancomycin 1000mg 
q6h 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults -  0.5g every 6 hours or 1 g 
every 12 hours.  
717 13 
y 
46.85 M IP Lymphoproliferative 
disease, EBV induced, 
admitted 24.10.08. - 
01.12.08. deceased                 
vancomycin 930mg tds IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Adults -  0.5g every 6 hours or 1 g 
every 12 hours.  
733 5 y 14.65 M IP Relapsed stage IV 
neuroblastoma, CNS 
disease, seizure control; 
deceased 30.8.08 
vancomycin 320mg tds IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children: 15mg/kg loading dose 
then 10mg/kg every 6 hours.  
945 10 
m 
8.6 M ED Impetigo vancomycin 130 mg qid 
over 2 
hours 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children: 15mg/kg loading dose 
then 10mg/kg every 6 hours.  
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960 11 
y 
51.65 M IP AML, sepsis after 4th cycle 
of chemo                                  
vancomycin 1000 mg tds 
= 58 
mg/kg/day 
IV IV yes no OL Dosage Greater dose than specified in MIMS. 
MIMS: Children: 15mg/kg loading dose 
then 10mg/kg every 6 hours.  
807 7 
m 
5.26 F IP CP, seizures and spasms, 
lissencephaly                           
vigabatrin 500 mg 
daily 
liquid PO yes no OL Age MIMS: no dosage given for children < 3 
years 
946 9 
m 
  M OP CF, pancreas insufficiency, 
bronchiolitis                             
Vitabdeck® 1/2 capsule 
daily 
caps PO yes no OL Age MIMS: Children 4-10 yrs: 1 cap daily; 
adults, children > 10 yrs: 2 caps daily. No 
dose for children < 4 years( Vitabdeck 
drops should be used in children < 4 year) 
961 3 
m 
  F IP CF, pancreas insufficient         Vitabdeck® 1 cap daily caps PO yes no OL Age MIMS: Children 4-10 yrs: 1 cap daily; 
adults, children > 10 yrs: 2 caps daily. No 
dose for children < 4 years( Vitabdeck 
drops should be used in children < 4 year) 
 
